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Coeliac disease, an autoimmune-mediated sensitivity to gluten, is known to affect at 
least 1% of the population. It is widely acknowledged that it is underdiagnosed, and 
that management beyond the implementation of a gluten-free diet is inconsistent, 
despite there being several guidelines now available. This study investigated these 
issues as they relate to the New Zealand context, testing the hypothesis “that general 
practitioners in New Zealand have limited disease-specific knowledge about coeliac 
disease.” 
Methods 
Surveys of New Zealand general practitioners and gastroenterologists were 
undertaken, investigating their likely practices with respect to a range of variables 
associated with the recognition, diagnosis, and management of coeliac disease. Nine 
years of data from one of New Zealand’s major laboratories, relating to testing for 
coeliac disease were also audited. 
Results 
General practitioners in New Zealand have patchy knowledge about whom to test 
for coeliac disease, and how to diagnose and manage the condition. There is also a 
lack of consistency among gastroenterologists about aspects of its management. 
However, rates of testing for coeliac disease have steadily increased over time in 
the majority of regions examined, and its incidence is high in Otago-Southland. 
Furthermore, when people with very high coeliac antibody levels are biopsied, they 
almost always have evidence of coeliac disease. 
Conclusions 
General practitioners in New Zealand do have gaps in their knowledge about coeliac 
disease. Agreeing on a set of New Zealand-specific practice guidelines to promote 
consistent practice among clinicians, targeting gaps in knowledge, and reviewing 
policies around who should undergo biopsy to confirm the diagnosis, could all 
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In 1980, in the British Medical Journal, Swinson and Levi published a study on 
coeliac disease (CD) titled “Is Coeliac Disease Underdiagnosed?”1 They were 
reporting on work they had conducted investigating the prevalence of CD in their 
local district, having observed that their own hospital in Middlesex, England, was 
diagnosing many more patients than other hospitals in the region. One of the 
conclusions they reached was that CD was variably recognised by medical 
practitioners, which in turn led to variable rates of investigation and subsequent 
diagnosis. The extension of this, they suggested, was that perhaps CD was 
underdiagnosed. In the decades since their research was presented, their 
suggestion has been proven correct. The answer to the question posed in their title 
is a resounding “Yes”, as evidenced in numerous studies from around the world. 
(See for example Rubio-Tapia et al.,2 Makharia et al.,3 and Mustalahti et al.4)  
In 2004, aged in my mid-30s, I was diagnosed with CD. This came as a great 
surprise to me, although in retrospect it should not have done so. I had had 
symptoms for many years but had failed to identify them as such. But what 
surprised me more was that I was also a General Practitioner (GP), and had been 
for several of those years of symptoms. How had I not known what had been going 
on? And of more concern, if I had not been able to recognise CD in myself even 
though I was living with it, how many patients had I also failed to diagnose? As I 
began to discuss CD with colleagues it seemed that I was not alone in my ignorance. 
If that was the case, the implication was that there were people in our communities 
with CD who were receiving less than optimal care, perhaps not even realising that 
this was the cause of their illness. This would not have surprised those who had 
been studying CD, as it was by then a well-documented phenomenon. 
This thesis, and the studies it describes, arose out of a desire to determine the 
scale of the phenomenon in New Zealand. There was no particular reason to expect 
the situation to be any different in this country, but I wanted to know to what extent 
was my failure to recognise CD simply a gap in my own knowledge? Or, as the 
literature from elsewhere suggests, was I but one of many doctors who have a CD-
shaped blind spot? And if it transpired that such a blind spot does exist, what could 
and should be done about it?  
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1.1 A brief description of coeliac disease 
Coeliac disease is an autoimmune condition that renders those who suffer from it 
unable to tolerate gluten, a group of proline- and glutamine-rich proteins found in 
wheat, barley, and rye. In genetically predisposed individuals, the small intestine is 
attacked by the immune system in a reaction triggered by ingested gluten. Detection 
of CD is generally achieved with blood tests that identify the presence of CD-specific 
antibodies, but confirmation of the diagnosis depends on the presence of certain 
histologic changes seen in biopsy samples taken from the duodenum of patients in 
whom the condition is suspected.5-11 It should be noted here that with the release 
of updated European Society for Paediatric Gastroenterology Hepatology and 
Nutrition (ESPGHAN) guidelines in 2012,12 the requirement for biopsy 
confirmation in all circumstances has been called into question, at least for children. 
These guidelines are discussed in detail in Chapter Two of this thesis. 
In the past CD was regarded as a relatively rare, purely gastroenterological 
disease, which predominantly affected children, especially those of Northern 
European or Celtic descent.13 These children became very unwell on the 
introduction of gluten into their diets, presenting with diarrhoea, malnutrition, and 
failure to thrive.14 In recent decades however, understanding of the condition has 
changed significantly.15  
Firstly, it is now known that CD can affect people at any age and stage of life, 
and does so in much greater numbers than previously believed.11 It is in fact one of 
the most common of the autoimmune conditions.16 The estimated prevalence of CD 
is widely accepted to be approximately 1%, with evidence for this emerging in 
studies in New Zealand,17 Australia,18 the United States of America,2 and countries 
across Europe and Scandinavia.4 Coeliac disease has also been found to be a cause 
of morbidity in countries in both South and West Asia, such as India and Iran,19,20 
and parts of North Africa and the Middle East.21 As already noted, there is also 
widespread evidence that the majority of people with the condition remain 
undiagnosed. 
Secondly, it is recognised that, while the presence of gut damage remains one 
of the cornerstones of diagnosis (and biopsies of the small intestinal mucosa are 
generally still required to confirm this), the range of symptoms with which patients 
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can and do present is much greater than previously thought. These may include 
diarrhoea or constipation, vomiting, persistent fatigue, or neurological symptoms 
such as polyneuropathy.22 It is perhaps for this reason that it is so readily 
overlooked.23,24 
Thirdly, it is now clear that people with CD are at increased risk of developing 
other conditions such as anaemia, thyroid disease, osteoporosis and, on occasion, 
intestinal lymphoma.25 While this risk may be somewhat mitigated by the 
implementation of a gluten-free diet (GFD),26,27 which remains the only treatment 
available for CD, the implication is that it is not sufficient to assume that once on a 
GFD, the coeliac patient will be well. Management thus needs to be seen much more 
broadly than simply advising a GFD and then leaving patients to it.28-30 
To summarise: CD is common across ages and nations and is chameleon in its 
clinical manifestations and, as a consequence of this, is substantially 
underdiagnosed. Treatment revolves around removing the autoimmune trigger 
(gluten) from the patient’s diet, but should extend beyond this to managing the risk 
of potential complications. All of these issues are discussed in greater depth in 
Chapter Two. 
1.2 Confirming the need for the present project 
Following my diagnosis, I became involved with Coeliac New Zealand (CNZ), a not-
for-profit organisation that supports people with CD. It quickly became apparent 
that this organisation was, and is, firmly of the view that GPs in New Zealand do not 
know enough about CD. The organisation made, and continues to make, statements 
such as the following: 
Public recognition of coeliac disease and the potential reactions to 
gluten…have never been higher, yet awareness of the condition among 
medical professionals continues to be low. Coeliac disease remains one 
of the most underdiagnosed conditions in New Zealand and Australia. 
(CNZ Newsletter March 2015) 
And again the following month: 
With an estimated 65,000 kiwis having coeliac disease and 80% of those 
not even knowing, coeliac disease remains one of the most 
underdiagnosed conditions in New Zealand and Australia. Recognition 
of the condition among medical professionals also continues to be low. 
(CNZ Newsletter April 2015) 
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Though recent, these comments capture a sentiment that has prevailed over many 
years, fuelled by member experience and Australian research (among others) that 
continues to point to underdiagnosis.18 
Stories abound of members of CNZ experiencing years of ill-health and being 
given multiple alternative diagnoses before their CD was identified; of doctors 
(usually GPs) giving misinformation about when and how to test for the condition; 
and of there being little in the way of ongoing review or support once the diagnosis 
had been made. The substance of these anecdotes was borne out in a survey of CNZ 
members conducted in 2012 by University of Otago Masters of Dietetics student Kiri 
Sharp.31 In that survey, a sample group of over 900 CNZ members reported a mean 
length of time from the onset of symptoms to CD diagnosis of 11.6 years. A third of 
respondents reported consulting with two or more family doctors before the 
diagnosis was made. Alternative diagnoses they had attracted in the meantime 
included anaemia, stress, depression, and irritable bowel syndrome. 
In New Zealand, gastroenterologists are the clinicians who perform small 
intestinal biopsies to confirm the diagnosis, and, together with paediatricians who 
look after coeliac children, have traditionally been regarded as the specialists with 
respect to CD. However, as the clinical face of CD has changed over the years, it has 
increasingly become the domain of primary care practitioners (in New Zealand and 
elsewhere) to identify those in whom the diagnosis should be considered.32 They 
need to recognise symptoms that could be explained by CD, and appropriately test 
patients to determine who needs to be referred for endoscopy. It is in the primary 
care setting that the vast majority of patients will first present their symptoms, and 
to which they will return when the diagnosis has been made. 
Sharp’s evidence, which she has since published,33 signifies that patients’ 
symptoms have gone unrecognised as being indicative of CD, and raises questions 
about the quality and consistency of care that coeliac patients receive. In short, it 
suggests that New Zealand is indeed no different from elsewhere, and that CD in this 
country is both underdiagnosed and managed sub-optimally. Her research would 
also seem to vindicate CNZ’s concerns about GP knowledge. From this a number of 
questions arise about the nature of the limitations of that knowledge, and about the 




1.3 Previous CD research with a primary care focus 
Over the many decades in which the study of CD has been occurring, and among the 
many thousands of research papers published about the condition, only a tiny 
proportion of the work reported on has been conducted in the primary care setting. 
And while it may be tempting to attribute this to the fact that much of the research 
relating to CD has come from the United States of America (USA), where primary 
care and family medicine are comparatively less well developed than in other 
countries, this does not stand up to scrutiny. According to work published by 
Narotsky et al.,34 the United Kingdom (UK) and Italy, where primary care is well 
established, were two of the top three sources of CD publications (the other being 
the USA) in the period 1995 to 2009. The more plausible explanation is that the 
great majority of research relating to CD has focused on questions relating to 
pathogenesis, diagnosis (including diagnostic criteria and prevalence), and 
principles of management, much of which has required histological data to test 
hypotheses. These data are of necessity usually generated in secondary and tertiary 
care settings.  
The relatively few studies undertaken with a primary care focus have generally 
investigated rates of recognition of CD (analysing testing and referral data),32,35-37 
and patterns of presentation among people with the condition.38 These emphases 
have been adopted as a means of quantifying levels of undiagnosed disease,39 and 
to evaluate the impact of case-finding strategies in particular.40-42 A more recent 
study by Spencer et al.43 investigated family physicians in the USA, using a survey 
to evaluate their likelihood of testing for CD among patients with iron deficiency 
anaemia.  
In addition to these studies, information from the UK GP Research Database has 
been utilised to try and quantify healthcare costs of patients before and after the 
diagnosis of CD,44 and general practice data have sometimes been included in wider 
incidence studies, such as that conducted in Wales by Hurley et al.45 One study in 
Scotland has also looked at prescribing habits relating to gluten-free foods,46 finding 
that there was significant under-prescribing compared with local guidelines, 
although the authors did not draw any conclusions about why this might be. 
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Point-of-care testing (POCT) as a means for increasing the diagnosis of CD has 
also been evaluated with a primary care focus. In an early study of this technology,47 
Korponay-Szabó and colleagues investigated the efficacy of POCT in the hands of 
district nurses in Hungary, while a more recent “proof of concept” study by Urwin 
et al.48 explored the role of community pharmacists in the UK in identifying people 
who may have CD. Both studies suggest that POCT used by healthcare professionals 
other than doctors may be a useful way of reaching and recognising undiagnosed 
CD patients, although a relatively recent review of the technology (for primary care 
users) warns that negative tests cannot be relied upon to rule out CD.49 
There have only been two studies that have explicitly examined what primary 
care doctors know about CD: one in North America,50 which involved internists and 
family doctors caring for adults, and one in Italy,51 involving family paediatricians. 
Other projects undertaken in this setting could, however, be regarded as reporting 
proxy measures of knowledge. One team of Italian researchers, led by Lanzarotto,52 
were quite specific about this. They identified far fewer people with confirmed CD 
than expected based on assumed community prevalence data, and found that nearly 
a third of these people had not received appropriate dietary management. Based on 
these findings they called for increased awareness about CD symptomatology and 
management, to ameliorate “the under diagnosis of celiac disease in the primary 
care setting” that is “compounded by mismanagement”.52(p.283)  
In Finland, where considerable effort over many years has gone into educating 
physicians about CD, Collin et al.53 investigated the impact of this effort. They found 
that in Tampere, the region in which there had been the greatest focus on physician 
education, the prevalence of diagnosed CD had risen to 0.7%, not far short of the 
1.1% figure found in population-based screening studies. This, they said, was 
“achieved mainly by increasing alertness for celiac disease among health care staff.” 
They further asserted that “if celiac disease is to be detected extensively, this has to 
take place in primary health care.”53(p.155) 
One further study, which sought to understand why the diagnosis of CD is so 
frequently missed in general practice, was undertaken by Kostopoulou and 
colleagues.54 The focus of their research was on the diagnostic reasoning process, 
and they included a scenario on CD in a larger project they were conducting on 
diagnosis in general. In this study, despite the presence of clinical cues, the majority 
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of family physicians participating did not think of CD as a possible explanation for 
the patient’s presentation. This made it impossible for the diagnosis to be reached. 
1.4 Investigating knowledge and practice about coeliac disease 
Despite the widespread recognition that CD is difficult to recognise and 
underdiagnosed, there has been very little research carried out to investigate what 
doctors (or any health professionals) actually know about, or how they practise, 
with respect to CD. Within the English language literature there have only been 
seven such studies published: two involving gastroenterologists ;55,56 two involving 
paediatricians;51,57 two involving primary care physicians (as mentioned in the 
previous section);43,50 and a recent study in India,58 which attempted to quantify 
knowledge of CD among all physicians in that country. Unfortunately this project, 
which was based around an emailed questionnaire, was hampered by a very poor 
response rate, with only 10% of surveys returned.  
The study by Kostopoulou et al.54 discussed in the preceding section could also 
be considered as having explored clinicians’ practice relating to CD, and one other 
study,59 which endeavoured to quantify how often haematologists consider CD as a 
cause for iron deficiency anaemia, could also broadly be described as assessing 
knowledge of CD. As with the Indian study, this too relied on an email survey, and 
was also limited by a poor response rate (of 8.5%). 
Perhaps not surprisingly, all but one of these knowledge studies have 
demonstrated that there are wide variations in practice among the professionals 
studied, and/or deficits in practitioner knowledge about CD. It would seem also that 
all aspects of CD are affected, as the different studies have had a range of foci. So, for 
example, the gastroenterologist survey conducted by Silvester and Rashid focused 
on the management of CD in Canada,55 while Zipser et al.50 investigated awareness 
of CD by surveying primary care physicians in the USA about a number of variables 
associated with the condition, such as symptoms, complications and co-morbidities. 
The former found that gastroenterologists in Canada varied widely in their practice, 
and often diverged from the guidelines available at the time,55 while the latter 
showed that nearly two-thirds of respondents were unaware that CD could present 
in adulthood, and that few were aware of the association between CD and other 
conditions such as Type 1 Diabetes Mellitus (T1DM).50 Similarly, paediatricians in 
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Brazil surveyed by Vieira et al.57 were described as having “superficial information 
about CD” (p.799), with (for example) only 22% of respondents acknowledging that 
CD could be asymptomatic, and the majority being unaware of an increased 
association between CD and several other conditions. The USA family physician 
study by Spencer et al.43 found a majority of their participants would start a GFD in 
patients with positive coeliac blood tests, before the diagnosis had been confirmed 
by histology. 
The exception was a piece of work carried out among family paediatricians in 
the Puglia region of Italy by Fortunato et al.51 In this survey-based study, which had 
a 37% response rate, participants were asked to rate their level of knowledge about 
CD as high, medium, low, or none. Their responses were linked to the number of CD 
patients they tended to see, about whom they had also been asked to provide 
information. The great majority reported their knowledge levels as medium or high 
with respect to making the diagnosis, although the authors did suggest that “they 
were probably missing the CD diagnosis in some children with atypical symptoms 
as the proportion of children typical symptoms [sic] was higher than what has been 
shown in screening studies.”51(p.4 of 6) 
Chapter Three of this thesis, which describes the methods employed for this 
project, will include details about how some of these existing studies informed the 
present work. 
1.5 The research questions formally described 
This project arose in the context described in the preceding sections. Its principal 
task was to describe what is happening in New Zealand with regards to the 
recognition, diagnosis, and management of CD, particularly as it affects adults. 
While not excluding consideration of CD in children, the emphasis was placed on CD 
in adult patients for the following reasons: they are the patients who report much 
longer delays to diagnosis;33 recognition that CD can develop and present in 
adulthood has only relatively recently become widely known;60 and the ongoing 
care of adult patients with CD is much more likely to reside with GPs than when it 
arises in childhood, when paediatricians maintain oversight of management for 
some time. (Although during the course of preparing this thesis this circumstance 
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has changed in New Zealand, with an increasing expectation emerging that GPs will 
also assume responsibility for the care of children with CD.) 
At the project’s heart is the question of knowledge, which gave rise to the 
hypothesis to be tested: that GPs in New Zealand have limited disease-specific 
knowledge about CD. If this hypothesis were to be correct, then this might be 
evidenced by the following: 
a) CD is under recognised and/or 
b) CD is underdiagnosed and/or 
c) CD is sub-optimally managed. 
A number of research questions were formulated to capture information about 
these issues.  
The first major question pertained to GPs: What do GPs in New Zealand know 
about coeliac disease?  
This was broken down into subsidiary questions: 
 Whom do they test, and under what clinical circumstances will they 
test them? 
 On what clinical information do they base decisions about 
diagnosis? 
 How do they manage patients with the condition? 
 From where (or whom) do they get their information about these 
issues? 
A second major question related to the practice of gastroenterologists with 
respect to CD, specifically: How do gastroenterologists in New Zealand manage the 
condition?  
This was important to understand because they are the secondary care providers 
most closely involved in looking after adult patients with CD, and their practice is 
most likely to influence that of GPs. In addition to this, the management of adult CD 
is not solely the domain or responsibility of GPs; and until relatively recently there 
has been a dearth of evidence-based guidelines about the management of CD, 




The third major question that emerged from consideration of the central 
hypothesis was: Is CD in this country really as underdiagnosed as asserted by CNZ, 
and as it has been demonstrated to be in prevalence studies in other countries? That 
is: What is the prevalence of diagnosed CD in New Zealand today? 
To explore these questions three separate investigations were undertaken: a 
survey of New Zealand gastroenterologists; a survey of New Zealand GPs; and an 
interrogation of ten years of laboratory data relating to testing for CD. Together 
these studies were designed to provide the evidence necessary to test the project’s 
overarching hypothesis.  
In the course of developing the study to answer the question relating to 
underdiagnosis, it emerged that the data were not readily available to enable an 
accurate calculation of a prevalence figure. The laboratory data that were accessible 
were limited to certain regions, and to the preceding decade, meaning that a 
number of assumptions would be required to generate such a figure. It would, 
however, be possible to calculate the incidence of CD in the regions from which the 
data arose, and to evaluate patterns of testing as a marker of practitioner 
knowledge, so this is what was done. These issues are discussed in more detail in 
Chapter Three. 
1.6 Outline of the thesis 
This thesis describes and brings together the three studies conducted to address 
the research questions outlined above. Following this introductory chapter, Chapter 
Two expands the definition of CD by drawing from the extensive literature that has 
been written about the many aspects of the condition: history, pathogenesis, 
prevalence, presentation, diagnosis, management, and complications. CD research 
that has been carried out in New Zealand is incorporated into the relevant sections 
of the chapter.  
Chapter Three is a description of the methods employed in each of the three 
studies of this project. It provides background to why particular methods were 
chosen, and identifies some of the challenges that arose during implementation. 
Chapters Four, Five, and Six separately present the results of the 
gastroenterologist, GP, and laboratory studies respectively. Presenting these results 
in individual chapters has been done to simplify the structure of this part of the 
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thesis, which otherwise risked becoming unwieldly. In addition to this, some very 
specific actions relating to each study, but that might be more strictly regarded as 
“methods”, have been included in the relevant results chapters. This has been done 
to assist the reader with following what was done at certain junctures. 
The results chapters are followed by Chapter Seven, which discusses the 
important findings of each study. These are considered in the context of the recent 
literature, and are drawn together to provide a synthesis of what they collectively 
reveal about the recognition, diagnosis, and management of CD in New Zealand. The 
strengths and limitations of each study, and the project as a whole, are also 
considered. 
The thesis concludes with Chapter Eight, in which the central hypothesis tested 
is considered in the light of the data generated by the three studies. The chapter 
concludes with recommendations for changes in practice that could improve the 
care of patients with CD, and gives some suggestions for future directions in 
research.  
1.6.1 Conventions followed in this thesis 
Throughout this work I have followed the University of Otago’s thesis guidelines 
with respect to formatting, and American Medical Association Manual of Style 
conventions relating to the use of voice, grammar, numerals, and punctuation such 
as quotation marks. I have used the first-person pronoun on occasions (such as this) 
to assist with clarity, particularly when discussing actions that I took during each 
phase of the research.   
Throughout this thesis the word “gluten” is intended to mean the collective 
group of proteins found in wheat, barley, and rye, which are responsible for 
triggering the coeliac reaction. The word “coeliac” is spelled according to the British 









: About Coeliac Disease 
2.1 Introduction 
Coeliac disease has a long and complex history about which much has been written. 
In recent decades it has also been the subject of a burgeoning research programme, 
driven in part by the search for a treatment that would remove (or at least ease) the 
requirement for people with the condition to adhere to a strictly gluten-free diet for 
life, and partly because CD has become an exemplar of autoimmune disease. It has 
a known trigger (gluten), the mechanism of injury induced by that trigger has been 
well characterised, in the majority of patients much of the harm caused is reversed 
on removal of the trigger, and many of the genetic prerequisites for developing the 
condition have been identified. It is also one of the most common autoimmune 
conditions, and its prevalence is increasing, and it is seen by many as a condition 
that has the potential to unlock at least some of the mysteries of autoimmune 
disease more generally.61 Ovid Medline searches on “coeliac disease” and “celiac 
disease” elicit many thousands of articles covering a vast array of research into the 
condition. Every year several hundred more titles are added. Similarly, a Google 
Scholar search (in April 2016) for only those articles with either “coeliac disease” 
or “celiac disease” included in the title generated a list with over 12,000 hits. At the 
time of searching, 183 of these articles had been added in 2016.  
2.1.1 Search strategy 
Given the huge amount that has been published on CD, material for this chapter was 
gathered in a range of ways, starting with review articles in the major medical 
journals.5-7,62-66 New reviews were added as these were published during the course 
of this project.8,9,11 Frequently cited references from these articles were followed-
up and reviewed. In addition to this, key journals including Gut, Gastroenterology, 
The American Journal of Gastroenterology, Clinical Gastroenterology and Hepatology, 
The Journal of Pediatric Gastroenterology and Nutrition, and Alimentary 
Pharmacology and Therapeutics, were searched. Special editions relating to CD that 
featured in the journals Seminars in Immunopathology, and Best Practice and 
Research Clinical Gastroenterology, were also consulted, and searches were made 
for publications by known experts in the field. As guidelines documents became 
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available, these too were consulted.12,67-72 For any work retrieved, references cited 
were reviewed, and those that were of particular relevance to this project were also 
obtained. Ovid Medline searches on specific sub-topics were also conducted, but the 
primary focus of literature selected for this review largely remained on key authors 
and/or key journals. As this project spanned several years, these search processes 
were repeated every six to twelve months. 
2.2 The History of Coeliac Disease 
As with many conditions, CD has its origins in antiquity. This is not unexpected 
given that wheat, the principal source of gluten, has been a part of the human diet 
for millennia. Approximately 10,000 years ago, in the Neolithic period, humankind 
began the transition from living in small, nomadic, predominantly hunter-gatherer 
groups, to settling in larger agriculture-based communities.73 At about this point in 
time the cultivation of wheat began in the area known as the Fertile Crescent, a 
sweep of land in the region of Egypt and Mesopotamia and incorporating the Tigris 
and Euphrates rivers. This led to an increasing dietary dependence on wheat (and 
the related grains barley and rye), opening the way for CD (and other wheat-
induced conditions) to develop. In fact, this represents what some have described 
as an “evolutionary paradox”,74(p.1) given that CD (especially when it is untreated) 
renders those with the condition weak and ill, and sometimes infertile. Where this 
might have been expected to exert evolutionary pressure against the continuation 
of the condition, CD remains prevalent across the globe, including in countries in 
Europe and the Near East that have “long histories of wheat agriculture”.74(p.1) It 
has been postulated by some, such as Abadie et al.75 and Lionetti et al.,76 that this is 
a consequence of advantageous immune reactions also conferred on those early 
communities by the components of the immune system responsible for CD. 
The first written description of what is generally accepted to be CD comes from 
the noted physician Aretæus of Cappadocia, who lived and wrote in the second 
century CE (or possibly the first, the dates are contested).77 What remained of his 
work was translated into English by Francis Adams, and published in 1856 by the 
Sydenham Society of London.78 In Chapter VII, Book II of On the Causes and 
Symptoms of Chronic Disease, Aretæus describes “the Coeliac Affection”. (Coeliac 
here has been translated by Adams from the Greek κοιλιακός, which also means 
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abdominal or “of the bowels”.) He wrote that this was a “very protracted and 
intractable illness” in which: 
The stomach being the digestive organ, labours in digestion, when 
diarrhoea seizes the patient. Diarrhoea consists in the discharge of 
undigested food in a fluid state; and if this does not proceed from a slight 
cause of only one or two days’ duration; and if, in addition, the patient’s 
general system be debilitated by atrophy of the body, the Coeliac disease 
of a chronic nature is formed…78(p.350) 
He went on to describe the range of symptoms he had observed, namely that “the 
bowels rumble, evacuations are flatulent, thick, fluid or clayey”; that the patient may 
experience “heavy pain of the stomach now and then”; and that he or she was 
“emaciated and atrophied, pale, feeble, incapable of performing any of his 
accustomed works.” In addition to this, he noted that “[t]his illness is familiar to old 
persons, and to women rather than men”.(p.351) The predominance of CD as an 
illness affecting women continues to this day, and there is evidence that it is a 
condition that ought not to be overlooked in the elderly, as its incidence among this 
group is increasing over time.79,80 And while some, such as Schuppan et al.,81 
comment that Aretæus related the condition to diet (which is now known to be 
true), this needs to be considered in the context in which Aretæus was practising 
and writing. At that time one of the principal explanations for disease was that it 
was caused by a disruption of the balance that existed between “pneuma” and “the 
humors”. Dietary deficiencies were believed to be one of the leading factors in such 
disequilibrium occurring, thus in treating the majority of the sick there was “above 
all, an emphasis on dietary regimen.”77(p.32) 
That CD has an ancient history is supported by the discovery in 2008 of the 
remains of a young woman who lived in Cosa, Italy, in the first century CE.82 She was 
short and had fragile bones, and the enamel on her teeth was poorly formed. It is 
likely that she had suffered from severe malnutrition. She had lived in a region in 
which the economy was based on olives and wheat, and when her remains were 
recovered, it was hypothesised that she had had CD. It was postulated that the 
wealth of her family, as evidenced by the quality of her tomb and by the jewellery 
with which she had been buried, had ensured that she had a “good amount of wheat 
in her diet”.(p.502) Hers are the only remains found at the site that showed evidence 
of malnutrition, and subsequent work on her DNA conducted by the team who 
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discovered her detected the presence of Human Leukocyte Antigen (HLA) DQ2.5, 
one of the genetic haplotypes associated with CD.83 
Following Aretæus, it was not until 1888 that CD once again featured in the 
medical literature, when Dr Samuel Gee published in the St Bartholomew’s Hospital 
Reports the text of a lecture “On the Coeliac Affection” that he had given the previous 
year.84 It is generally accepted that he chose his title with Aretæus (and perhaps 
also his translator, Adams) in mind.85 In their respective histories of CD, both 
Dowd85 and Paveley84 note that Gee was the first person to signal that CD affected 
people of all ages, and that it was “especially apt to affect children between one and 
five years old.”84(p.1646) Gee’s very careful description of the condition, 
reproduced by both authors, is as follows: 
There is a kind of chronic indigestion which is met with in persons of all 
ages…Signs of the disease are yielded by the faeces; being loose, not 
formed, but not watery; more bulky than the food taken would seem to 
account for; pale in colour, as if devoid of bile; yeasty, frothy, an 
appearance probably due to fermentation; stinking,…the food having 
undergone putrefaction rather than concoction.84(p.1646),85(p.46) 
In addition to this he noted that children with the condition were pale and weak, 
with muscle wasting,85 observations that are consistent with malnutrition. And 
although the cause of CD was still more than 50 years away from being identified, 
Gee’s clinical instinct was that treatment of the condition resided with dietary 
interventions. He experimented with putting his patients on a range of diets, 
including one child “who was fed upon a quart of the best Dutch mussels daily” and 
“throve wonderfully” until the season was over. Perhaps not surprisingly the child 
refused to go back to this diet the following season, and Gee commented in his paper 
that this was “an experiment I have not yet been able to repeat.”84(p.1647) 
Following Gee’s description of CD, interest in the condition slowly and steadily 
increased, as discussed by Paveley and, among others, Auricchio and Troncone,60 
Losowsky,86 and Tommasini et al.87 Each of these writers begins their narrative with 
Aretæus and moves on to Gee. From there they trace similar paths, summarised on 





•R.A. Gibbons reports on the coeliac affection in children, describing four cases he had managed 
with diets in which "farinaceous foods" were to be limited, as recommended by Gee. He suggests 
that "a functional disturbance of the nervous supply" of the abdominal organs is cause of the 
disease.84 (p.1647)
1903
• W.B. Cheadle gives a lecture at St Mary's Medical School in which he discusses a condition called 
"acholia", so named because of the very pale stools which suggest an absence of bile. He 
speculates that "difficult dentition" might play a role in the aetiology of the condition.84 (p.1647)
1908
•C.A. Herter postulates that chronic inflammation of the intestine due to overgrowth of intestinal 
flora is to blame, and coins the name "Intestinal Infantilism" (after bacillus infantilis). He is the 
first to write of the condition in the US literature, and suggestes that carbohydrates are less well 
tolerated than proteins and fats.60,86
1918 
•G.F Still gives a series of lectures in London about "coeliac disease or intestinal infantilism, name 
it what you will", in which he draws attention to the "surprising inconsistence of the child's size 
with its age".84 (p.1647) He notes in particular that bread is poorly tolerated.84,86
1921
•J. Howland delivers an address to the American Pediatric Society on the "Prolonged Intolerance to 
Carbohydrates"', including a case presentation of a child with similar symptoms to those earlier 
described by Herter. He recommends a diet which "rigourously excludes" carbohydrates, instead 
relying on proteins as the primary source of nutrition.88
1924
•S. Haas promulgates "the banana diet" on the back of heavy promotion of bananas by the United 
Fruit Company (UFC), which had included multiple endorsements from the medical profession 
about their nutritive value. For children with CD he advocates a diet restricted to a small range of 
protein sources, and several bananas a day. He becomes closely allied with the UFC.84,88
1940s
•W. Dicke makes the link between "Gee-Herter's Disease" (CD) and wheat. He publishes his first 
report on the wheat-free diet in 1941, based on experiments he had conducted in the 1930s. The 
outbreak of war and ensuing grain shortages in Holland confirms his theory.60 In the US the war 
leads to a banana shortage, impacting celiac children following Haas' diet.84,88
Early 1950s
•W. Dicke and J. van de Kamer develop a technique for measuring faecal fat content. They also 
identify gliadin as the component of wheat which is toxic in CD. In 1952 in the UK C. Anderson et 
al. confirm the link, replicating work by Dicke (not published in English until 1953), measuring 
changes in faecal fat content with diet.60,84,86,87 The GFD as treatment emerges.
Mid- to Late 
1950s
•J.W. Paulley confirms characteristic histological changes of CD in samples taken from patients at 
laparotomy. In 1956 M. Shiner develops a "biopsy tube" for obtaining duodenal samples. In 1957
W.H. Crosby and H.W. Kugler develop the more flexible Crosby Capsule; J.M. French links adult 
ideopathic steatorrhoea to CD when he observes patients recovering on a wheat-free diet.60,84,86
1960s and 
beyond
•With the identification of antibodies to gliadin, endomysium, and tissue transglutaminase, and 
the recognition of specific genetic markers, CD is redefined as an inherited autoimmune disease. 
The ability to test for the presence of these antibodies, and the advent of flexible endoscopy 
revolutionises the diagnostic process. The search for alternative treatments continues ...
Figure 2-1: The course of CD from Gee to the present day 
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An additional player not mentioned by these writers but discussed by Emily 
Abel,88 is Luther Emmett Holt, a North American paediatrician of the late nineteenth 
and early twentieth centuries. While Gee might be considered the father of modern 
discussions of CD in Europe and the UK, it was Holt, as Professor of Diseases in 
Children at the Babies’ Hospital of the City of New York, and as one of the 
inaugurators of the Rockefeller Institute of Medical Research, who drove North 
American progress in trying to understand and better manage the condition. What 
Gee had referred to as the coeliac affection, Holt called “chronic intestinal 
indigestion”. His descriptions of children with the condition mirrored Gee’s, and 
while he did not undertake research into the disease himself, he encouraged Herter, 
Howland, and Haas to do so.88(p.6) 
2.2.1 What is gluten? 
One of the most crucial steps in unlocking the puzzle of CD was made by Willem 
Dicke,89 when he identified wheat as the trigger for the clinical signs he observed in 
his patients. Together with his colleagues Jan van de Kamer and others, he followed 
this by isolating gluten (and in particular the gliadin fraction) as the harmful 
constituent of wheat.90 
Gluten is the major storage protein in wheat, comprising approximately 80% 
of the total grain protein (which in turn constitutes between 8-15% of the grain, 
depending on its variety).73,91 Gluten itself has two principal components – the 
alcohol-soluble gliadin monomers, and the alcohol-insoluble glutenin polymers, 




Figure 2-2: Constituents of wheat gluten 
* Low- and high-molecular-weight, respectively 
The gliadins and LMW glutenins are all rich in the amino acids proline and 
glutamine, and it is this aspect of their make-up that renders them toxic to patients 
with CD. The α- and ω-gliadins contain the highest number of proline residues and 
are known to be the most immunogenic of the prolamins (the collective name for 
alcohol-soluble, proline- and glutamine-rich peptides). The HMW glutenins contain 
less proline, and would also seem to be less harmful to CD patients.92 Proteins that 
are high in proline are relatively resistant to digestion (proteolysis) in the small 
intestine, resulting in moderately large peptide groups remaining in the lumen.5,93 
As discussed in more detail in a later section of this chapter, in susceptible 
individuals, these peptide molecules are the progenitors of the CD pathogenic 
process. 
Gluten is also the collective name given to the principal storage proteins found 
in rye and barley, which are also toxic to people with CD. In the past this group also 
included oats. The secalins in rye, and the hordeins in barley are analogous to the 
gliadins in wheat, and they too are rich in proline and glutamine. Both these grains 
are closely related to wheat, having evolved from a common ancestor in the grass 
family.91 Oats are more distantly related to wheat, and their potential toxicity in CD 
remains contested. The storage proteins in oats are the avenins, and while they have 
some similarities to the gluten proteins of the other grains already discussed, their 
differences outnumber these. Additionally, avenins form a much smaller portion of 












rye and barley.94 While it is recognised that a small percentage of people with CD 
(perhaps 5%) are truly sensitive to oats, it is generally accepted that the toxicity 
attributed to oats in the past was likely to have been due to wheat contamination.95 
2.2.2 The Coeliac enteropathy 
As alluded to in Figure 2-1, in the mid-1950s J.W. Paulley confirmed that patients 
with idiopathic steatorrhoea (later to be recognised as adult CD) displayed a typical 
pattern of histological changes in their intestinal mucosa.96 These changes had been 
noted for some time in autopsy samples, but it was not clear whether they were 
genuine markers of CD, or if they were a post mortem artefact of autolysis.86 Using 
tissue obtained from steatorrhoea patients undergoing laparotomy, Paulley was 
able to demonstrate that the changes that had been previously observed were 
indeed present in patients with symptoms akin to those earlier described by Samuel 
Gee. He described finding evidence of “chronic inflammation of the jejunum”, and 
detailed his observations further: 
The steatorrhoea villi were approximately double the width of the 
controls. Other obvious differences are in the shape and cellularity of the 
villi, the presence of large numbers of inflammatory cells in the mucosa… 
In one case he noted that 
[t]he inflammatory process had advanced to a stage of atrophy and 
fibrosis, and the villi were short and thick…and the delicate conifer-like 
appearance of the normal jejunal mucosa…was missing.96(p.1321) 
These appearances of mucosal inflammation quickly became acknowledged as 
typical in such patients, and by 1958, following the advent of instruments enabling 
per-oral biopsies to be taken from the jejunum, W.T. Cooke was describing 
“mucosal, mainly villous atrophy affecting the jejunum” as “the characteristic 
feature of adult coeliac disease.”97(p.263) 
The histological features of CD identified by Paulley, Cooke and others remain 
at the centre of descriptions of the condition today, albeit in more nuanced forms. 
Over time it has become appreciated that there is a spectrum of change that can be 
seen at the histological level, just as it has also been clearly established that there is 
a spectrum of symptoms with which patients present.98-101  
There are now three established classification systems for grading histological 
changes. The first to be developed was by Michael Marsh in the early 1990s.102 
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Marsh was motivated by the desire to add rigour to the process of describing 
mucosal changes in the biopsies of CD patients and, as he has written more recently, 
by the hope that to do so might lead to renewed interest in the underlying 
pathogenic processes at work.103 He strongly advocated for a system that took 
account of the spectrum of observable histopathological changes, which he grouped 
according to the degree of mucosal damage detected. As he put it in his original 
paper, he “arbitrarily” labelled these groupings “infiltrative, hyperplastic, and 
destructive (flat)”.102(p.338) The determinants of damage that were to be routinely 
noted under his proposed classifications were the numbers of intraepithelial 
lymphocytes (IELs), and the architecture of the crypts and villi present in biopsy 
specimens. Marsh suggested two additional labels: “pre-infiltrative” for those 
biopsy samples that were indistinguishable from normal but had come from 
patients with other gluten-sensitive conditions (usually dermatitis herpetiformis); 
and “hypoplastic” for the most severely damaged mucosa, arising in patients 
unresponsive to treatment with the GFD.102 This lesion is mostly irreversible and 
strongly associated with intestinal lymphoma. 
The Marsh classification system was adopted by pathologists until 
modifications were proposed in 1999 by Oberhuber et al.,104 who sought to simplify 
the system while at the same time allowing for more discrimination of findings at 
the severe end of the spectrum. They also included numeric values for what 
constituted increased IELs, including in their discussion paper a description of how 
they had arrived at their suggested cut-off figure of 40 IELs per 100 epithelial cells 
(EC).104(p.1186) Their recommendations were widely embraced and the “Marsh-
Oberhuber” (or “Modified Marsh”) system became the classification system of 
choice.  
In 2005, a third method of classification was proposed by Corazza and 
Villinacci, to “make the work of pathologists more uniform and to facilitate the 
relationship between pathologists and clinicians.”105(p.574) In the intervening 
years between the release of Oberhuber’s paper and their own work, they reported 
that the accepted upper limit of normal for numbers of IELs per 100 ECs had been 
reduced, from 40 to 25, so they incorporated this change into their classification 
system. A review paper aimed at pathologists published the following year 
indicated that 30 IELs per 100 EC might be a preferable limit,106 but a subsequent 
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parallel serology and histopathology study by Walker et al.107 has confirmed that 
>25 IELs/100 ECs “is the likely cut off for abnormality”.(p.117) 
Corazza, Villinacci, and colleagues followed up the introduction of their revised 
classification with a study that compared the inter-rater reliability of their system 
and the Marsh-Oberhuber system.108 They had six pathologists use each system to 
evaluate 60 duodenal biopsy samples on two separate occasions. They found that 
where the Marsh-Oberhuber classifications afforded only a fair degree of 
comparability between users (mean kappa 0.35), their own system led to a 
moderate degree of concordance (mean kappa 0.55). Despite this, the Marsh-
Oberhuber system remains in use, alongside that developed by Corazza.  
The three classification systems are compared and contrasted on the following 




Table 2.1: Systems for describing intestinal mucosal changes seen in coeliac disease 
Marsh102 Marsh-Oberhuber104 Corazza105 
Type 0: Pre-infiltrative 
Normal mucosal architecture 




<40 IEL/ 100 EC 
Normal 
Type 1: Infiltrative 
Normal mucosal architecture 





>40 IEL/ 100 EC 
Non-atrophic: Grade 
A 
Isolated increase in 
IELs  
(>25 IEL/ 100EC) 
Type 2: Hyperplastic 
Enlarged crypts 




>40 IEL/ 100 EC 
Type 3: Destructive 
Flat mucosa 
Infiltration with IELs of 
varying morphology 
Type 3a 
> 40 IEL/ 100 EC 
Hypertrophic crypts 
Mild villous atrophy 
Atrophic: Grade B1 
> 25 IEL/ 100 EC 
Villous Crypt ratio < 3:1 
Detectable villi 
Type 3b  
> 40 IEL/ 100 EC 
Hypertrophic crypts 
Marked villous atrophy 
Type 3c 
> 40 IEL/ 100 EC 
Hypertrophic crypts 
Total villous atrophy 
Atrophic: Grade B2 
> 25 IEL/ 100 EC 
No detectable villi 
Type 4: 
Hypoplastic/Atrophic 
Complete absence of normal 
architecture consistent with 




Normal IEL counts 
Flat mucosa 





A fourth system, which is a hybrid and modification of the classifications 
featured in Table 2.1, has been proposed more recently by Ensari.109 However, it 
does not seem to have been widely adopted, and the Marsh-Oberhuber system 
generally remains the most utilised.110 
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Additional histopathological features of CD, which do not feature in any of the 
classification systems discussed, have also been identified. These include reduced 
numbers of goblet cells, thickening of the basement membrane, changes to the 
enterocytes themselves, and an increase in plasma cell density in the lamina 
propria.106,110,111 
It should also be noted that along with the typical histological features of CD, 
many patients will also display changes in the duodenum, visible at endoscopy. 
These include mucosal fold loss, and nodularity, scalloping, and fissuring of the 
mucosa. In severe cases the mucosa may have a mosaic appearance. These findings 
occur variably, therefore their presence cannot be relied upon to confirm the 
diagnosis without the need for biopsy, and nor can their absence be regarded as 
evidence that the patient does not have CD.112 
Recently Marsh, Johnson, and Rostami have reignited debate about these 
classification systems,113 in a rebuttal of Oberhuber’s revisions, which they describe 
as “untenable”.(p.99) This has sparked a flurry of argument and counter-argument 
about the merits of each system,114-118 but it remains to be seen if this will lead to 
substantive change in practice. What should not be lost sight of is that CD cannot be 
diagnosed on biopsy alone, given that the histological features described, 
particularly those at the mild end of the spectrum, can also occur in a range of other 
conditions. These include drug-induced changes (especially due to non-steroidal 
anti-inflammatory drugs and proton pump inhibitors), infection (particularly with 
Helicobacter pylori), other food protein allergies, other autoimmune disease, and 
inflammatory bowel disease (IBD).70,119-121 As Dickson has written: 
In the interest of the patient, the diagnosis of coeliac disease is most 
soundly achieved through candid communication between the clinician 
and the pathologist. It necessitates incorporating details of the patient’s 
history and adjunct investigations, with the histopathological 
assessment of the small bowel mucosa.106(p.1014) 
2.2.3 Coeliac antibodies 
The discovery in the late 1950s and 1960s that people with CD produced antibodies 
to gluten marked the beginning of a new era of understanding about the nature and 
aetiology of the condition, more clearly implicating the immune system in its 
genesis.86 Soon afterwards, the conception of CD as being immune-mediated 
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expanded, with the identification of auto-antibodies, first to reticulin and then to 
endomysium – both constituents of connective tissue, and both being gluten-
dependent.87 Anti-jejunal antibodies were also identified, although they would 
appear not to have been pursued beyond recognising that they occur.122 Then, in a 
breakthrough discovery in 1997, Dieterich et al.123 identified tissue 
transglutaminase-2 (tTG) as the autoantigen being targeted in the smooth muscle 
endomysium of the small bowel. Alongside all of these discoveries, the capacity to 
test patients for the presence of these antibodies evolved, opening the way to earlier 
recognition of greater numbers of patients with CD than was possible when the only 
test available was the jejunal (or duodenal) biopsy.124 More recently antibodies to 
deamidated gliadin peptides (DGP) have also been recognised, and a test developed 
that enables these too to be measured.124 
Of the antibody tests that emerged over the years, those that have been utilised 
most extensively in clinical practice are tests for anti-gliadin antibodies (AGA), anti-
endomysial antibodies (EMA), and anti-tTG antibodies.122,124,125 In the present day, 
DGP antibody testing is also gaining an increasing role.126 The following table 
presents key attributes of each of these tests, summarised from several 




Table 2.2: Coeliac antibody test characteristics 
Test Description125 Sensitivity Specificity 
AGA An ELISA* test using gliadin 
extracts as its substrate. 
Can be automated. 






IgG: 76% to 
88%.122 
IgA: 85% to 
94%. 
IgG: 88% to 
92%.122 
EMA Relies on indirect 
immunofluorescence, which 
needs interpretation by the 
test operator. Expensive. 
Uses either monkey 
oesophagus (MO) or human 
umbilical cord (HU) as its 
substrate; both difficult to 
source. 
Usually Ig A-based, but IgG 
tests sometimes available.  
IgA: (Pooled) 
93% (95% CI 
92.1 – 93.8%);  






99.7% (95% CI 
99.5 – 99.8%); 
 MO 99.3% in 





An ELISA test, using either 
guinea pig liver (gp) or 
human recombinant (rh) 
tTG extracts as substrate. 
Most now use rh, as 
sensitivity and specificity 
both higher. 
IgA and IgG tests available. 
Test kits produced by a 
number of different 




93% (95% CI 
91.2 – 94.5%)129 
IgG: >70% 
(Range 54.7 – 





96.5% (95% CI 
95.2 – 97.5%)129 
IgG: >90% 






An ELISA test, using 
synthetic peptides.  
IgA and IgG tests available.  
May be detected earlier 
than anti-tTG antibodies in 
some patients. 
May be more accurate in 
children, especially those 
under two years old. 
IgA: (Pooled) 
87.8% (95% CI 
85.6 – 89.9%)129 
IgG: >80%;124 
(Range 80.1 – 
98.6%)127 
IgA: (Pooled) 
94.1% (95% CI 
92.5 – 95.5%)129 
IgG: >95%;124 
(Range 90.3 – 
100%)127 
* ELISA – Enzyme linked immunosorbent assay 
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There is some evidence to indicate that the performance of these antibody tests in 
the “real world” is less impressive than “research world” studies would 
suggest,130,131 and that this varies between kits produced by different 
manufacturers. Not surprisingly, there is also evidence that the greater the degree 
of villous atrophy, the more sensitive will be the antibody tests.125,129 
As will be discussed in more depth in section 2.9 of this chapter, all current 
guidelines recommend that IgA-tTG antibodies should be the first-line test for CD, 
either singly,69,72,132 or in combination with EMA or anti-DGP antibodies.70 Tests for 
AGA have become largely obsolete due to their comparatively inferior sensitivity 
and specificity in detecting CD,22 including in young children in whom they were 
previously thought to be more reliable.133 Some do suggest that AGA assays may 
have a place in the detection of gluten ataxia, and non-coeliac gluten 
sensitivity.134,135  
2.3 Classifying and Defining Coeliac Disease 
In 1993 Ferguson et al. published a “Leading article” in Gut, on the “Clinical and 
pathological spectrum of coeliac disease – active, silent, latent, and potential.”99 This 
was one of the first pieces to be written that formally classified CD into these 
subgroups, although the terms had been appearing sporadically in the literature 
before that time. The article focused largely on the histopathological subtleties, and 
the “several forms of coeliac disease”(p.150) emerging as the CD diagnostic net 
widened to include people without the symptoms of classical CD (as previously 
described by Gee). They described “so called active coeliac disease”, which 
encompassed “malabsorption, and nutritional deficiencies” ranging “from profound 
to minimal”, and referred to “clinically silent coeliac disease” as disease that was 
being identified by testing people such as the families of existing CD patients.(p.150) 
This they reported as being on the increase. Together, active and silent disease 
comprised what they called “fully expressed” gluten sensitive enteropathy. “Latent 
CD” was a term that they suggested should be limited to very specific situations, 
namely to describe patients who had “a normal jejunal biopsy while taking a normal 
diet” but who at some point had had or would have “a flat jejunal biopsy which 
recover[ed] on a gluten free diet”.(p.150) They argued that even subtle 
abnormalities (such as high IEL counts) on biopsy samples taken while the patient 
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was on a normal diet would require the diagnosis to “be revised from latent to low 
grade or mild gluten sensitive enteropathy”. An alternative label they suggested for 
this group was “potential coeliac disease”.(p.151) 
In the years since this paper was published, the terms Ferguson et al. suggested 
have been variably applied, and the subject of much discussion. Other descriptors 
have also emerged including typical, atypical, symptomatic, asymptomatic, overt, 
and subclinical. It is these sub-classifications that exemplify some of the 
complexities of the disease in the twenty-first century. The following table 
compares the classifications used to describe CD in its various forms in review 
articles from some of the leading journals since the late 1990s. (Table 2.3) 
Table 2.3: CD Classifications used in the recent past 
Author CD Classifications utilised 
Maki & Collin (Lancet, 1997)63 Clinical 
Silent 
Latent 





Green & Jabri (Lancet, 2003)64  Classic 
Silent 
NIH Consensus Development 







Green & Cellier (NEJM, 2007)5  Symptomatic/ active/ classic 
Asymptomatic or silent 
Latent 
Hopper et al (BMJ, 2007)6 Typical/ classic 
Atypical or silent 
Potential 









In separate efforts to tackle the issue of defining CD, two panels were convened 
in 2011. One (the Oslo group)22 took CD “and related terms” as its primary focus, 
while the other (Sapone et al.)134 took a broader view and considered the “spectrum 
of gluten-related disorders”, among which is CD. Both panels (which included 
several of the same CD experts) sought to bring order to the array of terms being 
used to describe CD and other gluten-induced clinical entities. Each group published 
the outcome of their work in 2012, in which year ESPGHAN also published its 
updated guidelines for the diagnosis of CD in children.12 The ESPGHAN document 
also included definitions of CD, which are discussed here. Their diagnostic 
guidelines are discussed more fully in the next section of the chapter. 
The Oslo group was particularly concerned with the variability of definitions 
being used in research (especially with regards to CD) and the impact that this could 
have on how such research is conducted and reported.22 The panel was convened 
ahead of the International CD Symposium which was held in Oslo in June of 2011. 
Between them panel members conducted an extensive literature review, completed 
a web-based survey of proposed definitions, and participated in multiple 
discussions (both face-to-face in Oslo, and via phone conferences), before arriving 
at a consensus on a principal definition of CD, and on the definitions of the sub-
classifications of CD that they believe should be routinely in use. They also 
formulated definitions for other gluten-related conditions that have emerged in 
recent decades, and identified a number of terms (including some listed in Table 
2.3) that they believe should be removed from regular clinical parlance.  
Sapone et al.134 were focused on setting CD within the broader context of 
gluten-related disease, and clarifying the nomenclature to be used when 
considering the range of conditions this comprises, in order to assist health care 
professionals grappling with the surge in “individuals embracing a gluten-free 
diet”.134(p.1) The group met in London in February 2011, and developed a series of 
consensus statements, derived from the literature and from the outcomes of their 
discussions on the range of topics each member had been assigned to present.  
The ESPGHAN group, which had begun its work in 2007, had a primary aim of 
updating the available guidelines “to achieve a high diagnostic accuracy and to 
reduce the burden for patients and their families.”12(p.136) Defining CD was a 
necessary part of this task, but not their major objective. 
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The principal definitions of CD that each group advanced are the least 
controversial aspect of the work that they undertook, and are therefore reasonably 
similar. In referring to the condition, the Oslo group discouraged the continued use 
of historical terms such as sprue, coeliac sprue, non-tropical sprue, and idiopathic 
steatorrhoea.22 They also recommended against the use of the labels “gluten-
sensitive enteropathy” and “gluten intolerance”.(p.45) Instead they suggested that 
the condition always be referred to as “coeliac disease”, defined as “a chronic small 
intestinal immune-mediated enteropathy precipitated by exposure to dietary 
gluten in genetically predisposed individuals.”22(p.43) Similarly, Sapone et al. 
defined CD as “an immune-mediated enteropathy triggered by the ingestion of 
gluten in susceptible individuals."134(p.4) Meanwhile, the ESPGHAN group, which 
gave the most comprehensive of the three descriptions, defined it as: 
…an immune-mediated systemic disorder elicited by gluten and related 
prolamines in genetically susceptible individuals, characterised by the 
presence of a variable combination of gluten-dependent clinical 
manifestations, CD-specific antibodies, HLA-DQ2 and HLA-DQ8 
haplotypes, and enteropathy.12(p.140) 
Where the groups differed more substantively however, is in their sub-
classifications of CD.  
The “Oslo Definitions” paper is devoted almost exclusively to CD,22 and focuses 
entirely on providing definitions for the range of sub-types of the condition that 
they identify. These are therefore more extensive than those given by Sapone et 
al.,134 and by the ESPGHAN group,12 which dedicates most of its publication to its 
practice guidelines. The Oslo definitions include terms that are recommended for 




Table 2.4: CD Descriptors from the Oslo Definitions 
Recommended descriptors of CD Descriptors not to be used 
Classical CD: presents with signs and 
symptoms of malabsorption 
Typical CD: not recommended because 
it has tended to refer to “classical” CD, 
but also implies that this is the most 
common form, which is not the case. 
Non-Classical CD: presents without 
signs and symptoms of malabsorption 
Atypical CD: implies that this is a less 
common form of presentation, 
contrary to what is now known. 
Symptomatic CD: identifiable 
symptoms of CD (either 
gastrointestinal or extraintestinal) 
attributable to gluten intake. 
Overt CD 
Asymptomatic CD: no identifiable 
symptoms even on direct questioning 
and on removal of gluten from the diet. 
Silent CD: has been used to describe 
asymptomatic and subclinical CD, 
(and, by Green,64 to describe atypical 
disease) which are not synonymous 
with each other, so risks confusion.  Subclinical CD: CD which is “below 
the threshold of clinical detection 
without signs or symptoms sufficient 
to trigger CD testing in routine 
practice.”(p.46) 
Latent CD: has been used to describe 
several different variants of CD 
ranging from undiagnosed CD, to the 
definition intended by Ferguson et al.99 
described above, to include patients 
with CD diagnosed sometime after 
diagnosis with another autoimmune 
condition. Too imprecise to be 
meaningful. 
Potential CD: normal duodenal 
histology in the presence of elevated 
CD antibodies, indicating increased 
risk of developing CD. 
 
Refractory CD is also defined, as “persistent or recurrent malabsorptive symptoms 
and signs with villous atrophy (VA) despite a strict GFD for more than 12 
months”.22(p.46) And there is a series of definitions relating to tests associated with 
CD, and for other gluten-related disorders.  
Taking “Gluten Related Disorders” as their start point, Sapone and her team 
subdivided these on the basis of pathogenesis.134 They classified CD as one of three 
autoimmune-mediated gluten-related diseases, along with Dermatitis 
Herpetiformis and Gluten Ataxia. Coeliac disease was further divided into 
“Symptomatic”, “Silent”, and “Potential” sub-types. (Note the continued use of 
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“silent”, in contrast to the Oslo recommendations.) These labels are enlarged upon 
in the text as follows: 
The clinical spectrum of CD is wide…and includes symptomatic cases 
with either classical intestinal (for example, chronic diarrhoea, weight 
loss) or non-classical extraintestinal (for example, anemia, osteoporosis, 
neurological disturbances) features and silent forms that are 
occasionally discovered by use of serological testing.134(p.4) 
“Potential CD” was said to be the diagnosis in patients who are auto-antibody 
positive but who are found to have normal intestinal mucosa on biopsy.(p.4) Sapone 
et al. also included detailed discussion about the other gluten-related conditions 
(wheat allergy and non-allergic, non-autoimmune gluten sensitivity), providing up-
to-date information about the epidemiology, pathogenesis, clinical presentations, 
and diagnosis of each.  
Following their detailed overarching definition of CD, the ESPGHAN also 
included nomenclature to differentiate sub-types of the condition.12 They described 
five sub-types, two of which are at odds with the Oslo group recommendations. 
Their classifications are as follows: 
1) CD with gastrointestinal symptoms and signs; 
2) CD with extra-intestinal symptoms and signs; 
3) Silent CD: positive CD-specific antibodies, positive HLA, positive 
biopsy, but insufficient symptoms and signs to have aroused clinical 
suspicion; 
4) Latent CD: compatible HLA and normal biopsy in someone with 
previous gluten-dependent enteropathy; may or may not have 
symptoms and/or positive antibodies; 
5) Potential CD: positive CD-specific antibodies, compatible HLA, negative 
biopsy; may or may not have symptoms and may or may not go on to 
develop enteropathy in the future.12 (p.140) 
Thus, despite the best efforts of several of the leading CD researchers and 
clinicians from around the world, consensus on descriptions pertaining to the 
varying clinical manifestations of the condition remains elusive. This point was 
highlighted in an editorial piece by Mäki,137 (another CD expert who was on neither 
consensus panel but who was in the ESPGHAN working group), and is further 
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evident in publications that have followed the release of each of the three 
documents discussed.  
In a Letter to the Editor of Gut published alongside the Oslo paper,138 Di 
Sabatino and Corazza queried the appropriateness of describing as “non-classical” 
the extra-intestinal manifestations of the disease that have been recognised since 
the 1960s. As a way of circumventing the issue of whether a symptom is truly 
classical or non-classical (or typical or atypical), they suggested a return to the 
terms “major” and “minor” disease, which they had previously proposed.7 Marsh 
similarly registered his unhappiness with the Oslo definitions,139 arguing against 
their exclusion of some terms (such as latent CD, and gluten sensitivity), while 
questioning their choice of others (such as chronic, instead of lifelong). Meanwhile 
Guandalini et al.,140 having acknowledged that the panels just discussed had been 
convened to “put order in this chaos” of “a babel of nomenclatures” surrounding CD 
(p.9), suggested yet another variant on a principal definition, recommending the 
sub-classifications silent, potential and latent.  
There is no immediately obvious solution to this issue, although Mäki has 
suggested that the way forward is to “focus on the patients and define who has a 
gluten-related treatable disorder”.137(p.306) He goes on to divide these into three 
categories: coeliac gluten sensitivity, non-coeliac gluten sensitivity, and wheat 
allergy. But there the sub-classifications stop. Mäki’s concern would seem to be that 
getting caught up in debates about whether to label people as having silent, latent, 
or potential CD (for example) results in under-treatment. His view is that people in 
each of these categories should be treated by removing gluten from their diets, and 
he asks the question “[w]hy wait for end-stage disease?”(p.306), which is how he 
regards enteropathy. He is clearly advocating a more liberal interpretation of what 
constitutes treatable CD, which moves the discussion from a consideration of 
definitions and into the broader territory of diagnostic criteria. 
2.4 Diagnostic criteria for CD 
Alongside the clinical definitions of CD that have evolved over the years, specific 
diagnostic criteria have also been determined, bringing together its clinical and 
histopathological components. These have been promulgated by various 
professional bodies such as the ESPGHAN (who were the first),12,141,142 its North 
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American (NASPGHAN)143 and British (BSPGHAN)67 equivalents, the American 
College of Gastroenterology (ACG),69 the British Society of Gastroenterology 
(BSG),70,144 the United States’ National Institute of Health (NIH),62 and the World 
Gastroenterology Organisation (WGO).68,72 The UK National Institute for Health and 
Care Excellence (NICE) has also produced guidelines relating to the recognition and 
management of CD, which includes a brief direction about diagnosis,132 while the 
American Gastroenterological Association (AGA) has produced two “technical 
reviews” on its diagnosis and management.65,122 
The first acknowledged guidelines were issued by the European Society for 
Paediatric Gastroenterology (the group that became ESPGAN, and that is now 
known as ESPGHAN) following their 1969 annual meeting at Interlaken.141 These 
were “expert opinion” derived rather than strictly evidence-based, arising from 
consensus among the experts gathered for the meeting. In the paper released 
following the meeting,141 CD was defined as a “permanent gluten intolerance”, as 
evidenced by characteristic histological changes to the intestinal mucosa, obtained 
from biopsy of the duodenum or jejunum. To be certain of the diagnosis required 
three biopsies: the first to identify that changes were present; the second (one or 
two years later) to determine that these had resolved on a GFD; and the third to 
ascertain that they had recurred with the re-introduction of gluten. The second 
biopsy was deemed necessary to ensure that gluten was indeed the cause of 
enteropathy in the patient, while the third biopsy was regarded as necessary 
because “recurrence of disease…may even be silent.”(p.462) Thus the minimum 
criteria for reaching the diagnosis were “abnormal morphology of the small 
intestinal mucosa, its normalization on gluten withdrawal, and the reaction on 
reintroduction of gluten.”(p.462) The abnormal morphology to which they refered 
was characterised by “absent or almost absent villi”. As Lebwohl et al.145 have 
pointed out, these first diagnostic criteria made no reference to the presence (or 
otherwise) of CD-related antibodies in patients, which at the time was a newly 
emerging aspect of CD research. 
By 1990, with the release of the first formal revision of the Interlaken 
recommendations,142 the number of biopsies required to confirm the diagnosis had 
been reduced to one, to be performed on patients in whom CD was suspected, and 
who continued to consume gluten. While the presence of CD-specific antibodies in 
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the serum of a patient increased the likelihood of that patient having CD, having 
histological evidence of enteropathy was considered an absolute requirement for 
the diagnosis. Findings that were consistent with CD enteropathy (which predated 
the first Marsh criteria summarised in Table 2.1 on page 23) were defined as 
“hyperplastic villous atrophy with hyperplasia of the crypts and abnormal surface 
epithelium”,142(p.910) and an elevated IEL count. The second mandatory 
requirement was that patients showed demonstrable clinical improvement on the 
GFD “in a matter of weeks rather than many months”.(p.909) The need for a follow-
up biopsy was reserved for those patients who had been asymptomatic at the time 
of diagnosis (for whom resolution of symptoms on a GFD could not be used as a 
marker of improvement, and therefore as a proxy confirmation of the diagnosis), 
and for those who did not show the expected improvement after several months. 
This strategy was endorsed in subsequent recommendations intended for adult 
practice,62,65,68,122,144 and in the 2005 NASPGHAN paediatric guidelines,143 an 
evidence-based extension of the 1990 ESPGAN recommendations. In each of these 
guidelines Marsh 3 histological changes were regarded as diagnostic of CD, and 
Marsh 2 as “compatible with” CD subject to correlation with symptoms and 
serological evidence of disease. Marsh 1 findings were deemed not specific for CD.  
2.4.1 ESPGHAN 2012 
The CD diagnostic environment has become somewhat more contentious since 
2012, when the ESPGHAN released their revised guidelines.12 As had been 
undertaken by the NASPGHAN, the European group moved to an evidence-based 
process and, following this, controversially recommended that in certain contexts a 
biopsy is no longer required for the diagnosis. The criteria they provided for 
invoking this option, or at least discussing it as a possibility with the parents and 
child concerned, are set out in a comprehensive algorithm that is summarised here. 
In a child or adolescent with suspected CD, the diagnosis can be made without a 
biopsy if all four of the following criteria are met: 
1) the presence of symptoms and/or signs consistent with CD; 
2) a tTG antibody level that is 10 times the upper limit of normal for the 
test which has been used; 
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3) a positive EMA titre, drawn on a separate occasion from the initial tTG 
sample; 
4) positivity for either of the genetic markers HLA-DQ2 or DQ8. 
This last requirement is the most flexibly applied, and in the text of the guidelines 
document the authors wrote that it “is advisable to check for HLA types in patients 
who are diagnosed without having a small intestinal biopsy to reinforce the 
diagnosis of CD.”12(p.138) (My emphasis.) Confirmation of the diagnosis comes with 
the resolution of symptoms and with a fall in antibody levels, the corollary of which 
is that if these things do not happen then the issue of biopsy should be revisited. The 
guidelines team acknowledged that their revised recommendations do require “a 
period of implementation and testing”(p.154), and “should be evaluated 
prospectively.”(p.136)  
It is the lack of prospective data about the potential impact of observing the 
ESPGHAN’s recommended protocols that initially drew most comment, and which 
has led to a mixed response from guidelines groups since. At the time of completing 
this thesis (in late 2018), the updated BSPGHAN guidelines relating to CD in 
children in the UK (developed jointly with Coeliac UK),67 remain the only ones to 
promote the ESPGHAN processes. The NASPGHAN has yet to update its 2005 
guideline document, although Ivor Hill, one of the key authors of that document has 
gone on record urging caution in omitting the biopsy.146 He is particularly 
concerned about the reliability of CD tests in North America, both in terms of a lack 
of standardisation between test kits produced by different companies, and in the 
variability of results across different laboratories. Hill has reiterated this view in a 
2014 publication endorsed by the NASPGHAN,147 which makes it seem unlikely that 
that group will move to including a no-biopsy route to diagnosis in the foreseeable 
future. A more recent retrospective study by Elitsur and colleagues,148 in which 
records for children with CD from a number of North American clinical centres were 
reviewed with respect to how the diagnosis was reached, lends support to this 
position. 
Hill’s concerns have also been echoed by some with expertise in antibody test 
performance,149,150 who argue that attempts to compensate for the lack of 
standardisation of assays by trying to “harmonise” results using multiples of the 
upper limit of normal (ULN) cut-offs is “the wrong approach”.149(p.733) The 
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contention of Egner et al.149 (based on audit data they have collected) is that the 
same patients, tested using different kits at different laboratories, would experience 
different outcomes using the ESPGHAN algorithm, due to the performance 
characteristics of the tests and laboratories. On the basis of this they have suggested 
that the guidelines as they currently stand are not generalisable, and should instead 
be interpreted (and applied) in the light of local test-performance characteristics. 
Their work has been corroborated more recently by Paul et al.,151 who suggested 
that standardising anti-tTG assays (in this case in the UK) should be a priority if the 
ESPGHAN diagnostic criteria are to be successfully implemented. 
None of the more recent guidelines applying to adult patients have endorsed 
the ESPGHAN algorithms either. Instead they maintain the status quo that the gold 
standard for diagnosis is a duodenal biopsy demonstrating the changes typical of 
CD.69,70,132 This position has been defended by Kurien and colleagues on at least two 
different occasions.152,153 They base their defence on the following: that in the 
general population (as opposed to the often “CD-rich” research environment) the 
positive predictive value (PPV) of serology has been demonstrated to be not high 
enough to ensure that patients are not wrongly diagnosed with CD; that there are 
often other reasons that adult patients might require upper endoscopy anyway; that 
it provides an opportunity to assess the severity of the disease; and it “provides 
reassurance to the patient that the diagnosis is irrefutable, justifying the need for 
being gluten-free for life.”153(p.146)  
An additional concern with the ESPGHAN recommendations, which applies 
equally to diagnosing CD in children and adults, has been identified by Smarrazzo 
and colleagues.154 In one of the few prospective studies conducted to date, they 
investigated the diagnosis of CD across 13 Mediterranean countries and found that 
in countries with limited resources, not all tests required to fully adhere to the 
ESPGHAN protocol are available. All countries performed duodenal biopsies, and 
thus relied on these to confirm the presence of CD. These findings echo those of an 
earlier retrospective study by Tucci et al.,155 also conducted in several 
Mediterranean countries. 
However, the reluctance of the adult guidelines groups to incorporate a no-
biopsy option in their documents has also drawn criticism. Proponents of this 
option draw attention to the fact that biopsies also do not have a 100% PPV 
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(because of the patchy way in which mucosal lesions develop and because 
interpretation is dependent on specimens being correctly prepared), and cite 
increasing evidence that the diagnosis can be safely and reliably made without 
recourse to such an invasive procedure.156  
In fact, the ESPGHAN were not the first to propose a no-biopsy route to 
diagnosis. As early as 2003, Scoglio et al.157 asked the question “Is intestinal biopsy 
always needed for diagnosis of celiac disease?”, in a study in which they 
retrospectively examined correlations between antibody levels and biopsy results 
in a mixed population of adults and children. On the basis of their findings, they 
suggested that in select groups of patients, serial antibody testing with two different 
tests might obviate the need for biopsy to confirm the diagnosis. Barker et al.158 
undertook similar work in a paediatric population, concluding that in children with 
antibody levels significantly higher than the ULN of the test kits they were using, 
the diagnosis of CD could accurately have been made without a biopsy. In 2008 
Peter Hill,159 in a third study pre-empting the new ESPGHAN recommendations, 
calculated a tTG antibody level that would have a 100% PPV for CD, and which he 
believed could reliably be extended to “most second-generation transglutaminase 
antibody kits.”(p.572) He too concluded that a biopsy ought not to be mandatory to 
secure the diagnosis in patients with very high antibody levels. And in a study 
published at around the same time as the ESPGHAN Guidelines,160 Zanini et al. 
similarly concluded “that changes of the diagnostic paradigm involving serology 
alone for the diagnosis of CD is a potentially viable strategy”.(p.284) 
Since the release of the revised ESPGHAN recommendations, research studies 
have steadily emerged that cautiously endorse the safety and utility of the 
suggested approach, in both children and adults. It should be noted that many of 
these are retrospective,161-164 and two have involved patients being screened for 
CD,165,166 which is outside the parameters the ESPGHAN suggest for being able to 
avoid biopsy. At least three prospective studies have also been completed, two in 
children,167,168 and one in adults.169 Together they involved close to 1200 patients 
from a wide range of countries, and concluded that the ESPGHAN recommendations 
can be safely applied, even when a number of different test-kits had been used. 
In New Zealand one retrospective examination of paediatric CD diagnoses in 
Christchurch,170 although limited by incomplete data relating to all the ESPGHAN 
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criteria for avoiding biopsy, suggests that the ESPGHAN guidelines may well be 
appropriate to implement here, subject to prospective evaluation confirming 
acceptable levels of specificity and sensitivity. But a note of caution for Australia 
and New Zealand has been sounded by members of Coeliac Australia’s Medical 
Advisory Committee.171 They presented data at the 2013 Australian 
Gastroenterology Week, which demonstrated high inter-laboratory variability 
between laboratories in both countries that evaluated coeliac antibodies from the 
same patient (with biopsy-confirmed CD). They also found that not all laboratories 
used EMA testing, one of the tests required in the ESPGHAN algorithm, and that only 
a minority reported a tTG antibody result that was greater than or equal to ten times 
the ULN. Their conclusion was that these factors compromise the local application 
of the ESPGHAN guidelines, and work needs to be done before they could be reliably 
implemented in either country.(p.122) 
2.5 Genetics and Pathogenesis of Coeliac Disease 
With the discovery of gluten as its trigger, the recognition of the role of the immune 
system in its genesis, and the identification of hallmark mucosal changes present in 
the small intestines of patients with the condition, there have followed decades of 
intensive research aimed at piecing together the puzzle that is CD. Many of the 
underlying pathological and immunological mechanisms at the centre of the disease 
process have been elucidated, and much is now known about its genetic 
determinants. It is concisely described by Abadie and colleagues,75 as “a complex 
multigenic disorder that involves HLA and non-HLA genes, adaptive and innate 
immunity, and environmental factors.”(p.495) 
The answer to the question of why some people develop CD while others do not 
remains elusive, but continual progress is being made towards solving this. Multiple 
research teams are also working on novel treatments targeting different steps in 
the pathogenic pathways that lead to disease manifestation.172,173 
2.5.1 The genetics of CD 
It is well established that CD has a clearly genetic component to its development. 
This is evidenced by the facts that over 99% of patients with CD carry one of two 
genetic haplotypes; that up to 20% of first-degree relatives of coeliac patients will 
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also be affected; and that there is 75% to 80% concordance between monozygotic 
twins.174  
The most well-defined genetic elements of the condition are the HLA proteins 
encoded for in an area on the short arm of Chromosome 6 known as the Major 
Histocompatibility Complex (MHC). The MHC also contains genetic information for 
much of the immune system. There are three classes of HLA molecules, of which the 
class II variety are associated with CD. Class II molecules interact with peptides that 
have arisen outside cells, such as bacteria or those derived from food-protein, (as 
opposed to Class I molecules that respond to endogenous peptides, for example 
from tumour cells).175 Within HLA class II there are three groups: DQ, DR, and DP, 
encoded for by a diverse range of alleles. HLA-DQ has been identified as the 
principal HLA genetic player in CD, and accounts for an estimated 40% of the 
heritability of the condition.176 
Each HLA molecule has two α-chains and two β-chains, for which there are 
different genes. In HLA-DQ molecules, the α-chains are encoded for by the HLA-
DQA1 gene, and the β-chains by the HLA-DQB1 gene. Together these chains form a 
protein complex (heterodimer) that acts as a receptor on the surface of antigen-
presenting cells (APCs), binding antigens for presentation to T-lymphocytes.  
When referring to HLA genes, the preferred way of expressing this is HLA-
DQB1*02:01, where “02” indicates a specific allele group, and “01” a particular 
protein.174 Both the DQA1 and DQB1 genes can be comprised from a range of alleles, 
including ones known to be associated with increased CD risk. The DQ-A1 alleles 
associated with CD are 02:01, 03:01, 05:01, and 05:05, and the DQ-B1 alleles are 
02:01, 02:02, and 03:02.75,174 Any of these alleles may be carried alongside each 
other (cis) on the Chromosome 6 inherited from one parent, or separately (trans) 
on the two chromosomes inherited from both parents, but CD only occurs when 
they are inherited in certain combinations. 
The highest risk allele combinations for CD are HLA-DQB1*02 (either 02:01 or 
02:02) with HLA-DQA1*05 (either 05:01 or 05:05). The HLA heterodimer that this 
encodes is referred to as HLA-DQ2.5, and it is present in approximately 90% of 
people with CD.177 A moderate degree of risk is conferred by HLA-DQB1*03:02 with 
HLA-DQA1*03:01, which together encode HLA-DQ8, while the low risk HLA-DQ2.2 
arises from HLA-DQB1*02 and HLADQA1*02.177 The greatest risk of all occurs in 
41 
 
people who are homozygous for the genes associated with HLA-DQ2.5. These 
people have both a higher likelihood of developing CD, which they are more likely 
to develop at an early age, and of experiencing complications of the disease.174 
It is possible to test patients for the presence (or absence) of the risk-associated 
HLA alleles, although the results of these tests need to be thoughtfully interpreted, 
as it is well documented that they are present in substantially more of the 
population than is affected by CD. At least 30%, and in some places perhaps more 
than 50% of the population are either HLA-DQ2 (2.5 or 2.2) or HLA-DQ8 positive.18 
This means that a positive test gives little useful information about whether an 
individual patient has CD, which has not always been appreciated by those 
requesting the test.177,178 On the other hand, given that more than 99% of people 
with CD display one of these haplotypes, a negative test can exclude CD with almost 
100% certainty. 
In recent years, genome-wide association studies and the development of the 
Immunochip platform, have identified additional non-HLA loci associated with CD 
(many with links to other autoimmune diseases as well). This work means that 
around 50% of the heritability of CD can be explained, although the clinical 
application of this information remains limited.179 Work continues to expand this 
further. 
2.5.2 The role of the environment 
Along with the necessary genetic make-up, and a gluten-containing diet, it is clear 
some other environmental trigger is also required in order for a person to develop 
CD. As already discussed, the role of gluten is well understood, as are some of the 
genetic components of the disease, while work continues to clarify others. As yet 
the environmental trigger, or triggers, has not been convincingly identified, but that 
it is required is evidenced by several factors. One of the most striking of these is that 
the prevalence of CD generally sits at around 1% in genetically susceptible 
populations but, as already mentioned, the prevalence of the HLA aspect of that 
susceptibility is, in some populations, in excess of 50%.18 And while it is known that 
HLA genotype accounts for only about 40% of the genetic predisposition to CD,176 
there is also evidence that clearly implicates environmental factors over and above 
gluten consumption in the aetiology of the condition. 
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One of these pieces of evidence is the variability in the prevalence of CD in 
otherwise similar populations. This has been most clearly demonstrated in a study 
by Mustalahti et al.,4 who found prevalence rates of CD among broadly similar 
groups of adults in Europe varied from 0.3% in Germany, to 2.4% in Finland. 
Similarly, Kondrashova et al.180  showed the prevalence of biopsy-proven CD was 
markedly different among children from Finland (1 in 107), and nearby Russian 
Karelia (1 in 486). The authors of this study suggested this difference cannot be 
accounted for by differences in genes, and was unlikely to be related to differing 
exposure to wheat. They drew attention to the vast socio-economic disparity 
between the two populations, and the attendant environmental differences that 
followed from this, and speculated on whether this was an example of the hygiene 
hypothesis at work. 
Another event that points strongly to the role of environmental triggers in the 
initiation of CD (at least in children), is the Swedish CD epidemic that occurred 
between 1983 and 1995. Over that time period there was a four-fold increase in the 
annual incidence rate of young children (aged under two years) presenting with 
CD,181 mostly in its classical form. This was followed by an abrupt drop in 
presentations in 1995, which saw the incidence rate return to its pre-1983 levels. 
The risk of developing CD has remained elevated among the children born during 
this period, as was made apparent in a 2009 study by Myléus et al.182 In this study 
a cohort of just over 7500 children born in 1993, the year of peak CD incidence 
during the epidemic, were screened for CD when they were 12 years old. Among 
this group the prevalence of biopsy-confirmed CD was found to be 3%, substantially 
higher than expected based on earlier prevalence studies from Sweden, and 
elsewhere in Europe.182 
Ivarsson et al.181 have pointed out that this pattern of a marked increase 
followed by a rapid decrease in incidence is typical of infectious disease outbreaks, 
and had never previously been seen with a chronic disease associated with either 
autoimmunity or diet, as CD is.181(p.168) It was clear from this event that there was 
something (or things) peculiar to the environment at the time that led to the spike 
in incidence. 
To explore this further, and as part of their analysis of what had occurred, 
Ivarsson and her colleagues examined the environment in Sweden at the time.181 
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They found that the onset of the epidemic coincided firstly with changes in advice 
to mothers about when to wean babies onto gluten-containing products (the 
recommendation became that this should be delayed until at least six months of 
age), and secondly with an increase in the total consumption of gluten (which nearly 
doubled due to a change in the composition of follow-on formulas). The sudden 
decline in CD presentations followed another change in advice, such that it was 
recommended that gluten be introduced into infants’ diets in smaller amounts, from 
the age of four months, and preferably while breastfeeding continued.181 Thus it 
became widely accepted that it was highly likely that breastfeeding patterns, the 
timing of the introduction of gluten into infants’ diets, and the amount of gluten 
introduced during weaning, played a role in the development of CD.  And although 
subsequent studies produced conflicting results about the impact of these variables, 
recommendations that were developed erred on the side of caution, and the advice 
to parents was that small amounts of gluten should/could be introduced when a 
child was between four and six months of age, and while still being breastfed.183 
 Recently these recommendations have been revised,184 following a systematic 
review and meta-analysis of available evidence,185 which included two recent 
prospective studies of babies at risk of developing CD.186,187 Between them these 
studies involved almost 1500 babies, and both found no discernible effect on the 
later incidence of CD from either the duration of breastfeeding, or its association 
with the introduction of gluten into infants’ diets. One of the two studies, conducted 
by Lionetti et al.,186 also compared the effects of introducing gluten at six months of 
age, or delaying it until twelve months, and found no difference in CD incidence by 
the age of five years. They did find that the age of onset was delayed in the second 
group, which they suggested “might reduce the negative effects of the disease on 
vulnerable organs such as the brain.”186(p.1300) The second study, by Vriezinga and 
colleagues,187 and part of the European “PreventCD” project, tested the impact of 
introducing small amounts of gluten between the ages of four and six months 
compared with placebo.187 Again, this study found no difference in the development 
of CD by the age of three years among their study groups. In the light of this recent 
work, the ESPGHAN’s latest position paper recommends the following: 
(1) Recommendations on BF [breastfeeding] should not be modified 
because of considerations regarding prevalence of CD. 
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(2) Introducing gluten while the infant is being breast-fed cannot be 
recommended as a means of reducing the risk of developing CD. 
(3) Gluten can be introduced into the infant’s diet between the ages of 4 
and 12 completed months. 
(4) No recommendation can be made regarding the type of gluten to be 
used at introduction 
(5) Despite the limited evidence…ESPGHAN suggests that consumption 
of large amounts of gluten should be discouraged during the first 
months after gluten introduction.184(p.512) 
Largely since the Swedish epidemic, other factors that have also come under 
scrutiny as possible triggers for CD include the season of a child’s birth, mode of 
delivery, and occurrence of childhood infections. These studies suggest that: being 
born in the summer leads to a small increase in the risk of developing CD, mostly 
apparent in children under the age of two;188,189 that the evidence is conflicting on 
whether elective caesarean delivery is associated with an increased risk;190,191 and 
that it has been unclear what influence, if any, exposure to infection, with or without 
treatment with antibiotics, has on the subsequent emergence  of CD.192  
Karl Mårild and colleagues have recently reviewed the research relating to 
perinatal influences on CD onset,193 including those mentioned above, as well as 
studies that have examined maternal health factors such as the use of antibiotics 
and iron supplements during pregnancy. They concluded that “[o]verall, the data on 
the perinatal environment and CD development are inconclusive”,(p.373) noting 
elsewhere in the article that “there is still only circumstantial evidence”(p.366) 
linking the two. Mårild has also been involved with a recently published large, 
prospective, cohort study investigating the relationship between childhood 
infections and CD.192 This study demonstrated a “modest but significantly increased 
risk for later CD according to infection frequency in the first 18 months of 
life”.(p.1483) This was particularly the case for respiratory tract infections, while 
gastrointestinal infections “yielded similar, but insignificant, increased relative risk 
estimates.”(p.1483) Antibiotic use (or not) did not affect this relationship. The 
authors urged caution in interpreting their results, pointing out that the association 
could also be non-causal. 
The pathway that might link all these potential aetiological variables, and 
which is the subject of increasing investigative scrutiny, is their impact on the gut 
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microbiome. The possibility of such a link has been explored in a review by Verdu 
et al.,194 in which they identify the key points in the trajectory of gut microbial 
colonisation: the prenatal environment, delivery mode (vaginal/caesarean), 
feeding type (breast/formula), treatment with antibiotics, and introduction of solid 
food.(p.498) 
While all of the factors just described have been studied with respect to the 
onset of CD in childhood, there has also been research examining the role of 
antibiotic use in the onset of CD, irrespective of the age at which it presents.195 This 
was a large population study involving almost 6000 people of all ages with either 
biopsy-confirmed CD or intestinal inflammation, or CD antibody positivity and 
normal histology, who were then compared with almost 30,000 controls. The 
authors found a possible association with prior antibiotic use (in the preceding 12 
months) and increased risk in all three subgroups, which led them to postulate 
intestinal dysbiosis as a plausible explanation for this finding. However, they did 
also point out that they could not rule out reverse causation, with antibiotic use 
being a consequence rather than a cause of subsequent CD.195(p.7) 
Verdu et al.194 refer to “the emerging role of the gut microbiota in the 
pathogenesis of coeliac disease”, but point out that while “[d]ysbiosis has been 
described in patients with coeliac disease…studies have failed to find a distinct 
coeliac microbiota signature”.(p.502) Much more work is needed to identify 
whether such a signature exists, and if so, how it is implicated in the initiation, and 
perhaps progression, of the disease. One hypothesis is that the microbiome changes 
immunological responses to oral antigens.196 The ultimate aim of present day 
research into the microbiome, and the extensive work directed at elucidating the 
complex web of environmental triggers of CD, is that therapeutic options for 
preventing CD, at least in people identified as being at high risk of the condition, 
may one day become a reality. 
2.5.3 Immune dysregulation and the pathophysiology of CD 
The culmination of the interplay between gluten and the factors just outlined is 
damage to the intestinal mucosa leading to the clinical entity that is CD. This damage 
is mediated through the immune system, in a process that activates both the 
adaptive and innate immune systems.75,197 Adaptive immunity is the arm of the 
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immune system deployed to mount a specific response to antigenic stimulus, 
utilising T-lymphocytes and B-lymphocytes that have adapted to respond to that 
stimulus. It must distinguish between harmful and beneficial stimuli, both of which 
are manifold in the gut. Innate immunity is a non-specific early response to 
perceived threat (usually infection) involving cells such as macrophages and 
Natural Killer (NK) cells.174 
As discussed earlier in this chapter (page 19),  the high proline content in some 
of the constituents of gluten makes them more resistant to proteolysis in the small 
intestine, meaning the peptide groups that remain in the lumen can be moderately 
large.176 A particular sequence of 33 amino acids derived from α-gliadin is one such 
peptide group.198 For people without CD this is of little consequence, but in 
susceptible individuals this particular peptide chain contains a recurring amino acid 
motif that is an essential component of the CD pathogenic process. 
In order for these peptides to exert their immunological effect they must come 
into contact with the cells that initiate the immune response. These cells are located 
in the lamina propria, which is generally not directly exposed to antigens. Because 
the epithelium of the gastrointestinal tract ordinarily forms a very efficient 
immunological barrier, how gluten peptides are able to cross into the lamina 
propria remains the subject of extensive investigation.199 Four possible ways in 
which this can occur have now been identified: they may be transported directly 
through intestinal epithelial cells (IECs); they may pass between IECs due to 
loosening of the links between cells known as “tight junctions”; they may be picked 
up directly from the luminal space by APCs such as dendritic cells; or they may gain 
access through damaged areas of epithelium, where the barrier function has broken 
down. (Figure 2-3) Increased intestinal permeability due to loosening of tight 
junctions has received particular attention with the identification of zonulin, a 
protein known to trigger this process, and that has been found in the intestinal 





Figure 2-3: Routes of passage across the epithelial barrier. To initiate inflammation, 
gluten peptides need to move from the intestinal lumen to the lamina propria, crossing 
the epithelial cell barrier. Pathways include (1) transcellular passage, (2) paracellular 
passage, (3) direct sampling by dendritic cells, and (4) passage through an injured 
area.198(p.42) 
(Figure and caption used with permission from Springer.) 
On gaining access to the lamina propria, gluten peptides are available to be 
acted upon by tTG. Found throughout the intestinal mucosa, tTG has a central role 
in the repair of damaged tissue. Under normal physiological circumstances it 
remains largely inert, but it becomes active in the presence of tissue damage and 
inflammation.201,202 
As well as its role in tissue repair, tTG also interacts strongly with gluten 
peptides, converting some of the neutral glutamine residues to negatively charged 
glutamate, in a process called deamidation.176 The deamidation of gliadin peptides 
by tTG is a crucial step in the adaptive immune response of coeliac patients, 
because the negatively charged gliadin peptides bind more tightly to the HLA 
heterodimers displayed on those patients’ APCs. These units then interact with 
gliadin-specific CD4+ T-helper cells that recognise these peptides as a threat, 
inducing an inflammatory reaction that includes the production of cytokines such 
as interferon-γ and interleukin-21.203 This inflammatory reaction contributes to the 
hallmark mucosal changes of CD, although it does not account for the degree of 
villous damage that occurs, or the chronicity of the inflammation.174,204  
As noted earlier in this chapter (page 25) tTG has also been identified as the 
autoantigen in CD pathogenesis,123 and the presence of IgA antibodies to tTG in the 
sera of people with CD is a key component of making the diagnosis. However, the 
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role of these antibodies in the pathogenesis of CD remains unclear.174,201 As pointed 
out by Setty et al.197, CD has a higher prevalence among people with IgA deficiency 
than the IgA-normal population, which calls into question the significance of the IgA 
antibody response in the genesis of the condition. 
The knowledge that people can have evidence of autoimmune activity (elevated 
anti-tTG antibodies) without histological evidence of disease (i.e. potential CD) has 
led researchers to examine what else is happening at the level of the intestinal 
mucosa that causes some people to manifest CD, when others do not.204-206 Innate 
immunity is crucial in this process, but what triggers and then drives this aspect of 
the immune response, which takes place within the intestinal epithelium,207 
remains elusive.208 
The central players in the destructive processes that lead to the crypt 
hyperplasia and villous atrophy of CD would seem to be IELs.174 As discussed earlier 
(pages 21 to 23), the presence of increased numbers of IELs is one of the criteria on 
which the histological diagnosis is made. Under normal physiological (and 
immunological) conditions, IELs have a harm-minimisation role, responding to 
stress signals from IECs by producing anti-inflammatory proteins that promote 
healing and have “low cytolytic properties”.204(p.555) In CD, however, the stress 
response of IECs is characterised by the release of interleukin 15 (IL-15), a pro-
inflammatory protein that induces a change in IELs to cytotoxic variants. CD8+ T 
cells and NK cells proliferate, and in a complex interplay between the range of 
receptors expressed on these cells, as well as on epithelial cells, and the cytokines 
that they produce, destruction of intestinal tissue takes place.174,206,209 The 
following image from Elliott summarises what is known about this process.198 
(Figure 2-4) Questions still remain, however, about the event (or events) that set 
the process in motion and about how the adaptive and innate immune responses 





Figure 2-4: Inflammatory circuits in CD. Multiple cell types are involved in the 
intestinal inflammation in CD. Anti-deamidated gliadin is taken up by an APC 
(macrophage or dendritic cell) and is presented to a T cells using a DQ2 or DQ8 
antigen-presenting molecule. The activated T cells make IFN-γ and IL-17. The IFN-γ 
instructs epithelial cells to display HLA-E. The APC also makes IL-15 that causes IEL 
to proliferate and display NK receptors that recognize HLA and MICA on epithelial 
cells. The activated IEL then kills the targeted epithelial cells. B cells in the lamina 
propria also can present antigen to T cells that help the B cells mature into plasma 
cells that make anti-TTG or anti-deamidated gliadin antibodies.198(p.45) 
(Figure and caption used with permission from Springer.) 
2.6 The Prevalence of Coeliac Disease 
It is now generally accepted that the worldwide prevalence of CD is approximately 
1% of the general population, albeit with variations between different nations and 
peoples. This was captured in a 2014 article by Lionetti and Catassi,76 in which they 
collated data gathered from prevalence studies conducted in a range of countries 
from across the globe, and tabulated the mean prevalence estimate to be 
1269/122858; that is, 1.0%.(p.1059) This makes CD one of the most common 
lifelong conditions known to affect humankind.  
As summarised by Catassi et al.,210 there is also evidence that the prevalence of 
CD is increasing over time. Lohi and colleagues in Finland demonstrated an increase 
from 1.05% to 1.99% over a 20 year period,211 and Murray et al.212 and Rubio-Tapia 
et al.213 similarly identified increases in two different study populations in the USA. 
It has not always been recognised that CD is common. For many years it was 
thought to be a rare condition that mostly affected children, and which was limited 
to people of European descent. This was largely due to the fact that up until the late 
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1950s, the diagnosis was made solely on clinical grounds, these being severe and 
persistent diarrhoea, associated with malnutrition. As already discussed, this 
changed with the advent of devices for obtaining jejunal biopsies, and the 
identification of characteristic changes in the intestinal mucosa. These were found 
to be present in patients (including adults) with a spectrum of symptoms, not just 
those who were desperately unwell.1  
In one of the earliest studies examining a possible genetic link in CD,214 Carter 
et al. postulated that the prevalence of CD in Great Britain “appears to lie 
somewhere between 1 in 2000 and 1 in 6000.”(p.268) In their concluding remarks 
they refined the population risk to “about 1 in 3000”, and also noted that the risk 
among family members of patients was much higher than this.(p.272) Six years 
later MacDonald referred to this work,215 writing that the “prevalence of celiac 
sprue in the United States is not known and is difficult to estimate…(but) 1 in 
3000…is compatible with general clinical experience in North America”.215(p.474) 
By 1969 this figure had been revised to 1 in 1850, in UK work cited by Swinson,1 
and by 1973 a study from the West of Ireland found a prevalence of 1 in 303, 
“[w]hen allowance is made for presentation of disease in adult life”.216(p.703) 
Studies of CD prevalence, and insights into the wide range of peoples it affects, have 
steadily accumulated since then. 
Since the mid-2000s several systematic reviews of CD prevalence studies have 
been published.217-221 Additional reviews include those by Barada,21 Catassi,13 
Cummins,222 Lionetti,223 and Yuan.224 Between them these papers cover hundreds 
of studies, and the investigations reviewed encompass vast swathes of the globe, 
including the USA, several countries from South America, a number of European and 
Mediterranean countries, North African and West Asian nations, India, Australia, 
and New Zealand.  
The following table (Table 2.5) summarises the prevalence data presented by 




Table 2.5: Global coeliac disease prevalence 
Low prevalence          
(up to 0.4%) 
Moderate prevalence 
(0.5% – 0.7%) 
High prevalence 
(>0.7%) 
Burkina Faso Brazil Ireland 
Germany Egypt  Libya  
Russian Karelia Iran Spain (children) 
Indian Punjab Netherlands Italy 
Spain (adults) Sweden (adults) USA (adults) 
USA (children) Argentina Turkey (no biopsy) 
Australia Tunisia (no biopsy) India 
 Turkey Iran 
 Italy United Kingdom 
 Portugal New Zealand 
  Sweden (children) 
  Finland 
  Algeria (no biopsy) 
 
The CD prevalence rates that have been determined for the nations comprising this 
table range from zero in the Mossi people of Burkina Faso,225 (where it has also been 
ascertained that HLA-DQ2 and HLA-DQ8 are almost completely absent, and that 
very little wheat is consumed), to 5.6% among the children of a Saharawi 
community living near Algeria.226 This rate is strikingly higher than that found 
anywhere else and, while some have hypothesised evolutionary reasons for why 
this might be,76,227 a definitive cause has yet to be identified.  
The Lionetti review also included more than one study from some countries, 
some of which found different prevalence rates. This is particularly apparent in 
studies from Iran, Italy, Sweden and Spain, and also Finland in which prevalence 
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ranged from 1.0% in children to 2.4% in adults. The USA data that found a difference 
in prevalence between children and adults was subgroup data from one study.228 
Singh et al.,221 in their 2016 systematic review and meta-analysis of CD 
prevalence in Asia, noted that there have been no reports of CD from many Asian 
countries, including all those that form Central Asia and the majority of those in 
South East Asia, while there are only isolated case reports from South Korea, 
Bangladesh and Yemen. There are also limited data available relating to CD in Japan, 
and it seems likely that its prevalence is truly low there, due to comparatively low 
wheat consumption, and the fact that HLA-DQ2 is largely absent in the Japanese 
population.222 A recent study by Fukunaga and colleagues supports this 
supposition.229 In a population sample of just over 2000 asymptomatic people, they 
found a prevalence of just 0.05%. 
At the time of completing this thesis, there have been no prevalence studies 
conducted in China, however it is known that CD is present there. From 2005 to 
2008, Wang et al.230 investigated a group of children from four different cities in 
China who had chronic diarrhoea. They found that 11.9% of the cohort of 118 
children had biopsy-confirmed CD. More recently Yuan and colleagues have carried 
out a systematic review of reports of CD, the frequency of the required HLA 
haplotypes, and gluten consumption in China.224 They conclude that “celiac disease 
is more common in China than commonly reported”(p.1 of 14), especially in 
Northwestern China where the population has both a higher frequency of HLA-DQ2, 
and wheat is a dietary staple. This was consistent among the dominant Han 
population, and the minority ethnic groups who also inhabit the region.224(p.12 of 
14) These researchers also predict that, with the expansion of “Western-style diets” 
across China, “a sharp rise in the prevalence of CD can be expected 
nationwide.”(p.13 of 14) 
2.6.1 The dissenting voice 
It should be noted that not all studies investigating the prevalence of CD are 
comparable. Some have reached their conclusions about disease prevalence based 
on screening blood tests alone, while others rely on biopsy confirmation of the 
diagnosis to determine this figure. And within the biopsy-determined studies, some 
authors have included in their calculations only those subjects found to have Marsh 
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3 changes, while others have taken a more liberal approach and included Marsh 2 
changes. In addition to this, some studies have been truly random population 
studies, while others have been conducted using particular cohorts of subjects, such 
as blood donors or members of the armed forces. It has been argued that these two 
groups are not necessarily representative of the population as a whole, calling into 
question the appropriateness of extrapolating results to that population.  
The variability in research methods and diagnostic criteria being utilised has 
been the source of at least one dissenting view about the conclusions that have been 
drawn about overall CD prevalence. In 2010 Biagi et al.218 conducted a systematic 
review of prevalence studies, which they published under the title “Are we not over-
estimating the prevalence of coeliac disease in the general population?” They argued 
that the figure of 1% that is so commonly cited in the literature is an overestimation, 
and that the true prevalence is likely to be closer to 0.62% (or 6.2‰, as the authors 
express it).218(p.557) Their reasoning was largely based on the fact that many 
studies they looked at solely relied on a positive IgA-tTG antibody as proof of 
diagnosis, increasing the likelihood that at least some cases identified would be 
“false-positive” diagnoses. They also suggested that including patients who had 
already been diagnosed with CD in such studies led to an overestimation of 
prevalence,218(p.559) although it is difficult to know why this would be the case. 
Curiously, they also included some blood donor studies in the papers they analysed, 
and reported that they “could not find any significant difference between adults, 
children and blood donors”, a finding they describe as “very difficult to 
explain.”218(p.559) Indeed, studies involving blood donors should if anything lead 
to an underestimation of prevalence, given that people who are iron deficient, with 
or without anaemia, are often precluded from donating blood. Iron deficiency is 
well-recognised for its association with otherwise subclinical CD, particularly in 
Caucasian people.231 
In their table summarising worldwide CD prevalence cited in the first 
paragraph of this section, Lionetti and Catassi noted the diagnostic criteria on which 
each included study based its calculations, and which populations were 
involved.76(p.1059). Studies involving blood donor populations were excluded.  
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2.6.2 More recent studies 
There are some additional prevalence studies that are worthy of comment but 
which were not included in the Lionetti review. For the most part they had not been 
published at the time she was conducting her literature search. 
In the USA, Mardini and colleagues analysed data from the National Health and 
Nutrition Examination Survey (NHANES), for racial differences in CD prevalence.232 
They found an overall seroprevalence of 0.79% in the study’s 14,700 participants. 
Subgroup analysis revealed a seroprevalence of 1.08% among non-Hispanic whites, 
0.23% in Mexicans, 0.22% among non-Hispanic blacks, and 0.38% in “other 
Hispanics”.232(p.1740) Meanwhile, a study in Denmark involving almost 2300 
participants has estimated the population CD prevalence to be 0.48%.233 The 
authors noted that this is “10 times higher than the registry-based prevalence”, 
which is Denmark’s record of diagnosed patients.(p.824) 
Elsewhere work is gradually emerging attempting to document the prevalence 
of CD in Asia. The first study from Malaysia,234 which involved 562 Kuala Lumpur 
university students, has found an overall seroprevalence of 1.25%. Subgroup 
analysis according to ethnicity showed this to be comprised of 0.8% among Malay, 
1.7% among Chinese, and 1.3% among Indian participants.(p.1 of 14) In this study, 
a CD diagnosis (for the purposes of determining prevalence) was made in those 
participants who had positive results in all three of AGA, IgA-tTG, and EMA 
antibodies. Samples from only those students who were positive for the first two of 
these were tested for EMA. Students who were only positive for IgA-tTG antibodies 
did not have the additional EMA titres done, and so were ruled out of consideration 
for having CD. This is somewhat surprising given that positive IgA-tTG antibodies 
alone has been all that was required for CD seroprevalence in many studies, and 
that the combination of this and EMA is regarded by many as being a reliable 
indicator of the condition. It is possible, therefore, that this study marginally 
underestimates the likely prevalence of CD in this cohort. The use of AGA tests is 
also questionable, as it is well known that they have poor sensitivity and specificity 
for CD, and their use is no longer recommended.69  
Recently another study from India involving over 23,000 adults has confirmed 
the variability of CD prevalence across the sub-continent.19 Ramakrishna and 
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colleagues recorded a prevalence of biopsy-confirmed disease of 0.85% in Northern 
India, 0.47% in North Eastern India, and 0.01% in the South. They also investigated 
HLA types and found that presence of the HLA-DQ2 and HLA-DQ8 genotypes did not 
vary significantly over the three regional groups tested. On the basis of this, and 
data they gathered on diet, they ascribe the difference in prevalence to wheat 
consumption, which was substantial in the North, and minimal in the 
South.19(p.115)  
In contrast to the northern regions studied by Ramakrishna et al., the large 
majority (8/9) of participants from the south who underwent a biopsy were 
classified as having “Marsh 0” findings.(p.120) Despite these people having elevated 
CD antibodies, many would regard this as a normal (and therefore negative) biopsy. 
Interestingly, in this study the authors chose to label all those who were antibody 
positive and biopsy negative as having “latent CD”, for which they also did 
prevalence estimations. 
2.6.3 Coeliac disease prevalence in New Zealand  
The first attempt to gain an indication of the likely prevalence of CD in New Zealand 
was carried out by Carrington in 1986,235 when she analysed membership records 
of the Coeliac Society (as CNZ was then known). While acknowledging that there 
were limitations to this method of predicting prevalence (namely that there were 
no data available about the proportion of newly diagnosed coeliac patients joining 
the society), she found that the membership rate of 9 per 100 000 population in 
New Zealand was one-third of that in England and Wales during the same time 
period. She postulated three possible reasons for this. Firstly it was possible that 
fewer patients with CD in New Zealand joined the society compared to similar 
societies in England and Wales; secondly she speculated on whether the actual 
prevalence of CD in this country might be lower, either due to differences in the 
toxicity of New Zealand wheat, or due to ethnic variation in the populations being 
compared (specifically she suggested that CD could be less common in New Zealand 
Māori due to a lower frequency of the necessary HLA gene); and thirdly she 
suggested that the diagnosis might be being missed more often in this country.235 
The following year Carrington and colleagues in Otago published the findings 
of a retrospective study looking at the prevalence of CD in the region.236 In addition 
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to this they sought to establish what proportion of people with CD joined the Coeliac 
Society. They reviewed the hospital records of children aged up to 12 years old who 
met at least one of the following inclusion criteria: they had been investigated for 
malabsorption or steatorrhoea; they had had a small bowel biopsy; they had a 
recorded diagnosis of coeliac disease. They conducted a similar review for adults, 
and also obtained information from paediatricians looking after children with the 
condition, from dieticians who had worked with people on the GFD, as well as the 
names of people who had had gluten-free goods provided by community services. 
They collated all this data and then matched it with membership data from the 
Coeliac Society. 
What Carrington and her colleagues found was an overall prevalence of CD in 
Otago of 9 per 100 000, which was low when compared to figures from overseas, 
and which they attributed to underdiagnosis. In addition to this, they found that 
only 35% of patients diagnosed with the condition in the period of their study were 
members of the Coeliac Society. They concluded their report with 
recommendations about the types of clinical situations in which the diagnosis 
should be considered, which went beyond the classical description of the condition 
as being one which affected children who presented with steatorrhoea and failure 
to thrive.236 
The most robust evidence available regarding the prevalence of CD in New 
Zealand is that from a study conducted by Bramwell Cook and colleagues in the late 
1990s.17 Indeed it is the only prospective adult CD prevalence study ever 
undertaken in this country. Their investigation was carried out in the South Island 
city of Christchurch and continues to be widely cited in the literature as one of the 
early investigations into the actual prevalence of CD in a population outside Europe 
and Scandinavia. A random sample of 1064 adults (over the age of 18 years) was 
selected from the New Zealand Electoral Roll, and each was screened for CD with 
the EMA test. Those who returned a positive test then went on to have upper 
endoscopy with duodenal biopsy. Cook and his colleagues discovered that 1.2% of 
their sample had CD. Only one participant was already on the GFD, having already 
been diagnosed, and two others had previously had positive EMA tests but had not 
had the diagnosis confirmed by biopsy. 
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Almost thirty years after the publication of that research, the generalisability 
of the prevalence figure of 1.2% to the New Zealand population as a whole, needs to 
be considered with some caution. Cook’s study sample was overwhelmingly 
Caucasian, with 96% of the study participants identifying themselves as New 
Zealand European. Clearly the makeup of this group is not representative of the 
New Zealand population today. Data from the 2013 Census indicates that only 74% 
of the population identifies as European, either singly or as one of a number of 
ethnicities.237 The other major groupings in New Zealand are Māori and Pacific 
Islander, for both of whom the limited HLA data available indicates a low frequency 
of the CD-risk alleles;238 and Asian, a label that extends to an extremely diverse 
group of peoples in which HLA frequencies vary, and which is the fastest growing 
group in New Zealand. 
In another more recent study, Tanpowpong et al. did find a CD prevalence of 
1%.239 This work was from a study nested within the New Zealand Asthma and 
Allergy Cohort study, in which a cohort of 1105 children born in Wellington and 
Christchurch between 1997 and 2001 are being followed to monitor their health 
and development. In 2009 their caregivers were surveyed to determine rates of 
gluten-avoidance within the cohort, and to compare this with the prevalence of 
doctor-diagnosed CD. Responses for 916 children were able to be analysed. The 
ethnic make-up of the group reasonably reflects that of the New Zealand population, 
with 78% identifying as European, 13% as Māori, 4% as Pacific, and 5% as 
“other”.(p.13) The researchers found that 1% of their sample group (including one 
Māori child) were reported as having been diagnosed with CD, although only 44% 
of these children had had the diagnosis confirmed with biopsy. What is particularly 
interesting about these findings is how they contrast with the vast body of research 
suggesting that CD is underdiagnosed. In most prevalence studies, the figure of 1% 
has been determined by screening populations, and identifying people with CD who 
were previously unaware of the diagnosis. It is therefore somewhat surprising to 
have a study in which the number of children with diagnosed CD is apparently 
almost exactly what would be predicted.  
There are several possible explanations for the contrast. Firstly, the reliance on 
biopsy to confirm the diagnosis in at least some of the prevalence studies that have 
been undertaken may have contributed to the lower rates of diagnosis seen in those 
58 
 
research populations. Secondly, perhaps there was something particular about the 
cohort Tanpowpong and colleagues were studying, which had led to an increased 
awareness of CD among the group. If this were the case, the 1% prevalence figure 
of diagnosed CD they found would not be representative of the state of affairs within 
the wider population. A third possibility is that the 1% figure in this study is 
unreliable as it relied on report by the parents of the children in the study, and was 
not verified against their medical records. However, it could also be that this finding 
indicates that perhaps the situation with regard to underdiagnosis, at least in New 
Zealand, is no longer as dire as previously documented. 
2.6.4 Prevalence based on other variables 
It should also be noted that the majority of the prevalence reviews discussed in the 
previous sections focus almost exclusively on the geographic (and therefore ethnic) 
distribution of CD. And while there is less information available regarding 
prevalence according to other variables such as sex, age, and risk factors associated 
with CD, the impact of these factors does need to be considered. 
It is generally accepted that the prevalence of CD is greater in women than 
men,9,122 with the female-to-male ratio often given as 1.5–2:1, or 2–3:1.7,70,227,240 The 
higher of these two figures comes from a North American study by Green et al.,241 
in which 1138 people with CD were surveyed. Among this group women 
outnumbered men by 2.9:1. More recently Green and colleagues have hypothesised 
that women may have been over-represented in this study because of, among other 
things, their “more regular health care interaction”.207(p.1100) Prevalence studies 
that have involved population screening, including Cook’s New Zealand 
investigation,17 have tended to find a more equal distribution of disease between 
men and women,228,242,243 although this is not a universal finding.244 
With respect to age, some writers report that CD occurs with equal frequency 
among children and adults,9,245 while others note that there are peaks in prevalence 
in early childhood, and again in the fourth and fifth decades of life.8,227 These 
differences are likely to have arisen from the alternative ways in which prevalence 
has been determined, either through population-wide screening studies, or audits 
of groups of CD patients. 
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There are also a range of conditions that are known to be associated with an 
increased prevalence of CD. In 2015 NICE reviewed a substantial number of studies 
pertaining to these conditions, to inform their updated guideline on CD.71 The 
following table presents some of their conclusions, on those conditions most 
commonly considered in discussions about CD. (Table 2.6) Also calculated was a 
pooled prevalence of CD among first-degree relatives of CD patients of 8.2% (95% 
CI 4.6 to 14.3%). The Guidelines development group (GDG) note in their report that 
the quality of the evidence on which they drew was generally low.71(p.38) 
Table 2.6: NICE data on CD prevalence associated with some pre-existing 
conditions71(p.38) 
Pre-existing Condition CD Prevalence 
Autoimmune thyroid disease 
Pooled prevalence 2.4% (95% CI 1.5 to 
3.8%) 
Type 1 Diabetes 
Pooled prevalence 6.0% (95% CI 4.0 to 
8.9%) 
Down Syndrome 
Pooled prevalence 3.2% (95% CI 1.3 to 
7.4%) 
Turner Syndrome 
Pooled prevalence 5.5% (95% CI 4.1 to 
7.4%) 
 
2.7 The Incidence of Coeliac Disease 
It is well established that the incidence of CD is well below what would be expected 
based on available prevalence data. This has led to one formulation of the “coeliac 
iceberg” image, in which the visible tip comprises those patients who have been 
identified, but a much larger submerged bulk of undiagnosed people sits below the 
diagnostic waterline.72,122,136 (Another configuration of the coeliac iceberg situates 
classical CD above the waterline and all other types below it,6,63 because these are 
the manifestations of CD that are much more likely to be overlooked.) 
In recent years, several studies have been undertaken that have investigated 
the incidence of CD, and how it has changed over time.45,246-251 In all but one, CD 
incidence has increased in the time periods studied, as shown in the following table. 
(Table 2.7) The exception is in Finland, where Virta el al.251 have recently 
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documented a fall in the incidence of biopsy-confirmed CD from 33 per 100,000 
person years in the 2005 to 2006 period, to 29 per 100,000 person years in 2013 to 
2014. 
Table 2.7: Increasing incidence of CD evidenced in recent studies 
Country 
Change in Incidence (measured in 
person-years) 
Netherlands 
2.72/100 000 to 6.65/100 000, between 
1995 and 2010.249 
Wales 
3.08/100 000 to 6.89/100 000, between 
1996 and 2005.45 
United Kingdom  
5.2/100 000 to 19.1/100 000, between 
1990 and 2011.252 
Scotland (children) 
1.8/100 000 to 11.7/100 000, between 
1990-94 and 2005-9.247 
Olmsted County (North America) 
11.3/100 000 to 17.3/100 000, between 
2000-01 and 2008-10.248 
The authors note a levelling off in 
incidence from 2004. 
United States Military 
1.3/100 000 to 6.5/100 000, between 
1999 and 2008.246 
 
That the incidence of CD has increased so markedly suggests that clinicians have 
greatly improved their efforts in looking for it, as evidenced in particular by the 
Welsh study by Hurley et al.,45 in which they also reported a 14-fold increase in the 
number of CD-related tests requested in the time period they examined.  
2.8 The Clinical Presentation of Coeliac Disease 
Through the late 1950s and early 1960s W.T. Cooke was one of the first clinicians 
to study a group of adults with CD, with the express purpose of characterising the 
condition among mature patients. He first published his work in 1963.253 In 
particular, Cooke and his colleagues wanted to “provide more factual 
evidence”(p.279) about what distinguished CD from other forms of idiopathic 
steatorrhoea. To that end, they collected data on a group of 50 patients, all of whom 
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had “flat” jejunal biopsies, carefully documenting their presenting symptoms, the 
results of a number of investigations, and their subsequent progress following 
diagnosis. They described a group of patients with “mild chronic ill health, recurrent 
glossitis, mild anaemia, and various degrees of intestinal upset”.(p.279) They drew 
attention to three additional symptoms: diarrhoea, which was present in all 50 
subjects, and was the principal symptom in 80% of the group; metabolic bone 
disease, which affected 18% of the group; and neuropathy, which had a pronounced 
impact on 8% of their subjects. Lassitude and weight loss were also present in many 
of the study participants, but the researchers noted that it was difficult to determine 
whether these were a consequence of the diarrhoea patients experienced, or 
separate symptoms of the underlying disease process itself. Overall their conclusion 
was that for “the majority of patients, adult coeliac disease is a relatively mild 
disorder”,(p.289) already a contrast to the portrait of CD that had previously been 
painted by Gee,85 and discussed earlier in this chapter. The notion that patients with 
CD might present with differing constellations of symptoms and on a spectrum of 
severity had begun to emerge. 
Now, several decades later, it is fair to say that CD has been extremely well 
characterised. In the vast body of literature written about the condition in the 
intervening years, a range of terms have been used to describe its clinical 
presentation. It has been referred to as a chameleon,254 as “the great imitator”,255 
and as a disease with “many faces”.100 Its presenting symptoms are protean, myriad, 
heterogeneous, diverse, variable, and non-specific, to give just some of the epithets 
used to describe them. And such characterisations of CD are generally followed by 
the same message: CD is common but underdiagnosed, and clinicians need to be 
alert to its many modes of presentation in order to remedy this problem. As is 
written in the introduction to the 2004 NIH Consensus Development Conference 
Statement on CD,62 the “single most important step in diagnosing celiac disease is 
to first consider the disorder by recognizing its myriad clinical features.”(p.S2)  
Patients with CD can and do experience a wide range of symptoms and/or 




Table 2.8: Symptoms and conditions associated with CD 
System Symptom/ condition 
General Fatigue; failure to thrive; delayed puberty; weight loss; 
Gastro-intestinal Diarrhoea; steatorrhoea; nausea; vomiting; anorexia; 
dyspepsia; gastro-oesophageal reflux; malnutrition; 
micronutrient deficiencies; abdominal pain; bloating; 
constipation; deranged liver function tests (hepatitis; 
cholangitis) 
Oral cavity256,257 Dental enamel defects; Aphthous stomatitis; atrophic 
glossitis 




Ataxia; peripheral neuropathy; migraine; seizures; 
depression; 
Haematological260 Anaemia; iron, folate, and/or vitamin B12 deficiency; 
hyposplenism; lymphoma; selective IgA deficiency; 
Reproductive Amenorrhoea; recurrent miscarriage; infertility 
Skin  Dermatitis herpetiformis; alopecia;  
 
Where previously the symptoms of CD were thought to be limited to the 
gastrointestinal tract, and the consequences of damage to the gut such as 
malabsorption, it is now widely recognised that this is far from the complete 
picture. Indeed, at the other end of the spectrum, it is not uncommon for patients to 
be overweight at presentation.261,262 
In many cases, the differing clinical manifestations of CD can be linked to the 
complex pathogenic processes now known to be at work. Some, such as diarrhoea 
and symptoms of malabsorption, can be directly attributed to the damage to the 
intestinal mucosa. Some, such as fatigue and (perhaps) arthralgia and myalgia, can 
be at least partly ascribed to inflammation being generated by the immune 
system.263 And some, such as the association of CD with T1DM and autoimmune 
thyroid disease, can be connected via a genetically mediated predisposition to 
autoimmune disease.264 
As presented earlier in this chapter (page 31) there are several different 
classifications of CD, each one signifying a different constellation of symptoms. 
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Using the Oslo definitions, Classical CD is characterised by diarrhoea and/or 
steatorrhoea, weight loss (or failure to thrive in children), and evidence of 
malabsorption and malnutrition, such as anaemia, or oedema due to 
hypoproteinaemia.22 Children with classical CD may also have abdominal distention 
and muscle wasting, and tend to present at a young age following the introduction 
of gluten into the diet.265  
Non-classical CD is CD in the absence of malabsorption. The example given is 
that of a patient with constipation and abdominal pain, and may also include many 
patients who would previously have been described as having atypical disease.22 
Symptoms cited by the Oslo group that would have been encompassed by the older 
label include irritable bowel syndrome-type presentations, abnormal liver function, 
peripheral neuropathy, depression, gynaecological dysfunction, bone disease, and 
skin and oral cavity lesions. Symptoms given by other writers include dyspepsia, 
fatigue, joint and muscle pain, and osteoporosis.6,7 In children, atypical CD would 
have also included nausea and vomiting, short stature, pubertal delay and dental 
enamel defects, as well as abdominal pain and constipation.265 Most of these 
symptoms, in both adults and children, appropriately come under the non-classical 
umbrella, although it is less clear under which Oslo label someone with low-grade 
abdominal symptoms and iron deficiency without anaemia would fit, or for that 
matter someone with osteoporosis due to impaired Vitamin D and calcium 
absorption. What is clear is that in adults and children alike, the patterns of 
presentation have changed over time. This has been formally demonstrated in 
several studies, both in New Zealand,266-268 and elsewhere.98,212,241,247,269-273  
One of the earliest of these studies is work conducted by Logan et al.,98 in which 
two Scottish cohorts of patients with CD were compared with respect to their 
presenting symptoms. The two groups each spanned five years, one from 1960 to 
1964, and the other from 1975 to 1979. The most striking difference that these 
researchers found was that in the earlier cohort 63% had had malabsorption 
syndrome (diarrhoea, weight loss, and anaemia, hypoproteinaemia, or 
hypocalcaemia), compared with just 13% of the second group who were similarly 
affected. In addition to this, among the first cohort of patients there were no 
presentations involving minor blood test abnormalities with no other associated 
symptoms, but this accounted for 29% of patients in the second cohort. In that 
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group a total of 55% of patients had “no gastrointestinal symptoms to attract 
attention to the relevant system”.98(p.97) 
Probably the most widely cited and most extensive study relating to clinical 
presentations of CD in adults is that by Rampertab et al.,269 in which the records of 
patients diagnosed in New York city between 1952 and 2004 were interrogated for 
information about their presenting symptoms. This study involved 590 people with 
biopsy-confirmed CD who were divided into six cohorts. The first group was of 
patients diagnosed before 1981, and included some who had been diagnosed as 
children as far back as 1952. All other patients were divided into quinquennial 
groups, according to when they had been diagnosed. Rampertab and his colleagues 
found that among the cohort diagnosed before 1981, 93% had presented with 
diarrhoea, whereas by 2004 this number had fallen to 37.2%. In the early groups 
no-one who had been diagnosed with CD had been asymptomatic at the time, but 
from the mid-1990s this changed, with up to 17% of patients being identified 
through screening. 
Most recently, Dominguez Castro and colleagues have published the results of 
their retrospective analysis of CD presentations in Ireland between 1960 and 
2015.273 They too have found that over that time period the numbers of people 
presenting with classical CD fell (from 85.2% prior to 1985 to 48.4% since 2011) as 
the numbers with non-classical disease increased (from 14.8% to 51.6%). In 
addition to this they noted that the adult median age at diagnosis steadily increased 
from 34 years prior to 1985, to 46 years since 2011. They did not present median 
age data for children, whom they classified as being under the age of 18 years.  
A recent study from Finland,274 which examined paediatric diagnoses over a 
similar time frame to the Irish study, charted an increase in the median age at 
diagnosis from 4.3 years prior to 1980, to 9.0 years between 1980 and 1999, then 
gradually falling again to 7.6 years by 2013. Interestingly in this study the authors 
tentatively suggested that the dramatic changes in presentation (and degree of 
histological damage) seen between cohorts of children diagnosed before and after 
1980 have largely plateaued since the beginning of this century. 
In New Zealand studies of patterns of presentation of CD, the emphasis has 
mostly been on children. In 2005, Westerbeek and colleagues published the findings 
of a retrospective review they carried out on the records of children diagnosed at 
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Auckland’s Starship Children’s Hospital.267 Their review covered the period 1999 to 
2002, and included 48 children with CD. The median age of presentation was 6.9 
years and, for children over the age of five years, the predominant symptom was 
abdominal pain, as opposed to failure to thrive, which occurred more frequently in 
the under-5s. Almost 20% of their sample was detected by screening of at risk 
children, who either had T1DM, or Down syndrome, or a family history of CD. More 
recently, a similar review has been conducted in Christchurch by Kho et al.268 Their 
study covers the 11-year period from 2000 to 2010, during which time 263 children 
under the age of 16 years were diagnosed with CD. The median age at presentation 
in this cohort was 7.9 years, and the study confirmed the findings of Westerbeek et 
al. that older children presented more commonly with abdominal pain, and that pre-
school children were more likely to present with diarrhoea and low weight. In the 
Christchurch group almost 15% were identified through screening for CD, and were 
asymptomatic.  
In similar studies of children from overseas, Whyte et al.271 found that 36% of 
South Wales children with CD were identified from screening, while Telega et al.270 
observed that over the 17-year period from 1986 to 2003, the numbers of 
symptomatic children being diagnosed at a Wisconsin clinic fell as the mean age of 
diagnosis increased. Those that were symptomatic were more likely to present with 
gastrointestinal symptoms if they were younger than three years old, while extra-
intestinal symptoms predominated in older children. Khatib et al.272 found that 
among a cohort of 165 New York children diagnosed with CD in the ten years to 
2013, over 50% presented with abdominal pain, and almost 40% suffered from 
constipation. Diarrhoea was present in only 31.1% of subjects. 
2.8.1 Facilitating the recognition of CD 
As already noted, the image of an iceberg is often used to describe CD, with the 
visible tip representing diagnosed patients, and the submerged bulk signifying the 
much greater number of people with the condition who are yet to be identified. In 
addition to this, there is good evidence from a number of countries that people with 
CD face delays in diagnosis of many (often in excess of ten) years.33,241,275-277 
Unsurprisingly this has a negative impact on quality of life, and contributes to years 
of unnecessary morbidity.278 Work by Vavricka et al.279 suggests that responsibility 
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for this delay sits with practitioners failing to consider the diagnosis in a timely 
manner, rather than with patients failing to seek medical help for their symptoms. 
In order to assist practitioners confronted with the coeliac iceberg, and in an 
effort to mitigate diagnostic delay, several guidelines have now been developed. 
Probably the most readily accessible of these are those from NICE. The first iteration 
of CD-related recommendations they produced were made available in 2009,280 and 
focused on recognition and assessment. These were updated in 2015, to include 
advice on management.71 NICE Clinical Guideline 20 (NG20) is a comprehensive 
synthesis of the available evidence pertaining to the recognition, assessment and 
management of CD, and applies to both adults and children. 
With respect to the recognition of CD, NG20 presents guidance on symptoms 
that should prompt clinicians to offer testing for the condition, and on clinical 
situations in which testing should be considered. (Tables 2.9 and 2.10) The 
distinction between the two tables is determined by the degree of confidence of the 
GDG about the relative benefits to patients in each situation. Thus, testing should be 
offered in circumstances when “for the vast majority of patients, [it] will do more 
good than harm, and be cost effective”, and should be considered when it “will do 
more good than harm for most patients, and be cost effective, but other options may 




Table 2.9: NICE Guidance on symptoms warranting testing for CD 
Offer serological testing for coeliac disease to first-degree relatives of 
people with coeliac disease; AND to people with any of the following: 
Persistent, unexplained abdominal or gastrointestinal symptoms 
Faltering growth 
Prolonged fatigue 
Unexpected weight loss 
Severe or persistent mouth ulcers 
Unexplained iron, vitamin B12, or folate deficiency 
Type 1 Diabetes (at diagnosis) 
Autoimmune thyroid disease (at diagnosis) 
Irritable Bowel Syndrome in adults 
 
Table 2.10: NICE Guidance on circumstances in which CD testing should be considered 
Consider serological testing in people with any of the following: 
Metabolic bone disorder 
Unexplained neurological symptoms, especially peripheral neuropathy and 
ataxia 
Unexplained sub-fertility or recurrent miscarriage 
Persistently raised liver enzymes 




It is clear that these tables do not present all of the symptoms, signs and associated 
conditions that could lead to a diagnosis of CD. However, these are the symptoms 
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(and signs) for which there is at least some evidence that patients experiencing 
them are more likely to have CD than patients without them. Both tables also 
contain fewer items than did the equivalent tables in the 2009 iteration of the 
guidelines.280  
Of the other recent CD-related practice guidelines available,12,67,69,70,72 the 
ACG,69 the WGO,72 the ESPGHAN and BSPGHAN,12,67 all make explicit 
recommendations about whom should be tested. All four guidelines have similar 
lists to those from NICE, with additions covering more of the symptoms and 
conditions included in Table 2.9. The BSG70 does not make separate 
recommendations about patients warranting testing, instead referring users to the 
2009 NICE guidelines.  
2.8.2 Conditions associated with CD 
As indicated in the NICE recommendations, there are several conditions that have 
been found to have an association with CD, although, as also noted by NICE, the 
evidence supporting some of these associations is weak.71(pp.38–43) Nonetheless, 
the presence of any of these conditions should prompt the clinician to consider 
testing for CD, and can be loosely organised into two groups: 
(1) conditions that have arisen as a consequence of undiagnosed (and therefore 
untreated) CD; and 
(2) conditions that are associated with an increased occurrence of CD among 
affected people, compared to the non-affected population. 
The first of these groups is comprised of disorders such as osteoporosis and 
anaemia, in which malabsorption of crucial nutrients can account for their onset. 
Persistent fatigue could also reasonably be included in this grouping, arising either 
as a consequence of the ongoing inflammatory process central to CD, and/or from 
anaemia. The second grouping consists primarily of autoimmune diseases, and also 
includes Down syndrome and Turner syndrome. Previously it was thought that 
Williams syndrome should also belong to this group, however a more recent study 
by Stagi et al.281 has found that CD is no more likely to occur in people with this 
disorder than in the non-affected population. 
Many of the autoimmune diseases are associated with an increased risk of CD, 
although as the NICE GDG pointed out, many of the studies pointing to this increased 
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risk are low quality.71 Associated autoimmune conditions include T1DM, 
autoimmune thyroid disease, Addison’s disease, Sjögren’s syndrome, rheumatoid 
arthritis, psoriasis, systemic sclerosis, alopecia areata, and vitiligo.  
In a 2016 review of CD and autoimmunity, Diamanti el al.282 reported that the 
prevalence of other autoimmune conditions among patients with CD is 30%, as 
compared to a prevalence of between 3% and 9.4% in the general (non-CD-affected) 
population. Of these the most commonly associated are T1DM and thyroid diseases. 
The authors also noted a higher prevalence of autoimmune conditions among close 
relatives of people with CD.  
It is postulated that the increased prevalence of CD among people with other 
autoimmune diseases could be explained by the presence of shared genetic loci. 
There is increasing evidence available to support this premise.264,283 Most, but not 
all, of the genetic overlap between CD and these conditions occurs at the MHC, with 
many sharing the HLA-DQ2 and/or HLA-DQ8 haplotypes. Non-HLA genetic loci in 
common with CD have also been identified in some of the autoimmune diseases, 
which may also indicate that there is a gene (or genes) for autoimmunity in 
general.284  
Down syndrome and Turner syndrome are also known to have an associated 
increased risk of CD.285,286 It remains unclear what the precise mechanisms are for 
these associations, but it is suggested that chromosomal abnormalities at the heart 
of each condition provide the explanation. Chromosome 21 is the site of the genes 
that encode interferon-α (IFN-α) receptors, which facilitate the action of IFN-α, one 
of the cytokines that has been shown to play an important role in the genesis of the 
CD immune reaction.75 Both the expression of IFN-α receptors, and IFN-α activity 
are increased in people with trisomy 21 (i.e. Down syndrome).174  
Women with Turner syndrome have either partial or complete monosomy of 
the X chromosome. It is now known that genes implicated in autoimmunity are 
located on the X chromosome,287 thus it is theorised that it may be a deficiency of 
immunoregulatory genes, due to the absent or incomplete X chromosome, that 
increases the risk of developing CD in this syndrome.286 
Perhaps paradoxically, it is also thought that the location of autoimmunity-
associated genes on the X chromosome may contribute to the observed increased 
prevalence of autoimmunity (including CD) among women when compared with 
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men. This points to the complex interplay between promoter and regulatory genes 
and gene dosage effects, and is one genetic avenue presently being explored in 
detail.287 
2.8.3 Dermatitis Herpetiformis and Gluten Ataxia 
Dermatitis herpetiformis (DH) is the dermatological manifestation of CD. It is 
characterised by an intensely itchy, papulovesicular rash that most commonly 
localises to the extensor surfaces of the elbows and knees, the proximal forearms, 
sacrum and buttocks.288 It is generally symmetrical, and can also affect the face, 
scalp, shoulders and neck. Diagnosis is confirmed by the presence of IgA deposits 
(seen under immunofluorescence) in the dermal papillae of samples taken from 
normal skin adjacent to a lesion.134 The vast majority of people with DH will have 
evidence of villous atrophy on duodenal biopsy,22 but, because of the ubiquity of 
this finding, it is not generally necessary for people with a confirmed diagnosis of 
DH also to undergo endoscopy.134 It has the same HLA associations as CD, and IgA-
tTG antibodies and EMA will usually be positive on serological testing. As with CD, 
treatment is with a GFD, although in some cases patients may also require dapsone, 
particularly in the early period following diagnosis. Over time, continued adherence 
to the GFD will enable many of those people to stop this additional treatment.22 
Much rarer than CD, a 2009 study from Finland found the prevalence of DH was 
eight times lower than that of CD in the same population.289 Curiously, in this study, 
and in a similar 2013 study conducted in the United Kingdom,250 the incidence of 
DH was found to have been steadily falling, in contrast to that of CD which continues 
to rise. It is not clear how these two observations are linked, but West et al.250 
postulated that perhaps diagnosing and treating CD prevented the onset of DH. 
Gluten ataxia (GA) is defined by the Oslo group as “idiopathic sporadic ataxia 
and positive serum antigliadin antibodies even in the absence of duodenal 
enteropathy.”22(p.48) It arises as a consequence of damage to the cerebellum, and 
in particular to the Purkinje cells, and is treated with a strict GFD. It affects men and 
women equally, and tends to come on gradually in the fifth decade. The primary 
symptom is gait ataxia, which affects all patients, with associated limb ataxia also 
affecting the majority.290  
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Although it is recognised as an autoimmune condition,134 GA’s relationship 
with CD is much less clear than that of DH and, unlike DH, it is not regarded as an 
alternative manifestation of CD. Antigliadin antibodies, which are required for the 
diagnosis of GA, are no longer used to reach a diagnosis of CD because they lack 
disease specificity,22 while the more CD-specific IgA-tTG antibodies are only 
positive in just over a third of people with GA.134 It is recommended that tTG 
antibody-positive GA patients should undergo duodenal biopsy to confirm the 
diagnosis of CD. Nonetheless, a GFD has been shown to halt the progression of, if 
not improve ataxia in AGA-positive patients, strongly implicating a role for gluten 
in GA’s aetiology. 
In the past decade interest has grown in the role of transglutaminases other 
than tTG (the autoantigen for CD; also known as TG2) in autoimmune diseases in 
general, and DH and GA in particular.291 Transglutaminase-3 (TG3; also known as 
epidermal transglutaminase) is now recognised as the autoantigen for DH,292 while 
antibodies to transglutaminase-6 (TG6) have been identified in neural tissue in 
patients with GA.293. Work by Stamnaes et al.291 and Hadjivassilou et al.293 suggests 
that TG6 antibodies in GA are gluten-dependent, and it is hoped that the 
development of reliable methods of testing for the presence of these antibodies may 
lead to a robust diagnostic pathway for this condition.  
2.9 Testing for Coeliac Disease 
All current guidelines pertaining to CD recommend that tTG antibody testing should 
be the first step in investigating both adults and children with possible CD.12,67,69-72 
As this is an IgA-based test, it is also generally recommended that IgA levels be 
measured concurrently, so that IgA-deficient patients are identified, and alternative 
IgG-based tests arranged.  
There are two schools of thought about whether tTG antibody testing should 
be the sole initial test for CD, or whether a combination of tests is required. 
Currently the more popular view is that IgA-tTG antibody testing alone is the 
appropriate first-line approach. This is recommended in guidelines from the 
ESPGHAN,12 the ACG,69 and NICE,132 and promoted in a number of recent review 
papers.11,81,207,240 Under this approach, a second test for EMA and/or anti-DGP 
antibodies may be recommended if the first test is equivocal, and IgG-based anti-
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DGP testing is advised when a patient is found to be deficient in IgA. The alternative 
view, promulgated by the BSG,70 is that initial testing should include both IgA-tTG 
and either EMA or DGP antibody testing concurrently. Kelly et al.10 indicate that 
either simultaneous or sequential testing is appropriate, while the WGO72 presents 
recommendations stratified according to resource availability, with the most cost-
effective test being the IgA-tTG antibody assay. Thus in better resourced countries 
the WGO indicates that any of IgA-tTG, EMA, or DGP antibody tests, either singly or 
in combination, would be an appropriate first-line investigation, while in less well-
off countries, IgA-tTG testing should be the priority.72(p.756) 
In studies that have directly compared the performance of available antibody 
tests,128,129,294,295 tTG, EMA, and DGP antibody tests have all performed well. In their 
2006 systematic review,128 Lewis and Scott found that overall EMA tests tended to 
have higher specificity, while the human-recombinant IgA-tTG test had higher 
sensitivity. This led them to recommend that IgA-tTG antibody testing should be 
preferred. In their subsequent meta-analysis of studies comparing tTG and DGP 
antibody tests,129 they concluded that although both tests performed well, tTG 
antibody assays were superior. They reiterated their recommendation that IgA-tTG 
antibody tests should be preferred over others.(p.73) This position was endorsed 
by Volta et al.294 in their review of the two tests, while the conclusions of a 
systematic review by Giersiepen et al.295, (focused on testing in children), also 
largely accorded with those of Lewis and Smith. 
Recently the role of DGP antibody assays in testing for CD has been receiving 
more attention.126 There is some evidence to suggest that IgG-based DGP antibody 
tests are highly specific,296 and more sensitive than their tTG equivalents,124,127 
rendering them the better option for testing IgA-deficient patients.10,125 There is 
also a suggestion that DGP antibody tests may be more reliable in young children, 
(although it has also been shown that young children can demonstrate positive CD 
antibodies that resolve without intervention).124  
It should be noted that a small subset of people with CD are seronegative; that 
is, antibody testing returns normal results, but they have villous atrophy on 
duodenal biopsy, and are HLA-DQ2 or DQ8 positive. Other causes of villous atrophy 
(such as drug-induced or infection) must be excluded before the diagnosis can be 
made.297 A 2016 retrospective study by Volta et al.298 involving 810 patients with 
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CD, found that 14 (1.7%) were negative for EMA and anti-tTG antibodies. Antibodies 
to DGP had not been tested in these patients, but a study by Hoerter et al.299 suggests 
that had they been done, perhaps two of those 14 would have returned a positive 
test. Clinicians need to maintain a high level of suspicion that CD might be present 
for these patients to be diagnosed. 
2.9.1 The gluten challenge 
A prerequisite for the accurate interpretation of coeliac serology results is that the 
person being tested is eating a gluten-containing diet at the time of testing. In this 
era of enormous popularity of the GFD, it cannot always be assumed that this will 
be the case. Clinicians requesting CD testing therefore need to determine that their 
patients are indeed consuming gluten, and if not, should recommend that they 
undertake a “gluten challenge” before having any tests performed. 
Until relatively recently the accepted norm for a gluten challenge comprised 
consuming 10gm of gluten per day (often recommended as four slices of bread), for 
six, and sometimes eight, weeks.8,69,122 In his 2008 review of CD, Anderson300 
suggested that between two and four slices of bread per day would be appropriate, 
and that the duration of the challenge could be adjusted according to what the 
patient could tolerate. 
With the exception of the 2015 NICE guidelines,132 which say that prior to 
testing a patient should “eat some gluten in more than one meal every day for at 
least 6 weeks” (p.2), all recent (adult) guidelines have referred to a 2013 paper by 
Leffler et al.301 In their study, Leffler and colleagues determined that “[o]ver 75% of 
adults will meet diagnostic criteria for coeliac disease after a 2-week gluten 
challenge”,301(p.996) and that 3gm of gluten (or approximately 1.5 slices of bread) 
per day is a sufficient dose. Thus they recommend that a modified gluten challenge 
should consist of an initial 2-week period in which the patient eats 3gm of gluten 
per day. Patients who are unable to continue beyond this should then undergo 
duodenal biopsy and serology testing, while patients who are tolerating the process 
should continue for as many more weeks as they are able, up to a total of eight 
weeks. Serology testing should be performed at the completion of the challenge, and 
if negative, be repeated two weeks later. (This is because they also found that 
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antibody titres continued to rise for some time after the challenge period had 
ended.)301 
While the study by Leffler et al. involved only 20 patients, and investigated 
patients with documented CD whom it would be expected would respond to the re-
introduction of dietary gluten, their recommendations have been picked up, or at 
least alluded to, by the ACG,69 BSG,70 and WGO,72 as the approach to take when 
investigating people who have already excluded gluten from their diets. 
2.9.2 The role of HLA testing 
As discussed earlier in this chapter (section 2.5.1) it is well established that CD is 
associated with the HLA haplotypes DQ2.2 and DQ2.5 (together known as DQ2), and 
DQ8. More than 99% of people with CD possess one or other.174 However, as also 
noted already, these HLA markers are present in at least 30% of the population, and 
in some places more than 50%,18 limiting their usefulness in testing for CD. 
In the context of CD, there are circumstances under which testing HLA status 
can be helpful, and is recommended. In all of these situations the utility of the test 
lies in its ability to rule out CD, rather than helping to confirm the diagnosis.125 Thus 
the majority of guidelines discourage the use of HLA testing as part of the CD 
diagnostic process.69,70,72,132 The exceptions are the 2012 ESPGHAN,12 and 2013 
joint BSPGHAN and Coeliac UK guidelines,67 both of which include HLA testing as 
one of the requirements for diagnosing CD in children without a biopsy. All available 
guidelines concur that HLA testing should be carried out on patients in whom the 
diagnosis of CD is being considered but who are already on a GFD, so that a gluten 
challenge (and further unnecessary investigation) can be avoided if testing is 
negative. Similarly all guidelines suggest that HLA testing can be used to try and 
rule-out CD in people who are at risk of the condition (e.g. Down syndrome, first-
degree relatives, T1DM), to spare them the need for ongoing surveillance. Other 
circumstances where an HLA test maybe helpful are in patients with negative 
serology but evidence of enteropathy on biopsy, patients with equivocal histology, 
and patients who do not respond as expected to a GFD.177  
Somewhat in contrast to the guidelines groups, Anderson et al.18 have 
cautiously proposed a diagnostic pathway for adults that does include HLA testing. 
The primary focus of their study was to determine whether it is possible to more 
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accurately (and cost-effectively) establish CD prevalence rates within communities 
than the current reliance on CD serology, with or without biopsy confirmation, 
allows. They found that by adding HLA testing to the process, people with false 
positive serology could be excluded from prevalence estimates, but also did not 
have to undergo costly endoscopies to confirm this. The reasonable conclusion to 
draw from this is that HLA testing of people with positive CD antibodies could 
reduce the number of unnecessary endoscopies by identifying those in whom CD is 
not a possible diagnosis. There is however a potential risk in following such a 
pathway. As is clearly stated in all discussions relating to CD and HLA-DQ2/DQ8, a 
positive HLA test does not confirm the diagnosis of CD. Unfortunately this message 
has not always been heard, as identified in a recent report by Paul et al.,178 in which 
they discussed cases of children being wrongly diagnosed with CD on the basis of 
positive HLA tests. This is in spite of ESPGHAN’s very clear directions on the 
appropriate ways to diagnose CD in children, which perhaps does not bode well for 
adopting similar pathways for adults. It might be that this risk would be ameliorated 
by standardised laboratory reporting of HLA test results, together with an 
interpretation of their significance, as suggested by Tye-Din and colleagues,177 but 
this remains to be seen. (There is some evidence to indicate that laboratory reports 
that include recommendations on responses to a result do influence practitioner 
behaviour.36 Sinclair and Duncan observed a substantial increase in referrals to 
gastroenterologists when their laboratory added a recommendation to do so on all 
new-positive anti-tTG and EMA antibody test results.) 
2.9.3 Point-of-care testing  
Since the early- to mid-2000s when they were developed in Finland,302 rapid test 
kits have been available that utilise fingerprick blood samples to test for CD- 
associated antibodies. Initially proposed as a means for improving diagnosis rates 
and as a tool for monitoring dietary adherence,5 interest remains in their role in 
early identification of disease.9 This is particularly the case in countries with limited 
healthcare resources and access to regular CD antibody assays.303,304 In the hands 
of a range of healthcare professionals, POCT enables more extensive testing to take 
place in communities, particularly in rural areas, that might otherwise be 
overlooked.47 Although as Costa et al.303 point out in their study of POCT in three 
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Mediterranean countries, the sensitivity and specificity of the tests varied markedly 
between users, signifying that a level of expertise is required to ensure their 
reliability. 
The general consensus regarding POC testing is that the data on their 
performance are not yet consistent enough to support their general introduction 
into routine clinical practice.10,81,101,305 All commentators specify that positive POC 
tests should be followed-up with laboratory serology testing and, if indicated, 
duodenal biopsy, so that patients do not commence a lifelong GFD without a 
confirmed CD diagnosis.  
2.10 The Management of Coeliac Disease 
Broadly speaking, the aims of the management of CD can be regarded as threefold: 
to promote mucosal healing; to resolve (or at least improve) patient symptoms and 
nutritional deficiencies; and to reduce the incidence of long-term complications and 
mortality.306 Achieving these outcomes will, it is hoped, improve the patient’s 
quality of life.  
Probably the most extensive review of CD management to have been conducted 
is that by Haines et al.28 Published in 2008, it preceded all the recent guidelines that 
now include recommendations pertaining to long-term follow-up.67,69,70,72,132 It 
followed a 2007 review of the then available guidelines carried out by Silvester and 
Rashid,307 who had determined that those guidelines that did address the issue of 
long-term management were highly variable. This was in large part due to a lack of 
clear evidence on which to base their recommendations. Haines and colleagues 
delved into the evidence that did exist, including 361 references in their review. 
These mostly concerned the potential complications of CD, and whether these could 
be predicted and/or influenced by review of the patient and management 
interventions. The authors concluded that “a planned long-term strategy for follow-
up is essential”,28(p.1042) and proposed a plan in which patients would be 
reviewed immediately following diagnosis, then at six weeks, six months, and 12 
months following diagnosis, and annually thereafter.(p.1054) 
Achieving mucosal healing is central to CD management, however there is 
conflicting evidence about its impact on future health. Some studies suggest that 
persistent villous atrophy is associated with an increased risk of 
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lymphoproliferative malignancy,308 and hip fracture,309 but others have shown that 
there is no increased risk of mortality among those who have not achieved complete 
mucosal recovery.310,311 There is also evidence both that symptoms can improve 
without complete healing having occurred,310,312 and that symptoms may persist 
despite complete healing,313 a conundrum that makes assessment of disease 
recovery and treatment adherence particularly challenging.  
Since the identification more than 70 years ago of gluten as the primary 
environmental trigger of CD, the mainstay of treatment for the condition has been 
adherence to a lifelong GFD. If strictly followed, this has been shown to lead to 
healing of the gut in a majority of people with CD, although this may take several 
years to achieve.310,312,314,315 However, this too is contested, most notably by Lanzini 
et al.316 In a study published in 2009 of 429 people with biopsy-proven CD, they 
found that just 8% could be said to have completely healed their intestinal mucosa, 
although another 65% were reported as having achieved “remission” but with 
persistently increased IELs.  It should be noted that the median time on a GFD 
among participants in this study was 16 months. 
Predicting who will achieve mucosal healing and who will not, remains 
problematic. A large study by Lebwohl et al.317 examined follow-up biopsy data 
from over 7600 patients over many years, and found that older age, being male, and 
being less educated were all associated with an increased risk of persistent villous 
atrophy. They also found that rates of healing have increased over time, perhaps 
because people are being diagnosed earlier (and therefore with lesser degrees of 
villous atrophy, a view consistent with work by Galli et al.312), or perhaps because 
access to gluten-free foods is improving. They postulated that the link between 
lower educational levels and persistent intestinal damage was mediated by poorer 
adherence to the GFD.  
As Haines et al.28(among others) demonstrated, the management of CD ought 
not to be limited to prescribing a GFD and leaving it at that. In recent years a more 
comprehensive approach to management has come to the fore in guidelines 
documents, and more broadly in the literature.e.g.29,69,70,318,319 This is especially 
important with respect to reducing long-term complications, and/or risk of 
associated conditions. In addition to this, as the various steps in the pathogenic 
process of CD have been elucidated, the way has been opened for the development 
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of novel treatments that it is hoped will relieve patients of the burden of adhering 
to a diet that is both challenging, and expensive to maintain. The following sections 
discuss these issues in more detail. 
2.10.1 The Gluten-Free Diet 
As has already been discussed in this chapter, gluten is the collective name given to 
the proline- and glutamine-rich proteins found in wheat, barley and rye. Removing 
these proteins from the diet therefore necessarily demands excluding the vast 
majority of products containing each of these grains, as well as triticale, a hybrid of 
wheat and rye. The list of food products that this encompasses is extensive, given 
the ubiquity of wheat in particular.(Table 2.11) Wheat-derived exceptions to the 
GFD are wheat glucose syrup, wheat dextrose, and caramel colour (occasionally 
made from wheat), which are produced from its carbohydrate component, and are 
so highly processed that no gluten remains in the end-product.320  
Table 2.11: Gluten containing grains and products in which they are found 







Breads and bread products, pizza bases, bagels, flour, pasta, 
breakfast cereals, bran, biscuits, cakes and other baked 
products, couscous, bulgur, semolina, pastry, processed 
meats such as sausages, tinned foods such as baked beans 
and spaghetti, flavourings, seasonings, sauces, thickeners, 
confectionary, medications, beer, soy sauce, communion 
wafers, wheat starch§ 
Barley  Breakfast cereals, breads, flour, soups, malt and malted 
products, beer 
Rye Bread, crackers, flour, whisky*, vodka* 
§  The place of wheat starch in the GFD remains controversial. It is a highly processed derivative of 
wheat but does retain detectable levels of gluten. It has long been included in the GFD in Europe, and 
more recently in the USA, but is excluded in New Zealand and Australia.306,321 
* Although whisky and vodka are derived from rye, the general advice from organisations such as 
Coeliac New Zealand is that they are safe to include in a GFD because the distillation process filters 
out gluten containing proteins. They do acknowledge that there is some debate about whether tiny 
amounts may remain. (www.coeliac.org.nz/eating-gluten-free/what-alcohol-is-gluten-free. 
Accessed 7th September 2017) 
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There are many food groups and products that in their natural states will 
always be gluten-free. These include eggs, unprocessed meats, fruits and 
vegetables, legumes, and pure grains such as rice, corn, millet, and quinoa. However, 
there are also many opportunities for those products to become contaminated with 
gluten, derived from any of the three grains in which it is found, and the range of 
products that may or may not contain gluten is vast. Being able to identify those 
items that are safe to eat as part of a GFD, and those that are not, poses a continuing 
challenge for patients with CD (and those with other gluten-related disorders).  
It is widely acknowledged that it is almost impossible to achieve a zero-gluten 
diet, which raises a question about whether there is a safe level of gluten that even 
people with CD can consume without doing themselves harm.306,321 This issue was 
addressed in 2008 in a systematic review by Akobeng and Thomas,322 in which they 
examined 13 studies investigating the impact that a range of amounts of gluten had 
on patients with CD. They reached the conclusion that “a daily intake of <10mg is 
unlikely to cause significant histological abnormalities”(p.1044), but also noted that 
there was a range in the amount tolerated. A figure of less than 10mg errs on the 
side of caution as no study included in their review found evidence of intestinal 
damage at this level. It is also consistent with the findings from a double-blind, 
randomised, controlled trial conducted by Catassi et al.323 to determine a safe level 
of exposure. Akobeng and Thomas further noted that only three of the studies they 
included were at low risk of bias, and recommended that further, rigorously 
designed studies are needed.322 
In the highly regulated food industry, the definition of what constitutes gluten-
free carries with it technical as well as practical implications. In its “Standard For 
Foods For Special Dietary Use For Persons Intolerant To Gluten”,324 the Codex 
Alimentarius Commission of the WHO defines gluten-free foods as those that do not 
contain any wheat, barley, or rye, and in which “the gluten level does not exceed 
20mg/kg in total”.(Section 2.1.1)a In addition to this, food products that do contain 
ingredients derived from these grains, but which have been processed to remove 
                                                        
 
a Oats are also named in the Codex standard as being gluten-containing, with a footnote that they 
“can be tolerated by most but not all people who are intolerant of gluten. Therefore, the allowance 
of oats that are not contaminated with wheat, rye or barley in foods covered by this standard may 
be determined at the national level.”324(p.2) 
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gluten, may also make the claim of being gluten-free, if the level of detectable gluten 
is also less than 20mg per kilogram. This value is commonly expressed as 20 parts 
per million (20 ppm) and, if present, would translate to 500gm of food containing 
the 10mg of gluten that is suggested as safe for people with CD. To put this figure in 
context, a single slice of bread contains 1-2gms of gluten, which is between 100 and 
200 times the safe level for a person with CD.306  
Gibert et al.325 have investigated the population-level of risk of unintentional 
gluten intake for those with CD in four European countries, using a probabilistic 
modelling approach. They incorporated three variables into their model: average 
consumption of commercial gluten-free products; the concentration of detectable 
gluten in a range of gluten-free-labelled products; and the gluten threshold for 
intestinal damage. They concluded that across the four countries they studied (Italy, 
Germany, Spain and Norway) the level of risk of mucosal damage was 0.47% if the 
threshold for harm was assumed to be 10mg of gluten. There was variability 
between countries, with Italy having the highest level of risk due to Italians’ higher 
average consumption of gluten-free wheat substitutes such as pasta. Almost all 
(99.5%) products they tested for gluten traces had less than 20ppm, and 94% of 
products had less than 5ppm (the lowest quantifiable level for the test kits they 
were using.)325(p.114) It would be interesting to undertake a similar study in New 
Zealand and Australia. 
While the Codex standard has been adopted by the Food and Drug 
Administration (FDA) in the United States, and the European Communities 
Commission of the European Union,306,321 New Zealand and Australia have taken the 
gluten-free labelling threshold a step further.326 Through the regulatory body Food 
Safety Australia and New Zealand (FSANZ) it has been determined that in these 
countries food may only be labelled as gluten-free if it contains “no detectable 
gluten; and no oats or oat products; and no cereals containing gluten that have been 
malted, or products of such cereals”.327(p.5) As technology has advanced, the 
capacity to detect the presence of trace amounts of gluten in foodstuffs has 
increased such that the threshold for “no detectable gluten” is now at less than 
3ppm.326 While this has advantages in terms of ensuring that gluten-free labelled 
products in New Zealand and Australia are very safe for people with CD, it also has 
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the potential to narrow the range of available products more than is necessary, 
given that the Codex standard allows a higher level of gluten.  
In their recent review of gluten thresholds, Bruins Slot et al.326 concluded that 
the labelling requirements legislated for in New Zealand and Australia should in fact 
be adopted internationally, to protect “sensitive and recovering patients”.(p.225) 
They argue that evidence suggests that this group do suffer from adverse outcomes 
when they consume foods with higher levels of detectable gluten, but which still fall 
within Codex sanctioned limits. They too advocate for more studies like that 
conducted by Catassi et al.,323 to determine safe thresholds of gluten ingestion for 
patients with CD with varying sensitivity.326 
2.10.1.1 Oats in the gluten-free diet 
As noted in the footnote on page 79, the position of oats with respect to their place 
in the GFD remains unclear, even in the Codex Alimentarius where it is left to the 
discretion of national regulatory bodies to decide. 
Oats are another grain closely related to wheat. As discussed earlier in this 
chapter, they too contain proline- and glutamine-rich proteins, known as avenins, 
and for some time were also thought to be unsafe for people with CD. However, as 
more evidence has come to light about how the avenins differ from the analogous 
constituents of wheat, barley and rye,94 it is now widely accepted that in the 
majority of patients, adverse outcomes previously attributed to oats were likely to 
have been due to their contamination by these other grains. This contamination was 
demonstrated by Lundin et al.328 in a study published in 2003, in which they tested 
a range of commercially available oats for evidence of gluten contamination, and 
also carried out an oats challenge (using “pure” oats) on 19 adult volunteers with 
CD. One patient among the study group developed villous atrophy following 
consumption of these oats, leading the researchers to conclude that “most CD 
patients tolerate oats in their diet…[h]owever, the finding that even pure oats can 
induce villous atrophy…in one CD patient raises some concerns.”328(p.1652) A more 
recent study by Kaukinen et al.329 investigated the effects of the inclusion of oats in 
the GFD over the long term (up to eight years), and found no evidence of adverse 
impact on symptoms or the intestinal mucosa. 
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There have been four systematic reviews published examining the safety of 
oats for people with CD.95,330-332 All have endorsed their safety, although with 
varying caveats. In 2006, Haboubi et al.330 were only prepared to recommend the 
inclusion of oats “if the patient is undergoing a lifelong regular review under 
specialist care.”(p.677) In 2007, Garsed and Scott95 concluded that uncontaminated 
oats were safe for the majority of people with CD, but recommended that they only 
be included in a GFD once patients were established on this, and that they should 
be excluded again if symptoms recurred. Pulido et al.331 made similar 
recommendations in 2009, also suggesting that only moderate amounts of the grain 
should be consumed. The most recent review was conducted by Pinto-Sánchez et 
al.332 and published in 2017. They have written that “the results of our systematic 
review evaluating oat safety in…CD are reassuring, and suggest that non-
contaminated oats are tolerated by the great majority of patients.”(p.408) The 
common theme from all four reviews is that caution is needed when drawing 
conclusions due to the lack of good quality data.  
In the years since Lundin’s study, formal recommendations regarding the place 
of oats in the GFD have gradually evolved such that they are now cautiously 
sanctioned in all the major guidelines,67,69-72 although there is some variation 
between them. The BSG guidelines are the most liberal, simply indicating that 
gluten-free oats may be included in the GFD from diagnosis.70 The NICE guidelines 
take a similar approach,71 while the WGO states that pure oats are permissible “in 
certain quantities”, noting also that there are concerns about contamination from 
other grains.72(p.763) The ACG is more conservative, advising that “oats should be 
introduced into the diet with caution and patients should be monitored closely for 
evidence of adverse reaction”69(p.665), while the most cautious recommendations 
come from the BSPGHAN.67 This group has recommended that oats not be 
introduced into a GFD until patients (in this case children) are clinically well, and 
established on a GFD. They suggest waiting up to a year, and then monitoring 
patients closely for evidence of relapse. 
In New Zealand and Australia, food products containing oats are not permitted 
to make the claim of being gluten-free. This means that there is still no formal 
recommendation from the coeliac support groups in either country that gluten-free 
oats may be included in the GFD.333  
83 
 
2.10.1.2 Adherence to the GFD 
In their recent review of the GFD,306 See and colleagues discussed the issue of 
adherence to the diet, including presenting a summary table of studies that have 
measured rates of adherence among people with CD. The rates of strict adherence 
vary considerably, from 40% to 96% among adults, with the writers pointing out 
that figures gathered via self-report (which applies to several of the studies they 
reviewed, including those with the highest measures) tend to be higher than those 
gathered by interview-based dietary assessments. It has been postulated that an 
important factor in this may be incomplete knowledge about potential sources of 
gluten, rather than a deliberate misrepresentation of behaviour.334 
The figures presented by See et al. are similar to the findings of Hall et al.335 in 
their 2009 systematic review of studies that investigated factors that might be 
associated with adherence to the GFD among adults with CD. This review included 
38 studies and reported a very similar range (42% to 91%) for strict adherence, 
despite there being little overlap between the studies interrogated by each team. 
Hall and colleagues noted that these rates depended heavily on how “strict 
adherence” to the diet was defined and measured. While noting there was only 
limited evidence to support their conclusions, they did conclude that adherence was 
“most strongly associated with cognitive, emotional and socio-cultural influences, 
membership of an advocacy group and regular dietetic follow-up.”335(p.327) They 
further indicated that there was a lack of robust evidence that clearly linked 
particular variables with non-adherence, and that high quality studies would be 
necessary to determine such links. (The “cognitive, emotional and socio-cultural 
influences” to which they refer include knowledge about the GFD, concerns and 
beliefs about the harmful effects of exposure to gluten, and the ability to follow the 
GFD outside the home. These variables were highlighted in a study by Leffler et al.336 
included in the review.)  
In work completed subsequent to the Hall review, two tools have been 
advanced to try and standardise the measurement of adherence to the GFD.337,338 
The Celiac Disease Adherence Test (CDAT) developed by Leffler et al.337 is a 7-item 
instrument that enquires about symptoms (headaches and low energy), self-
efficacy, and gluten avoidance habits, using a Likert-type scale to measure 
responses. The total score gives an indication of GFD adherence, which Leffler and 
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his colleagues showed correlated well with the “gold standard” assessment of 
adherence by an expert dietitian, and was more accurate than IgA-tTG antibody 
testing. Along similar lines, the tool developed by Biagi et al.338 utilises four yes/no 
questions focused on the strategies people with CD employ to avoid consuming 
gluten. The questions are asked sequentially, and an overall score from zero to four 
is given. The authors compared patients’ scores with their histological and 
serological response to the diet, and found a statistically significant correlation. 
These findings were confirmed in a subsequent validation study conducted by Biagi 
and his team,339 suggesting that the questionnaire is a reliable means of verifying 
GFD adherence. 
There is some significance in the fact that both these tools focus on variables 
other than specific details about what the patient is actually eating, and yet would 
seem to reliably indicate when someone is at risk of non-adherence. The important 
implication of this is that those administering either questionnaire do not 
themselves need to be expert in the GFD to be able to identify patients who would 
benefit from additional support with maintaining the diet. 
2.10.1.3 Challenges to adherence to the GFD 
The following issues have been identified as presenting challenges to adherence to 
the GFD for people with CD:306,321 
 Complexity of the diet, including knowing what is and is not safe, and reading 
and interpreting food labels; 
 The risk of gluten contamination of otherwise gluten-free products; 
 Cost; 
 The availability of gluten-free products, especially when travelling; 
 Difference from others, leading to awkwardness in social and work settings. 
Under the aegis of bodies such as FSANZ and the FDA, regulations relating to 
the labelling of gluten-free products have tightened considerably. Despite this, 
many people with CD report difficulties with interpreting the information 
presented on food labels,31,275 and there is evidence that shopping for gluten-free 
foods takes longer. In an opinion piece published in 2005,340 Pietzak discusses the 
issue of gluten-free labelling in the United States noting that checking labels for 
gluten content probably adds between 10 and 20 hours per month to shopping time. 
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While this figure may have dropped since the advent of more rigorous labelling, the 
extra time required for grocery shopping remains an issue for those with CD.341,342 
The gluten contamination of gluten-free foods, and avoiding this risk, also 
presents considerable challenges for people with CD. This contamination can occur 
at a number of junctures on the way from field to plate, some of which are under the 
control of the person needing to avoid gluten, and some of which are not. For 
example, Thompson et al.343 tested a range of inherently gluten-free products 
available in the USA and found that several of them (e.g. soy flour, white rice flour, 
and millet flour) were in fact contaminated by gluten. The following chart, adapted 




Figure 2-5: Contamination risks in the journey of gluten-free foods from field to plate  
In addition to the settings listed in Figure 2-5, travel to countries where the first 
language of the person with CD is not the local language brings an extra dimension 
of complexity to adhering to a GFD. Coeliac support groups worldwide play an 
Field
• Crop rotation between gluten-free and gluten-containing grains from season to 
season.
• Mixed crops grown in adjacent fields and/or harvested together and/or using the 
same equipment, and then packaged, stored and transported together.
Factory
• Gluten-containing and gluten-free grains milled, processed and stored in common 
faclilities.
• Gluten-containing and gluten-free products made on shared equipment.
Retail
• Bulk-bin products stored adjacent to each other with common scoops for 
dispensing.
• In-house products (e.g. breads) made in a shared environment and using shared  
equipment.
Home
• Shared kitchen space, bench tops, equipment (e.g. toasters), and utensils (e.g. 
bread knives, colanders).
• Common spreads (e.g. margarine), dips, and condiments . 
Eating out
• Inadvertent inclusion of gluten-containing ingredients (e.g. wheaten cornflour).
• Shared food preparation spaces, fryers, grills, and serving implements.
• Display of gluten-containing foods adjacent to and/or above gluten-free foods.
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important role in mitigating this particular challenge, by providing resources such 
as cards with translated questions about food safety (for example), for use when 
food shopping or eating out in a range of different countries.  
The increased cost of gluten-free foods when compared with gluten-containing 
equivalents is well documented,344-347 although it is not clear the degree to which 
cost impacts on adherence. While it undoubtedly affects the capacity of some people 
to maintain a strictly GFD, cost would seem to have a less significant role in 
deviations from the diet than do discomfort in social settings, difficulties 
understanding what is required, or finding foods unappealing.33,348 However it is 
possible that available studies underestimate the impact of cost on adherence, as 
people who are less well off financially may be under-represented in studies that 
have examined the issue. Neither of the studies just cited provide information on 
the socio-economic status of participants.  
One more recent study that has partially explored this issue,349 found that 
inadequate adherence to the GFD (as measured using the CDAT) correlated most 
clearly with lower levels of education, and to the belief that the cost of gluten-free 
foods was a limiting factor. Curiously there was only a “marginally significant 
correlation” between lower median annual household income and an unsatisfactory 
CDAT score,349(p.756) which suggests that it is perception of cost that contributes 
to poor adherence. People who had unsatisfactory CDAT scores were also more 
likely to believe that the GFD does not help their symptoms, and it seems plausible 
that these two factors might be related. 
As discussed by Estévez et al.350 the concept of the “basic food basket” is 
sometimes used in less well-off countries to determine the cost of maintaining 
adequate nutrition for their populations. In a 2016 study, they published a report 
on a “gluten-free basic food basket” in Chile.350 Not surprisingly they found that 
gluten-free products were much less readily available than their gluten-containing 
equivalents (even though they were regarded as basic to a nutritional diet), and the 
overall cost of their basket was three times higher. By way of comparison,  the 
following table gives examples of the differences in cost between some gluten-free 
items and their gluten-containing alternatives available at a Dunedin, New Zealand, 




Table 2.12: Comparative costs between gluten-containing and gluten-free products 





Factor of cost 
difference 
Plain flour 
$6.00 per 5 kg 
(=12c/100gm) 




$2.00 per 300gm 
(=67c/100gm) 




$5.50 per 1.2kg 
(=46c/100gm) 




$1.80 per 500gm 
(=36c/100gm) 




$1.09 per 600gm 
loaf (=18c/100gm) 




$3.99 per 480gm 
(=83c/100gm) 




$5.50 per 640gm 
(=86c/100gm) 




In New Zealand it is possible to obtain a limited range of partially subsidised 
gluten-free products (flour, pasta, bread mix, and baking mix) on prescription. 
Patients with biopsy-confirmed CD (or DH) are eligible for a Special Authority 
number that entitles them to the subsidy. However, since 2011 the New Zealand 
Pharmaceutical Management Agency (PHARMAC), which oversees the provision of 
prescription items in this country, has withdrawn from actively managing the 
funding of gluten-free foods. According to its website this means that they 
are no longer considering the listing of new products, or making subsidy, 
or other changes to the existing listings. As a result we anticipate that 
the range of funded items will reduce over time. Management of Coeliac 
disease with a gluten free diet is necessary for good outcomes. A range 
of gluten free options are available through retail outlets.  
(www.pharmac.govt.nz/Schedule?osq=Gluten%20free%20baking%20
mix&code=C4210012918 Accessed September 2017) 
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In the 2012 New Zealand Coeliac Health Survey,31 Sharp found that a little more 
than 50% of respondents had a Special Authority number, which suggests that their 
usefulness is declining.  
In addition to the prescription subsidy, people who meet the financial 
threshold for government support with a Community Services Card can also apply 
for a Disability Allowance to help cover the costs of gluten-free foods. This is a 
means-tested allowance, and requires applicants to furnish receipts or other 
evidence of the extra expenses they incur because of their illness. Sharp’s study did 
not report the number of people accessing this support. 
2.10.1.4 Nutritional adequacy of the GFD 
In 2017 Newberry and colleagues published a review of the history of the GFD,351 
drawing particular attention to what they termed “the nutritional implications” of 
the diet. Over many years concerns have been expressed about the nutritional 
adequacy of the GFD,352-357 both in terms of what it may lack (fibre and adequate 
amounts of micronutrients) and what it may contain (saturated fats and sugars).  
As summarised by Newberry et al.,351 across most studies it has been a 
consistent finding that pre-packaged gluten-free products (such as cereals and 
pastas), and/or the GFD in toto, are deficient in micronutrients, particularly iron 
and folate. This is in part due to the natural composition of gluten-free grains, and 
in part because gluten-free products are not usually fortified.356 
The findings have perhaps been less consistent with respect to macronutrients 
(fat, protein, and carbohydrates), although the GFD does tend to be lower in fibre 
and protein, and higher in sugars than gluten-containing diets. A large 2015 
Australian study conducted by Wu et al.358 compared the make-up of gluten-free 
products and gluten-containing equivalents with respect to these components. 
Somewhat surprisingly they found that the fat, sugar, and salt content of the gluten-
free products were on a par with their gluten-containing counterparts, at least as 
reflected in the Health Star Ratings (an Australian government endorsed system for 
providing nutrition information to consumers) and nutrition information panels of 
the products they examined. This should be of some reassurance to people with CD, 
however, as Staudacher and Gibson point out in their commentary on the study,359 
the GFD is, at its core, a diet of exclusion and the risk of nutritional deficiency lies in 
89 
 
the “insufficient inclusion of suitable alternatives.”(p.1540) This is particularly the 
case for fibre, the B vitamins, and folate, none of which Wu et al. were able to assess 
for comparability in the products they studied.358  
A nutritionally adequate diet depends both on the breadth of food choices of 
the person consuming the diet and on the nutritional quality of the foods he or she 
chooses to eat, issues that are acknowledged to affect the wider population than just 
those on a GFD.355,356,358 But the additional challenges to this presented by the GFD 
highlight the importance of ensuring that all people diagnosed with CD have access 
to skilled dietitians. Furthermore, many newly diagnosed patients are deficient in 
some or a number of micronutrients as a consequence of the disease so it is essential 
that their diets are adequate to meet any additional requirements. This may or may 
not include the use of supplements, but dietitians expert in CD management are best 
placed to guide patients accordingly.360 All guidelines relating to CD recommend 
that patients should be referred to a specialist dietitian once the diagnosis has been 
confirmed.67,69,70,72,132  
2.10.2 New treatment possibilities 
Because of the issues just discussed relating to the challenges of maintaining the 
gluten-free lifestyle necessary for the management of CD, extensive work has been, 
and continues to be done to produce alternative treatment options. Several studies 
have now demonstrated a desire among patients with CD for alternatives to the GFD 
to be developed.361-364 Alternatives being explored include treatments that would 
obviate the need for a GFD, and those that would be used as an adjunct to the diet 
by reducing the impact of the ingestion of trace amounts of gluten. The challenge in 
developing any new treatment is that it must be safe, as well as effective. As noted 
by Kaukinen and colleagues,173 “one must consider the possible risks versus 
benefits of the various treatments for a disease that is generally benign and 
reversed by a gluten-free diet that causes no major recognized adverse 
events.”(p.42) 
As the complex pathogenesis of CD has become increasingly disentangled, 
several different steps in the process have been identified as possible targets for 
intervention. These targets, along with the potential options for moderating them, 
have been summarised in a number of review papers published in recent 
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years.172,173,199,365-370 The following table distills the key points from these reviews. 
Many of the options suggested are in various stages of the development process, 
ranging from pre-clinical to Phase 2 trials,371 while future targets may include 
genetic risk loci that are implicated in the aetiology of CD.369 (Table 2.13) 
Table 2.13: Novel treatment targets and proposed interventions 
Gluten Immunogenicity 
Proposed interventions: Pre-luminal 
 Selective breeding of low-immunogenic varieties of grains.199,369 
 Genetic modification of  disease-activating grains.199,370,372 
 Pre-treatment of grains during food production (e.g. with Lactobacilli 
in sourdough bread making).199,369,372 
Proposed interventions: Intra-luminal 
 Gluten detoxification by oral proteases: break down proline- and 
glutamine-rich peptides so they do not accumulate in the small 
intestinal lumen.366,369,372 
 Gluten sequestration by oral polymeric resins: bind gluten peptides 
preventing proteolysis and absorption.173,366,369,372 
 Neutralisation of gluten antibodies (e.g. using cows’ milk derived IgG 
antibodies).367 
 Degradation of gluten by probiotics such as Bifidobacterium 
species.173,369 
 
Gluten uptake into small intestinal epithelium 
Proposed interventions: 
 Reducing intestinal permeability by targeting tight junction regulators 
(e.g. zonulin-antagonists).173,367,369 
 Blocking transcellular transportation of gluten peptides by targeting 
the sIgA-receptor pathway that has been identified.173,369 
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Table 2.13 (continued): Novel treatment targets and proposed interventions 
The CD Immune Response 
Proposed interventions: Gluten tolerisation 
 Down-regulate autoimmune response: Necator americanus (hookworm) 
infection.172,173,199,370 May be useful in the context of gluten 
contamination.369 
 Induce mucosal tolerance: vaccination with peptide antigens (e.g. 
Nexvax2)199,366,367 
Proposed interventions: Reducing inflammation 
 Suppression of inflammatory response by inducing lymphopaenia: 
glucocorticoids (e.g. budesonide, which is topically active so works 
locally; needs reformulation to be effective in small intestine).172,366,369  
 Inflammatory cytokine blockade: monoclonal antibodies (e.g. 
Infliximab)172,369,370 
Proposed interventions: Modulating the immune response 
 Blocking lymphocyte recruitment to the mucosa: e.g. CCR9 (chemokine 
receptor 9) blockade.172,173,199,367,369 
 Other: CD-specific HLA blockade with gluten peptide analogues; tTG 
inhibition to reduce deamidation of gliadin peptides; IL-15 blockade with 
anti-IL-15 antibodies.172,173,199,366,367,369 
 
2.10.3 Complications of CD 
The potential complications of CD have been widely canvassed in the literature, 
being discussed in many CD review papers,5,7-9,11,81,207,240 and referenced in several 
guidelines documents.69,70,72,122 Several papers focused on CD complications have 
also been published, with some reporting studies on specific potential sequelae 
such as pancreatitis,373 cardiovascular risk,374 or malignancy,26,375 and others 
examining morbidity and mortality more generally.25,27,376-378 One of the most 
comprehensive reviews of the topic is the 2014 book chapter by Lewis and 
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Holmes,379 in which an extensive list of co-morbidities is presented and discussed 
in the light of available research. The systematic review of long-term management 
by Haines et al.28 also presents an exhaustive list of potential complications. 
 As noted by Tack et al.,227 because of the increasingly wide range of clinical 
presentations recognised as being indicative of CD, there is some variability in what 
is classed as a complication of CD (as opposed to an association). This is a view 
shared by Lewis and Holmes,379 who suggest that “because CD is so common, it 
follows that many diseases will occur in association…as complications…as 
associations or simply as occurring by chance.”(p.210) However, all review articles 
cited in the previous paragraph list refractory CD, malignancy, and death as the 
potential complications that warrant particular attention from clinicians managing 
CD patients. Many also refer to hyposplenism (and/or infection) and osteoporosis, 
and some discuss an increased risk of other autoimmune diseases.  
2.10.3.1 Refractory CD 
For a small proportion of people with CD, adherence to a strict GFD does not achieve 
remission of the disease, leading to a state known as Refractory Coeliac Disease 
(RCD). This has been defined by the Oslo group as consisting of “persistent or 
recurrent malabsorptive symptoms and signs with villous atrophy…despite a strict 
GFD for more than 12 months”.22(p.46)  
The exact number of CD patients affected by RCD is unclear, with some writers 
suggesting it affects up to 5%,207 but others maintaining that it is very rare, with an 
incidence of much less than 1%.380 As suggested by Di Sabatino and Corazzo,7 who 
postulate that the 5% figure is an overestimate, the difference may lie in the 
populations from which these figures have been determined – tertiary referral 
centres for patients with persistent symptoms, versus the coeliac cohort as a 
whole.380 A recent study by Eigner et al.381 found an overall RCD incidence of 2.6% 
among a cohort of 1138 people, over a 25 year period. Within that period they noted 
that rates have been falling since a peak of 3.3% between 2000 and 2004, to 0.5% 
from 2010 to 2014.381(p.366) In their 2017 review article,382 Shannahan and 
Lebwohl put the prevalence of RCD at around 10% of people with non-responsive 
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CD, and 1% of CD patients overall.(p.85)b Studies are conflicting on whether men or 
women are affected in greater numbers,380,383 but it is agreed that RCD is never 
found in children, and highly unlikely in those under the age of 50.  
Refractory CD can take one of two forms, determined by the immunophenotype 
of IELs. The more common, and prognostically better, RCD-1 is regarded as being 
virtually indistinguishable from untreated and uncomplicated CD, and the 
phenotype of the IEL population is essentially normal.384 This is in contrast to RCD-
2, in which aberrant IELs show T-cell clonal expansion, and lack the usual 
immunological surface markers of normal cells.385 It is more likely to be associated 
with HLA-DQ2 homozygosity,386 and the clinical presentation with diarrhoea, 
weight loss and abdominal pain is generally more severe.380,385 The prognosis for 
RCD-2 is poor, with a 5-year survival rate of 44% to 58%. This is largely due to the 
much increased likelihood of developing enteropathy-associated T-cell lymphoma 
(EATL). Risk factors for 5-year mortality from RCD have been identified as age 
(mortality increases with increasing age at diagnosis), low serum albumin levels 
(risk of mortality is inversely proportional to serum albumin level at diagnosis), and 
the presence of abnormal IELs in duodenal biopsy samples.387  
Specifically associated with CD, EATL is a very rare but aggressive T-cell Non-
Hodgkin’s Lymphoma (NHL) of the upper small intestine,26 with a 5-year survival 
rate of less than 20%.388 Progression to EATL among people with RCD-2 occurs 
within five years of diagnosis in up to 52% of patients,385,386 although in absolute 
terms this represents a tiny proportion of people with CD. In their study of 12,243 
CD patients,380 Ilus et al. found an overall RCD prevalence of 0.3%, with RCD-2 
diagnosed in 0.08% (10) of the study population. Among their whole study group, 
two people died from EATL. 
Before the diagnosis of RCD can be confirmed, it is essential that other possible 
causes of ongoing symptoms and persistent villous atrophy are excluded. Chief 
among these is continued ingestion of gluten, either deliberately or unintentionally, 
thus the assessment of a patient presenting with possible RCD must include a 
                                                        
 
b This article actually states that “RCD develops in about 10% of patients with non-
responsive RCD” which I have interpreted as a typographical error, with the 
intended meaning being 10% of patients with non-responsive CD. 
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thorough review of his or her diet. In addition to this it may be that these patients 
warrant a trial of an even more rigorous diet than would usually be advocated. 
Daum et al.384 refer to a diet that is “as gluten free as possible”, making specific 
recommendations about what it can include, while Sharkey et al.318 implement a 
“Supersensitive Diet” (SSD) in their incompletely-responding patients. A “Gluten 
Contamination Elimination Diet” (GCED) has also been trialled by Hollon and 
colleagues.389 In their study of a cohort of patients with ongoing symptoms and/or 
persistent villous atrophy, adherence to the very restrictive GCED led to recovery 
in the majority. Included in this group were six patients who initially met the criteria 
for a diagnosis of RCD, five of whom recovered on the GCED. All of these patients 
had been assessed by an experienced dietitian as being adherent to the GFD, lending 
support to the belief that even traces of gluten are problematic for some patients. 
Other steps that should be taken prior to making the diagnosis of RCD is 
confirming that CD was correctly diagnosed in the first place, which includes 
ascertaining that the patient is either HLA-DQ2 or DQ8 positive; ruling out 
alternative additional diagnoses, such as pancreatic insufficiency, microscopic 
colitis, other food intolerances, and malignancy; and repeating duodenal biopsies to 
confirm the presence of ongoing villous atrophy.11,69,70,386,390 Additional 
investigations such as video-capsule endoscopy and radiological imaging may also 
be required.382 
Treatment of RCD remains limited, particularly in the setting of RCD-2. 
Aggressive nutritional support and corticosteroids are the current mainstays of 
management, with other immunosuppressant agents such as azathioprine having a 
role in those who are no longer steroid responsive.69,70 Steroids will generally effect 
symptomatic improvement in both groups, and may lead to histological 
improvement in RCD-1. Immunosuppressant medications also ameliorate 
symptoms, but they do not bring about histological improvement, and, in patients 
with RCD-2, can increase the already high risk of progression to EATL. In these 
patients the treatment of last resort is myeloablative chemotherapy and autologous 
stem cell transplant, although this has had only limited success. Treatments 




2.10.3.2 Malignancy and mortality 
According to a 2005 review by Catassi et al.,26 the association between CD and 
malignant disease such as lymphoma has been recognised for many decades – 
perhaps even as early as the 1930s. Early on it was thought that CD carried with it 
a substantial increased risk of NHL in particular, but in more recent years this has 
been found not to be the case.  
A large 2014 study, conducted by Ilus and colleagues,392 examined the 
incidence of malignancies in over 32,000 adult CD patients. They confirmed that the 
incidence of NHL was higher in those with CD, as were other small intestinal 
malignancies, but the magnitude of that risk was only modest. They calculated the 
Standardised Incidence Ratio (SIR) for NHL to be 1.94 (95% Confidence Interval: 
1.69 – 2.29), finding almost twice as many cases of NHL than would have been 
expected based on incidence rates for the whole population. Small intestine cancer 
had an SIR of 4.29 (95% CI: 2.82 – 6.24). By way of comparison, within their paper 
Ilus et al. also calculated SIRs for data derived from earlier pieces of research, all of 
which had found much higher levels of risk of NHL. For example, studies by Grainge 
et al.375 (in 2012) and Elfström et al.393 (in 2011) generated NHL SIRs of 12.0 (95% 
CI: 6.6 – 20.1) and 4.3 (95% CI: 3.4 – 5.4) respectively. Somewhat in contrast, a 
separate 2012 study of 28,882 CD patients by Elfström and colleagues394 led to a 
lower SIR for small intestine cancer of 2.2 (95% CI: 1.2 – 4.1). The increased risk 
was greatest in the first year following diagnosis, but did persist over the long term.  
 Ilus and his team also found that other cancers (specifically breast, lung, renal, 
bladder and pancreatic) occurred less frequently in people with CD, thus the overall 
risk of any malignancy was not increased (SIR 0.94; 95% CI: 0.89 – 0.98).392 These 
findings are consistent with the outcomes of an earlier (2012) meta-analysis of 
studies investigating all-cause mortality, any malignancy and lymphoid malignancy 
in CD,395 although in the Ilus study, the any-malignancy risk did increase after more 
than five years of follow-up to an SIR of 1.31 (95% CI: 1.04 – 1.63).392 It is not 
immediately clear why this might be the case, and the authors offered no 
explanation for this finding. On inspection of their published results it seems likely 
to have been accounted for by an increased risk of colon cancer, which only emerged 
with longer follow-up.(p.1474) 
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The evidence for an increased risk of colon cancer among CD patients is 
conflicting. Ilus et al.392 found a small overall increased risk, Elfström et al.394 found 
an increased risk that went back to the population risk after 12 months, while Volta 
et al.396 found a reduced risk among a cohort of 1757 Italian patients (SIR 0.29; 95% 
CI: 0.07 – 0.45). It is not obvious why these studies differ in their findings, but Volta 
and colleagues postulate that it may be related to differences in diet and the genetic 
background of the populations studied. 
Data on mortality are also conflicting, with the most recent study to examine 
the risk of all-cause mortality among people with CD378 finding no increased risk 
relative to the general population, and only a 0.15% excess risk of dying from NHL. 
This is in contrast to earlier studies such as those led by Ludvigsson,397 and 
Grainge,377 and the meta-analysis by Tio et al.395 that concluded that patients with 
CD do have an increased risk of all-cause mortality (Odds Ratio 1.24; 95% CI: 1.19 
– 1.30). This risk decreases over time, and the conclusion in recent review articles 
is that the absolute risk of death for people with CD is low or modest.9,11 
Biagi and Corazza398 have speculated that apparently discrepant findings 
relating to mortality could be related to national variations in gluten consumption 
and CD management, as well as to differences in the study populations with respect 
to definitions and the severity of disease affecting included patients. 
2.10.3.3 Hyposplenism and infection 
Splenic hypofunction is a well-documented phenomenon among people with CD,379 
although it is not clear how many CD patients are actually affected.399 The 
mechanism of its aetiology is postulated to be due to chronic folate deficiency, and 
perhaps secondary to lymphocyte losses in the atrophic and inflamed small 
intestine.379 Some evidence suggests that it is more common in CD patients with 
additional autoimmune conditions, in which group the prevalence may be as high 
as 59%, and RCD in which it may occur in up to 80% of patients.400 Among a study 
population of 36 patients with uncomplicated CD, Di Sabatino and his colleagues 
found a prevalence of hyposplenism of 19%.400 It does not appear to affect children 
with CD,399,401 which may be due to their much shorter period of pre-diagnosis 
exposure to gluten.379 
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The principal reason for being aware of the possibility of hyposplenism is that 
it predisposes patients to more serious illness when they are infected with 
encapsulated bacteria such as Streptococcus pneumoniae. The spleen plays an 
important role in fighting infection and regulating immune responses, so impaired 
function has the potential to lead to significant morbidity and even death.401  
Work in 2008 by Ludvigsson et al.402 found a “modestly increased risk of sepsis” 
among a cohort of over 15,000 people with CD. This was largely accounted for by 
pneumococcal infection, and they postulated that hyposplenism was one 
mechanism likely to be at play. Similarly, Zingone et al.,403 in their study of 
community acquired pneumonia (CAP), also found that an increased incidence of 
pneumococcal infection contributed to the increased relative risk of CAP among CD 
patients who had not previously been vaccinated against Strep. pneumoniae. More 
recently, a large cohort study404 that investigated the link between CD and invasive 
pneumococcal disease found a 46% increased risk among people with CD, although 
the actual incidence of infection among their cohort of over 29,000 patients was just 
0.15%. A recent systematic review and meta-analysis of similar studies,405 and 
including this one, has confirmed the increased risk of pneumococcal infection.  
There is mixed support in current guidelines documents for actively managing 
this risk, with only the BSG70 and WGO72 recommending that patients with CD 
should be offered pneumococcal vaccination. Two recent review articles, by 
Mooney8 and Lebwohl11 also include this recommendation. Separate pneumococcal 
vaccination is not an issue for children with CD as most childhood immunisation 
schedules include this already. 
2.10.3.4 Osteoporosis 
It is well established that CD impacts on bone health, and as discussed earlier in this 
chapter, “metabolic bone disorder” is one of the indications that should prompt 
consideration of testing someone for CD.132 It is known that between 50% and 70% 
of newly diagnosed patients will have reduced bone mineral density (BMD),25,258,263 
and a recent systematic review and meta-analysis of studies relating to fracture risk 
in CD suggests that this is also increased.406 Interestingly a recent small 
retrospective analysis of New Zealand patients who underwent bone density 
scanning in the year following diagnosis of CD found that while the average bone 
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density Z-score was slightly lower than expected, it still lay within the normal range 
for the great majority of patients.407  
In untreated CD, the mechanism by which BMD is reduced is thought to be 
primarily due to calcium and vitamin D malabsorption, but it is also likely that 
circulating inflammatory cytokines interfere with bone formation, and it may be 
that autoimmune factors are playing a role.263,406 There is good evidence to show 
that BMD will recover, at least to some extent, following implementation of a GFD.408 
2.10.3.5 Other autoimmune diseases 
As also discussed earlier in this chapter, the presence of a range of autoimmune 
diseases is associated with an increased risk of CD. There are mixed data on whether 
this association is bidirectional, and on whether implementing a GFD will reduce 
the risk of other autoimmune conditions developing.28,379  
The two conditions for which there is some evidence of increased risk of these 
developing in CD patients are T1DM,409 and thyroid disease.410 Children and 
adolescents (up to the age of 20 years) with CD were found to be between two and 
three times more likely to develop T1DM than non-coeliac population controls.409 
Patients with CD were also found to be between two and six times more likely to 
develop any type of thyroid disease. The highest risk was associated with 
hypothyroidism, and children were more at risk.410 
2.10.4 Monitoring after diagnosis 
In view of the range of complications that can arise in the context of CD, and given 
the challenges patients face in adhering to treatment, it is now widely 
recommended that the care of patients with CD should include ongoing support and 
surveillance by a healthcare professional with expertise (or at least an interest) in 
managing the condition.67,69,70,72,132 That professional may be a primary care 
physician, a gastroenterologist, a paediatrician, a dietitian, or a nurse working in 
either the primary or secondary care sector. A survey of 126 UK patients conducted 
in the early 2000s by Bebb et al.411 found that their preferred follow-up option 
would be with a dietitian, with medical back-up if required. However, the study also 
found that almost 40% of respondents were not having regular follow-up of their 
CD, and subsequent studies from North America have indicated that among those 
who are being reviewed on a reasonably regular basis, the substance of their follow-
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up has been variable.29,55 (Although it should be noted that both these studies were 
completed before the release of the ACG guidelines that include formal 
recommendations about long-term management,69 so consistency in practice may 
have improved since then.) 
In the past few years updated CD guidelines documents have been produced by 
the ACG,69 BSG,70 NICE,71 and WGO.72 Having also developed separate paediatric 
guidelines,67 the BSG guidelines are specific to adults with CD, while the other three 
encompass CD in all age groups.  
All guidelines include recommendations on monitoring after diagnosis, 
although there is variation between them with respect to some aspects of 
management. All acknowledge the importance of adherence to the GFD as being 
central to recovery and ongoing good health, and all recognise that how best to 
assess adherence is uncertain. All indicate that an expert dietitian should be 
consulted when the diagnosis is first made, and should also be involved when there 
is concern about adherence. It has been suggested by NICE that it could be a dietitian 
who conducts any routine reviews,132 while the WGO recommends clinically stable 
patients see a nutritionist every one or two years.72 All guidelines either 
recommend, or imply, that blood tests to assess micronutrient levels, and state of 
health more generally, should form part of the early assessment of newly diagnosed 
patients. The ACG gives the most extensive list of suggestions including a range of 
vitamin levels, and copper, zinc, and carotene.69 Tests in common between the 
guidelines are a full blood count, ferritin and iron studies, folate, vitamins B12 and 
D, calcium, and alkaline phosphatase.  
The BSG is the only group to address the issue of testing for possible 
complicating associated conditions. They suggest annual thyroid function, liver 
function, and glucose testing in the body of their document,70(p.7) although this has 
not made it into their separately identified (and presumably more formal) 
recommendations. Other writers have suggested that, at least with respect to the 
possible endocrine complications of CD, a reasonable approach to take would be to 
screen patients for suggestive symptoms, and target testing to those in whom there 
is a suspicion, however faint, of concomitant disease.412 
100 
 
2.10.4.1 Repeat serology testing 
Despite the fact that CD serology tests have proven so successful in facilitating the 
diagnosis of the condition, the same cannot be said for their use in monitoring. It is 
widely accepted that they lack the sensitivity to determine whether a CD patient has 
achieved mucosal healing, although a recent meta-analysis of studies investigating 
the correlation between serology and persistent villous atrophy found that IgA-tTG 
antibody and EMA tests have high specificity in this setting.413 Thus, while a 
negative serology test does not reliably indicate mucosal healing has occurred, a 
positive test is highly suggestive of ongoing damage, and indicates that the patient 
is probably continuing to ingest gluten, either knowingly or inadvertently. The 
utility of repeat testing therefore lies in predicting non-adherence.28 This is not 
universal however, as demonstrated by Newnham and colleagues.314 They found 
that among their cohort of 49 patients with positive tTG antibodies at diagnosis, 23 
still had elevated levels after 12 months on a GFD, but of these, seven had normal 
histology on rebiopsy. This equates to 14.3% of the initial cohort, but 30.4% of those 
with persistent antibodies. 
The available guidelines documents all indicate that there is a place for CD 
serology in the surveillance of the condition, but that it should be used in 
conjunction with other aspects of monitoring such as a reviewing symptoms and 
diet adherence.69,70,72,132 All recommend repeating serology tests in the first year 
following diagnosis, generally in association with a clinical review. Thereafter, the 
ACG advocates testing tTG or DGP antibodies on an annual basis,69 while the WGO 
recommends “periodic” evaluations.72 The BSG and NICE make no reference to the 
use of serology for monitoring purposes, although the BSG document includes the 
comment that “it is reasonable to assume that positive antibody titres correspond 
to some gluten intake”.70(p.8) 
There is evidence (albeit from a small study)414 to suggest that coeliac 
antibodies (tTG, DGP, and EMA) fall significantly during the first year of a GFD, and 
that strict compliance has more of an impact on overall levels than does partial 
compliance. This same study also found that after more than four years on the diet, 
antibody levels for strictly compliant patients had continued to fall, whereas levels 
in the partially compliant had tended to flatten or even increase slightly.414 The 
guidelines’ recommendations are generally consistent with this study. 
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2.10.4.2 Follow-up biopsy 
The place of rebiopsy in the monitoring and management of CD remains unclear, as 
summarised in this statement in the BSG guideline document: “There is no 
conclusive evidence of the benefit of universal follow-up biopsy, and we were 
unable to reach a consensus.”70(p.14) The essence of the dilemma is whether 
rebiopsy should be routine for all CD patients, or whether it should only be offered 
on an “as indicated” basis. At the centre of the dilemma is whether clinical outcomes 
(and the patient’s best interests) are influenced by the practice, especially given that 
it is an expensive and invasive procedure to undertake.  
On the one hand are groups such as the Cambridge Coeliac Clinic who include 
routine rebiopsy in their CD pathway.318 They found that this practice enables them 
to stratify their patients into different treatment pathways (e.g. early discharge to 
primary care versus increased dietetic intervention), and thus predict more 
accurately which patients need closer clinical supervision. Haines et al.28 similarly 
advocate for the inclusion of rebiopsy as part of follow-up, “no earlier than 1 – 2 
years after commencement of the GFD”.(p.1055) On the other hand, a recent study 
from Finland415 found no difference in long-term clinical outcomes between those 
who underwent routine follow-up biopsy at around 12 months following diagnosis, 
and those who did not. The authors therefore concluded that “a more personalised 
follow-up” would be appropriate, for individuals selected on specific clinical 
grounds, and at least two years following diagnosis.(p.8)  
The guidelines groups have on the whole opted for a middle road. The ACG 
notes that it is “reasonable to do a follow-up biopsy in adults after 2 years of starting 
a GFD to assess for mucosal healing”69(p.12), but they make a strong 
recommendation that rebiopsy should be undertaken in patients who fail to 
respond, or whose symptoms relapse despite a GFD. Similarly, the BSG recommends 
that follow-up biopsies “may be considered in patients with CD, and are potentially 
helpful in identifying patients at increased risk of lymphoma”, but they “should be 
undertaken in patients with CD whose condition does not respond to a GFD.”70(p.7) 
The WGO likewise states that “intestinal biopsies should be considered mandatory 
in patients with persistent symptoms despite evidence of a strict GFD”72(p.765), 
while NICE advise referring for endoscopy patients who have persistent symptoms 
and/or high antibody titres that are not changing after 12 months of a GFD.132  
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Recently Silvester et al.413 have identified an important issue with regards to 
persistent villous atrophy, commenting “that it is an important question whether 
persistent villous atrophy is related to lack of healing, or if there are interspersed 
periods of healing and re-injury.”(p.698) It would seem prudent to bear these two 
possibilities in mind when discussing positive rebiopsy results with patients. 
2.10.4.3 Bone density assessment 
As already discussed, reduced bone density is common among people with CD. 
However, if and when this should be formally assessed by DEXA scanning remains 
an open question. In their 2008 systematic review Haines et al.28 proposed that this 
should be done as part of the initial work-up of newly diagnosed patients, but that 
subsequent assessments should be based on overall risk of fracture. More recently 
the BSG has recommended that bone density should be assessed after a year of the 
GFD, in patients over 55 years of age, or who have other risk factors for 
osteoporosis.70 However, they do also recommend testing calcium, Vitamin D, 
alkaline phosphatase, and parathyroid hormone levels as part of the initial 
assessment of coeliac patients. The NICE guideline recommends that decisions 
about DEXA scanning should be made in accordance with their separate 
osteoporosis guidelines,132 while the WGO has suggested that in the first year of 
follow-up a DEXA scan “can be performed to provide a baseline measure”.72(p.764) 
The ACG is agnostic on the issue, making no reference to DEXA scanning in any of 
their recommendations, but including it, with a question-mark alongside, in the 
monitoring algorithm presented in the document.69(p.666) 
2.10.4.4 Annual review 
All of the listed guidelines recommend that patients should be reviewed on an 
annual basis, or, in the case of the WGO, “every 1 – 2 years” once they are clinically 
stable.72 In fact, as noted in Silvester and Rashid’s 2007 review of management 
guidelines,307 this is not new. Without being specific about what they should consist 
of, the BSG nicely captures the role of such reviews as being “to ensure response to 
symptoms, prevention of consequences, and continued maintenance of motivation 
to remain gluten free.”70(p.14). The ACG expresses a similar set of goals.69 
The NICE guideline recommends that an annual review should include 
measuring height and weight, and reviewing symptoms, dietary adherence, and the 
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need for specific blood tests.132 The BSG formally recommends “annual 
haematological and biochemical profiles”70(p.9), but the ACG does not make any 
specific recommendations about what to include. The WGO recommends that 
patients should see a nutritionist every one or two years.72  
Paediatric guidelines from both the UK,67 and North America,143 recommend 
that children should also be reviewed annually, for growth and development, 
symptoms, adherence, micronutrient status, and IgA-tTG antibody levels. 
2.10.5 Management additional to the GFD 
Alongside treating CD with a GFD, there are other management interventions that 
are variably recommended. Thus the BSG,70 NICE,132 and WGO,72 each explicitly 
recommend that newly diagnosed patients should be encouraged to join, or be given 
information about local coeliac support groups. Paediatric guidelines make similar 
recommendations.67,143 And although the ACG does not formally recommend this, 
reference is made to the role of support groups in an algorithm for suggested 
management presented in the guideline.69(p.666) Earlier statements on CD from 
the American Gastroenterological Association Institute make explicit reference to 
the importance of these groups.122,416 
The testing of first-degree relatives of newly diagnosed CD patients is another 
issue that is addressed in some guidelines, although not at the level of formal 
recommendations. It is also noted within the earlier algorithm proposed by Haines 
et al.28 Within the body of their document the ACG notes that “newly diagnosed 
patients with CD should inform their first-degree family members of the potential 
increased risk for CD and the recommendation for testing.”69(p.658) The statement 
is made in the context of discussion about testing for CD, rather than management 
per se. Similarly, the WGO note that “first-degree relatives of index cases should be 
screened for CD”72(p.759), when considering who should be tested for the 
condition. The BSG and NICE do not make any reference to newly diagnosed 
patients informing their families about increased risk, but both include having a CD-
affected first-degree relative as an indication for testing for CD.70,132 A 2015 survey 
of patients with CD found that recommendations to have their first-degree relatives 
tested were not being routinely made by treating clinicians.417 
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As already noted in the earlier discussion of the complications of CD, whether 
or not to offer people with CD specific vaccinations is also variably acknowledged. 
The BSG make a clear (level C) recommendation that newly diagnosed patients 
should be vaccinated against Streptococcus pneumoniae, but note that whether they 
should also be vaccinated against Haemophilus influenza, Neisseria meningitidis, or 
the influenza viruses is “unclear”.70(p.9) The WGO recommends that vaccination 
against all three bacteria should be performed,72 while the ACG and NICE do not 
refer to the issue at all.  
2.11 The Patient’s Perspective 
While a diagnosis of CD may bring with it a sense of relief to patients who have 
struggled with unexplained symptoms for many years,418 it is also a condition that 
is challenging to manage. The complexities of the GFD already discussed, and the 
fact that this is still the only available treatment for people with CD, mean that for 
many the burden of the disease is high. This is exemplified in work by Shah et al.342 
In this study, alongside people with a range of other chronic health conditions, 
including end-stage renal disease (ESRD), people with CD were surveyed about 
their health and perceived burden of treatment. Despite the fact that those with CD 
reported the highest health state of all groups, they also had some of the highest 
levels of treatment burden, equal only to that of the patients with ESRD. A recent 
study from North America has also suggested that partner-burden is relatively 
common among the life-partners of people with CD,419 with more than 35% of the 
study group reporting mild-to-moderate burden associated with their partner’s CD. 
(It should be noted that this was a small study involving 94 patient/partner pairs, 
corresponding to a response rate of only 22% from those who were invited to 
participate. Nonetheless it suggests that this is an issue that warrants further 
investigation, and attention by clinicians involved in the care of people with CD.) 
A number of surveys of patients living with CD have been conducted over the 
years in an effort to assess their quality of life (QoL),e.g.275,345,347,348,420 and how that 
has been impacted by CD. The consistent finding is that while adhering to a GFD 
improves QoL from pre-diagnosis levels,278 it is onerous and, in particular, 
negatively affects dining out, travel, and social events. As found by Barratt et al.,420 
for many people with CD it is the degree of difficulty adhering to the GFD that has 
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the greatest impact on them. Specifically because of the negative effects noted 
above, at least one study (by Lee et al.348) has found that high numbers of people 
with CD (80% of a study population of over 1700) deliberately compromised their 
GFD in social situations, despite also reporting a high degree of adherence overall. 
And in another pointer to the burden of the GFD, Whitaker et al.345 found that people 
who had been diagnosed with only minimal symptoms, or on the basis of screening, 
were more likely to regret having being diagnosed than their classically-
symptomatic counterparts. This was despite the screening-detected individuals 
generally having similar or better QoL scores than the symptomatic participants in 
the study. 
In addition to survey-based inquiries into the impact of living with CD, there 
have also been qualitative studies that have sought to capture the experiences of 
affected patients.e.g.341,421-423 These too demonstrate that the GFD is burdensome, 
providing personal insights into the issues people with CD face. Interview subjects’ 
comments include “I miss…being able to just eat anything...I hate having to think 
about it. I hate having to explain that I can’t eat it” from Taylor,341(p.5); “It impacts 
what I eat, where I eat, when I eat, if I can eat…”, from Leffler et al.423(p.641); and 
from Rose and Howard “I sometimes feel I have lost myself…”422(p.36), and (from 
another participant) “[I]f I was ever told I could eat a normal diet again I would eat 
so much I would burst…I am probably healthier than I was but I don’t enjoy my life 
as much as I used to when I could go out and eat anything”.422(p.37) From their 
analysis of written narratives by 130 adults with CD,422 Rose and Howard conclude 
that the “losses and changes entailed [in gluten-free living] impact on the personal 
and social identities of those living with coeliac disease, and on the behaviour of 
others towards them.”(p.30)  
There are now a number of tools that have been developed to try and measure 
health-related quality of life (HRQoL) specific to CD. These include the Celiac 
Disease Questionnaire (CDQ),424 the CD Quality of Life instrument (CD-QOL),425 and 
the recently developed CD Quality of Life questionnaire (CDQL).426 However, while 
these tools may prove useful for research purposes, and in trials of potential new 
treatments in particular, it is not clear how they should best be deployed in the day-
to-day clinical setting. They each take some time to complete, ranging in complexity 
from the CD-QOL that comprises 20 items with a 5-point Likert scale tick-box for 
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each,425 to the CDQL that includes over 40 items to be rated.426 Scoring and 
interpreting patient responses also takes time. The combined impact of these 
factors seems likely to inhibit their routine use with CD patients, and yet the burden 
of living with CD does need to be appreciated by treating clinicians. A review of the 
literature by Zingone et al.427 pertaining to psychological morbidity associated with 
CD concluded that CD leads to “considerable psychological impact”, at least some of 
which relates to “the patient’s subjective perception of the disorder and of the GFD 
used to treat it.”427(p.141) 
A possible way forward might be to develop a much briefer screening tool, 
somewhat like the depression screening questions advanced by Arroll and 
colleagues.428 They identified two questions that can be asked of patients verbally 
(rather than requiring them to complete a paper-based questionnaire), the answers 
to which can be used to determine whether or not a more formal evaluation of the 
patient’s mood is indicated. With respect to living with CD, several domains that 
affect HRQoL have been identified, but they almost all come back to the challenges 
associated with adhering to the GFD. Perhaps then there would be merit in 
exploring whether a single question to patients about how they are managing the 
challenges of a GFD (for example) could be used to identify those in whom it would 
be important to assess their HRQoL more extensively. Encouraging clinicians to 
include one such question during reviews of patients with CD is likely to be 
considerably more acceptable (to clinicians and patients alike) than implementing 
comprehensive HRQoL assessments as part of routine CD follow-up, although this 
too would need to be evaluated. 
As already noted in the previous section, when patients were asked about what 
they want with regards to their CD care,411 their preference was for dietitian follow-
up, but with medical review available. Barratt et al.420 also concluded that dietitians 
are “best placed to safeguard the Coeliac individual’s QOL in the long term, and with 
the greatest potential for benefit.”(p.245) In New Zealand, where access to dietetic 
services is often limited, being able to identify those patients who would stand to 
gain the greatest benefit from ongoing dietitian input would be of value. The 




This chapter has traversed the extensive history of CD from the earliest descriptions 
given by Aretæus of Cappadocia, to the identification of gluten as the principal 
trigger, the recognition of typical histological changes seen in the intestinal mucosa 
of affected patients, and the discovery of tTG as the target autoantigen in the small 
bowel. Clinical definitions of the condition, its complex pathogenesis, and its varying 
prevalence in different populations have been discussed, along with its myriad 
patterns of presentation, and recent guidelines relating to testing and management. 
Issues relating to the GFD have also been explored, together with future treatment 
possibilities that are under investigation, and a discussion about the impact that 
living with CD and having to adhere to a GFD have on patients.  
With respect to the studies that comprise this project, the principal areas of 
interest are: 
(1) The many and varied ways in which CD may present, which requires of 
practitioners an understanding that it is more than a disease of the 
gastrointestinal tract, and a level of knowledge that enables them to 
recognise CD as a potential explanation for a patient’s constellation of 
symptoms. (Section 2.8) 
(2) Pre-requisites for making the diagnosis are that the person being 
investigated is consuming an adequate amount of gluten; that appropriate 
tests are requested; and that test results are correctly interpreted. (Section 
2.9) 
(3) Management of CD encompasses much more than advising the patient to go 
on a GFD. It should also include ongoing support, and surveillance for 










As outlined in Chapter One, the principal task of this project was to describe what 
is happening in New Zealand with regards to the recognition, diagnosis, and 
management of CD, with a particular emphasis on adult disease. The major 
hypothesis underpinning this task is that GPs in New Zealand have limited disease-
specific knowledge about CD. If this hypothesis is indeed correct, then this might be 
evidenced by the following: 
 CD is under recognised and/or 
 CD is underdiagnosed and/or 
 CD is sub-optimally managed. 
As also discussed in the earlier chapter, the primary hypothesis gives rise to a 
number of research questions: 
 What do GPs in New Zealand know about CD? 
This question is elaborated by the additional questions 
i. Whom do they test, and under what clinical circumstances will 
they test them? 
ii. On what clinical information do they base decisions about 
diagnosis? 
iii. How do they manage patients with the condition? 
iv. From where (or whom) do they get their information about these 
issues? 
 How do gastroenterologists in New Zealand manage patients with CD? 
and 
 What is the prevalence of diagnosed CD in New Zealand today? 
In order to adequately address these questions the project was broken down 
into three separate studies, all of which were observational studies with a 
descriptive emphasis. Observational studies are those in which the study describes 
the current state of affairs within a population with regards to a topic of interest. 
Limited analysis of associations between variables are sometimes undertaken, but 
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research questions are predominantly “what” questions and interest is centred on 
profiling particular characteristics of the study population. This is as opposed to 
experimental studies in which the project includes making an intervention and then 
assessing its impact on a group of interest within the study population.429  
Two of the studies in this project were cross-sectional and utilised self-
administered surveys. That is, they investigated the populations of interest at a 
specific point in time.429 The third interrogated laboratory data relating to CD that 
covered an extended period of time. These data had been processed by Southern 
Community Laboratories (SCL), one of the major laboratory service providers in 
New Zealand.  
This chapter describes the methods employed in each of the three studies. 
Although the two survey studies had many aspects in common with each other, they 
also had a number of differences and are therefore discussed individually. 
Following on from this is a description of the laboratory data investigation.  
3.1.1 Why surveys? 
Self-administered surveys are a well-recognised way of gathering descriptive 
information from and about a population of interest.430 For this project, they were 
chosen as the most appropriate way in which to gather the necessary information 
from gastroenterologists and GPs because, as discussed by Boynton and Greenhalgh 
in their BMJ “Hands-on guide to questionnaire research” series,431,432 they “offer an 
objective means of collecting information about people’s knowledge, beliefs, 
attitudes and behaviour”.432(p.1312) By gathering this information in a systematic 
fashion from a representative sample of a population, it should be possible to 
generalise results to that population as a whole.433 
As well as using self-administered questionnaires, survey data can also be 
gathered via telephone or face-to-face interview in which a surveyor personally 
administers the survey questions to participants, or by asking participants to 
complete the survey with the investigator present to assist with any questions they 
might have. Neither of these options was going to be practical for the present 
studies, which were to involve large numbers of busy health professionals 
dispersed across New Zealand. 
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There are also alternative options for evaluating physician practices, none of 
which were deemed appropriate for this project. These are direct observation of 
consultations (either with someone sitting in, or by recording them and reviewing 
those recordings at a later date); having practitioners see standardised patients 
(either knowingly or unknowingly) and assessing their management against a pre-
determined set of outcomes; or conducting reviews of sets of doctors’ medical 
records. Each of these is time-consuming and likely to be expensive. Each can also 
lack the objectivity afforded by utilising a well-designed survey, in which questions 
are standard for all participants and can cover a much broader range of topic-
specific issues than any of these three modes allows. This was particularly 
important for this project, in which broad knowledge about CD was the primary 
area of interest. Moreover, the first two of these modes of evaluation focus quite 
explicitly on the individual and do not afford participants any anonymity, at least 
while the data are being collected. These forms of data-gathering could much more 
readily be construed by participants as being a “test” of them as individuals, which 
is counter to the aim of a research project such as the present one, which was to be 
able to describe practices at a population level. In a 2005 review on the use of 
vignettes in surveys of health professionals,434 Veloski et al. pointed out there is a 
risk that even when completing surveys, participants may be drawn into treating 
the exercise in the same way that they would take an exam. That is, they may give 
the answers they believe to be right according to textbooks or guidelines, rather 
than which represent their actual practice. It is not unreasonable to assume that 
these more individually-focused alternative forms of investigation of physician 
practice would be likely to magnify this effect, beyond what might occur with a 
survey.  
3.1.1.1 Total Survey Error 
An issue that does need to be borne in mind when conducting surveys is that of 
“total survey error”, a term used by Dillman (a leading expert on survey design and 
delivery) to encompass the ways in which surveys can fail to produce accurate data 
that can be confidently generalised to the population of interest.435 He has divided 
total survey error into four groups:  
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 coverage error, which arises when not all members of the target survey 
population have the same chance of being included in the sample population; 
 sampling error, which arises because not every person in the population is 
sampled; 
 non-response error, which arises when not everyone who was sampled 
responds; and  
 measurement error, which arises when respondents’ answers are inaccurate 
or imprecise. (pp. 16-18) 
The importance of addressing each of these potential sources of error is widely 
covered in the survey methods literature.429-433,435 The first two sources of error can 
be minimised by appropriate sample selection, and the latter two by maximising 
design features that reduce ambiguity and other potential sources of 
misinterpretation, and by implementing strategies to promote participation. Steps 
taken to ameliorate these sources of potential error in the two surveys that were 
part of the present project are described in the following discussion of methods. 
3.1.1.2 Using incentives to increase survey response rates 
There is extensive research investigating the use of incentives in survey-based 
research as a means for increasing response rates (and thus reducing non-response 
error), including studies that have looked specifically at the impact on surveys 
involving medical practitioners. The majority of these studies have found that using 
incentives has a positive impact on response rate, particularly when they are 
monetary and unconditional (i.e. included with the survey rather than dependent 
on a completed survey being returned).436-442  
The use of incentives in each of the two survey-based studies of this project was 
carefully considered. For the survey of gastroenterologist the initial decision was 
not to use incentives at all. Including money with the survey was ruled out both 
because the initial means of sending the survey was via email, but also because this 
has not been the norm in studies conducted in New Zealand and it did not seem an 
appropriate step to take. The evidence for the impact of including conditional 
incentives (i.e. a “reward” given on receipt of a completed survey) is weaker and so 
the study proceeded without this.436 
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The issue was revisited for the GP study, principally because surveys of GPs (as 
compared to other physicians) are particularly prone to poor response rates.442-444 
It was therefore important to consider any strategy that might go some way 
towards ameliorating this. Once again including an unconditional monetary 
incentive with every survey was ruled out. Reasons included that it would be too 
expensive to do so, that there were practical limitations given that the survey was 
being sent to some people in electronic form only, that there was no guarantee that 
it would reach the intended recipient, and that New Zealand Post had restrictions 
around sending money through the mail. The same reservations about the propriety 
of including money that had arisen with regards to the gastroenterologist survey 
also remained. But on this occasion it was decided that it would be worth utilising 
a conditional incentive. This took the form of a prize-draw which participants could 
choose to enter. The prize was donated by bpacnz (The Best Practice Advocacy 
Centre New Zealand), which was acknowledged in the letter that went out with the 
survey, and comprised a $750.00 travel voucher to be used to attend a conference 
or educational event of the recipient’s choice. 
3.2 Timeline 
Of the two survey-based studies, the survey of gastroenterologists was developed 
and conducted first. The rationale for this was twofold. Firstly, because the survey 
population was relatively small it would be possible to evaluate different 
techniques relating to survey delivery, assessing their overall efficacy in the New 
Zealand context, while also being able to augment the process if response rates were 
proving to be unsatisfactory. Secondly, a possible survey instrument was already 
available, potentially reducing the amount of time required in getting the study 
underway. The survey was delivered in the latter part of 2013 and early 2014. The 
study involving GPs then followed, and the experience gained from the first study 
was able to be incorporated into its development. This survey was delivered in May 
2015. 
As will be discussed later in this chapter, the development of the laboratory 
study was an entirely different process and occurred in parallel with the two 
surveys. Initial laboratory data were obtained in early 2014. Additional data were 
gathered through the second half of 2015 and the first half of 2016. 
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3.3 Ethical Review Process 
Each of the three studies that comprise this project was submitted separately for 
Ethical Approval from the University of Otago Human Ethics (Health) Committee. 
As part of the approval process, each study protocol was first peer reviewed by two 
academic members of staff from within the Department of General Practice and 
Rural Health, Dunedin School of Medicine. Any necessary amendments were made 
following each review, and then each protocol was endorsed by the Chairperson of 
the department’s Research Committee.  
Proposals for each were also submitted to Te Komiti Rakahau ki Kāi Tahu, the 
Ngāi Tahu Research Consultation Committee. This is a committee of the Ngāi Tahu 
Rūnanga formed as part of a Memorandum of Understanding with the University of 
Otago. It reviews proposed research projects and makes recommendations to 
researchers to ensure that their research has an appropriate focus on Māori health. 
Appendix A contains the Ethics Committee approvals and Ngāi Tahu Committee 
responses relating to each study. It also includes additional correspondence about 
issues on which the Ethics Committee sought clarification, and which were resolved 
to that committee’s satisfaction.  
3.4 The Survey of Gastroenterologists 
3.4.1 Introduction 
Because the diagnosis of CD still depends on histological analysis of duodenal tissue 
obtained through endoscopy, gastroenterologists play an important role in 
assessing and managing patients with CD. As already discussed in the introduction 
to this work, CD was traditionally regarded as a primarily gastrointestinal disease. 
Although that view has been modified in recent decades with our increasing 
understanding of the underlying autoimmune-mediated mechanisms of the disease, 
gastroenterologists continue to be regarded as the CD specialists, especially with 
respect to adult patients. As such their practice relating to the diagnosis of CD and, 
perhaps more importantly its management, is likely to influence that of the GPs 
whose patients they see, and would be expected to contribute to the knowledge GPs 
have about the condition. As was also discussed in the introductory chapter, there 
is evidence that the practices of gastroenterologists with respect to the 
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management of CD are not always consistent with guidelines, or with each 
other.29,55 In situations in which GPs might be consulting with gastroenterologists 
for advice, or be receiving correspondence from them relating to their patients with 
CD, inconsistencies in practice between individuals raises the possibility that 
patient care will also be inconsistent. For these reasons it was appropriate to 
investigate the practices of New Zealand gastroenterologists relating to CD.  
3.4.2 Background 
There are two publications with which this study primarily interacts, particularly 
where methods are concerned. Both were introduced in Chapter One. The first was 
conducted by Silvester and Rashid,55 and published in 2010. They had already 
published a review of the then current practice guidelines relating to the long-term 
follow-up of people with CD,307 and they followed this with a study designed to 
examine the practices of Canadian gastroenterologists with respect to their 
management of their CD patients. The second was an article by Deepak Parakkal 
and colleagues,56 published in 2012. This paper reported on their investigation of 
the question “Do gastroenterologists adhere to diagnostic and treatment guidelines 
for celiac disease?”  
The additional studies that also investigated physician knowledge about CD 
referred to in Chapter One were of less direct relevance to the present study 
because of their almost exclusive focus on the recognition, rather than the 
management of CD.50,57 The study of Italian paediatricians by Fortunato et al.51 had 
not yet been published when the present study was being conducted. 
The study by Silvester and Rashid55 was a survey-based investigation in which 
all Canadian gastroenterologists were mailed a copy of a questionnaire. The 
principal aim of the study was “to investigate the practices of Canadian 
gastroenterologists who provide care to patients with celiac disease”.55(p.500) The 
emphasis of the project was on how this practice may or may not coincide with 
available guidelines, particularly with regards to management over the long term. 
Participants were also asked for details about the make-up of their practices, their 
familiarity with CD practice guidelines, and about their actual practice in the care of 
patients with CD. 
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In their study,56 Parakkal and colleagues set out to test the hypothesis that 
there is significant variation between what guidelines suggest should be best 
practice relating to CD, and what is the actual practice of gastroenterologists. They 
used an international group of acknowledged CD experts to benchmark best 
practice as it applied to a set of vignette-type scenarios, against which they then 
compared the responses of their target group. Participants in their study were 
gastroenterologists from the USA attending the 2009 Digestive Diseases Week 
conference, who were invited to complete a self-administered survey during the 
course of the conference.  
The tool Parakkal et al. used was a survey they had designed around four 
“controversial scenarios” relating to CD, and which included elements of both 
diagnosis and management.56 The scenarios they designed related to the following 
topics: 
1) A patient already on a GFD, with a probable diagnosis of CD based on blood 
tests done five years previously. The test used had been anti-Gliadin 
antibodies, which are now known to be the least reliable of the available 
serology tests. The patient wants to know if he does in fact have CD.  
2) An asymptomatic (at least with respect to the gastrointestinal tract) patient 
referred for investigation and management, on the basis of a positive family 
history (paternal uncle) and positive IgA anti-tTG antibodies, and found to 
have normal histology on biopsy. An alternative scenario in which the 
patient is symptomatic was also put for consideration. 
3) A patient with dermatitis herpetiformis and a family history of CD but no GI 
symptoms herself, referred for investigation of possible CD. 
4) A series of mini-vignettes relating to questions around when to screen for 
CD. 
While a few questions were in the single-best answer format, most questions 
associated with each vignette asked participants in the study to rate the given 
options using a 1 – 9 “RAND Appropriateness Scale” (RAS). The authors then took 
these ratings and calculated various measures of agreement and disagreement 
between the study participants and the expert panel, who had also been asked to 
complete the same questionnaire. 
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Initially it seemed that here was a ready-made questionnaire that could be used 
in the present investigation, with only some minor adjustments required to take 
account of the local context. The actual questionnaire was available as an online 
supplement to the published article (Appendix B), and permission was granted by 
one of the authors to use it for a New Zealand-based study (Appendix B). However, 
on closer examination of the questionnaire it became apparent that it was going to 
need extensive revision before it could be used for this study. 
Firstly, the vignettes themselves contained ambiguities that made the 
interpretation of the data associated with them problematic. In some cases it was 
not clear what the question was that was to be answered by participants. For 
example, from the first vignette: 
Five years ago, a 25 year old Caucasian male was diagnosed with 
probable celiac disease on the basis of positive IgG anti-Gliadin 
antibodies and started on a gluten free diet (GFD). He now wants to 
know if he really has celiac disease as the GFD is severely affecting his 
quality of life. 
1) Please rate the appropriateness of the following diagnostic tests as an 
initial step in the work up: … 
The problem with this question was with the word initial. Did this mean when the 
patient first presented five years ago, or did it mean the initial steps to take in the 
current presentation? It seemed most likely that the latter was intended, but an 
ambiguity was present nonetheless.  
Secondly, inferring actual practice (or adherence to guidelines) from responses 
to questions relating to the appropriateness of suggested options carries with it the 
assumption that respondents do what they believe is most appropriate. While it is 
likely that this is the case, it does not allow for other circumstances that might also 
influence practice, such as resource availability and patient preference. 
Thirdly, and perhaps most crucially, the use of an RAS in this context seemed 
questionable, and the methods employed by the authors of this study differed 
noticeably from the RAND Appropriateness Method (RAM) that they purported to 
be using. Appendix C gives a detailed description of the RAM, and how Parakkal et 
al. deviated from standard RAM practice. Ultimately these deviations led to the 
decision to move away from utilising an RAS when developing the survey 
instrument to be used in this study.  
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It is interesting to note that in a more recently published study, Valérie Pittet 
and colleagues conducted a RAM study among gastroenterologists,445 relating to the 
management of IBD, and consistent with the processes outlined in the RAM User’s 
manual.446 In their paper they cited Parrakal et al., not as another example of using 
the RAM, but as an example of a study in which “(c)linical vignettes have been 
used…to study variation in treatment decisions, processes of care, and physician 
adherence to guidelines”445(p.133) Where the present study also drew on 
Parakkal’s study was in the use of vignettes to try and elicit information about the 
practices of participants, and in the content of some of those vignettes. 
3.4.3 Development of the survey instrument 
In similar vein to Silvester and Rashid,55 the aim of the present study was to 
investigate the approach of New Zealand gastroenterologists to the diagnosis and 
management of CD in adult patients. It also included questions about what 
information they would be likely to communicate to GPs, and what they might 
expect of GPs involved in that management. A second aim was to compare New 
Zealand gastroenterologists’ practice with the available guidelines (discussed in 
Chapter Two) and with the practice of their international peers, as evidenced in the 
studies discussed here. Of particular interest were those areas of practice in which 
there was no clear consensus on what should constitute standard follow-up, and 
thus the degree of consistency of practice across New Zealand. 
The final version of the questionnaire was developed over several months, with 
input from multiple sources. Topic areas to include were identified, along with 
questions related to each, and then patient vignettes relating to these topics were 




Table 3.1: Content development for survey of gastroenterologists 







How important are 
various aspects of 
follow-up? 
Who should be 
responsible and for 
what? 
What will you advise 
GP? 
What is your advice 
about including Oats 
in the GF diet? 
35 year old woman 
with positive (Marsh 
3) biopsy performed 
by you.  
Series of options 
related to 
management to rate 
in importance and 
















What will you do 
next? 
What will you call 
this? 
What will you advise 
patient and GP? 
Young man with 
positive serology on 
screening coming 
forward for biopsy, 












What to do with the 
patient refusing 
biopsy? 
What constitutes a 
gluten challenge? 
 
GP phones you for 
advice about a 
patient with positive 
serology refusing a 
biopsy. 
Subsequently 
patient wants biopsy 












Vignettes were chosen as the means to set the scene for each set of questions, 
because there is some evidence to suggest that in studies comparing vignette-based 
surveys with direct observation, “clinicians’ self-reported estimates of their 
behaviour were, overall, close to those generated by the direct measure”.447(p.18 of 
20) The systematic review paper in which this comment was made did urge caution 
because the number of studies suitable for making valid comparisons between 
direct and proxy measures was small (only four studies met their inclusion criteria 
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for the review), and because this result concealed instances when over-reporting 
and under-reporting of likely practice cancelled each other out. But the authors also 
suggested that “careful and rigorous development of vignette cases” might 
overcome this problem.447(p.19 of 20) Jon Veloski and colleagues’ guide to writing 
vignette-based surveys was very helpful in this respect.434 
When it came to specific content, material that had been investigated in the 
Parakkal and Silvester studies was incorporated when this was thought to be 
germane to the project. This included one scenario that was very similar to one 
which featured in the Parakkal questionnaire, modified to suit the New Zealand 
context, and to minimise ambiguity. Areas of potential controversy relating to CD 
management that had been dispersed through the Parakkal instrument were 
grouped together into another scenario explicitly concerned with what advice the 
gastroenterologist would give to a GP if asked for it. The Systematic Review of CD 
management published by Haines et al.28 was also reviewed, and aspects of 
management discussed there, and not already in the instrument, were also 
considered for inclusion.  
Initial versions of the survey also included a series of questions relating to 
testing for CD, based on the 2009 NICE Guidelines,280 however these were removed 
following pre-testing, which identified that the survey would take approximately 45 
minutes to complete. Indications for testing patients for CD are clearly defined and 
relatively uncontroversial, so these questions were likely to have added the least 
value when it came to assessing consistency of practice among intended study 
participants. 
Survey questions used a mix of formats, but were mostly closed-ended in order 
to avoid some of the difficulties posed by using open questions. As outlined by 
Dillman and colleagues, open questions have a higher tendency to deter potential 
respondents from either answering the question, or even completing the survey 
itself, as they “require more work to answer”.435(p.72) In addition to this, responses 
can be so brief as to be unhelpful, while those that are more expansive are time-
consuming and sometimes difficult to enter and code for subsequent analysis. 
Therefore, for this survey, participants were asked either to select a single-best 
answer from a range of options (nominal responses), or to rate particular options 
on Likert-type scales (ordinal responses).433 Some scales were unipolar with 
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options ranging from “not at all important” to “very important” (that is, the zero-
point is at one end of the scale), while others were bipolar with options going from 
“highly unlikely” through “neutral” (the zero-point in the middle of the scale) to 
“highly likely”.435 Dillman et al. suggest that the optimal number of options on a 
unipolar scale is four or five, and on a bipolar scale five or seven.435 (p.137) In the 
interests of maintaining a consistent approach throughout the survey, all scales in 
this questionnaire used five points. 
The most notable potential drawback of using closed-ended questions in the 
context of this survey was that identified by Veloski et al.434 and Pham et al.,448 
namely that when used in conjunction with vignette-based surveys this format has 
been found to lead respondents to somewhat overestimate their practice. This is 
thought to be due to a cueing effect when participants are presented with a list of 
possible options they could or would take in a particular situation and are then 
asked to select those that apply to them (or similar instruction). To try and mitigate 
this, wherever possible questions were worded such that respondents were asked 
to rate how likely they would be to perform each of a range of actions, rather than 
simply to indicate which of those actions they would be likely to do.  
When there was no clear range of options to list on a scale then open-ended 
free-text options were used. Participants were also given several opportunities 
through the survey to add comments if they wished. These were generally included 
to enable respondents either to extend a range of possible responses for single-best 
option questions (e.g. Other; please specify…), or to expand on a response to a 
question (e.g. Please comment on your response…).449 
3.4.3.1 Pre-testing and pilot testing the instrument 
The survey instrument was pre-tested during a departmental research meeting in 
the Department of General Practice and Rural Health, which included both lay and 
medically trained staff. Feedback was sought and given on issues relating to 
formatting and presentation, and on the wording of the scenarios and related 
questions. Following this meeting additional individual feedback was provided by 
senior academics in the department. 
A link to the survey was then sent to four of the five paediatric 
gastroenterologists in New Zealand, as experts in CD who would not also be 
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participating in the survey, but who could provide feedback on the content range 
and validity. The fifth was one of the study’s supervisors and so was already familiar 
with the instrument. Unfortunately only one of these people was able to give 
feedback but he provided valuable comments, including drawing attention to the 
fact that as it stood, it took at least 40 minutes to complete. 
Following his feedback the questionnaire was modified to remove content (as 
discussed earlier). Demographic questions, which had been modelled largely on the 
Silvester instrument,55 were also modified to reduce the burden that answering 
these might pose. The modified survey was then sent to a retired local academic 
gastroenterologist, and to a personal acquaintance who is a gastroenterologist in 
Australia, neither of whom would be in the study sample. Both thought that the 
content was appropriate and reasonable, and the questions unambiguous. It was 
also a manageable length, down to around 25 minutes. Follow-up discussion with 
the retired gastroenterologist drew the further observation that patient choice 
complicates many of the issues raised in the questionnaire, and that this was not 
addressed. After some discussion about how this might be achieved it was 
concluded this would add a layer of complexity that risked creating ambiguity in 
how questions might be interpreted, so the issue was left. 
3.4.4 Identifying the survey population 
The population of gastroenterologists in New Zealand is relatively small thus 
selecting a sample from that population to participate in the survey would have 
resulted in low numbers of participants overall, even if a high response rate was 
assured. Glenn Israel, in his widely cited document “Determining Sample Size”450 has 
discussed the implications of sampling from small populations, the principal risk of 
which is to the level of precision able to be claimed for results. For this reason it was 
decided to invite the entire New Zealand gastroenterologist population to 
participate; that is, to conduct a census, as Israel recommends, rather than a 
probability-sample study. Silvester and Rashid adopted the same approach, when 
they sent their survey to all gastroenterologists in Canada.55 
It was, however, surprisingly difficult to identify all the gastroenterologists in 
New Zealand. To do this I first went to the New Zealand Medical Council (NZMC), 
but it transpired that they do not specifically collect this level of information, as 
123 
 
gastroenterologists are vocationally registered in the discipline of Internal 
Medicine and so are grouped with physicians in the other Internal Medicine 
specialities (such as Cardiology and Respiratory Medicine). I then sought assistance 
from the New Zealand Society of Gastroenterologists (NZSG). As this is the body that 
supports their ongoing professional development in the discipline, it was not 
unreasonable to assume that all gastroenterologists in New Zealand would belong 
to this organisation, and could therefore be reached through it. 
After reviewing the study objectives and a final draft of the survey, the NZSG 
executive agreed to assist with the project, and gave permission for the survey to be 
sent out to its members. However, this would be done on my behalf by the secretary 
of the organisation, rather than by giving me access to their database. In addition to 
this they did not want the secretary to have to spend time selecting eligible 
participants from the broader membership of the organisation, so the survey was 
to be sent to the entire mailing list, which included nurses and dietitians, as well as 
medical professionals. The survey would be sent as a link embedded within an 
email, as this would be the most convenient way for it to be distributed. 
Subsequent to this, and as the study progressed, I went to additional sources in 
an effort to more clearly identify the target population. Firstly, I went through the 
list of participants who had attended the 2013 NZSG Annual Scientific Meeting. 
These participants came from a diverse range of health professions, so I cross-
checked names with the New Zealand Medical Register to determine who among 
them were vocationally registered in Internal Medicine. I also searched District 
Health Board (DHB) websites (some of which give lists of specialists), and the 
Southern Cross Endorsed Providers list for endoscopy, and followed links to private 
health clinics throughout New Zealand. The outcome of those endeavours is 
discussed in Chapter Four. 
3.4.5 Implementing the survey 
The questionnaire was developed to be web-based using SelectSurvey.NET 
software, and hosted at survey.otago.ac.nz. This was a software programme freely 
available to University of Otago staff at the time and had a range of tools for 
designing questions in a variety of formats. These included matrices for covering a 
wide range of topics in single questions, multiple choice type questions, and text 
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boxes for open questions. Radio-buttons were used where only one response was 
required (or desired), while tick-boxes were used when more than one answer was 
requested. Questions could also be made “compulsory”, which meant that 
respondents could not progress until an answer had been entered. (Appendix D is a 
printed version of the online questionnaire.) The survey was able to be configured 
so that, if they wished, respondents could save their answers and leave the survey, 
to return later to complete it. It was also configured so that respondents could only 
complete the survey once. 
The survey was first sent in electronic format as a link to the website embedded 
in an email, distributed to members of the NZSG by the secretary of that 
organisation. This email was sent in mid-September 2013, and included 
information about the aim of the study, the names of those involved in the study, 
and a statement that the study had been approved by the University of Otago 
Human Ethics committee. Intended recipients were gastroenterologists, 
gastroenterology trainees, and surgeon endoscopists, which was also clearly stated 
in the email. (Appendix E). The first page of the survey contained additional 
information about how to complete it, assured participants that their responses 




Figure 3-1: Screen shot of opening page of online gastroenterology survey 
In line with best practice recommended by Dillman et al.,435 a follow-up 
reminder email was to be sent two weeks later, however, as the secretary of the 
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NZSG was away at that time, there was a delay of approximately two weeks before 
this occurred. (Appendix E) It seems unlikely that this delay would have had a 
substantial impact on the study.  
In November 2013 the NZSG held its Annual Scientific Meeting in Wellington. 
In order to improve response rates to the survey, I took hardcopy versions of the 
questionnaire to that meeting and used a Coeliac NZ stand as a platform for 
distributing and then collecting them. During the course of the meeting 
announcements were made over the loud-speaker system inviting conference-
goers to visit the stand to collect a copy of the survey, and during breaks in 
proceedings I approached individuals inviting them to participate. Following that 
meeting a third email was sent asking anyone who had taken a hard copy at the 
conference to return it, and once again inviting people who had still not completed 
the survey to do so. (Appendix E) 
In early 2014, following some preliminary analysis on completed surveys, it 
became apparent that female gastroenterologists, and gastroenterologists 
practising in the greater Auckland area were under-represented among 
respondents. Therefore, at that stage a targeted mail-out was made to those two 
groups. Each person was sent an individually addressed letter explaining why he or 
she was being approached again, with a request to return the survey in a reply-paid 
envelope provided for the purpose. (Appendix E) As an extra prompt to participate, 
a pen was included with each survey. 
In summary, the survey was delivered over a 7-month period in 2013 and 2014, 
utilising mixed modes, delivered sequentially. The decision to start with the online 
mode of delivery was a pragmatic one, because this was going to be the only way in 
which to access the target audience, at least in the initial stages of the project. As 
outlined above, the NZSG were prepared to facilitate the delivery of the survey, but 
in a limited way. Adopting a sequential approach to survey implementation has 
been shown to improve response rates from doctors when compared to those 
surveys which rely on online participation alone.451 In this study it was a means of 
addressing concerns about coverage, sampling, and non-response errors, which 
relying on a single mode of contact would have risked increasing. 
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3.4.6 Data entry and analysis 
One of the advantages of online and web-based surveys is that participants enter 
their own data. While the survey is open to participants it can be configured such 
that only one person at any particular IP address can complete the survey, meaning 
that each person can only participate once. Their responses are stored on the 
platform that hosts the survey, in a form able to be exported for later analysis. Once 
the survey has closed the site can be reconfigured so that it is possible for one 
person to enter multiple survey responses. This means that responses that have 
been returned in hard copy are able to be entered into the same database. This was 
the process that was employed for this survey. 
Once all the data had been entered, the dataset was exported from the website 
in Comma Separated Variables format. This was then converted into Excel 
spreadsheets. Data were then coded to facilitate analysis using Stata Corp statistical 
software (Version 13.1, Stata Corp, College Station, Texas, USA). The process of 
coding was also used to check that the data in the spreadsheet had been entered 
correctly.  
Data generated were both ordinal and nominal. Analysis was primarily 
descriptive but, where appropriate, bivariate analysis of possible associations was 
undertaken using Pearson Chi-square or Fisher’s Exact tests. Thus frequencies of 
responses were measured, and associations between responses and the 
demographic profiles of respondents were examined. Patterns of responses 
between questions and scenarios were also investigated. Statistical significance was 
determined based on an alpha of 5%, (p≤0.05). 
3.5 The Survey of General Practitioners 
As discussed in both the introductory Chapter of this thesis, and in the introduction 
to this chapter, the primary research question of this project is “What do GPs in New 
Zealand know about CD?” This arm of the project was designed to be the principal 
resource with which to answer that question, once again by means of a survey. 
3.5.1 Development of the survey instrument 
This study is the first such study about CD to have been undertaken with primary 
care practitioners so there were no previously used instruments available which 
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could be used or modified. While aspects of the gastroenterologist survey could also 
be used in this second study, the focus of this enquiry was to be slightly different, 
and the range of topics to be covered broader, so many questions had to be 
developed de novo. 
In the survey of gastroenterologists, the primary focus was on the likely 
practice of gastroenterologists in representative situations, for example when 
managing a patient newly diagnosed with CD. This meant the questionnaire could 
be developed around vignettes that exemplified such situations, and which would 
elicit responses from the group of participants about how they would each manage 
a similar patient. Among other things, their responses would identify variations in 
practice, as well as examples of when that practice was reasonably consistent. 
The focus for the GP survey was to be GPs’ overall knowledge about CD, as might 
be evidenced by their practice in a wide range of clinical situations. Therefore, to 
use vignettes in this context risked having a questionnaire that would be either too 
specific to be able to draw conclusions about overall knowledge, or comprised of so 
many different vignettes as to render it too cumbersome (and therefore 
unappealing to potential respondents). For these reasons, the question stems that 
were developed were of a more general nature than those of the gastroenterology 
survey, and did not utilise vignettes. In addition to this, material relating to the 
recognition of CD and the steps necessary to reach the diagnosis did need to be 
included. As discussed in Chapter One, practices relating to these issues were at the 
heart of the concerns expressed about what GPs know about CD. 
Content for the questions that constituted this survey was drawn principally 
from the 2009 NICE Guideline relating to CD (Clinical Guideline 86),280 which clearly 
sets out those situations in which patients should be tested for CD, those in which 
they could be tested, and how they should be tested and diagnosed. As a GP I was 
also aware of issues relating to CD that my colleagues sometimes found to be 
problematic, so questions addressing these issues were incorporated, along with 
examples of apparently erroneous practice that had been reported to me by CNZ. 
Management questions were modified from the gastroenterologists’ survey, and 
focused on areas of practice in which there remained a lack of clarity around what 
might be regarded as best practice. Review articles28,307 and Guidelines’ 
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documents69,70,72 discussed in Chapter Two were also used to inform these 
questions. 
The survey was divided into three sections with questions grouped 
accordingly. The first related to “Coeliac Disease in General”, the second to “Coeliac 
Disease in Your Practice”, and the third to “Demographic Information”. At the end 
of the first section respondents were invited either to continue with the next section 
if they had patients with CD, or to go straight to the demographics section if they 
did not. 
As with the gastroenterologist survey, questions were mostly closed-ended, 
and utilised Likert-type scales with which participants were to rate their responses. 
Matrices were used when there was a wide-range of related variables to cover (e.g. 
presenting symptoms in a patient that might prompt testing for CD), and open-
ended questions were also included when necessary. “I don’t know” options were 
also included for some questions, and for the two principal matrices one or two 
“sleeper questions” (i.e. deliberately incorrect options) were included. This is a 
strategy recommended by Aday and Cornelius that can be helpful in evaluating 
responses to knowledge-related questions.429(p. 273) 
In the second part of the survey relating to their experience with patients with 
CD, participants were asked to rate how often they would be likely to undertake a 
number of different actions. Once again, this was done to try and ameliorate the 
potential cueing effect of asking participants to tick a range of options. Response 
options were generally on a scale ranging from “almost never” to “almost always”. 
Because the focus was on knowledge, and to try and capture more nuanced 
information about motive, the “almost never” option was split into three: 
o Almost never, I don’t think this is necessary. 
o Almost never, I wasn’t aware that this was necessary. 
o Almost never, I assume a gastroenterologist does this. 
Respondents were also reminded in every question that they should be thinking 
about their adult patients with CD and, as recommended by Dillman and others,435 
what was expected of them in each question (e.g. Please choose one option). 
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3.5.1.1 Pre-testing and pilot testing the instrument 
When the development of the questionnaire was nearing completion it was 
presented to a group of first-year GP trainees for their input. They were asked to 
comment on the content and wording of questions, and on options for formatting 
the paper-based version that was to be mailed out to the study sample. They each 
completed the draft survey and then as a group we discussed it. In that discussion 
they identified some questions in which there was ambiguity about what was 
intended by the question, and this was subsequently able to be rectified. They were 
also strongly in favour of an A5 booklet format, rather than A4 pages stapled 
together, regarding the former as less intimidating. In the light of this feedback, and 
given that Dillman et al. also strongly recommend using booklets, this format was 
adopted.435 
Once the booklet format had been finalised and necessary amendments made 
to individual questions, the questionnaire was then piloted with a group of GPs in 
Dunedin. They were asked about the appropriateness of the questions, whether 
there were any other questions that should be included, and how long the survey 
took to complete. All were positive about the content and presentation of the 
survey, and only a very few minor wording changes were suggested. They reported 
that the survey took approximately 20 minutes to complete, which they felt was not 
unreasonable. 
3.5.1.2 Design features to improve response rates 
Following pilot testing the final version of the questionnaire was sent for 
professional printing. It included a University of Otago Logo on the front cover, and 
a letter of introduction that outlined the purpose and context of the study, and why 
the recipient’s participation was requested. Each of these factors has been 
demonstrated to effect small increases in response rates to surveys.436  
The letter of introduction formed the front cover of the booklet, rather than 
being separate from it, to minimise the number of pieces of paper that would 
confront recipients, and to make it more likely that the actual survey made it into a 
recipient’s hands (as opposed to being disposed of without a glance on reading a 
letter of request). The inside of the cover included the information that participants 
had been randomly selected and that the study had received ethical approval from 
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the University of Otago Human Ethics Committee, and gave an assurance of 
respondent anonymity. These factors are also regarded as important elements of 
survey design.435 The final version of the survey can be found in Appendix F. 
3.5.2 Calculating the sample size 
As already discussed, the aim of this study was to answer the question “What do 
GPs in New Zealand know about CD?” As there are well over 3500 GPs in New 
Zealand, this would require a probability-sample study as opposed to a census, as 
had been conducted with the gastroenterologists. A biostatistician was consulted 
for advice on how to proceed with this. 
Because this study was to be descriptive rather than analytical, the issue of 
sample-size calculation was not clear-cut. There was no single question that could 
be said to test the major hypothesis of the project (that GPs have limited disease-
specific knowledge about CD) and thus calculating a sample-size to ensure that the 
study was adequately powered to detect statistically significant differences 
between groups was meaningless. What was important was that the responses of 
participants could be reliably taken to be representative of the population from 
which the study sample had been drawn, and that the findings of the study derived 
from those responses would therefore be generalisable to the GP population as a 
whole.  
Sample-size in this context is calculated to enable outcomes of interest to be 
measured with a specified confidence level (usually 95%) and with a desired degree 
of precision (often ±5%). These calculations also need to include an estimate of the 
proportion of the population displaying a given attribute with respect to the 
variable of interest (e.g. agree or disagree).429,435,450 This was problematic for a 
survey such as the present one, which was comprised of multiple variables, the 
majority of which were not dichotomous. However, based on the parameters given 
above and using an online sample-size calculator available from Creative Research 
Systems (www.surveysystem.com/sscal.htm), for a GP population of 3600, a 
minimum required sample-size of 350 completed surveys was derived. 
In order to achieve this number of responses it was estimated that a sample 
population of 1200 would be required. This was because in recent years response 
rates to surveys from GPs in New Zealand have been relatively low (e.g. 26% in a 
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2013 study by Van Rij et al.452 investigating PSA testing practices among GPs, and 
32% in a 2012 study by Reeder et al.453 investigating GP practices relating to 
Vitamin D). In fact, as budget was available to sample a much bigger proportion of 
the GP population, it was decided that given the descriptive nature of the study and 
the desire to focus on the representativeness of findings, it would be appropriate to 
expand the study sample to include approximately 50% of GPs in New Zealand. 
3.5.3 Selecting the study sample 
As outlined earlier in this chapter, one of the sources of error that can impact on 
survey studies is coverage error. This occurs when not all possible members of the 
intended study sample have the same chance of being selected to be a part of that 
sample. This was an issue that needed to be addressed with respect to the present 
study when it came to procuring a list from which to select potential participants.  
One option was to purchase access to GP contact information from the 
Medidata Health Professional Database (available at medidata.co.nz). However, this 
database only held details for approximately 75% of GPs, which meant that at least 
25% of the GP population would not be available for selection for the study. An 
alternative option was to approach bpacnz, a not-for-profit organisation responsible 
for delivering educational and professional development material to health 
professionals, especially GPs. They estimate that their database covers more than 
95% of GPs in New Zealandc, and they were willing to grant access to this database 
for the purposes of this study. Utilising this source of data meant that less than 5% 
of the GP population would not be eligible for selection for the study, substantially 
reducing potential coverage error. 
In order to increase the representativeness of the study sample, particularly 
with respect to metropolitan versus regional and rural representation, a stratified 
random sampling technique was used.429,433 The sample frame (i.e. list from which 
the sample was to be drawn) was stratified according to DHB region of practice and, 
within each region, according to gender. A 50% sample was then randomly selected 
from each stratum. People for whom gender information was not available were 
also grouped, and 50% of that group were also randomly selected for inclusion.  
                                                        
 
c Personal communication with the CEO of bpacnz 
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Potential participants fell into one of three groups: those for whom only email 
addresses were available; those for whom only postal addresses were available; and 
those for whom email and postal addresses were both available. Including 
participants from all three of these groups further reduced the likelihood of 
coverage error, by not automatically excluding those without either postal or email 
addresses on record. 
3.5.4 Implementing the survey 
As with the gastroenterologist survey, this survey also employed mixed modes of 
delivery. As just outlined, it was developed as a paper-based booklet questionnaire, 
but on gaining access to email addresses for potential participants (including for 
people for whom there was no postal address on record) an online version was also 
developed using the SurveyMonkey™ platform. SurveyMonkey™ was chosen on this 
occasion because it had a wider range of design tools available when compared with 
SelectSurvey (used for the survey of gastroenterologists), and its mailing capacities 
were more straightforward to implement. 
Adding an email option to the delivery process also opened up the possibility 
of pre-contact with participants. There is some evidence in the literature that 
contacting people shortly in advance of sending out a survey enhances response 
rates, but for a postal-only survey this is expensive to implement.436 However, with 
access to email addresses this became practical to do, at least for the majority of the 
study sample, and conferred the added advantage that it would not be necessary to 
send a hard copy of the questionnaire to those people who chose to respond to the 
initial online invitation.  
The following chart outlines the steps taken in delivering the survey to each of 




Figure 3-2: Delivering the questionnaire 
Initial contact was made via email, for all those in the sample whose email addresses 
were available. One email was sent to those for whom postal addresses were also 
available, telling them that they would shortly be receiving a survey about coeliac 
disease. If they preferred to do so they were also invited to follow the link to an 
online version of the survey that was embedded in the email. (Appendix G) A 
different email was sent to those for whom postal addresses were not available, 
introducing the project and inviting them to participate by following the embedded 
link. (Appendix G)  
Emails were sent at lunchtime on a Thursday for the following reasons: 
(1) some might respond to it immediately in their lunchbreak; 
(2) it was close enough to the weekend for others to be able to put it aside until then, 
without forgetting it; 
(3) it was not Friday, which is often a very busy day in practice. 
The following week a hardcopy version of the survey was sent to all those for 
whom postal addresses were available. Those who had already responded to the 
email were removed from the mailing list. Included with the survey was a prepaid 
addressed envelope in which the completed survey was to be returned. A web-
address was also provided for those participants who might prefer to do the survey 
online but who may not have received the email invitation to do so. 
Because there is evidence that repeated contact will increase response rates,436 
reminder emails were sent approximately two weeks after the initial email had 
been sent. Once again these were sent on a Thursday. A reminder letter and second 
copy of the survey were sent to the postal-address-only group, and to those whose 















this second mail-out the letter was separate to the booklet and was personally 
addressed to each recipient. (Appendix G) This had not been possible to do within 
the survey booklet but it seemed that perhaps this had had a negative impact on the 
response rate from this subgroup, which at the time of second contact was the 
lowest of the three groups. There is conflicting evidence about the effects of 
personalised letters on response rate, but there is a suggestion that it may have a 
positive impact,439 so it was decided that it would be worthwhile taking this 
additional step. 
As mentioned earlier in this chapter, the survey also included an incentive, in 
the form of an invitation to enter a prize draw. To do so respondents had to give 
their name and a contact address. In the booklet version space for this was on the 
inside back cover so that it could be removed on receipt of the completed 
questionnaire, thus maintaining participant anonymity. In the online version this 
was the last screen to be completed. When response data were subsequently 
exported for analysis, columns of identifying information were removed. 
Completing the survey was taken as consent to participate in the study. 
3.5.5 Data entry  
Data entry and analysis for this study closely resembled that described for the 
gastroenterologist study, except that it was on a larger scale.  
Hardcopy responses were entered into the database that held the online 
responses, by a research assistant who was employed to undertake this work. (The 
research assistant was employed under a grant from the Royal New Zealand College 
of GPs.) Any answers that were unclear (either due to handwriting or to ambiguity) 
were discussed with me, and a separate “notes file” kept to record individual 
decisions that had been made about what to enter. When the research assistant was 
uncertain about what to enter but was unable to discuss this with me, she indicated 
this in the entered data by including a series of question marks. These were then 
followed-up as part of a subsequent data checking process. Each hard copy was 
numbered as it was entered into the database to facilitate this data checking, which 
was conducted once data entry was complete. 
At the conclusion of the data entry phase a random sample of 25% of hardcopy 
surveys was selected and reviewed against the responses entered into the database. 
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An overall error rate of 0.26% emerged for this sample, calculated by dividing the 
number of errors identified (16) by the total number of data-points that had been 
entered (6080). Among the errors identified, 50% involved responses being 
omitted. All but one of these instances arose when more than one answer had been 
given to a question. The remaining errors were data that had been incorrectly 
entered. Each of these errors was unique – that is, no more than one error was 
identified for any single survey question. Considering all of this information 
together, along with the fact that hardcopy responses constituted just under half  
(46%) of the total analysable dataset, it was decided to accept this level of error as 
being unlikely to significantly impact on the outcomes of the survey. 
Separate to the data checking outlined above, all comments from participants 
that had been entered by the research assistant were reviewed. Original surveys 
were consulted when the intent or coherence of comments was not immediately 
obvious, and in any instances that she had marked with question marks. Several 
amendments were made as a consequence of this process, generally because 
accurate interpretation of comments (particularly abbreviations) required a clinical 
background, which the research assistant did not have. 
Once all the data had been entered, the dataset was exported from the 
SurveyMonkey™ website in Comma Separated Variables format. This was then 
converted into Excel spreadsheets, and data coded to facilitate analysis using Stata 
Corp statistical software (Version 13.1, Stata Corp, College Station, Texas, USA). 
Questions that had been left blank were assigned the numerical value of 99, which 
was well outside the range for all questions. Most questions had an inherent 
numerical value (such as those utilising a 1 to 5 Likert-type scale), but for those 
questions that included the possibility of combinations of answers, separate 
numbers were generated to indicate particular combinations. A codebook was 
created to keep track of these assigned variables. 
3.5.6 Data analysis 
As with the gastroenterologist survey, data generated were both ordinal and 
nominal, and analysis was primarily descriptive, concentrated on measuring 
frequencies of responses. In addition to this, a small number of bivariate analyses 
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were undertaken, using Pearson Chi-square or Fisher’s Exact tests. Statistical 
significance was determined based on an alpha of 5%, (p≤0.05). 
Analyses were limited to investigating possible associations between question 
responses and the gender and rurality of participants, along with potential 
differences between those respondents who had patients with CD, and those who 
did not. These variables were selected because of the following: 
 the potential role of gender in influencing responses was important to 
examine once it became clear that women were over-represented 
among participants, because of implications for the generalisability of 
conclusions drawn from the results;  
 it seemed reasonable to expect that working in either a rural or urban 
location might affect practise (mediated through potentially differing 
access to resources); and  
 caring for patients with CD might be expected to influence knowledge 
and practise with respect to the condition. 
Chapter Five, the results chapter pertaining to this study, includes further 
description of how responses to the first two questions in the survey were collated 
and subsequently analysed. This has been done in order that the results these 
processes generated can be more readily interpreted in context. 
3.6 The Laboratory Study 
In the third component of the project, data relating to testing for CD were gathered 
from Southern Community Laboratories (SCL). They are the sole laboratory service 
provider for the lower half of the South Island of New Zealand, and have the largest 
network of diagnostic laboratories across the country. Having started out as a 
privately owned Dunedin-based service in the 1960s, SCL now provides medical 
laboratory services all over New Zealand, and is part of the HealthScope group of 
companies.d Regions where SCL are the sole provider of laboratory services are 
Otago and Southland, (where this has been the situation since 2006), Taupo, Nelson 
and Marlborough, South Canterbury, Wellington, and the Wairarapa. They are also 
                                                        
 
d Information obtained from SCL’s website www.sclabs.co.nz; accessed March 2016 
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the major provider in Hawkes Bay and Canterbury, although both these regions also 
have DHB owned laboratories providing services for their respective hospitals. The 
following table summarises information about the regions for which SCL provides 
services. (Table 3.2) 
Table 3.2: SCL Regional service provision 






Otago 100 Both Mid-2006 
Southland 100 Both Mid-2006 
Canterbury 95 - 100* Community only Mid-2012 
Hawkes Bay 100 Community only 2007 
Taupo 100 Both 2008 
South 
Canterbury 
100 Both Mid-2012 
Nelson/ 
Marlborough 
100 Both Mid-2012 
Wellington and 
Wairarapa 
100 Both End-2015 
* All information provided by SCL’s Otago Southland Quality Co-ordinator. This indicated that SCL 
provide 100% of community laboratory services in Canterbury, however National Health Committee 
data from 2015 suggests that this figure is 95%.454 
 
3.6.1 Background 
Initially it was thought that it would be possible to calculate the New Zealand 
prevalence of diagnosed CD by cross-checking laboratory data with information 
from additional sources such as the New Zealand Ministry of Health (MoH), and 
CNZ. However, as more information about the actual data that would be able to be 
utilised became available, it became apparent that this would not be possible. 
The first set of challenges arose with obtaining laboratory data that would 
encompass the whole population, and include all the necessary information (i.e. 
biopsy data as well as serology). In the past it was possible to access national data 
relating to blood tests performed in New Zealand, which was held in a laboratory 
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data warehouse. However, bulk data relating to coeliac serology tests are grouped 
with other autoimmune related tests, and so are not readily identifiable as a unique 
set.e A recent report from the National Health Committee also indicates that data 
held in the warehouse over recent years is not robust, and that there is no longer a 
single reliable repository for publicly-funded tests.454 This further confirmed that it 
would not have been possible to gather a reliable national dataset of laboratory 
results. In addition to this, as the guidelines still state that the diagnosis of CD should 
be confirmed with a duodenal biopsy in order to reliably determine prevalence, 
data gathered would need to include histology. In 2016, histopathology data 
relating to individual conditions such as CD were not included in bulk datasets and, 
at the time of planning this project, the only way of extracting this information was 
going to be to do a manual search for individual results. 
The fact of not having a set of laboratory data that covered the whole of New 
Zealand, and which included biopsy data, compounded a second set of challenges to 
being able to calculate the prevalence of diagnosed CD in New Zealand. These 
challenges resided with the possible alternative sources of the additional data that 
would be required to determine the prevalence of diagnosed disease in the 
community. (A complete set of national laboratory data would have enabled the 
calculation of annual incidence rates – the number of new diagnoses expressed as a 
proportion of the total population – but not prevalence, which is the total number 
of people in the community with the condition.)  
Possible sources for additional data were CNZ membership lists, and the MoH, 
which has a list of CD patients with a Special Authority number for subsidised 
prescription gluten-free foods, referred to in Chapter Two (page 87). Unfortunately, 
neither of these lists is complete as not all people with CD join CNZ, and not all 
people with CD want, or are recommended to get a Special Authority number. In 
addition to this, people with DH are also entitled to a Special Authority number, and 
would appear on any MoH list and would therefore have had to be identified and 
removed. Furthermore, in recent years CNZ has begun accepting membership from 
                                                        
 
e Personal communication from SCL’s Chief Executive Officer. 
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people without biopsy-proven disease, who would also have had to be identified 
and removed from their list. 
Calculating the prevalence of diagnosed CD would therefore have entailed the 
following steps: 
 Identifying positive serology results and manually searching for a 
biopsy result for each identified patient. 
 Matching those patients with a positive biopsy to those with Special 
Authority numbers. This would also have had to be done manually 
using patients’ National Health Index (NHI) numbers.   
 OR matching patients with a positive biopsy to those on the CNZ 
membership list, also a manual process, using patients’ names. 
 Calculating the proportion of patients with a positive biopsy who also 
had a Special Authority number. This would have needed to be done 
for several years’ data.  
 Calculating the proportion of patients with a positive biopsy who were 
also members of CNZ. 
 Applying these results to the datasets to calculate a predicted 
prevalence. 
Such a labour-intensive process would at best have yielded a ballpark prevalence 
figure, had national laboratory data been available. However, the lack of national 
data introduced another layer of estimation. It was possible to obtain regional data 
(as will be discussed shortly) and it would theoretically have been possible to make 
national projections from regional data. But the assumptions inherent in that, chief 
among them that each region behaves similarly to the next, would have rendered a 
calculated figure so speculative as to be not much better than guesswork. For these 
reasons it was decided to modify the laboratory study to achieve more modest aims. 
3.6.2 The study redefined 
As discussed in Chapter Two, there have been a number of recent incidence studies 
related to CD, some of which utilised laboratory data to determine their 
figures.45,248,249 In addition to this there have been two pieces of research published 
that investigated patterns of testing for CD.37,455 
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In the first of these, Evans et al.37 retrieved coeliac serology testing data from 
laboratory databases at Wycombe Hospital in England, for the period 1997 to 2006. 
The data they obtained related to all patients in their region who had been tested 
for CD, and their analysis included determining how many tests were requested 
each year and how this changed from year to year; what proportion of tests were 
positive and how this changed from year to year; the demographic characteristics 
of those who had been tested; the numbers of patients who went on to have a 
duodenal biopsy; and the correlation between serology and biopsy results.37  
The second study was conducted in Latvia.455 This study also looked at the 
numbers of coeliac serology tests being performed, this time at a national level and 
for the period 2004 to 2009. Unlike the English team they did not also look at 
biopsies, but they did calculate the proportions of positive results for the different 
types of tests performed, and they also compared the performances of different 
brands of tests.455 
Given that it would be possible to access testing data from SCL, which had the 
potential to provide information about several regions in New Zealand, the third 
arm of the project was reconfigured. The original research question relating to 
prevalence was modified to be one about incidence, and more thought was given to 
how available laboratory data could be used to corroborate information gathered 
in the survey arms of the project, and to the question “What information can 
laboratory data provide about the recognition and management of CD in New 
Zealand, particularly among GPs?” In addition to this, it would also be possible to 
situate this study within the recent international research context by analysing 
secondary issues relating to rates of positive serology tests, and correlations 
between positive serology and duodenal biopsies, such as had been done by both 
Evans and Leja and their teams. Thus the following questions were formulated to 
apply to the dataset provided by SCL: 
 Which coeliac serology tests are doctors requesting and how many of 
each have been requested? 
 How has this changed over time? 
 Which doctors (i.e. GP, Gastroenterologist, Paediatrician, or other 
specialist) are requesting coeliac tests? 
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 How many tests are positive? 
 How many positive serology tests are leading to patients having 
duodenal biopsies? 
 How many of those biopsies are positive? 
 How many patients are having more than one serology test, either with 
or without biopsy evidence of CD? 
 What are the demographic characteristics of people tested for coeliac 
disease, and those with positive tests? 
 Are there any regional differences in patterns of testing? 
3.6.3 Data retrieval  
Staff members from SCL involved in coeliac serology test analysis were consulted 
for background information about which tests are performed by the laboratory, 
how this has changed over time, and how test result information is stored. Using 
this information, a study protocol was developed and ethical approval sought and 
gained. (Appendix A) Because there would be a charge to retrieve the necessary 
information, funding was also obtained in the form of a University of Otago 
Research Grant, and from CNZ. 
Once the necessary approval had been given, IT personnel from SCL wrote a 
programme that enabled them to extract the required data from SCL databases. The 
extracted data were then provided in a series of Excel spreadsheets. These data 
included identifying information, so all spreadsheets were immediately password 
protected and the columns containing patient names were hidden.  
Data were initially provided for the years 2003 through to 2013 and, following 
a second extraction that took place in early 2016, for 2014 and 2015. Because SCL 
were not the sole laboratory provider for any region until 2006, it was decided to 
limit analysis to data covering the period from 2006 onwards. In addition to this, 
data from areas where a second laboratory provider is also present were excluded 
from analysis, to ensure that the datasets being interrogated were as complete as 
possible. For regions where SCL had become the sole laboratory services provider 




The serology results for each region included in the final set of data were all 
processed and analysed in SCL’s Dunedin laboratory. This continues to be the 
practice for these regions, and for centres outside Dunedin this necessitates sending 
samples by overnight courier. For the entire period of analysis, IgA-tTG antibodies 
were tested using Inova Diagnostics’ Quantalite kits, which are human red cell 
based, and which have an upper limit of normal of 20 units. Endomysial antibody 
tests were performed using Immuglo slides from Immco Diagnostics until the 
beginning of 2015, at which time the laboratory changed to slides from Inova 
Diagnostics. Both these brands of test kits use primate smooth muscle as the 
substrate for their slides. 
Histopathology data were not included in the information provided because 
they could not be retrieved as a bulk set. This meant that individual searches were 
required to obtain biopsy results. In order to do this, serology results, which had 
been given as numerical values, were sorted in rank order. National Health Index 
numbers for all those patients with values above the normal threshold (20 Units) 
were then used to search the laboratory database to determine (a) whether the 
individual had had a biopsy, and (b) what the result of that biopsy was. Biopsy 
results were added to the existing spreadsheets and coded for subsequent analysis. 
Searches were also made on EMA results that were reported as equivocal when 
these were not associated with an elevated tTG level; on results that were 
registering as indecipherable on the spreadsheet (usually in the form of “*******”); 
and on rows in which all results columns were empty, despite a laboratory request 
code and patient details being present. Results identified by laboratory staff as 
being indicative of IgA deficiency were also checked. The required biopsy 
information was held in two separate databases, one in Dunedin and one in 
Wellington. Access to these databases was facilitated by HealthScope New Zealand, 
the company that owns SCL, and by SCL staff in Wellington.  
Additional data relating to the ethnicity of patients was obtained from the New 
Zealand MoH, using the NHI information provided by the laboratory. Population 
data were taken from the 2007 and 2013 New Zealand Censuses.  
The NHI is a repository of information relating to healthcare service use in New 
Zealand. Its purpose is defined by the MoH as being “to help with the planning, co-
ordination and provision of health and disability support services across New 
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Zealand.”f The unique NHI numbers assigned to patients enable information to be 
collected and collated about a range of health-related activities, which (in coded 
form) is then used to inform health service policy and decision-making. 
 Ethnicity is one of the key variables about which information is gathered in 
association with NHI numbers. It is obtained by asking individuals to list up to three 
ethnic groups with which they identify. “Ethnic group” is defined by the ministry as 
“a group of people who have culture, language, history or traditions in common.” 
Once a person has identified his or her group (or groups), these are then recorded 
using codes that have been determined by Statistics New Zealand (SNZ), and which 
correspond to codes used for all government-mandated personal information 
records. In addition to this, a “prioritised ethnicity” is recorded, derived from an 
SNZ algorithm and applied when multiple ethnicities are given. Prioritised ethnicity 
data are central to MoH planning and service provision decisions. Of the 22 possible 
ethnic groups people can choose, the highest priority is given to Māori, and the 
lowest to New Zealand European. In practice this means that if a person gives her 
first ethnicity as NZ European, and her second ethnicity as Māori, Māori will be 
recorded as her prioritised ethnicity. In fact, any other ethnicity given along with 
NZ European will be regarded as the priority ethnicity. There are also codes for 
“don’t know”, “refused to answer”, and “response unidentifiable”, which are not 
prioritised.  
3.6.4 Data analysis 
The data provided by SCL were grouped and analysed to enable the questions set 
out on pages 140 and 141 to be answered. This was almost entirely descriptive 
work and, along with related calculations, was conducted within Excel (2016) 
spreadsheets. Limited analyses using Stata (version 13.1) were undertaken to 
determine if there were significant differences between years, between regions, and 
between male and female patients, with respect to rates of testing, positive IgA-tTG 
tests, and rates of biopsies undertaken. According to the comparisons being tested, 
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either two-sample proportions testing or Pearson Chi-square analyses were 
performed. This is indicated in the text at the relevant places. Statistical significance 
was determined based on an alpha of 5%, (p≤0.05). 
Prior to undertaking any analysis, extensive work was carried out cleaning and 
sorting the data. This included confirming whether patients were from the region 
to which their test results had been assigned, which was achieved by tracing the 
people who had requested the tests. Many of the doctors were known to me but, for 
those who were not, this involved consulting resources such as the NZMC register 
and the New Zealand Nursing Council register, and conducting Google searches. 
3.7 Conclusion 
In summary, three separate observational studies were undertaken to test the 
principal hypothesis that GPs in New Zealand have limited disease-specific 
knowledge about CD. Two of these studies utilised surveys, one of 
gastroenterologists and one of GPs, developed in accordance with best practice 
recommendations from experts such as Dillman et al.,435 and Aday and Cornelius.429 
The third study drew on data from SCL to determine patterns of testing and CD 
incidence rates over time in regions in which they were the sole laboratory 
providers. The results of each study are discussed in the next three chapters, with 
one chapter devoted to each study. Chapter Seven will draw the threads of these 
chapters together with discussion of the results and reflection on their implications, 




: Results from the Survey of Gastroenterologists 
4.1 Introduction 
The survey of New Zealand gastroenterologists was designed to capture 
information about their current practice with respect to CD. This chapter presents 
the results of that survey. 
The survey took place in the latter part of 2013, and early 2014. As discussed 
in Chapter Three, it was initially conducted as an online survey that was followed 
by the distribution of paper copies at the Annual Scientific Meeting of the NZSG in 
late 2013. Subsequent to this a targeted mail-out to Auckland-based and female 
practitioners was also undertaken, as these two groups were, at that time, under-
represented among respondents. 
The chapter begins by providing details about the overall response to the 
survey and goes on to describe the characteristics of participants. Their responses 
are then presented under the following headings: 
 Management of newly diagnosed CD. 
 Long-term management of CD. 
 When the histology is normal. 
 A patient declining endoscopy. 
These headings represent the principal areas of practice about which the three 
scenarios in the survey were designed to capture information. Responses are first 
described and then, when appropriate, analysis according to participant 
characteristics is reported. The chapter closes by drawing out the key findings. 
4.2 Response to the survey 
4.2.1 Identifying the survey population 
As discussed in section 3.3.4 of Chapter Three, it proved challenging to determine 
the exact number of gastroenterologists in New Zealand and thus to identify the 
intended recipients for the survey. Following extensive searching, the total number 
of gastroenterologists identified as practising in New Zealand in 2013 was 81. This 
compared with the figure of 64 gastroenterologists registered on the Medidata 
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databaseg, and 62 people who had recorded “gastroenterology” as one of their 
principal worksites in the New Zealand Medical Council (NZMC) Workforce Survey 
of 2012.h (As noted in Chapter Three, gastroenterologists are vocationally 
registered with the NZMC in the discipline of Internal Medicine, so the Council does 
not have more detailed information about their numbers than that volunteered in 
the annual Workforce Survey.) Basic demographic information available for these 
81 practitioners is summarised as follows. (Table 4.1) 




Male Female North Island South Island 





















There may still have been a small number of gastroenterologists who did not 
emerge through the searching process, but it seems highly unlikely that there would 
have been more than 85 gastroenterologists in practice in New Zealand at the time 
at which the survey was undertaken.  
4.2.2 Respondent numbers 
At the time of the survey there were 133 members of the NZSG, which was to be the 
principal point of contact with recipients. Due to the practical constraints discussed 
in Chapter Three, the request to participate initially went out to all 133 NZSG 
members, which included dietitians, nurses, and paediatric gastroenterologists, as 
well as the professional groups for whom the survey was intended. Following this, 
approximately 25 hardcopy versions were handed out or picked up from the CNZ 
                                                        
 
g Information from Medidata website (www.medidata.co.nz/database-count-results.php?PHYSIN-
GASTRO=on), accessed 9/12/13. 
h Personal email communication from NZMC Senior Information Systems Analyst, 12/12/2013. 
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stand at the NZSG conference in November 2013, and then, after provisional 
analysis of responses in early 2014, another 31 copies were posted to Auckland-
based and female practitioners.  
Response to the survey is outlined below. (Figure 4-1) 
 
Figure 4-1: Responses to the survey of New Zealand Gastroenterologists 
The 45 gastroenterologists who completed the survey represented 55.6% of 
identified specialists practising in New Zealand at the time it was undertaken. 
Responses from gastroenterology trainees were excluded because the three 
respondents represented just 12.5% of that group. As the focus of the survey was 
on adult disease, the paediatric gastroenterologist’s answers were also excluded. It 
had not been intended that the paediatric specialists should participate. No surgeon 
endoscopists completed the survey, despite being invited to do so. 
4.2.3 Respondent demographics 
Demographic information was available for analysis from 42 of the 45 
gastroenterologists who completed the survey. One person who participated online 
left the entire demographic section blank. Another, also online, commented that he 
or she was not happy with the level of personal detail being sought, writing “with 
my apologies, only Q37; 38; and 42 are definitely correct; the other questions may 
or may not be correct”. These questions corresponded to current position, years in 
Began the survey: 55
Completed the survey: 49
Final sample: 45 Gastroenterologists
Excluded: 3 Trainees, 1 Paediatric Gastroenterologist
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practice, and place of undergraduate training. A third online respondent evidently 
felt similarly, providing nonsense answers (e.g. “abc”) to several questions in this 
section of the survey. Because it was impossible to know which (if any) of these 
participants’ answers to the profile questions were reliable, they were excluded 
from presentation of demographic results. (Tables 4.2, 4.3 and 4.4) 
Table 4.2: Initial demographic information provided by survey participants 
Total number of respondents  45 
Gender Male Female Unknown 
Number of respondents 35 (77.8%) 7 (15.5%) 3 (6.7%) 
DHB region of practice North Island South Island Unknown 







Number of respondents 13 (28.9%) 28 (62.2%) 4 (8.9%) 
Postgraduate training NH SH Both Unknown 
Number of respondents 15 (33.3%) 13 (28.9%) 13 (28.9%) 4 (8.9%) 
 
When considered as representatives of the New Zealand gastroenterologist 
community identified at the time the survey took place, the percentages of men and 
women who participated were 53.3% (35/66) and 46.7% (7/15) respectively, with 
three people undeclared. 
Participants were asked to identify the DHB regions in which they worked but, 
in view of the very small numbers working in some regions and the expressed 
concerns about anonymity, this information was combined. Respondents 
represented 45.9% (28/61) of North Island, and 70% (14/20) of South Island 
practitioners, with three people undeclared. Information was also sought about 
where participants had undertaken their undergraduate and postgraduate training. 
Once again responses were grouped, this time into the Northern and Southern 
hemispheres. (Table 4.2) Of the 28 people who completed their medical degrees in 
the Southern hemisphere, 25 did so in New Zealand. 
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Table 4.3: Professional profiles of gastroenterology survey participants 
Total number of respondents 45 
Number of years 
practising 
gastroenterology 
1 – 10 11 – 20 21 – 30 > 30 Unknown 
Number of respondents 
9 







3     
(6.7%) 
Number of clinical 
tenths worked in 
gastroenterology 
< 3 3 – 5 6 – 8 > 8 Unknown 
Number of respondents 








3     
(6.7%) 





Both Other Unknown 




(8.9%)     
28 
(62.2%)  
0 3     
(6.7%) 
Number of clinical 
tenths in private 
practice 
None 1 – 3 4 – 6 7 – 10 Unknown 







3     
(6.7%)     
3     
(6.7%) 
Academic post Yes No Unknown 
Number of respondents 
14                
(31.1%) 
28                
(62.2%) 
3     
(6.7%) 
 
As a follow-on from the questions relating to participants’ clinical practice 
setting, a free text question asked for comments about “any factors about the setting 
(or settings) in which you work which may impact on your management of patients 
with possible coeliac disease.” Nineteen people responded to this invitation to 
comment, the majority being clinicians who worked in both the public and private 
settings. Of these, more than two-thirds (13/19) indicated that constrained 
resources in the public sector (or more readily available resources in the private 
sector) had impacted on their practice. This was apparent either in the timeframe 
to endoscopy, or in outpatient clinic capacity for the follow-up they offered. The 
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remaining six commenters reported no differences in management between the 
two settings, or thought that their coeliac patients could be “managed appropriately 
in all aspects” by DHB services. 
There was a range of sub-specialty practice areas among respondents, with the 
biggest group (28.9%; 13/45) being those who identified IBD, either singly or in 
combination with other aspects of gastroenterology. Only one participant included 
CD as a sub-specialty area of their practice. 
The survey also asked respondents to indicate how many adult coeliac patients 
they saw in a range of circumstances. (Table 4.4)  
Table 4.4: Number of gastroenterologists seeing numbers of patients in differing 
contexts 
Number of patients 





1 – 10 
per 
month 














3       
(6.7%) 




















4       
(8.9%) 










4       
(8.9%) 
For review; concern 









4       
(8.9%) 
 
As indicated in this table, the CD-related work undertaken by the majority of 
gastroenterologists who completed the survey related to diagnosis, in particular 
carrying out duodenal biopsies, and follow-up of the newly diagnosed. With only 
15.6% of respondents reporting seeing ten or more patients per year for long-term 
follow-up, it would seem that this aspect of CD management in adults was, on the 
whole, not being carried out in the secondary or tertiary care settings. This is 
unlikely to have changed in the years since the survey was conducted. 
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In addition to these demographic details, information was also sought about 
the sources from which participants got their information about CD, in a question 
that asked them to rate their likelihood of using Gastroenterology Conferences, 
Medical Journals, Practice Guidelines, Colleagues, and Coeliac New Zealand for this 
purpose. (Figure 4-2) Three people did not answer this question. 
 
Figure 4-2: Sources of information about CD likely to be used by gastroenterologists 
Among this group of practitioners, it is clear that conferences (at 84.4%) and 
medical journals (at 75.6%) were the means of updating clinical knowledge about 
CD that were most likely to be utilised. UpToDate was the only other source of 
information accessed, specified by one participant. 
4.3 Management of newly diagnosed Coeliac Disease 
The first scenario of the survey was developed to capture information about 
practices relating to newly diagnosed CD. Questions referred to the management of 
Lucy, a 35-year-old woman who had been referred for endoscopy with elevated IgA-
tTG antibodies, and a long history of gut symptoms. Her biopsies had revealed that 
she had Marsh 3 histological changes consistent with a diagnosis of CD.  
Respondents were unanimous that they were the person who would normally 
be responsible for referring this patient to a dietitian, and all but one person was 


























Highly likely/likely May or may not Highly unlikely/unlikely
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letter to Lucy’s GP. They were also almost unanimous in thinking that it would be 
important or very important for her to see a gastroenterologist following her 
endoscopy to discuss the diagnosis, with 95.6% (43 of 45 participants) responding 
accordingly. One person declared himself as neutral on the issue, and one that it 
would not be very important for such follow-up to take place. This person wrote 
that he would have discussed the diagnosis and its implications prior to endoscopy. 
Three people commented that a GP and/or a dietitian could also conduct this 
consultation. 
A series of questions about Lucy’s management in the next year then followed. 
The first of these asked participants to rate the importance of various elements of 
her follow-up. (Figure 4-3) 
 
Figure 4-3: Importance of aspects of management in first 12 months of follow-up 
after CD diagnosis 
It can be seen from this chart that there was greatest agreement on the importance 
of monitoring abnormal blood tests, such as low iron, to ensure that they returned 
to normal. There was also widespread agreement that Lucy should be reviewed to 
confirm that any CD-related symptoms resolved, and a clear majority view that an 
application should be made for a Special Authority number, and that she should be 
advised to suggest to her first-degree relatives that they be tested for CD. Opinion 
was more divided on the issue of advising her to join CNZ, the importance of follow-
up IgA-tTG antibody testing, DEXA scanning and, most notably, the need for follow-















































Important/very important Neutral Not very/not at all important
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Participants were also given the opportunity to provide comments on follow-
up in the first 12 months following diagnosis, and in particular on whether there 
were any other things that they thought should be included in management. There 
were 17 responses to this. Most reinforced or expanded on the answers they had 
already given, with DEXA scanning drawing the greatest number of comments (five) 
relating to a single issue. These comments indicated practitioners would delay 
scanning either until menopause, an “older age”, or for at least a year after 
commencement of the GFD because “bone density rapidly returns to normal once 
on a GFD”. One person would only request DEXA scanning if there was some other 
indication to do so (such as a previous fracture). In addition to the comments about 
DEXA scanning, one person commented that follow-up biopsy should be delayed 
until at least two years after diagnosis, and one person suggested Vitamin D 
supplements should be given. Three participants noted they would include 
discussion about the importance of maintaining a strict GFD. 
4.3.1 DEXA Scanning 
As is apparent in Figure 4-3 (on the previous page), and in their comments just 
noted, respondents were divided on the importance of DEXA scanning for Lucy. Just 
over 55% believed including this in her management in the next year would be 
important or very important, while 44.4% were neutral, or regarded it as not 
important. The topic was further explored towards the end of the scenario with a 
more general question that asked participants “[w]hen do you think adults with 
newly diagnosed coeliac disease should be referred for DEXA scanning?” Of the 45 
respondents, 26 (57.8%) thought that this should almost always happen, and 17 
(37.8%) thought it should only occur in certain clinical situations. Two respondents 
(4.4%) thought that it should almost never happen. 
Clinical situations that warranted DEXA scanning were given as older age, 
especially if the diagnosis had been preceded by a long period of symptoms; 
malnourishment or weight loss; a past history of fractures (particularly low impact 
fractures); other risk factors for bone disease; and the patient being a woman. One 
person also commented that implementing a GFD will lead to bone recovery in the 
first 12 months, so DEXA scanning should be delayed until after this time had 
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elapsed, as well as only being carried out in those patients with prolonged 
symptoms before diagnosis. 
4.3.2 Follow-up IgA-tTG antibody testing 
As also shown in Figure 4-3 on page 152, the majority of respondents believed that 
it was important or very important for Lucy to have follow-up IgA-tTG antibody 
testing, although at 60% of the participant group, this was a smaller majority than 
for other aspects of follow-up. This was also the aspect of follow-up that drew the 
second highest percentage of responses (17.8%) in the “not very” or “not at all 
important” categories. 
Follow-up serology testing was teased out further with a question that asked 
when this should take place. A wide range of responses were given to this question, 
although the most favoured option was “Routinely at 6 months”. (Figure 4-4)  
 
Figure 4-4: Preferred timing of follow-up IgA-tTG testing 
“Other” comprised “Routinely at 6 months, and if symptoms don’t resolve”; 
“Routinely at 6 months, and then repeat test until normal”; and “Routinely at 3 and 
12 months, and if symptoms recur”. 
4.3.3 Rebiopsy following diagnosis 
Respondents were most divided on the importance of Lucy having a follow-up 
biopsy at around 12 months after her diagnosis. (Figure 4-3, page 152) On this issue, 
53% indicated that it would be not very, or not at all important; 11.1% declared 
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It is worth noting that these differences in attitudes occurred between respondents 
from within the same DHB regions, as well among those working in different 
regions. 
A further question later in the survey also dealt with the topic of rebiopsy 
following diagnosis. In this question, in which respondents were asked to think 
more broadly than 35-year-old newly-diagnosed Lucy, reference was made to the 
fact that in some countries it is recommended that all patients should undergo a 
repeat biopsy approximately a year after diagnosis. Participants were asked to rate 
the importance of this practice. Their responses were then compared to their 
responses to the similar question about Lucy. (Figure 4-5) 
 
Figure 4-5: Importance of follow-up biopsy in the first 12 months after CD diagnosis 
When the two “not important” counts and the two “important” counts are collated 
for each scenario they are not too dissimilar. The “not important” tallies become 
24/45 for Lucy, and 22/45 in the general case, while the “important” totals are 
16/45 for both groups. On inspection of individual responses, the groups of 
respondents constituting the “important” group are identical, while there are a 
small number who have moved from “not important” to “neutral”, or vice versa. This 
gives rise to a pairwise correlation of r=0.90 between the two sets of responses, 



























This question also drew comments from just over 75% of respondents, in 
support of the answers they had given. Not surprisingly these comments ranged 
over a spectrum of views from “if symptoms have resolved outcome of biopsy is 
irrelevant” (rebiopsy not at all important) to “lifelong GFD is a considerable 
imposition and I think it is important to confirm a good response and the diagnosis 
as accurately as possible” (rebiopsy very important). This second writer went on to 
say that rebiopsy “also reinforces the concept that this is a ‘significant’ condition not 
just a lifestyle choice”.  
Among those who favoured rebiopsy, the majority of those who commented 
made reference to issues such as being able to reassure the patient, confirm a 
histological response, and identify patients who were not responding as expected. 
Those who did not regard rebiopsy as important generally indicated that they relied 
on other indicators of recovery, especially the IgA-tTG antibody result. In between 
were those who reserved further biopsies for patients with ongoing symptoms, 
continued evidence of malnourishment, or IgA-tTG antibody levels that did not fall.  
Four people commented on the resource implications of rebiopsy, suggesting 
that, in a resource-constrained environment, the expense and invasive nature of the 
procedure were not justified by the likely yield of useful information. One among 
these said he would do more such biopsies “in an ideal world”, while another 
acknowledged doing more biopsies “in private if patient symptomatic post 
diagnosis and treatment”. Another four respondents believed that 12 months was 
too early to be doing a further biopsy, saying that they wait at least 18 to 24 months 
before doing this. 
4.3.4 Analysis by demographics: Management of newly diagnosed CD  
Responses to questions of management in the first 12 months following diagnosis 
were analysed with respect to the demographic characteristics of participants, 
using Fisher’s Exact test. All demographic variables were included in this process, 
except areas of sub-specialty practice, which were too varied to meaningfully 
interpret. Responses were also analysed by participants’ likely use of guidelines 
documents as a source of information about CD. 
Initial analysis, without grouping Likert-scale responses, suggested that there 
were a small number of areas in which there were statistically significant 
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differences between groups of participants, and an additional few areas in which 
differences approached statistical significance. (Table 4.5) Analysis was then 
repeated with Likert-scale responses grouped together  (important with very 
important, and not at all important with not very important and neutral). (Table 
4.5) It is reasonable to postulate that these groupings would be more likely to 
represent clinically significant differences in practice, suggesting that any 




Table 4.5: Factors influencing aspects of Lucy’s management in the year following CD 







Grouped     
p-value 
Follow-up biopsy 
(at 12 months) 
Number of patients 
seen for long-term 
follow-up 
0.001 0.062 
 Number of patients 





 Number of patients 
seen for review due 













Numbers of patients 
seen for long-term 
follow-up 
0.057 0.027 
Advise to join CNZ Use of practice 
guidelines 
0.008 0.63 
Advise to have 1st 
degree relatives 
tested 
Gender 0.037 0.488 
 Years in practice 0.042 0.239 




As presented on page 157, the importance of performing follow-up biopsies at 
around 12 months following diagnosis was the point on which there was least 
agreement among participants. There were no statistically significant differences in 
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participants’ attitudes to this issue according to their gender, (p=0.44), their years 
in clinical gastroenterology practice, (p=0.96), whether they worked in the private 
and/or public sectors, (p=0.72), whether they worked in the North or South Island, 
(p=0.96), whether they held an academic post or not, (p=0.56), or where they had 
undertaken their postgraduate training, (p=0.80).  
Table 4.5 shows that their differences of opinion did reach statistical 
significance with respect to numbers of patients seen for (a) long-term follow-up, 
and (b) when the diagnosis had not previously been considered. They approached 
statistical significance according to how many tenths were worked in 
gastroenterology, and how many patients were seen for review because of concern 
about recovery and/or complications. However, as is also evident in this table, when 
the Likert-scale responses were grouped, these p-values changed, such that some of 
the variables identified were no longer associated with significant differences in 
responses, and one new significant association emerged. Thus, those people who 
placed lower importance on follow-up biopsy in the first 12 months of management 
were more likely to work in gastroenterology fulltime (i.e. >8 tenths), see between 
one and ten patients per year because of concerns about their progress, and be 
variable in their use of practice guidelines. Almost all of those who rated follow-up 
biopsy as important (11/13) were likely to use practice guidelines as a source of 
information about CD. 
When responses to the question about rebiopsy in general were grouped and 
analysed, p-values were identical to those found with respect to follow-up biopsy 
for Lucy across all variables, which further illustrates the consistency of 
participants’ answers between these two questions. 
The remaining points on which statistically significant differences in opinions 
were detected were the importance of follow-up IgA-tTG antibody testing, and 
advising patients to have their first-degree relatives tested. Participants who saw 
no patients for long-term follow-up of their CD were less likely to think that follow-
up antibody testing was important, while those who worked more than half-time in 
private practice all thought that it was important or very important to advise 
patients about having their first-degree relatives tested. 
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4.3.5 Responsibility for follow-up actions 
Following the question on Lucy’s management in the next 12 months, respondents 
were asked about whom they felt should be responsible for arranging four of the 
follow-up tasks that had been included in that question. These were: applying for a 
Special Authority number for prescription gluten-free foods; referring her for a 
DEXA scan; advising her to join CNZ; and advising her that her first-degree relatives 
should be tested for CD. Options given were: I don’t think this is necessary; Me; One 
of my team; Her GP; Other. (Table 4.6) 
Table 4.6: Who should take responsibility for arranging follow-up tasks? (Majority 






Her GP Other 
Applying for SA 
number 




2     
(4.4%) 
1     
(2.2%) 












2     
(4.4%) 
Advising her to 
join CNZ 





















It is very clear from this table that the majority of respondents believed that the 
responsibility for arranging these events rested with them. This is especially the 
case with regards to applying for a Special Authority number, and discussing the 
need for first-degree relatives also to be tested for CD. “Other” suggestions were 
that dietitians could apply for the Special Authority number, and that any (or all) of 
the three groups identified could be responsible for recommending CNZ. One 
respondent noted that he would discuss CNZ, but not recommend it, and another 
pointed out that as DEXA scanning was not funded, it was not always feasible for 
patients to obtain. 
Responses from those participants who thought that the identified tasks were 
not necessary were then compared with their ratings of the importance of those 
same tasks in the earlier question. (Table 4.7) 
161 
 




Not very or 






Applying for SA 
number 
5 4 1 0 
Referring for 
DEXA scan 
4 2 1 1 
Advising her to 
join CNZ 
3 2 1 0 
Advising her 
about relatives 
5 2 3 0 
 
At first glance it seems that at least one respondent had been inconsistent in his 
responses, rating the need for DEXA scanning as important but then deeming it not 
necessary. In fact, this participant had also written a comment relating to DEXA 
scanning in which he indicated that he thought that, given that bone mineral density 
recovers in the first year of a GFD, DEXA scanning should be delayed beyond 12 
months after diagnosis. Viewed in the light of this comment, his response to the 
subsequent question, which referred explicitly to follow-up in the 12 months 
following diagnosis, is not at all incongruent. There were no comments from the 
three people who were neutral on the importance of advising Lucy that her close 
relatives should be tested for CD, who then indicated that they thought that this was 
not a necessary part of her follow-up in the next 12 months. 
At the conclusion of the section based on the Lucy scenario, some of these 
issues of responsibility for follow-up were explored further, albeit from a slightly 
different angle. At this point in the survey, respondents were asked about how often 
they discuss joining CNZ with their newly diagnosed coeliac patients, and about how 
often they discussed the issue of testing those patients’ first-degree relatives. More 
than 75% of respondents indicated that they discussed these issues almost always 




Figure 4-6: How often joining CNZ and testing first-degree relatives is discussed 
Reviewing answers to these questions with reference to participants’ earlier 
responses to the questions about how important they believed these aspects of 
management to be, and who should be responsible for undertaking them, revealed 
generally good levels of consistency. This is especially true among those who 
believed the tasks are important, or very important. Of the 28 respondents who had 
indicated it would be important, or very important, to discuss joining CNZ with 
patients such as Lucy, 26 (92.9%) reported they mostly or almost always did this, 
and 25 (89.3%) had indicated it was their responsibility to do so. Only one of the 28 
specified a GP should do this, and this person indicated he discussed the issue about 
half the time. The other two respondents answered that one of their team should be 
responsible, but then reported that they do this most of the time in one case, and 
almost always in the other.  
When it came to discussing the testing of a newly diagnosed patient’s first-
degree relatives, 90% (27/30) of those who had rated this as important or very 
important with respect to Lucy reported doing this with their patients most of the 
time, or almost always. Two specified they did this about half the time, and one, 
some of the time. Of the 30 respondents placing importance or high importance on 
this issue, all but one (96.7%) had indicated that it was their responsibility to have 
this discussion. The remaining person assigned responsibility for this to the 




























Almost never Some of the time About half the time Most of the time Almost always
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the time. Among those who placed a lower level of importance on one or both of 
these aspects of management for Lucy, there was less consistency in their responses 
to how likely they would be to discuss these issues with their patients. (Table 4.8)  
Table 4.8: Discussions about joining CNZ, and testing relatives, among those who did 
not rate these tasks as important 
Importance of CNZ 













12 0 2 1 5 4 
Not 
important 
5 3 0 1 1 0 
Importance of advising 
testing of relatives 
Discuss testing 1st degree relatives 
Neutral 
importance 
12 2 5 0 4 1 
Not 
important 
3 0 0 0 1 2 
 
A lack of consistency is particularly apparent among those who placed little or no 
importance on advising Lucy that her first-degree relatives should also be tested for 
CD, but then indicated they had this discussion with patients most of the time or 
almost always. One possible explanation for this is that these discussions are (at 
least in part) driven by patients asking questions, rather than solely by what the 
gastroenterologist may deem important. 
4.3.6 The letter to Lucy’s GP 
The final question concerning the management of newly diagnosed CD was framed 
in terms of what information participants would include in their letter returning 
Lucy to the care of her GP. Once again they were asked to rate a range of issues 
pertaining to her management, this time on how likely they would be to comment 
on them in their letter. Figure 4-7 presents the findings that emerged with respect 
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to her management in the next 12 months. (Note: one person did not provide 
answers for the final three variables given here.) 
 
Figure 4-7: Likelihood these management issues will be commented on in letter to GP 
When comparing participants’ responses to this question with their earlier 
evaluations of the importance of each of these events forming a part of Lucy’s 
management, there were very good correlations within most pairs of variables. 
Pairwise correlations ranged between r=0.39 for the review of CD-related 
symptoms, to r=0.85 for joining CNZ, with r values for the other four pairs all lying 
in the 0.7 to 0.8 range. The low correlation with respect to reviewing CD-related 
symptoms is largely accounted for by the answers of four individuals. Two of them 
reported that they were highly likely to include comment in their letters about the 
need to ensure CD-related symptoms were resolving, having rated themselves as 
neutral on the importance of this task, while the other two responded oppositely, 
rating the task as important, but their likelihood of including this in their letter as 
low.  
4.4 Long-term management of Coeliac Disease 
Scenario One also included questions relating to the long-term management of CD, 
continuing to focus on 35-year-old Lucy. Once more, participants were asked to rate 












































Figure 4-8: Rating of importance of aspects of long-term management of CD 
They were also invited to comment on the actions identified, and to indicate if there 
were additional tasks that they thought should be included. Eleven people chose to 
do this. Among them, one commented that he would “seek ID [infectious diseases] 
advice with respect to Pneumococcal vaccination”, and two others noted that this 
vaccination was only indicated in the presence of hyposplenism. Two people 
suggested that DEXA scanning should be performed every few years, and four 
people advocated testing for absorption (e.g. blood count, iron studies, vitamin B12, 
folate) as well as associated conditions such as thyroid disease. 
Two additional questions then explored the issue of whether Lucy should have 
an “Annual Review” of her coeliac management,(Figure 4-9), and, if so, who should 
be responsible for that.  
 





























































From this chart it can be seen that 60% of participants (27/45) agreed that it would 
be important or very important for Lucy to have an annual review. Within this 
group, however, only a small number regarded this as very important. Nearly a third 
of respondents (14/45; 31.3%) gave a neutral response, and the remaining 8.9% 
(4/45) indicated their belief that an annual review was not important.  
When it came to who should carry out such a review, 73.3% (33/45) indicated 
that this should be done by Lucy’s GP, while 15.6% (7/45) answered that a 
gastroenterologist would be the most appropriate person. No participants 
responded that a GP Practice Nurse should carry out this task, and only one person 
indicated that a dietitian should do so. One person wrote that anyone who could 
give appropriate advice and access any necessary services or professionals could 
carry out such a review, and one specified that it would depend on the patient’s 
clinical state: if she were well and compliant with the GFD then a GP could review 
her, but if she were symptomatic or had issues with complying with the diet then 
she would be at risk of complications, and as such should be reviewed by a 
gastroenterologist. One respondent who had responded that an annual review was 
not necessary wrote that “probably coeliac patients who are otherwise well need 2 
yearly follow-up in gastro clinic”.  
As already noted, participants were also asked to indicate how likely they 
would be to comment on specific areas of management in their letter returning Lucy 
to her GP. This included aspects of her long-term care. (Figure 4-10)  
 
Figure 4-10: Likelihood these long-term management issues will be commented on in 
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167 
 
As with Lucy’s early management, there were generally good correlations 
between respondents’ assessments of the importance of these components of her 
long-term follow-up, and the likelihood that they would discuss these in their 
discharge letters. Pairwise correlations ranged from r=0.58 with respect to 
reinforcing the importance of the GFD, to r=0.87 relating to the need for periodic 
serology testing. But given that 73.3% of respondents indicated that they thought 
Lucy’s GP should be responsible for carrying out an annual review of her CD, it is 
worth noting that only just over half of these practitioners (19/33) answered that 
they would be likely or highly likely to refer to this in their discharge letter. The 
remainder were either neutral on the issue (8/33) or unlikely or highly unlikely to 
mention it (6/33). This gave rise to a pairwise correlation of r=0.58 for this aspect 
of care.  
4.4.1 Including oats in the gluten-free diet 
As discussed in Chapter Two, the issue of whether oats may be included in the GFD 
remains controversial. Therefore, in order to determine the attitudes of New 
Zealand practitioners to this topic, a question was included in the survey asking 
them what they “think about coeliac patients including non-cross-contaminated 
oats in their gluten-free diet?” Their answers were divided among the options given. 
(Figure 4-11)  
 


















































The two people who answered “other” to this question both commented. One said 
that he discussed the issue with patients but “would advise against, in an effort to 
simplify the situation and avoid mistakes”, while his colleague would “see how 
symptoms go”. 
A follow-up question asked about the place of rebiopsy in the ongoing 
surveillance of patients who did include oats in their GFD. (Figure 4-12) 
 
 
Figure 4-12: Rebiopsy practice when oats are included in the GFD 
It is apparent that respondents were divided in their views on this, but with a small 
majority indicating they do not rebiopsy. One respondent did not select any of the 
available options, writing that “the oats are irrelevant”.  
4.4.2 Analysis by demographics: Long-term management of CD  
Attitudes to the importance of various aspects of Lucy’s long-term management 
were also analysed with respect to the demographic characteristics of participants, 
using Fisher’s Exact test. Likert-scale responses were first analysed without 
grouping them, and then with them collated. It is apparent that when it came to 
Lucy’s long-term management there were few variables associated with statistically 
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The importance of reinforcing adherence to the GFD reached statistical significance 
because all respondents who did not think this was important, or who were neutral 
on the issue, and for whom demographic information was available (6/8), saw more 
patients in whom the diagnosis of CD had not previously been considered. 
Participants who worked a higher number of tenths in private practice were more 
likely to rate the need for periodic screening for associated symptoms as important. 
There were no statistically significant differences in opinion across all 
demographic parameters with respect to annual influenza vaccination, 5-yearly 
pneumococcal vaccination, or the importance of patients having an annual review 
of their CD. 
Fisher’s Exact analyses for significance were also carried out on responses to 
the questions about whom should be responsible for carrying out annual reviews, 
whether non-cross-contaminated oats could be included in the GFD, and on the 
place of rebiopsy if oats were a part of the diet. 
With respect to annual reviews, after excluding people who had indicated that 
they did not think this was necessary, only the number of patients seen per year for 
biopsy to confirm a CD diagnosis was determined to be a statistically significant 
variable, (p=0.046). This was because the one person who saw more than ten 
patients for biopsy per month, and who thought that annual reviews were 
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necessary, was the only person who thought that a dietitian should be responsible 
for them. Responses according to number of tenths worked in private practice 
approached statistical significance, (p=0.062). As the number of tenths worked in 
private practice increased so too did the proportion of people who thought that 
responsibility for this should be with gastroenterologists. No-one who worked 
solely in the public sector thought that a gastroenterologist should carry out annual 
reviews, compared with 50% (2/4) of those who worked in the private sector, and 
18% (5/28) of those who worked across both sites, although these differences did 
not reach statistical significance, (p=0.086).  
Opinions about the inclusion of oats in the GFD were generally not significantly 
associated with any demographic variable, apart from the view that they should 
“only be included if the patient had biopsy-proven recovery of the gut”. All three 
people who held this position worked in a South Island DHB and worked solely in 
the public setting, thus the p-values for these two variables were 0.046 and 0.034 
respectively. With reference to if and when someone including oats in their GFD 
should be re-biopsied, only the number of patients seen for long-term follow-up 
influenced these responses to a statistically significant level, (p=0.026). Participants 
who saw more patients for long-term follow-up were more likely to routinely 
rebiopsy following the introduction of oats, while those who saw fewer than ten 
long-term follow-up patients per year were more likely to not rebiopsy.  
4.5 When the histology is normal 
Case study B in the survey explored likely practice when the diagnosis of CD is 
uncertain. The “patient” in this second scenario was Joshua, a 20-year-old man who 
had been referred with significantly elevated IgA-tTG antibodies, detected when he 
was screened following his sister’s recent CD diagnosis. On questioning about 
symptoms, he reported he had never noticed any. 
In response to the first question about their most likely course of action on 
receipt of the referral, 82.2% (37/45) of participants indicated they would proceed 
to biopsy. Just 6.7% (3/45) indicated they would repeat the tTG antibody test, and 
biopsy if it remained elevated, and only 4.4% (2/45) answered that they would 
repeat the IgA-tTG, and test EMA and HLA-DQ2 or DQ8 status, and then biopsy if 
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these were all positive. No-one would recommend a GFD without biopsy if all of 
these tests were positive. 
The question was then posed about what respondents would do if they 
biopsied Joshua and the result was reported as normal (Marsh 0). They were 
presented with a range of possible actions and asked to rate these according to how 
likely they would be to do each of them. (Figure 4-13) 
 
Figure 4-13: Rating of follow-up actions in context of an asymptomatic patient with 
normal biopsy result 
From this chart it can be seen that there are very high levels of agreement on some 
issues, such as not performing a capsule endoscopy, but divided opinion on others, 
for example requesting additional blood tests such as EMA and HLA-DQ2/DQ8. 
Respondents were also split on how likely they would be to recommend that 
nothing further happen in the meantime, but that Joshua be re-investigated at some 
point in the future, or if he became symptomatic. 
In response to the opportunity to comment on whether there was anything else 
they would do in this situation, three participants stressed the importance of 
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further management following that. One also indicated that he would do additional 
blood tests, specifically a full blood count, iron, vitamin B12 and folate levels. 
The scenario then stated that it had been confirmed that Joshua’s biopsy result 
was indeed normal. Participants were now asked to indicate what they would 
advise Joshua and his GP about his likely diagnosis, if he was also found to be HLA-
DQ2 or DQ8 positive, and if his IgA-tTG antibody levels remained elevated. (Figure 
4-14) 
 
Figure 4-14: Advice to Joshua and his GP about likely diagnosis given normal biopsy 
The “Other” category was utilised by those who wished to comment, or vary their 
answer slightly from the options given. One would offer capsule endoscopy at this 
stage, three would offer a further biopsy, either now or in 12 months, and one would 
recommend a GFD, but wrote that it “doesn’t have to be completely gluten free”. One 
of those who would offer rebiopsy would also discuss a GFD trial, and another 
would monitor his micronutrients. 
Joshua’s situation was then varied such that he was symptomatic, and the same 
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Figure 4-15: Rating of follow-up actions in context of a symptomatic patient with 
normal biopsy result 
Not surprisingly the presence of symptoms altered participants’ likely practice 
when it was compared to how they responded in the context of an asymptomatic 
patient.  This can be seen most clearly when the numbers of people who were likely 
or very likely to undertake a particular action in the presence or absence of 



















































Figure 4-16: Comparison of likely or highly likely responses for undertaking 
particular actions in asymptomatic and symptomatic patients with a normal biopsy 
Where 71.1% (32/45) of respondents would have reviewed the histology with a 
pathologist when Joshua was asymptomatic, 88.9% (40/45) would do so if he were 
symptomatic. There were also noticeable increases in the numbers who would be 
likely or highly likely to repeat the biopsy in the near future (from 6 to 17/45; 13.3% 
to 37.8%); those who would be likely or highly likely to arrange a capsule 
endoscopy (from 1 to 10/45; 2.2% to 22.2%); and those who would be likely or 
highly likely to start Joshua on a GFD (from 6 to 22/45; 13.3% to 48.9%). 
Conversely, when Joshua was reported as being asymptomatic, 44.4% (20/45) 
indicated they would have been likely or highly likely to have done nothing further 
apart from advising re-investigation at some point in the future, or if he became 
symptomatic. This compared with only 11.1% (5/45) doing nothing further if he 
had been symptomatic at the outset. With the exception of checking his HLA status 
and checking an EMA, all these differences reached statistical significance on 
Pearson Chi-square testing, with p-values ranging from 0.0004 for doing nothing 



















































There was also a change in the advice that respondents would have given to 
Joshua and his GP, with an increase in those who would have recommended that 
Joshua start a GFD (from 9 to 15/45; 20% to 33.3%), and a decrease in the number 
who would adopt a watch and wait approach (from 28 to 18/45; 62.2% to 40%). 
(Figure 4-17) 
 
Figure 4-17: Comparison of advice most likely to be given to Joshua and his GP if he 
were asymptomatic or  symptomatic 
As can be seen from this chart, the number of people answering “Other” also 
increased with the introduction of symptoms to the scenario. Among these, two 
would recommend a trial of a GFD to see if this made a difference, while two 
commented that it was likely that he did have CD but that biopsies may have missed 
this due to the patchy nature of the disease. Four thought that Joshua should 
undergo repeat biopsy, with two of these people saying this should occur after “high 
dose gluten”, and one commented that his symptoms needed to be reviewed to 
clarify their significance.  
Of the changes shown in Figure 4-17, only the difference in numbers likely to 
advise that he may or may not have CD reached statistical significance, (p=0.035). 
4.5.1 Analysis by demographics: When the histology is normal  
As with the first scenario of the survey, responses to case B (Joshua) were analysed 
with respect to the demographic profiles of participants, and their likely use of 
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scale responses were analysed before and after being grouped. In this process a 
number of variables reached or approached statistical significance. Those that were 
significant on grouping responses are presented. (Tables 4.10 and 4.11) 
Table 4.10: Factors influencing management actions when Joshua, an asymptomatic 
patient, has positive serology but normal histology, with p-values 
Management action Demographic variable Grouped 
p-value 
Repeat biopsy in near 
future 
Years in gastroenterology practice 0.006 
 Number of patients seen for review 
due to concern about recovery or 
complications 
0.008 
 Number of tenths worked in private 
practice 
0.034 
 Number of patients seen for long-
term follow-up 
0.042 
Check HLA-DQ2 or DQ8 Number of recently diagnosed 
patients seen for follow-up 
0.002 
 Number of patients seen for biopsy 
to confirm diagnosis 
0.039 
Check EMA Number of tenths worked in clinical 
gastroenterology 
0.013 
Advise to start a GFD; 
repeat serology to 
document a fall 
Number of patients seen for review 
due to concern about recovery or 
complications 
<0.0001 
 Number of patients seen for long-
term follow-up 
0.047 
Advise nothing further 
now; repeat 
investigations in future 
Number of patients seen for review 




Respondents’ likelihood of arranging capsule endoscopy was not significantly 
influenced by any demographic variable, and nor was the advice they would be 
likely to give Joshua’s GP about the possible diagnosis. 
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On examination of the statistically significant differences in the context of 
Joshua being asymptomatic, the following emerged:  
(1) While 34 of 43 respondents were unlikely to arrange a repeat biopsy in 
the near future, there was a 50% likelihood that those who were likely to 
do this had worked in clinical gastroenterology practice between 21 and 
30 years, and a 50% likelihood that those who had worked in 
gastroenterology for this number of years would be likely to rebiopsy. 
(2) Two-thirds (4/6) of those who were likely to rebiopsy Joshua saw 
between one and ten patients per month for review because of concerns 
about their recovery, and they comprised just over half (4/7) of the people 
who saw this number of patients for this type of follow-up. 
(3) The majority of those who were not likely to rebiopsy Joshua (28/34) 
worked fewer than four tenths in private practice, while those who were 
likely to rebiopsy worked a range of tenths privately. 
(4) No-one who did not see any patients for long-term follow-up of CD 
indicated they would be likely to rebiopsy Joshua, while the one person 
who saw more than ten long-term follow-up patients per month was likely 
to rebiopsy him. 
(5) Respondents who saw fewer recently diagnosed patients for follow-up 
were less likely to request HLA testing for Joshua, as were those who saw 
greater numbers of patients for biopsy to confirm a CD diagnosis. Those 
who saw fewer numbers of patients for biopsy were more likely to request 
HLA testing for Joshua. 
(6) People who did more clinical tenths in gastroenterology were much more 
likely to request EMA testing for Joshua. 
(7) Only six people were likely or highly likely to recommend that Joshua 
commence a GFD now, with repeat serology at a later date to document a 
fall in levels. These people were more likely to see between one and ten 
patients per month for long-term CD follow-up, and people who saw this 
many patients for this type of review were also much more likely to make 
this recommendation than people who saw fewer than ten such patients 
per year (50% versus 8%).  
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(8) Five of the six people who were likely to recommend that Joshua start a 
GFD saw between one and ten patients per month for review due to 
concern about their recovery, and the majority of those who would not 
have given this advice (33/35) saw fewer than ten such patients per year. 
(9) The group of participants who would be unlikely to recommend doing 
nothing further for Joshua at this stage includes all those who see between 
one and ten patients per month for review due to concern about their 
recovery. 
Analysis of responses to the amended scenario of Joshua being symptomatic 
revealed far fewer statistically significant differences. (Table 4.11) 
Table 4.11 Factors influencing management actions when Joshua is symptomatic and 
has positive serology but normal histology, with p-values 
Management action Demographic variable Grouped 
p-value 
Repeat biopsy in near 
future 
Number of recently diagnosed 




Number of years in practice 0.052 




Further investigation of these results identified that the majority of respondents 
who saw fewer than ten newly diagnosed patients per year for follow-up were 
unlikely to rebiopsy a symptomatic Joshua, while the majority of those who saw 
between one and ten such patients per month were likely to rebiopsy him. The 
majority of participants who had been in practice fewer than 30 years were unlikely 
to arrange capsule endoscopy, but just over half (4/7) of those who had been in 
practice more than 30 years indicated they were likely to do so. All participants who 
did not see any CD patients for long-term follow-up were likely to request HLA 
testing for him. 
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4.6 A patient declining endoscopy 
The final part of the survey dealt with the increasingly common issue of patients 
with positive CD antibodies declining endoscopy, preferring to go straight to 
treatment with a GFD. In order to explore this question, participants were given the 
following scenario: 
You are contacted by a local GP who has a patient whom she suspects 
has coeliac disease, based on symptoms and moderately positive IgA 
anti-tTG antibodies. The patient is unwilling to undergo endoscopy for 
biopsy, and has already commenced a gluten free diet. The GP asks you 
how you think she should proceed with this patient. 
A range of possible courses of action were presented and participants were asked 
to rate how likely they would be to suggest each of these to the patient’s GP. (Figure 
4-18) 
 
Figure 4-18: Likelihood of suggesting various actions to the GP of a patient declining 
biopsy 
A large majority of respondents (80%) indicated they would be likely or highly 
likely to recommend that the GP continue to encourage the patient to reconsider 
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group, 66.7% (24 of 36 people) were highly likely to give this advice. They 
represented 53.3% of the respondent group. When it came to HLA testing, 75.6% 
were likely or highly likely to recommend this, to help determine whether CD was 
possible or not. Once again, among this group the majority (26 of 34 people) 
indicated they would be highly likely to do this, representing 57.8% of all 
participants. 
Somewhat surprisingly, respondents were more divided over whether they 
would suggest to the GP that it could be assumed that the patient had CD. (Figure 4-
19) 
 
Figure 4-19: Likelihood of advising GP to assume that the patient has CD, and to 
manage her accordingly 
On further inspection of these responses it was apparent that there was a 
degree of inconsistency when they were compared with responses to the essentially 
contradictory course of action informing the patient that the diagnosis of CD is 



























Table 4.12: Cross-tabulation of apparently contradictory question responses; (dark 
beige = consistent responses, blue = inconsistent responses) 



















































0 0 0 1 1 2 
Unlikely 0 0 0 1 0 1 
Neutral 0 0 2 2 2 6 
Likely 2 2 3 3 2 12 
Highly 
likely 
11 4 4 1 4 24 
Total 13 6 9 8 9 45 
 
From this table it can be seen that all 19 respondents who had indicated they would 
be unlikely or highly unlikely to recommend that the GP assume the diagnosis of CD, 
had also indicated they would be likely or highly likely to advise her that the 
diagnosis was unreliable without biopsy. Similarly, the three people who had 
answered they would be likely or highly likely to suggest that the GP assume the 
patient does have CD, were all unlikely or highly unlikely to advise that the CD 
diagnosis is unreliable without a biopsy. Together these two groups of consistent 
responders constitute 48.9% of the total participant group. In contrast, ten 
participants (22.2% of respondents) indicated they would be likely or highly likely 
to suggest both possibilities to the GP. One participant acknowledged that 
“obviously some decisions are mutually exclusive, but depend on what patient 
decides after discussion”. Eleven people were neutral on one or other of the options 
and likely, or highly likely, to suggest the alternative to the GP. 
There was an opportunity to comment following this set of questions, and, in 
addition to the comment above, seven other respondents did so. Here too their 
comments diverged, with one saying that he would 
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try to persuade the patient that biopsy is confirmatory for the diagnosis 
and helps to monitor the response to treatment. Persistently abnormal 
histology has implications re complications of coeliac disease. 
while another wrote that “if the patient feels better on GFD and is happy with 
uncertainty of diagnosis, no need to investigate further as will not alter 
management.” One commented that he would prefer to see the patient himself to 
“counsel her accordingly”, and one person commented that it was the patient’s 
choice and that “it is difficult to suggest re-challenge and biopsy” if she felt better 
on the GFD. One participant noted that the patient would not be eligible for a Special 
Authority number without biopsy, while another would recommend monitoring of 
micronutrients. The final comment related to HLA testing, with a note that if this 
were negative CD could be excluded, but the patient could continue on a GFD if she 
wished. 
4.6.1 The gluten challenge 
As a follow-up question to the scenario outlined above, participants were asked 
what their advice would be regarding a gluten challenge, should the patient change 
her mind and decide to proceed with an endoscopy. In a free text question, they 
were asked how much gluten-containing food would constitute an adequate 
challenge.  
Two people left the question blank, one person wrote “plenty” and one that the 
patient should “just eat a normal diet without gluten restriction”, but all other 
respondents referred to slices of bread per day, which had been given as an example 




Figure 4-20: Recommendations regarding quantity of bread (in slices per day) 
required for an adequate gluten challenge 
It can be deduced from this figure that the majority of respondents thought that 
consuming somewhere between two and four slices of bread daily would constitute 
an adequate gluten challenge. One person added the rider that the bread should be 
“stodgy white bread”, and another that it should be “cheap". 
Participants were also asked to choose from a range of options for how long 
they would recommend the gluten-challenge should continue. There was a range of 
views on this, with the most popular option being “at least 4 weeks”, chosen by 
46.7% (21/45). “Until she is symptomatic” was also given as an option, however no 






























Figure 4-21: Recommendations relating to the appropriate duration of a gluten 
challenge 
The two “Other” responses were “at least 3 weeks” from one person, and “my 
preferred option is 4 weeks, but some will not tolerate this”, from the other. 
4.6.2 Analysis by demographics: A patient declining endoscopy  
On Fisher’s Exact testing of grouped Likert-scale responses, there were no 
statistically significant influences on participants’ likely advice to the GP in this 
scenario. With respect to the duration of a gluten challenge, statistical significance 
was reached for number of tenths worked in gastroenterology, (p=0.019), and for 
the hemisphere in which postgraduate study was undertaken, (p=0.048), while the 
influence of the setting in which participants worked approached statistical 
significance, (p=0.053). Thus those participants who indicated a gluten challenge 
should last at least four weeks were much more likely to work more than six tenths 
in gastroenterology, and were more likely to work in both the public and private 
settings, or in the private sector alone. People who worked in the public setting only 
were more likely to recommend a challenge of at least two weeks. The majority of 
those who thought that a gluten challenge should last at least six weeks had done 
their postgraduate training in the Southern Hemisphere, although this is of no 
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4.7 Key findings of the survey 
To conclude this chapter the key findings of the survey are summarised as follows.  
4.7.1 Response to the survey and respondent characteristics 
This survey gathered information from approximately 55% of gastroenterologists 
identified as practising in New Zealand at the time it was carried out, representing 
53.3% of male and 46.7% of female gastroenterologists. The majority worked in 
both the public and private healthcare settings, had been practising in 
gastroenterology for up to 20 years, and worked six or more clinical tenths per week 
in the specialty. Most of their CD-related work related to diagnosis and immediate 
management, with 60% reporting they saw between one and ten patients per 
month for biopsy to confirm the diagnosis, and 44.4% seeing a similar number of 
recently diagnosed patients for follow-up. Only seven respondents (15.6% of the 
group) saw 10 or more patients per year for long-term follow-up, and only one 
participant declared a sub-speciality interest in CD. Conferences and medical 
journals were the sources of information most likely to be used to update 
knowledge with respect to CD, while 64.5% indicated they were likely or highly 
likely to utilise practice guidelines for this purpose. 
4.7.2 Management of newly diagnosed CD 
With respect to the management of newly diagnosed CD and follow-up in the first 
12 months following diagnosis, the key findings are that there were high levels of 
agreement among respondents about the importance of monitoring abnormal 
blood test results to ensure that these return to normal, and widespread agreement 
that patients should be reviewed to confirm that CD-related symptoms resolve with 
treatment. There was much less accord with regards to follow-up CD serology 
testing, both in terms of its importance and the timing of when such testing should 
be undertaken. Opinion was also divided on the need for DEXA scanning to be 
performed, and in particular on the place of rebiopsy in the first 12 months 
following diagnosis. In general, reference to follow-up tasks that respondents rated 




4.7.3 Long-term management of CD 
There was less concordance among respondents when it came to considering long-
term management of the condition, with the only aspect of care receiving a clear 
majority of support being the need to regularly reinforce the importance of 
adherence to the GFD. Just over 50% of respondents expressed themselves as 
neutral on the importance of annual influenza and 5-yearly pneumococcal 
vaccinations. With regards to implementing an “Annual Review” for CD patients, 
60% rated this as important or very important, while 73.3% indicated that this 
should be carried out by a patient’s GP. However, just under 60% of those who 
thought the GP should be responsible for this were likely or highly likely to note this 
in their discharge letter.  
On the inclusion of non-cross-contaminated oats in the GFD, attitudes varied 
towards if and when this should be recommended, and whether there should be any 
caveats attached. Opinion was also divided on the place of rebiopsy when oats are 
introduced, with a small majority (57.8%) of respondents simply advising patients 
to stop eating oats if symptoms re-emerge, compared with 26.7% who indicated 
they routinely rebiopsied if oats were included in the diet. 
4.7.4 When the histology is normal 
In the context of a patient with elevated IgA-tTG antibodies and a normal duodenal 
biopsy, there was a range of views on next steps in his assessment and management. 
The presence or absence of symptoms had a noticeable and statistically significant 
impact on this.  
If the patient were asymptomatic there were high levels of agreement that it 
would be important to review the result with a pathologist, that arranging a capsule 
endoscopy would not be appropriate, and that recommending he starts a GFD at 
this juncture would also not be appropriate. However, opinions were clearly 
divided on the merits of checking his HLA status and EMA levels, and on how likely 
participants would be to recommend doing nothing further at this stage.  
In the presence of a positive HLA test, ongoing elevated IgA-tTG antibodies, a 
confirmed normal biopsy, but no symptoms, just over 60% of respondents would 
have advised the patient’s GP that he may or may not have CD and to watch, wait, 
and reinvestigate in a year, or if symptoms emerged. 
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When symptoms were introduced into the scenario, opinions changed. A 
greater majority would have sought review of the histology, and higher numbers 
indicated that they would be likely or highly likely to request HLA and EMA testing. 
Most notably, almost 50% of respondents were likely or highly likely to recommend 
that the patient start a GFD (compared with 13.3% in the absence of symptoms), 
and just 11.1% would have been likely or highly likely to recommend doing nothing 
further. The proportion of participants advising a watch and wait approach also fell 
(to 40%). 
4.7.5 A patient declining endoscopy 
As with the other scenarios covered in this survey, responses were mixed with 
regards to how participants would advise a GP seeking their input on how to 
manage a patient with positive IgA-tTG antibodies, but already on a GFD. The large 
majority (80%) indicated they would be likely or highly likely to advise the GP to 
inform the patient that diagnosing CD without a biopsy is unreliable, and just over 
75% would recommend testing her HLA status. Opinion was, however, divided on 
whether or not respondents would be likely to advise the GP that a diagnosis of CD 
could be assumed in this patient, with some inconsistent responses on this issue 
relative to other issues. There was also a diverse range of ideas on what constitutes 









: Results from the Survey of General Practitioners 
5.1 Introduction 
The survey of GPs was designed to capture information about their practice relating 
to CD with respect to both its recognition and management, as a means of measuring 
their knowledge about the condition. It took place in the first half of 2015, and as 
discussed in Chapter Three, was delivered in both electronic and hard-copy formats. 
This chapter presents the results of that survey. 
The chapter begins by providing details about the overall response to the 
survey and goes on to describe the characteristics of participants. Their responses 
are then presented under the following headings, which follow the structure of the 
survey itself: 




 Coeliac Disease in Your Practice 
o Newly diagnosed patients 
o Long-term management 
Responses are first described and then, when appropriate, sections conclude with 
analysis according to participant characteristics. The chapter closes by drawing out 
the key findings. 
5.1.1 Sample size 
As outlined in Chapter Three (page 132), the sample for this survey was drawn from 
a database held by bpacnz. A stratified random sampling technique was used, 
selecting 50% of males and 50% of females on the database for each DHB region. As 
some people in the database had not stated their gender, a 50% sample was selected 
from this group in each region also. This process generated a sample population of 
2178. 
Prior to sending out the survey to this group, preliminary data cleaning was 
undertaken, firstly to identify people within the population who might not be 
intended recipients, and secondly to try and ascertain the gender of the almost-300 
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people for whom this information was not held. It was important to check the 
eligibility of potential recipients because the services provided by bpacnz are not 
exclusively for GPs, and for some of those on the list, the contact address given 
suggested that they might not work in general practice. In addition to this, the 
spreadsheet made available by bpacnz included the number of years of medical 
practice of those listed. Several people on the list had been in practice for 45 years 
or more, so it seemed reasonable to assume that at least some of them would be 
retired. Through a process of checking the New Zealand Medical Register and 
conducting online searches, an initial group of 171 people were identified as not 
being eligible for the survey, leaving 2007 people who could be included. Common 
sense and online searching meant that the gender of the vast majority of potential 
participants was also able to be determined. (Figure 5-1) 
 
Figure 5-1: Sample size information 
If the sample group of 2007 had been entirely comprised of people working in 
general practice and eligible to participate, this would have represented 
approximately 46% of the general practice workforce, as determined in the New 
Zealand Medical Council’s (NZMC) Workforce Survey of 2014.456 Due to the size of 
the sample however, it was not possible to check the eligibility of every intended 
participant. It is very likely that more people on the list were also ineligible, and 
indeed some of those people identified themselves once the survey was sent out. 














Women constituted 47.9% of the study sample of 2007, and men 51.7%, which 
was equivalent to the proportions of women and men who were working in general 
practice at the time the survey was conducted.457  
5.1.2 Modes of contact 
As also discussed in Chapter Three, contact details for intended study participants 
took one or both of two forms: email addresses and postal addresses. In the course 
of the study period, participants for whom only email addresses were available 
were sent two emails; those for whom email and postal addresses were available 
were sent two emails and one hard copy of the survey; and those for whom only 
postal addresses were available were sent two hard copies. For the majority of the 
group, both forms of contact were available. (Table 5.1)  
Table 5.1: Mode of survey delivery and numbers of intended recipients for each 







Email only 39 38 
Email first, to be followed by 
posted hard copy  
1545 1525 
Posted hard copy only 423 415 
TOTAL 2007 1978 
 
This table also gives the numbers of people whom it is assumed actually received 
the survey. The difference between intended and actual recipients is accounted for 
by bounced or blocked emails, and postal surveys returned to sender and unable to 
be redirected.  
During the process of sending follow-up emails and surveys, a further eight 
people were identified as being overseas or retired, thus reducing the eligible 
sample group to 1970. The proportions of women and men in this revised sample 
group remained essentially the same, with 48.1% of the group being women, and 




5.2 Response to the survey  
Overall there were 736 responses to the survey, including seven people who 
declined to participate. One of these indicated that the lack of a “don’t know” option 
meant that he or she “could not complete this questionnaire without confabulating”, 
a point that will be discussed in Chapter Seven. Another person wrote a letter saying 
that in his 50 years of medical practice he had “not seen one patient with this 
condition”, although he had seen a few patients with DH, all of whom “had gluten 
allergy”. This too will be discussed further in Chapter Seven, along with a comment 
from a third respondent that he did not do surveys as “they are always used to 
pillory GPs”. In determining a response rate for the survey, all seven of these 
respondents were included in the group of eligible participants, but excluded from 
the number of people who completed the survey.  
5.2.1 Response rate 
The final response rate for the survey was derived as follows. (Figure 5-2)
 
Figure 5-2: Response rate calculations for the survey of GPs 
From this figure it can be seen that there were 23 people who indicated that they 
were either retired, overseas, or not in clinical general practice, rendering them also 
ineligible for the survey. In the final calculation of response rate, these people were 
removed altogether. This gave an eligible sample group of 1947, and an overall 
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conservative figure, as it is highly likely that additional surveys, other than the ones 
noted in Table 5.1 on page 190, did not reach their targets, due to a change in 
address (for example). It is also possible that there were more recipients who were 
ineligible, either through retirement, or not being in clinical general practice, but 
who did not respond to indicate this. 
5.2.2 Mode of response 
There were three modes of response utilised by the 706 eligible respondents to the 
survey. As noted in Chapter Three, a link to the survey was embedded in the emails 
that were sent out, and the booklet version included a web address that could also 
be accessed to enable hard copy recipients to complete the survey online if they so 
wished. (Table 5.2) 
Table 5.2: Modes of response to the survey of GPs from eligible respondents 
Mode of 
delivery 
Delivered Eligible respondents 
Response 
rate 
Email only 38 14 







Online/web-based: 359 (64%) 
37.4% 




Web-based: 15 (11.5%) 
32.2% 
Paper: 116 (88.5%) 
Totals 1947 706 




Incomplete: 14 (2.0%) 0.7% 
 




5.2.3 Respondent characteristics 
As is usual practice, the survey included a number of questions seeking information 
about participant demographics. Data generated by these questions are presented 
on the following pages. (Tables 5.3, 5.4, and 5.5, and Figures 5-3, 5-4, and 5-5) 
Details are given on the proportions of participants for each variable, and as 
proportions of overall response rates. 
Table 5.3: GP survey recipient and respondent gender 
Gender Male Female Not answered 
Number of 
respondents 
269 420 3 
Proportion of 
respondents (% of 
N=692) 
38.9% 60.7% 0.4% 
Response rate ( % of 








* Gender information was unavailable for six recipients of the survey 
As can be seen in this table, women are over-represented in the respondent group. 
When it came to identifying the DHB regions in which they worked, there were 
29 people who indicated that they worked in more than one region. These people 
have been counted as respondents from the region to which they had been assigned 
when the survey was sent out. All but two of them did some of their work in this 
“DHB of origin”. (Table 5.4) Regional information was unavailable for two 
respondents only, one of whom did not have a designated DHB in the original 
sample, and one who did not complete this section of the survey and for whom the 
information could not be traced. It is apparent from Table 5.4 that although all DHB 
regions were represented in the respondent group, some regions drew higher 















Northland 76 26 34.2% 3.8% 
Auckland 260 118 45.4% 17.1% 
Counties 
Manukau 
152 37 24.3% 5.3% 
Waitemata 203 65 32.0% 9.4% 
Bay of Plenty 100 44 44.0% 6.4% 
Waikato 154 56 36.4% 8.1% 
Tairawhiti 18 3 16.7% 0.4% 
Lakes 50 10 20.0% 1.4% 
Taranaki 47 13 27.7% 1.9% 
Mid-Central 64 9 14.1% 1.3% 
Hawkes Bay 81 30 37.0% 4.3% 
Whanganui 25 7 28.0% 1.0% 
Wairarapa 18 6 33.3% 0.9% 
Capital and 
Coast 
156 57 36.5% 8.2% 
Hutt Valley 60 16 26.7% 2.3% 
Nelson 
Marlborough 
76 25 32.9% 3.6% 
West Coast 10 6 60.0% 0.9% 
Canterbury 245 88 35.9% 12.7% 
South 
Canterbury 
21 6 28.6% 0.9% 
Southern 153 68 44.4% 9.8% 
Unknown 1 2 N/A 0.3% 
196 
 
The vast majority of respondents (634 people, 91.6% of the study sample) held 
vocational registration with the Royal New Zealand College of General Practitioners 
(RNZCGP), and their professional profiles are summarised as follows. (Table 5.5) 
Table 5.5: Participant professional profiles 

















(% of N=692) 
326 
(47.1%) 

















(% of N=692) 
37 
(5.4%) 
















(% of N=692) 
28 
(4.1%) 






1     
(0.1%) 
 
Respondents who selected “Other” for their work setting included GP registrars, 
people who held multiple positions (e.g. employed by a DHB and working as a locum 
in several practices), and those who had specialty roles (e.g. medical officer in 
prisons or aged-care facilities, or in occupational medicine). 
Among respondents 540 (78.0%) reported that their place of work was 
situated in an urban area, while 137 (19.8%) were based rurally. This question was 
not answered by 15 people (2.2%). These figures are comparable to those reported 
by the RNZCGP for 2015, in which 76% of respondents identified themselves as 
urban-based, 17% as rural-based, and 6% as not clearly rural or urban.457  
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On further analysis of the demographic information provided by participants, 
it was apparent that male respondents were more likely to be practice owners, 
while female respondents were more likely to be working as long-term locums or 
associates. The men were also more likely than the women to be working more than 
five half-day sessions per week, and to have been working in general practice for 
more years. The numbers of male and female respondents working in rural practice 
were equivalent, but this represented a greater proportion of male participants. 
These differences all reached statistical significance on Pearson Chi-square testing. 
There was no significant difference between the genders with respect to vocational 
registration. 
Participants were also asked about the ethnic group or groups with which they 
identified. This was a free text question, and responses were subsequently grouped 
according to SNZ’s standardised codes, available from the MoH. The majority of 
respondents (531 people; 77% of the study sample) identified as either “New 
Zealand European” or “Other European”, while another 32 people wrote that they 
were “Kiwi” or “New Zealander”. Only 12 people identified as Māori. There were 43 
participants who identified as Asian, 18 of them Indian and 15 Chinese. Four people 
were Pacific Islanders, while two people identified as Middle Eastern, one as Latin 
American, and one as South African-coloured. In addition, 66 people did not answer 
the question, either by leaving it blank, by giving an unrelated answer (e.g. secular), 
or by noting that they refused to answer this question. (Figure 5-3) 
 




43, 6% 12, 2% 8, 1%
Ethnicity of respondents
European (NZ/other) Did not answer Kiwi Asian Māori Other
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By way of comparison, the 2015 RNZCGP Workforce Survey reported that 83% of 
GPs identified themselves as European.457 
5.2.4 Patient/practice characteristics 
The survey included questions about the populations and patients cared for by 
participants. Free text questions were used to gather information about the 
predominant socio-economic and ethnic groupings of respondents’ patients. 
Answers were coded post hoc and collated. (Figures 5-4 and 5-5) 
 
Figure 5-4: Predominant Socio-Economic Status of practice populations of GP survey 
respondents 
 














































































Predominant ethnicity of practice populations
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It is apparent from these graphs that the majority of patients cared for by 
participants in the survey were in the lower and middle socio-economic groups, and 
of European ethnicity. Patients from these socio-economic groups comprised at 
least 58.7% of those seen by survey respondents, while just over 77% of 
participants cited “European” as a predominant group in the composition of their 
practice populations. 
5.2.5 Sources of information about CD 
The final question in the demographics section of the survey asked people to 
indicate the sources from which they had acquired their overall knowledge about 
CD. They were presented with a range of choices, along with the option of citing any 




Figure 5-6: Sources of information about CD utilised by GPs 
 “Other” sources included having CD oneself, or affecting a close family member or 
friend, which was cited by 40 participants (5.8% of the group); other internet 
sources such as UpToDate or BMJ Learning, listed by 22 respondents (3.2%); Health 
























Preferred Sources of Information
(* Continuing Medical Education)
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learning, or other training or expertise (such as in Nutrition Medicine) which were 
cited by 32 people (4.6%).   
The majority of respondents indicated that they utilised more than one of the 
options listed, with the range extending from only one option being utilised by 36 
people (5.2%), through to all options being used by one person. Almost 68% of the 
respondent group indicated that they used between three and six of the resources 
given. The median number of sources used was 4, with a mean of 4.38 (standard 
deviation 1.97). 
5.3 Coeliac Disease in General 
The first section of the survey asked respondents to consider their approach to CD 
in general terms, focusing on issues such as whom they would be likely to test, how 
they would be likely to test them, and how likely they would be to implement a 
range of possible management options. This section was completed by 692 
participants, although occasional questions were left unanswered. In these 
instances, the number of non-respondents to a question is included in the 
presentation of results. 
5.3.1 Recognition of coeliac disease 
The first two questions of the survey investigated the issue of testing for CD, asking 
respondents to rate how likely they would be to order coeliac testing for patients 
with any of the listed signs and symptoms (Question One), or conditions (Question 
Two), who were otherwise asymptomatic. (Tables 5.6 and 5.7)  
Within the lists of symptoms and conditions included in the matrices of options 
for these questions were recurrent back pain (Question One), and asthma and 
Paget’s disease of the bone (Question Two). None of these appear as an indication 
for testing in any of the available guidelines relating to CD,68,69,71,156,280 and as such, 
it was not unreasonable to expect that clinicians with a reasonable degree of 
knowledge relating to CD would be unlikely to regard them as an indication for 
testing. They also served as “sleeper” questions, as suggested by Aday and 
Cornelius,429 and discussed in Chapter Three.  
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Table 5.6: Likelihood of testing for CD in otherwise asymptomatic patients with the 




Likelihood of testing  
Highly 
Unlikely 
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As revealed in this table, several of the signs and symptoms listed elicited quite 
high numbers of “neutral” responses. This was most noticeable in the situation of a 
patient with an unexplained elevation of liver transaminases, with 230 people 
(33.3% of those who completed the survey) answering in this way. Over 25% of 
participants were also neutral about how likely they would be to test patients with 
unexplained infertility, recurrent aphthous stomatitis, or chronic constipation.  
Apart from chronic diarrhoea, the presence of two or more of the symptoms 
and signs listed in Question One was more likely to lead to testing for CD than a 
presentation with any one of the possibilities given. Chronic diarrhoea was the 
single symptom most likely to prompt participants to test for CD, followed by 
unexplained iron deficiency, unexplained folate deficiency, and persistent fatigue. 
This information is displayed below, along with data relating to the symptoms and 
signs least likely to prompt CD testing. (Figure 5-7) 
 




























Likely or highly likely Unlikely/highly unlikely
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Table 5.7: Likelihood of testing for CD in otherwise asymptomatic patients with the 
conditions listed; conditions most likely to lead to testing in bold 
 
Condition 
Likelihood of testing 
Highly 
Unlikely 
































































































































































* Due to an oversight that occurred in the transfer of the questionnaire from the 
booklet form to the online format, autoimmune liver disease appeared in the paper-
based version of Question 2, but not in the electronic copy. This means that only the 
318 people who completed the survey in its hardcopy form answered this part of 
the question. Percentages reported in Table 5.7 and Figure 5-8 refer to this 
subgroup of participants. 
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As is apparent in Table 5.7, when it came to testing for CD in the presence of 
particular conditions, only two among those listed were likely or highly likely to 
lead to testing. These were IBS, and having a first-degree relative with CD. And apart 
from DH, for all other conditions more respondents were unlikely or highly unlikely 
to test for CD than were likely or highly likely to do so. (Figure 5-8) 
 
 
Figure 5-8: Comparative likelihood of testing for CD in the presence of specific 
conditions 
Participants were also invited to comment on whether there were any other 
indications that would lead them to test someone for CD, and 332 people did so. 
This represents 48% of the total group. Of these, 316 (45.7% of the total group) 
gave reasons additional to those that had been included in the preceding questions. 
A wide range of examples were given, and these were grouped around common 


























Likely/highly likely Unlikely/highly unlikely
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Table 5.8: Additional signs, symptoms, and conditions which lead to CD testing 
Sign, symptom, or condition 
Number of 
respondents (% 
of N = 692) 
Weight loss/ failure to gain weight 94 (13.6) 
Abdominal pain and/or bloating 91 (13.2) 
Patient request 61 (8.8) 
Gluten or wheat intolerance 40 (5.8) 
Bowel symptoms (not otherwise specified) 30 (4.3) 
Vitamin B12 deficiency 24 (3.5) 
Second degree relative affected/ family history of CD 13 (1.9) 
Gastritis/ Gastro-oesophageal reflux/ dyspepsia 11 (1.6) 
Anxiety and /or depression 8 (1.2) 
Malabsorption 8 (1.2) 
Autism/ ADHD/ behavioural issues 7 (1.0) 
Other: eczema, nausea, “brain fog”, vasculitis, 
autoimmune disease in general, joint and/or soft 
tissue “issues”, rheumatoid arthritis, failure to 
respond to iron supplementation, amenorrhoea, 
headaches/migraine 
< 1% 
5.3.1.1 The incorrect options 
From Table 5.6 and Figure 5-7 (on pages 200 and 201 respectively) it can be seen 
that the majority of participants (79%) indicated they would be unlikely or highly 
unlikely to test for CD in a patient with recurrent back pain. A further 17% of 
respondents were neutral on the issue, while only 23 people (3.3% of the group), 
said that they would be likely or highly likely to do so. In Table 5.7 and Figure 5-8 
(on pages 202 and 203 respectively) it is also apparent that the majority of 
respondents would be unlikely or highly unlikely to regard either asthma or Paget’s 
disease as indications for testing for CD (74.7% and 62.9% respectively). Of these 
two, Paget’s disease, which is much less common than asthma in New Zealand, drew 
the higher number of neutral responses (30.2%, compared with 21.7%), suggesting 
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that participants were less certain about the relevance of CD testing in this situation. 
More participants (46 people, 6.6% of the total group) were also likely or highly 
likely to test for CD in the presence of Paget’s disease, than they were in the 
presence of asthma (23 people, 3.3% of the group). 
On further inspection of responses from the people who were likely or highly 
likely to test for CD in the presence of one (or more) of these “sleeper” options, it 
seems probable that at least four individuals had inadvertently reversed the 
polarity of the scales, intending “1” to be “highly likely”, and “5” to be “highly 
unlikely”. Several more only used the “4” and “5” options across the whole matrix 
of options, to which the use of a “sleeper”’ is designed to draw attention. 
5.3.1.2 Cumulative testing patterns 
In order to provide an overview of their likely testing patterns, participants’ ratings 
of the likelihood that they would test for CD under each of the circumstances which 
comprised questions one and two were collated. The maximum possible scores 
were 60 for Question One, and 50 for Question Two, which would have arisen if 
participants had rated every option in the question (including the incorrect options) 
with a “5”. Total scores for the first (symptoms) ranged from 8/60 to 58/60, while 
those for the second (conditions) ranged from 10/50 to 47/50. The following 
histograms show the distributions of scores for each of these two questions. 
(Figures 5-9 and 5-10) 
 
Figure 5-9: Histogram showing frequency distribution of Question 1 cumulative scores 
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The person with the lowest score of 8/60 in the first question only gave 
answers for two of the symptoms listed (chronic diarrhoea and persistent fatigue), 
leaving all the other symptoms blank. Another respondent indicated that he was 
highly unlikely to test for CD with every symptom listed, giving him a total score of 
12/60. (In a subsequent question this participant stated that he does not test for 
CD.) One person did not answer the question at all. 
In the second question, three people indicated that they would be highly 
unlikely to test for CD in the presence of any of the conditions listed, giving them 
total scores of 10/50. This includes the participant noted above who scored 
similarly in Question One.  
 
Figure 5-10: Histogram showing frequency distribution of Question 2 cumulative 
scores 
5.3.1.3 Optimal cumulative scores for testing 
For each question an optimal score range was then calculated with optimal values, 
based on recommendations from the 2009 NICE Guidelines,280 assigned to each 
symptom, sign, or condition. Thus symptoms and conditions for which NICE 
indicated that testing for CD should be offeredi were given an optimal score of 5 
(which equated to highly likely to test), and an acceptable score of 4 (likely to test).  
                                                        
 
i Question 1: Unexplained iron deficiency, Unexplained folate deficiency, Chronic diarrhoea, 
Persistent fatigue, and Two or more symptoms; Question 2: Type 1 Diabetes, Autoimmune thyroid 




Symptoms and conditions for which NICE recommended that testing should be 
consideredj were assigned an optimal score of 4 (likely to test), and an acceptable 
score of 3 (neutral). The optimal score for symptoms and conditions not associated 
with CD was 1 (highly unlikely to test), and an acceptable score was 2 (unlikely to 
test). 
Once each symptom, sign and condition in the question matrices had been 
assigned a score, these values were collated and then grouped, using the rubrics set 
out in the following table. (Table 5.9)  
Table 5.9: Collated score ranges for Questions 1 and 2 of the GP survey 
Rubric 
 Question 1 Collated 
Score range 
Question 2 Collated 
Score range 
Possibly over testing > 51 > 39 
Likely to be 
appropriately testing 
41 – 51 33 – 39 
Possibly under-
testing 
36 – 40 28 – 32  
Probably under-
testing 
30 – 35 23 – 27 
Under-testing < 30 < 23 
 
Ratings for likelihood of testing for autoimmune liver disease were removed from 
calculations, because these scores were available for fewer than half of participants. 
Participants’ cumulative scores were then calculated and grouped according to 
the process just described. (Figure 5-11) 
                                                        
 
 
j All other symptoms and conditions listed in questions 1 and 2, apart from Recurrent back pain, 




Figure 5-11: Cumulative scores of likelihood of testing for CD in the presence of 
particular symptoms and conditions, among GP survey participants 
The median and mean scores for Question One were both 38, which sits at the 
upper end of the “possibly under-testing” range. The standard deviation for the 
mean was 8.26, standard error 0.31, and 95% confidence interval 37.38 to 38.62. 
The median and mean scores for Question Two were 29 and 28.66 respectively, 
once again sitting in the “possibly under-testing” range, but this time at the lower 
end of that range. The standard deviation for the mean was 7.48, standard error 
0.28, and 95% confidence interval 28.10 to 29.22. Pairwise correlation of the two 
scores generated r=0.666, indicating a moderate to strong positive correlation 
between them. 
5.3.2 Analysis by demographics: Recognition of CD 
Analysis of responses to the questions relating to the recognition of CD centred on 
the cumulative scores that had been calculated utilising participants’ individual 
item ratings. Using Pearson Chi-square or Fisher’s exact tests (when individual cell 
numbers were less than five), these were analysed with respect to participant 
gender and rurality. Responses were also analysed by whether or not participants 
had patients with CD.  
Optimal scores for testing in the presence of particular signs and symptoms 


































Qu 1: Symptoms Qu 2: Conditions
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differences according to the gender of respondents, (p<0.0001), and whether or not 
they had patients with CD, (p=0.009), but not with respect to rurality, (p=0.357). 
Optimal scores for testing in the presence of certain conditions (derived from 
Question Two), were also associated with statistically significant differences 
according to the gender of respondents, (p=0.011), but not with rurality or whether 
or not they had patients with CD, (p=0.902 and p=0.088 respectively). 
With respect to gender, for both sets of cumulative scores a greater proportion 
of female than male respondents were in each of the “possibly over-testing”, “likely 
to be appropriately testing”, and “possibly under-testing” ranges, while a greater 
proportion of male than female participants were in the “probably under-testing” 
and “under-testing” ranges. In addition to this, mean cumulative scores were also 
analysed by gender using a two-sample t-test. Female participants had a mean 
cumulative symptom score of 39.2 (CI 38.4 – 39.9) compared to their male 
counterparts whose mean score was 36.2 (CI 35.1 – 37.3), (p<0.0001). Cumulative 
conditions scores were 29.6 (CI 28.9 – 30.3) and 27.3 (CI 26.4 – 28.2) respectively, 
(p=0.0001). 
Having patients with CD was more likely to be associated with cumulative 
symptoms scores in the “possibly over-testing” and “likely to be appropriately 
testing” ranges, and not having patients with CD was more likely to be associated 
with all three variants of under-testing. There was no significant difference in 
cumulative conditions scores between those with and without patients with CD. 
 Additional analyses were performed with responses separated into male and 
female groupings. There were no new significant associations identified in this 
process, and the effect of having CD patients on cumulative symptom scores was 
reduced. Thus, when cumulative scores for female respondents were analysed by 
whether or not they had CD patients, this generated p=0.055. For male respondents 
this value was p=0.310. 
5.3.3 Diagnosing coeliac disease 
Questions in the survey then moved on to explore issues pertaining to diagnosing 
CD, beginning by asking participants which test (or tests) they requested from 
among those listed, when they first tested someone for the condition. (Figure 5-12) 
The results shown include respondents who indicated they would request more 
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than one of the tests on the list. (Note: The “Coeliac antibodies” option came with 
the descriptor “the lab will do what is appropriate”.) 
 
 
Figure 5-12: Tests requested as part of initial testing for coeliac disease 
Among the 21 people (3.0% of respondents) who requested HLA testing, only one 
selected this test alone, although she also indicated that she tested for “antibodies 
to all the other wheat proteins”. The remaining 20 people did HLA testing in 
combination with one or more of the other options, most commonly “coeliac 
antibodies”. Three respondents indicated in subsequent parts of the survey that 
they did not know what the HLA-DQ2/DQ8 test is. 
Just over 7% of respondents (50 people) included “Other” in the suite of tests 
they requested. The majority of these (31 people; 62% of this subgroup) noted they 
also did IgA testing, with some indicating that this was done routinely by their 
particular laboratory provider, and some saying that they would request it if the 
laboratory did not automatically do this. Another seven people indicated they 
sometimes requested HLA testing, either as a follow-up test or to clarify an antibody 
test result, while eight people included other tests such as a full blood count and 
iron testing as part of their initial investigation of possible CD. One person 
commented that she would like to do more HLA testing but that she was “actively 
discouraged to do so by the lab”. Only three people indicated that they tested for 







































5.3.3.1 Referrals for endoscopy 
Participants were next asked about how often they refer their adult patients for 
gastroscopy, when they return a positive coeliac test. (Figure 5-13) Two people did 
not answer this question. 
 
 
Figure 5-13: Frequency of referrals for gastroscopy when coeliac serology is positive 
An opportunity to comment on this question was provided, to which 323 
participants (46.7%) responded, making this the issue that drew the greatest 
number of “additional comments” in the survey. Several major themes emerged 

































% of total 
respondent 
group 
Biopsy is the gold standard/ necessary for 
diagnosis/ necessary for Special Authority 
number 
68 (21.1%) 9.8% 
Depends on patient willingness to 
continue with or reintroduce gluten/ 
willingness to undergo endoscopy 
56 (17.3%) 8.1% 
Access to endoscopy is limited/ takes a 
long time/ difficult to get 
56 (17.3%) 8.1% 
Would refer to a gastroenterologist for 
review and decision on further 
investigation 
29 (9.0%) 4.2% 
Would depend on the presence of, or 
severity of symptoms 
28 (8.7%) 4.0% 
 
As can be seen from this table, just over 20% of those who commented did so 
to indicate their understanding that biopsy is the gold standard or necessary for a 
CD diagnosis, and/or is necessary for patients to be eligible for subsidised 
prescription GF foods. This particular issue was cited by 12 people as a reason for 
almost always referring, but also by two people as a reason for seldom referring for 
endoscopy. In their words: “the only reason I can see for gastroscopy is so that they 
would be entitled to subsidised gluten free products”, and “main reason is 
histological diagnosis for SA number”. Another person, who referred about half the 
time, commented that “In the past referral was for a subsidy on gluten-free 
products. Today it is easier to do gluten-free without subsidy”.  
Of note, among the comments were five from people pointing out that it was 
not gastroscopy that these patients needed, but endoscopy with duodenal or jejunal 
biopsy. Three of these people had indicated that they almost never referred for 
gastroscopy. On reflection, the use of the word “gastroscopy” in this question was 
imprecise, and may well have led to others answering similarly. However, 
additional comments were made by almost 60% of the people who indicated that 
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they almost never refer patients with a positive coeliac test (31 out of 53), and only 
three of them mentioned this issue. A further 16 people also made reference in their 
comments to endoscopy and/or duodenal biopsy.  
Table 5.10 also shows that access to timely endoscopy was an issue for many, 
as was the issue of patients being unwilling to continue consuming gluten, or to 
resume eating it, in order for an endoscopy (and reliable biopsies) to be undertaken. 
These issues were often linked. Problematic access to endoscopy was identified by 
participants from 14 of the 20 DHB regions. When these data were analysed with 
respect to total numbers of respondents from each region, it emerged that there 
were four regions in which more than 20% of survey participants indicated that 
there were long delays in accessing this service. These figures need to be viewed 
with caution however, as three out of these four districts had very small numbers 
of respondents overall. It should also be noted that four people commented that 
they had excellent access to endoscopies in their particular areas, in contrast to 
others from the same regions who indicated that there were difficulties. None of 
these positive comments related to the four areas with the highest rates of 
dissatisfaction. 
Another 15 respondents (not included in Table 5.10) used the opportunity for 
comment to note that they always refer patients, rather than “almost always” doing 
this, while 13 people commented about how rarely (if ever) they have found a 
positive result. One of these people, who almost always referred, wrote that it “is so 
uncommon to get a positive test that I get excited to see the endoscopy result.” Ten 
people indicated that they trialled a GFD first and only referred those patients who 
did not improve with this. An additional 35 comments traversed a range of 
individual opinions. 
A question then followed concerning the advice that participants would give to 
patients who were being referred for biopsy, and when to start a GFD. (Figure 5-14) 





Figure 5-14: Advice about the timing of commencing a GFD with respect to having a 
biopsy 
Of the 82 people who selected the “other” option, 69.5% did so to indicate that 
their practice was one of two combinations of the other two options, both involving 
patients being advised to be on a gluten-containing diet prior to the endoscopy. In 
the first of the combination responses, participants noted that they recommended 
that patients waited until they had had a gastroscopy before starting the GFD, but 
that for many patients this proved intolerable due to the length of time it generally 
took until this occurred. In these circumstances they would advise the patient that 
he or she must be on gluten for some weeks (the range varied among respondents) 
before the endoscopy was performed. The second combination was that 
respondents told patients that they could start the GFD immediately, but that they 
would need to reintroduce gluten prior to endoscopy. Another 13.4% commented 
that their practice depended on how long it would take for the endoscopy to occur, 
without indicating how that influenced their practice. The common theme among 
all of these responses was that there was almost always a lengthy delay between 
positive serology results and biopsies, unless the patient had the capacity to pay for 
the procedure, and that this posed challenges for their patients and for themselves 
in how best to proceed. 
The remaining “other” responses included comments that patients should 
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relied on patients being guided by what a gastroenterologist tells them when they 
are seen prior to endoscopy; and that the respondent would seek advice before 
making any recommendation to the patient. A small number of respondents also 
indicated that they advised their patients to eat additional gluten-containing foods 
to ensure the biopsy is accurate. 
A related question concerned the serology testing of patients who had already 
excluded gluten from their diets, an increasingly common occurrence in this day 
and age. Participants were asked to indicate what they would advise someone 
already on a GFD, whom they thought should be tested for CD. In this situation 
52.9% of respondents (366 people) indicated that they would recommend that the 
patient reintroduce gluten into his or her diet, and if the patient did not wish to do 
this they would not go ahead with testing them for CD. This compared with 39.2% 
(271 people) who would test for CD, even if the patient declined to reintroduce 
gluten, and 7.5% (52 people) who would not make any recommendations about 
changing their diet, and would simply test them. Three people did not answer this 
question. 
5.3.3.2 The gluten challenge 
Participants were then asked about how much gluten-containing food they would 
suggest patients should re-introduce into their diets, prior to testing for CD. This 
was a free text question that drew a large range of responses, with 36 different 
identifiable options given. There was a prompt within the question that gave “slices 
of bread per day” as an example, and the vast majority of respondents gave their 
answer with reference to that. An “I don’t know, I would need to find out” alternative 
was also provided, and was utilised by 253 participants (36.6% of those who 
answered the question). Suggested quantities of gluten ranged from half a slice of 
bread per day recommended by one participant, through to six to eight slices per 
day recommended by another participant. Responses were grouped for ease of 
representation. (Figure 5-15) Thirteen people did not answer this question, 
including four of those who had previously indicated they would not recommend 





Figure 5-15: Amount of gluten to reintroduce prior to testing for CD 
Just over 41% of those included in the “2 – 4 slices” range (115 people) specified 
that the amount should be 4 slices of bread per day (or equivalent), making this the 
most favoured option overall. “Other” suggestions included “enough to provide a 
reaction”, “until symptoms return”, “as much as tolerated”, and one person who 
answered “gluten 2.5 – 5 gm per day”. Across all the options suggested, 59 people 
(8.5% of respondents) qualified their answers by indicating that they would need 
to check to be certain, including some who wrote that they were guessing. Another 
four participants (not included in Figure 5-15) made a distinction between adults 
and children, recommending that adults consume 4 slices of bread per day, and 
children 2 slices of bread.  
A follow-up question asked about how long these patients would need to be 
consuming gluten before testing them for CD. (Figure 5-16) There were two people 
who did not answer this question, while four people noted that they would need to 



































Figure 5-16: Required duration of gluten-containing diet prior to testing for CD 
Answers from those who selected the “other” option ranged from five days (one 
person) to over six months (one person), with the majority of the remainder of this 
group settling on three weeks (eight people) or four to six weeks (six people). 
Participants were then asked to choose the two most likely options they would 
utilise if they needed to check what constituted an adequate gluten challenge. 
(Figure 5-17)  
 
 




















































Almost half of the group (317 people; 45.8%) selected only one option from the 
available list, with just over half of these indicating that they would “Go to an 
internet source such as BPAC or patient.co.uk”. Very few respondents relied solely 
on colleagues, dietitians, or Coeliac NZ for this information. Those who used more 
than one source of information chose myriad combinations of the available options, 
with the most popular being “Google” and “an internet source such as BPAC", 
selected by 74 people (10.7% of the group). “Other” sources that would be 
consulted included HealthPathways, identified by 29 respondents, and local 
laboratories (or laboratory generated resources), chosen by 18 people. The 
question was not answered by 27 people, 26 of whom it seems likely did not feel 
the need to ask for advice on this issue. 
5.3.3.3 Confirming the diagnosis of CD 
The survey also explored the issue of what results participants would be likely to 
consider as confirmation that a patient has a diagnosis of CD. They were provided 
with six options and asked to rate them on a scale from “highly unlikely” to “highly 
likely”. Their responses are presented in the following table (Table 5.11). Answers 





Table 5.11: Likelihood that GPs will regard a range of test result options as confirming 












































































































From this table it can be seen that a number of respondents did not give answers 
for every test result option listed. This is most noticeable for the finding of a positive 
HLA-DQ2/DQ8 test on its own, followed by positive serology combined with 
positive HLA-DQ2/DQ8. This may indicate either that these participants were 
unsure about how to interpret an HLA test result, or that they were so certain that 
the HLA test was not an appropriate tool for confirming the diagnosis of CD that the 
“highly unlikely” option did not express this definitively enough. The high number 
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of “neutral” responses for the HLA-alone option also suggests participant 
uncertainty about this test. In addition to this, two participants indicated that they 
were uncertain about the entire question and would have to look up the answers. 
They were not included among the “did not answer” group, having actually 
indicated a response to the question. 
Participant responses were collated, likely with highly likely responses, and 
unlikely with highly unlikely responses. (Figure 5-18) 
 
 
Figure 5-18: Collated responses of the likelihood that GPs will regard positive test 
results as confirming the diagnosis of CD 
The responses of the eight people who indicated that they were unlikely or 
highly unlikely to accept “positive serology followed by a positive biopsy” as 
confirming CD were scrutinised more closely. They include three people whom it is 
likely had reversed the polarity of this scale, as they had done in earlier questions, 
and one other who probably reversed the polarity for this question alone. 
5.3.4 Analysis by demographics: Diagnosing CD 
Responses to key questions relating to diagnosing CD were analysed with respect 
to gender, rurality, and whether or not participants had patients with CD, using 
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less than five.  Analyses were also performed with responses separated into male 
and female groupings. (Table 5.12) 
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The first of the actions analysed concerned the timing of serological testing 
among patients already on a GFD. As shown in Table 5.12, this was found to be 
influenced by whether or not participants looked after patients with CD.. Thus those 
without any coeliac patients were more likely just to test for CD rather than making 
any recommendation to the patients being tested about reintroducing gluten into 
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their diets. This difference  was influenced by gender, with separated analyses 
confirming the statistical significance in the responses from women, but not men.  
When it came to analysing the frequency with which participants referred 
patients with raised coeliac antibodies for endoscopy, the gender of respondents 
was found to be significant. It was apparent that a greater proportion of the men 
than the women indicated they referred patients for endoscopy almost never or 
some of the time, while a greater proportion of the women than the men referred 
such patients most of the time or almost always. Those who currently had patients 
with CD in their care were much more likely to almost always refer for endoscopy 
than those who did not, and this was true for both men and women.  
A possible association between the predominant SES of participants’ practice 
populations and their likelihood of referring for endoscopy was also investigated, 
but no such association was found. Specific comparisons were also made between 
low and high SES populations, again with no significant differences detected.  
With regards to what advice participants gave to patients about when to start 
a GFD, women were more likely to recommend a combination of the response 
options provided (i.e. they selected “other” more frequently). Male respondents 
without CD patients were more likely to recommend starting the GFD immediately.  
The other important issue explored in relation to diagnosing CD was the range 
of test result options that participants would be likely to accept as confirming the 
diagnosis. (Table 5.11; page 220) Pearson Chi-square analyses were performed, in 
which participants Likert-scale responses were grouped: likely with highly likely, 
unlikely with highly unlikely, and neutral. This was done to more closely reflect 
likely clinical outcomes. The only scenario that showed a significant difference was 
that of the likelihood of participants accepting a positive serology test alone as 
confirming the diagnosis. Having patients with CD influenced responses to this 
question, (p=0.029), with a much higher proportion of participants with patients 
with CD being likely or highly likely to do this. On separated analysis by gender, the 
difference remained for female participants, (p=0.009), but not for the males, 
(p=0.764). Women without patients with CD were more likely to be neutral in their 




5.3.5 Managing coeliac disease: annual reviews 
The final part of the first section of the survey focused on the issue of annual reviews 
for patients with CD. Context was provided in the stem for the first question of the 
series, as follows: 
Gastroenterologists in NZ and abroad are beginning to recommend that 
patients with coeliac disease have their management reviewed by a 
health professional on an annual basis. Assuming that children are 
reviewed in paediatric clinics, how necessary do you think this is for 
adult coeliac patients? 
As well as being asked how necessary they believed an annual review to be, 
respondents were also asked about whom they thought should carry out such a 
review, whether this was in fact something they already did for their patients, and 
what they would include if this were to become a routine part of CD management. 
(Figure 5-19). Three people did not answer this question. 
 
Figure 5-19: How necessary is an Annual Review of adult CD patients? 
The 20 people who responded “Other” mostly did so to indicate what might be 
included in a review. Four people thought a review every two or three years would 
be sufficient, especially if the patient was well, while one person thought reviews 
should happen 3- to 6-monthly, especially when a patient was newly diagnosed. 
When asked about who should usually perform an annual review, participants 
overwhelmingly thought this should be the GP, with 542 (78.3%) responding 





































should usually be conducted by a gastroenterologist, while 32 (4.6%) thought a 
dietitian should do it. A tiny number (11; 1.6%) indicated that the role should be 
given to practice nurses. A further 50 respondents (7.2%) selected the “Other” 
option, of whom 30 thought that such a review could be carried out by either a GP 
or a Practice Nurse (or Nurse Practitioner), or a gastroenterologist, or a dietitian, or 
some combination of these. Some stipulated a GP could do this following an initial 
assessment by a gastroenterologist, and four people indicated that they either did 
not know, or did not have an opinion on whose responsibility this should be. Four 
people did not answer this question. 
A free text opportunity to make additional comments about annual reviews, 
and who might do them, then followed. Almost one-third of participants (226 
respondents) commented, of whom 180 (79.6%) had indicated that GPs should 





Table 5.13: Themes of comments about CD Annual Reviews 
Theme of Comments 
Number of 
participants (% of 
comments) 
% of total 
respondent group 
Suggesting reviews could be 
carried out by different 
providers at different times 
and for different reasons  
70 (31%) 10.1% 
Requesting that guidelines or 
more education be provided 
47 (21%) 6.8% 
Affirming the value of an 
Annual Review and/or noting 
what it should include 
33 (14.6%) 4.8% 
General Comments about CD 
and related issues (such as the 
trend for gluten free diets) 
27 (11.9%) 3.9% 
Noting that there are resource 
implications (e.g. cost to 
patient, scarce specialist 
resources, lack of time) 
19 (8.4%) 2.7% 
Questioning the value and/or 
the available evidence to 
justify an Annual Review  
8 (3.5%) 1.2% 
Other 22 (9.7%) 3.2% 
 
Other comments mentioned issues such as patient choice; that who conducted a 
review might depend on patient symptoms; or merely endorsed the provider option 
that the respondent had selected in the preceding question. 
When it came to whether an annual review was something participants in the 
survey already tried to do for their adult patients with coeliac disease, they 
responded as follows. (Figure 5-20). Eleven people did not answer this question, 






Figure 5-20: Is an annual review something you try to do for your adult coeliac 
patients? 
The “some of my adult coeliac patients” option included the additional question 
“Which ones and why?”, and was answered by 141 of the 169 people (83.4%) who 
had indicated that this was their practice. Among those who answered, 40 reported 
that these were the patients who were willing to come in for an annual review, the 
corollary being that they also had patients who declined the invitation to attend. 
Another 45 people wrote that they conducted such reviews on an opportunistic 
basis when patients were being seen for other things, which one person noted 
meant that those who never presented for anything did not get reviewed. (Seven 
people who had selected “Other” were also coded to this group, having indicated 
that they did in fact review their patients opportunistically). Other groups of 
patients identified include those who were unwell and/or not improving as 
expected, those who were getting prescriptions for gluten free foods, and those who 
were no longer being seen by a gastroenterologist. A small number of respondents 
(11 people) noted that they did not yet have a formal recall system in place for CD 
annual reviews, but would think about doing so in light of this survey.  
The “Other” group included two people who had only recently diagnosed a 
patient with CD, and one who wrote that “I would rely on them requesting it and 
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5.3.5.1 Content of annual reviews 
In another free text question, participants were asked what they would include if 
they were to do an annual review of management with their CD patients. Of the 692 
people who completed the survey, 32 (4.6%) did not answer this question. Twenty-
five (3.6%) said that they did not know, were unsure, or would refer to any 
guidelines that were available. Another person wrote that he “wouldn’t do it”, while 
two others gave broad answers such as “all the usual stuff”, or “part of an annual 
health check”, which could not be otherwise classified. Two indicated that they 
would want to see good evidence both for the need for an annual review, and for 
what should be included in such a review, if indeed it were necessary, and one 
person’s comment was “I would need to discuss that with the person once they were 
diagnosed.” Answers from the remaining 630 people (91.0% of survey 
respondents) were able to be classified, and grouped thematically. (Table 5.14) 
Table 5.14: Management options that respondents would include in an annual review 
of CD patients 
Component of Annual Review 
Number who would include 
this (% of N = 692) 
Blood tests 560 (80.9%) 
Questioning about symptoms (including 
those related to associated conditions) 
419 (60.5%) 
Weight measurement 310 (44.8%) 
Review of diet and any associated 
difficulties 
245 (35.4%) 
Consideration of need for DEXA scanning 147 (21.2%) 
Clinical examination (other than weight) 124 (17.9%) 
 
Responses varied greatly in the amount of detail included, with some merely 
writing “bloods” or “general check and routine bloods”, compared with others who 
gave an extensive list of the blood tests they would request, and the symptoms 
about which they would enquire.  
Details of the blood tests that participants would request were further 
analysed. (Table 5.15) 
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Table 5.15: Blood tests forming part of CD Annual Review 
Blood test 
Number who would 
request (% of N = 580) 
% of total respondent 
group (N = 692) 
Ferritin and/or iron 
studies 
333 (57.4%) 48.1% 
Full blood count 259 (44.7%) 37.4% 
B12 and/or folate 257 (44.3%) 37.1% 
Coeliac 
antibodies/serology 
141 (24.3%) 20.4% 
Thyroid function tests 120 (20.7%) 17.3% 
Liver function tests 112 (19.3%) 16.2% 
Glycated Haemoglobin 
(HbA1c) 
93 (16.0%) 13.4% 
  
Small numbers of people (fewer than 15) also indicated that they would test other 
things such as zinc, magnesium, calcium, renal function, lipids, and “vitamin” levels 
not otherwise specified.  
With respect to the questioning and examination of these patients, 40 people 
(6.3% of the 630 who positively answered the question) specifically mentioned that 
they would screen for other autoimmune diseases, 19 people (3.0%) indicated that 
they would check their skin, and 15 people (2.4%) that they would check for 
evidence of malignancy. Nine of these specified that they would be concerned about 
lymphoma. Of note, five people would include assessing the need for colonoscopy 
screening as part of their review. 
5.3.6 Analysis by demographics: Managing CD 
As for the sections of the survey related to the recognition and diagnosis of CD, 
responses relating to this part of the survey were analysed by gender, rurality, and 
having patients with CD. Once again Pearson Chi-square or Fisher’s Exact tests were 
used.  
Caring for patients with the condition did significantly influence opinions on 
the necessity of annual reviews, (p=0.002). More than half of those without CD 
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patients thought that an annual review was probably necessary, while those with 
CD patients expressed a wider range of views. On analysis separated by gender, 
significance remained for male respondents only, (p=0.01; female p=0.192). When 
it came to who should carry out such a review, none of the variables investigated 
showed a significant association with particular responses.   
5.3.7 Part A: Additional comments  
Part A of the survey concluded with an invitation for participants to note any 
additional comments they might wish to make about CD in general. Just over 26% 
of respondents (182 people) took advantage of this opportunity. Their comments 
ranged over a number of issues, and while many used the space to make a general 
comment about CD, there were some common themes.  
Almost 35% of comments (63/182) related to some of the confusion 
surrounding the prevalence of diagnosed CD. Within this grouping were references 
to the issues of self-over-diagnosis (11 people), underdiagnosis (26 people), that it 
is more common than we think (8 people), and that it is a “fashionable” or “trendy” 
or “popular” or “vogue” or “fad” diagnosis at present. One person summed up this 
view, writing  
significantly underdiagnosed in community but also self 
"overdiagnosed" creating an issue in community that it is a current 
trendy diagnosis – significant confusion regarding coeliac disease and so 
called gluten intolerance.  
In similar vein, another person commented that the “current fad for 'gluten 
sensitivity' is making it a bit hard to diagnose as so many patients refuse to take 
gluten prior to testing”. 
Another 18% of comments (33/182) were to do with the respondent’s level of 
knowledge about CD, as typified by the following: 
“You’ve proved my ignorance",  
“Probably need to know more!!”, and  




5.4 Coeliac disease in your practice 
Part B of the survey was intended for those participants who had adult coeliac 
patients in their practice, or under their care, and focused on the management of 
those patients. It was completed by 542 people, constituting 78.3% of the 
population who returned the survey. Results from Part B are reported in the 
following sections of this chapter as proportions of this subgroup. 
5.4.1 Participant characteristics 
Characteristics of respondents with coeliac patients in their practices, and who 
went on to complete this second section of the survey, were compared with those 
of the total group of survey participants. (Table 5.16)  
Not included in this table are the DHB regions in which people with coeliac 
patients worked. All DHBs were represented in this cohort and, as with the total 
participant group, the three DHB regions with the highest representation were 
Auckland (83 participants; 15.3% of the group), Canterbury (78 participants; 
14.4%), and Southern (58 participants; 10.7%). Also not included is the ethnicity of 
respondents with CD patients. The ethnic make-up of this group closely resembled 





Table 5.16: Characteristics of participants with coeliac patients compared with the 






(% of N=692) 
B: Respondents with 
coeliac patients with 
characteristic          
(% of N=542) 
B/A (%) 
Male 269 (38.9%) 205 (37.8%) 76.2% 
Female 420 (60.7%) 336 (62.0%) 80% 
FRNZCGP 634 (91.6%) 504 (93.0%) 79.5% 
Own practice 326 (47.1%) 297 (54.8%) 91.1% 
Long term 
locum/associate 
279 (40.3%) 213 (39.3%) 76.3% 
Work in many 
practices 
43 (6.2%) 10 (1.9%) 23.3% 
Other work 
situation 
28 (4.0%) 13 (2.4%) 46.4% 
Work < 3 tenths 37 (5.3%) 11 (2.0%) 29.7% 
Work 3 – 5 
tenths 
184 (26.6%) 138 (25.5%) 75% 
Work 6 – 8 
tenths 
279 (40.3%) 243 (44.8%) 87.1% 
Work > 8 tenths 174 (25.1%) 139 (25.7%) 79.9% 
1 – 10 years in 
practice 
28 (4.0%) 17 (3.1%) 60.7% 
11 – 20 years in 
practice 
130 (18.8%) 102 (18.8%) 78.5% 
21 – 30 years in 
practice 
308 (44.5%) 259 (47.8%) 84.1% 
> 30 years in 
practice 
225 (32.5%) 164 (30.1%) 72.9% 
Rural  137 (19.8%) 109 (20.1%) 79.6% 
Urban 540 (78.0%) 424 (78.2%) 78.5% 
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From this table it can be seen that the subgroup of participants with patients 
with CD in their care were slightly more likely to be female and vocationally 
registered in general practice, clearly more likely to own their own practice (and 
much less likely to work in several practices), and somewhat more likely to work 
more half-day sessions in general practice. They were reasonably similar with 
respect to years in clinical practice and rurality. Differences in the proportions of 
people who owned their own practice, worked fewer than three half-day sessions a 
week, and worked in many practices, reached statistical significance on Pearson 
Chi-square testing, (p= 0.01, p=0.003, and p<0.001 respectively).  
Analysis of the characteristics of this subgroup of respondents was also 
conducted with respect to gender, with statistically significant results mirroring 
those from the whole sample population. Thus men with patients with CD were 
more likely to be practice owners and the women were more likely to work as a 
locum or associate in one practice; male respondents were more likely to work 
more than five half-day sessions per week and to have been in clinical practice for 
longer; and female participants were more likely to work fewer than five half-day 
sessions and to have been in clinical practice between 20 and 30 years. The women 
were also much less likely to have been in clinical practice for more than 30 years, 
and to work in urban settings.  
5.4.2 Patient/practice characteristics 
Patient and practice characteristics for participants in the survey who had patients 
with CD were also much the same as for the complete study group, as can be seen 
in the following figures, which present comparative data relating to the 
predominant SES of practice populations, (Figure 5-21), and the predominant 





Figure 5-21: Predominant SES of practice populations of all respondents compared 
with those with patients with CD  
The differences between groups at each SES level were not statistically significant, 
but approached significance when SES levels were grouped middle through to high, 
and low with low to middle and mixed, (p=0.053). 
 
 
Figure 5-22: Predominant ethnic makeup of practice populations of all respondents 
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There were no statistically significant differences between the groups with respect 
to any ethnic groupings within practices. 
5.4.3 Newly diagnosed coeliac disease 
The first set of questions in this section of the survey addressed issues relating to 
the early management of adults recently diagnosed with CD. The subject matter of 
questions paralleled questions from the survey of gastroenterologists included in 
the scenario which featured newly diagnosed Lucy, discussed in Chapter Four. 
5.4.3.1 Referrals to dietitians and for Special Authority numbers 
Participants were firstly asked about who usually refers newly diagnosed adult 
patients to a dietitian, and who usually applies for a Special Authority Number for 
prescription gluten-free foods. (Figure 5-23). Both questions were not answered by 
3 people.  
 
 
Figure 5-23: Person responsible for referring patients newly diagnosed with CD to a 
dietitian, and for applying for Special Authority numbers 
Two respondents indicated that they did not refer patients to a dietitian at all, 
instead utilising practice staff who have CD themselves. With respect to applying 
for Special Authority numbers, 36 people (6.6% of the group) responded that “No-
one does; they’re not necessary”. In subsequent comments a small number 
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5.4.3.2 Referrals for DEXA scanning 
The questionnaire then asked how often participants referred their newly 
diagnosed adult patients for DEXA scanning. Respondents were fairly evenly split 
between those who almost never referred these patients for DEXA scanning 
(48.7%), and those who did (51%), with the majority of those who almost never 
referred indicating that they were unaware that this might be necessary. (Figure 5-
24) Two people did not answer this question. 
 
 
Figure 5-24: Patterns of referral for DEXA scanning among respondents with patients 
with CD 
Among the 150 participants who referred patients for DEXA scanning “only in 
certain clinical situations” a variety of different reasons were given for doing so. Age 
was the most commonly identified variable that respondents took into 
consideration, being cited by 63 people (11.6% of the total subgroup), but the age 
that triggered such referrals varied greatly. One person would refer anyone over 
the age of 18 years old, while several indicated they would wait until a patient was 
in his or her fifties. Being a woman, and in particular a post-menopausal woman 
with CD was identified by 36 people (6.6%) as being an indication for requesting 
DEXA scanning, while the presence of risk factors for osteoporosis such as low body 
mass index, past fractures, family history, and cigarette smoking, also influenced 





































Cost and availability also featured as an issue, with 31 people (5.7% of the total 
group) indicating that the patient’s ability to pay, or the fact that if a 
gastroenterologist requests the test it will be free, influenced their practice. Two 
people noted that, in their DHB regions, as GPs they were unable to request DEXA 
scanning at all, and one person wrote that none of the options given applied because 
“it is not subsidised and most won’t pay. So – ‘almost never, aware it is a good idea 
but unfunded’.” 
5.4.3.3 Prescribing gluten-free foods 
Just over three quarters of respondents (421 people; 77.7%) indicated that they 
either currently provided prescriptions for subsidised gluten-free foods to their 
patients with CD, or had done so in the past. When then asked how they would 
determine the appropriate amount of food to include in each prescription, 408 
participants (97% of those who prescribed) answered. Of these, 55.6% (227 
people) relied on the patient to tell them how much of each product they needed. A 
further 12.5% (51 people) used information from dietitians and/or 
gastroenterologists, while 9.8% (40 people) left it to a pharmacist to work out. The 
remaining participants reported either that they did not know, or would guess how 
much to prescribe, or that it was many years since they had written such a 
prescription. Many of these commented that patients now generally did not seek 
prescriptions for subsidised gluten-free products because it was no longer worth 
their while to do so.  
5.4.3.4 Testing first-degree relatives and joining Coeliac New Zealand 
Participants were also asked about how often they discussed the issue of testing 
first-degree relatives with patients newly diagnosed with CD, and about how often 
they discussed joining CNZ with these patients. (Figure 5-25) These questions were 
not answered by four and seven people respectively. Three people commented that 
they were not aware of CNZ, while one person annotated her copy of the survey, 
changing the option from “Almost never; I wasn’t aware this might be necessary” to 





Figure 5-25: Likelihood of discussing the need for testing of first-degree relatives and 
of joining CNZ with adult patients newly diagnosed with CD 
5.4.4 Analysis by demographics: Newly diagnosed CD 
Analysis of responses in Part B of the survey again consisted of Pearson Chi-square 
or Fisher’s Exact testing, investigating possible associations with gender and 
rurality. The three “almost never” options were grouped for these analyses because 
all three would lead to the same clinical outcome. 
The first question in this section of the survey investigated the issue of who, in 
the experience of the respondent, usually took responsibility for referring newly 
diagnosed patients to a dietitian. The majority of participants indicated it was either 
themselves or a gastroenterologist who did this. Gender and rurality both 
influenced this experience such that a higher proportion of male respondents 
reported it was usually they who had referred to dietitians, while a higher 
proportion of female respondents indicated that in their experience it was usually 
gastroenterologists who had done this, (p=0.01). In the rural setting, respondents 
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doing this in the urban setting, (p=0.027). This was influenced by gender, with 
women in the rural setting being more likely to refer themselves, (p=0.007), but 
there being no significant difference in the experiences of the men, (p=0.831) 
The frequency with which participants were likely to refer newly diagnosed 
patients for DEXA scanning was also influenced by gender, (p=0.031). Thus a higher 
proportion of male respondents indicated they almost never referred patients for 
DEXA scanning, while a higher proportion of the women were more likely to refer 
for scanning in “certain situations”.  
 When it came to whether or not participants would discuss the need for CD-
testing of first-degree relatives of patients, gender was again influential, (p=0.02),  
with a greater proportion of female respondents indicating they almost always did 
this.  
With respect to whether or not respondents recommended to their patients 
that they join CNZ, there was an association with rurality among men only, 
(p=0.001). Rural respondents were more likely to recommend CNZ almost always 
when compared with their urban counterparts, while urban respondents were 
more likely to almost never do this.   
5.4.5 Long-term management 
Questions then turned to the longer-term management of adult patients with CD, 
focusing on aspects of that management identified in the literature, and discussed 
in Chapter Two. These included the need to review patients with regards to their 
CD, the need to reinforce the importance of adherence to the GFD, if and when to 
retest serology, if and when to test for conditions associated with CD, and if and 
when to recommend influenza and/or pneumococcal vaccinations. 
When it came to how often this group of respondents reviewed their adult 
patients with CD specifically with respect to their disease, the following practices 




Figure 5-26: Frequency of review of adult patients specifically with respect to CD 
This chart shows that 61% (330 of the 542 participants in this survey who had adult 
patients with CD) reviewed those patients and their CD management either 6-
monthly, annually, or opportunistically when they saw them for something else. 
Another 12.7% (69 people) did this occasionally, while 11.4% (62 people) indicated 
“Other”. In the majority of cases this option was utilised to enable participants to 
give a more nuanced response, which generally combined the options. Thus some 
indicated they reviewed their patients between 6- and 12-monthly, some asked 
them about their CD annually when they are being seen for something else, and 
some reviewed them “as often as required”. Within this group a small number also 
commented that they did not formally recall these patients, but would consider 

























people) almost never reviewed their patients specifically with respect to the 
condition. 
The survey then asked participants about whether they ever reinforced the 




Figure 5-27: Frequency with which participants reinforce the importance of the GFD 
to their adult patients with CD 
Among the 33 people who selected “Other” were two principal groups: one in which 
respondents indicated that they did this “occasionally”, “sometimes”, or “from time 
to time”; and the other in which they indicated that reinforcing the diet was not 
necessary because their patients tended to be so sensitive to gluten that they were 
highly motivated to remain gluten-free. 
The issue of retesting coeliac serology as part of the long-term management of 
patients drew an enormous range of responses. Participants were asked when they 
retested coeliac serology in their adult coeliac patients, and were given a list of ten 
possible options from which to choose. They were given the instruction that they 
could choose as many answers as necessary, and many chose several. (Figure 5-28) 
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Figure 5-28: Coeliac serology retesting practices 
On further examination of responses, it was apparent that 355 participants (65.5% 
of the group) had selected only one option. Of these, 229 (64.5%) indicated that they 
almost never retested serology for one of the three reasons given: they did not think 
it was necessary, were not aware that it might be necessary, or assumed that a 
gastroenterologist did it.  
Among the 181 respondents who selected more than one option for retesting 
serology, 63 different testing practice combinations were chosen. The most popular 
of these were:  
(a) “if coeliac symptoms do not settle” along with “if coeliac symptoms recur” 
(25 people, 13.8% of the subgroup); and 
(b) “if coeliac symptoms do not settle”, along with “if they recur” and “if the 
patient requests testing” (24 people, 13.3% of the subgroup).  
The highest number of options selected by any participant was 6, and this was done 
by two people. The mean and median numbers of retesting practices were both 3, 

























As can been seen from Figure 5-28, a small number of people (8.7% of the group 
who answered the question) selected “Other”. In selecting this option, respondents 
were able to comment on their answers, which most of this group did to explain 
their practice further. Almost a quarter of this group indicated that they retested 
serology when they had concerns about a patient’s adherence to the diet, or if there 
were other changes (such as new iron deficiency) to suggest an increase in disease 
activity. A small number noted that they tested “opportunistically”, while a few 
tested on the advice of a gastroenterologist. Other comments included “there is no 
evidence to guide this”, “NB – our lab complains if we reorder it often”, and that “this 
varies with the individual client”. 
The practices of respondents with respect to testing their adult coeliac patients 
for conditions associated with CD were less varied than those associated with 
serology retesting. (Figure 5-29) Nine people did not answer this question. 
 
 


























The 13 people who selected “Other” included two who screened at diagnosis, two 
who screened from time to time and/or in the presence of symptoms, and two who 
would offer it annually but only if the patient came for review. One person 
commented that he “would need to know the degree of predictive association” 
because some associated conditions (such as Graves’ disease and Vitamin B12 
deficiency) are “often tested, rarely seen”. Two people also commented that they 
would not necessarily test, but would examine their patients for signs of conditions 
associated with CD. 
The last two questions pertaining to the long-term management of adult CD 
patients asked respondents about how often they recommended that these patients 
had an annual influenza vaccination, and/or a 5-yearly pneumococcal vaccination. 
(Figure 5-30) Nine people did not answer either question. 
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From this figure it can be seen that there was a great deal more uncertainty about 
the place of pneumococcal vaccination in CD management than there was about 
vaccinating against influenza.  
A small number expanded their answers in comments that followed. One 
person who did not believe either vaccination was necessary wrote:  
I am not aware of evidence that for people concordant with a gluten free 
diet there is any additional cost benefit from these imms (sic). I am not 
clear why there would be lowered immunity or increased susceptibility. 
If there is no evidence then stick with standard recommendations. 
In contrast, three people indicated that they recommended the influenza 
vaccination to all their patients, irrespective of whether they had any underlying 
medical conditions, and another eight made reference to the cost of pneumococcal 
vaccination being a deterrent.  
5.4.6 Analysis by demographics: Long-term management of CD 
As with earlier parts of the survey, participant responses to questions in this final 
section were analysed with respect to their  gender and rurality, using Chi-square 
or Fisher’s Exact tests. Once again, the three options of the “almost never” responses 
were grouped. 
On the issue of how often respondents reviewed their patients with respect to 
their CD, the women were more likely to do this opportunistically, while the men 
were more likely to do this annually, (p=0.036). Neither gender nor rurality 
impacted on participants’ practice with respect to reinforcing the need for a GFD, 
but rurality did impact on frequency of testing for associated conditions, (p=0.027). 
Rural respondents were more likely to assess their patients with CD for the 
presence of associated conditions on an annual basis, while urban participants were 
more likely to do this from time to time. Additional analysis showed that gender did 
not affect this.  
Neither gender nor rurality had any impact on practices relating to giving 
pneumococcal or influenza vaccinations. Responses relating to retesting coeliac 




5.4.7 Final comments from participants 
At the conclusion of this section of the survey, participants were once again given 
the opportunity to offer any additional comments. Seventy-one people did this. Of 
the comments made, 19 referred to the preceding questions about influenza and 
pneumococcal vaccinations, while the remainder covered a range of issues, mostly 
revisiting areas that had been canvassed in the survey. Among the comments, were 
25 from people who alluded to their knowledge about the condition either by 
expressing thanks for the prompt to update their learning about CD, or by 
acknowledging that they were “a bit rusty”, or by making a request for the answers 
and/or guidelines to be provided. 
Three people sought to put CD (and, by extension, this survey) into context 
within the busy general practice setting and today’s highly GFD-aware 
environment, with one of them summing this up as follows: 
this is perhaps coeliac management for Doc who have OCD. Excellent 
management could be achieved with intense effort and resources but it 
is a small part of our practice and patients are motivated by symptoms 
to self manage.  This survey brings into relief need perhaps to be a little 
more proactive but GF is really a call for all the crazies in your practice 
to express dietary choices they have gleaned from social media - coeliac 
disease is diagnosed by every quack web page from here to eternity - so 
we had better be clear about this or we will be overwhelmed by the 
misinformed worried well.  
5.5 Key findings of the survey 
To conclude this chapter the key findings of the survey are summarised as follows. 
5.5.1 Response to the survey 
This survey gathered information from 692 GPs from across New Zealand, who 
represented 35.5% of invited participants. Surveys were completed in both 
hardcopy and online formats, with the latter providing 53% of the final sample. 
The rural/urban split of respondents was similar to that of the GP population 
in New Zealand at the time of the survey, but women were over-represented among 
participants. All DHBs were represented. Almost half of respondents owned their 
own practice, and 77% had been working in clinical practice for more than 20 years. 
247 
 
The practice populations served by participants were predominantly New Zealand 
European, and tended to be from the lower to middle socio-economic groups. 
The first section of the survey investigated “Coeliac Disease in General”, and 
was completed by 692, while the second section was for people with adult patients 
with CD under their care. This part included more specific questions about their 
management of the condition, and was completed by 542 (78.3% of the total study 
sample). This subgroup of survey participants was generally similar to the overall 
sample group, but with statistically significant differences in the proportions who 
owned their own practice, worked fewer than three half-day sessions per week, and 
worked in many practices. While the proportion of women in this subgroup was 
higher than in the whole cohort, this did not reach statistical significance. 
5.5.2 Part A: Recognition of CD  
Participants’ capacity to recognise CD was investigated with questions about whom 
they would be likely to test for the condition, from an array of presenting symptoms, 
signs, and conditions. This revealed that there some presentations that would lead 
the great majority to test (e.g. chronic diarrhoea, iron deficiency, IBS, and having a 
first-degree relative with CD), but many more that were not so likely to do so. 
Cumulative testing scores derived from responses to these questions suggest that, 
overall, respondents were likely to be under-testing for CD in both contexts 
investigated. There were significant associations between these findings and the 
gender of respondents. 
5.5.3 Part A: Diagnosing CD 
In this part of the survey participants were asked about how they tested for CD, and 
what test results they would be likely to accept as confirming the diagnosis. This 
section also included questions about what constitutes an adequate gluten 
challenge. 
The majority indicated they would request “coeliac antibodies” from their 
laboratory provider, or specified which antibody tests they would do. A small 
number would include an HLA-DQ2/DQ8 test as part of their initial testing.  
When a patient returned a positive coeliac antibody test, the majority would 
refer for endoscopy most of the time or almost always. Only a small proportion of 
respondents almost never referred for this investigation. Almost half of 
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respondents made additional comments in relation to this issue, and a common 
theme among their comments was that access to timely endoscopy is problematic 
both for their patients and themselves. This was reinforced in comments relating to 
the advice they give with respect to when patients awaiting endoscopy can start a 
GFD. While more than 80% indicated they tell patients to wait until they have had 
their biopsy before starting the diet, practical constraints on this recommendation 
were identified by several. 
The issue of an adequate gluten challenge drew a wide range of suggestions, 
both in terms of how much gluten needed to be consumed, and for how long. Many 
respondents opted for the “Don’t Know” option, or indicated that they would need 
to check this out. Their preferred source of information was “an internet source 
such as BPAC”. 
With respect to which tests could confirm the diagnosis of CD, positive serology 
followed by positive biopsy was almost unanimously accepted as doing so. However 
several other options were also likely or highly likely to be regarded as confirming 
the diagnosis by a majority of respondents. These ranged from “positive serology 
alone” at 58.5%, to “positive serology followed by symptomatic improvement on a 
GFD” at 70.5%. Gender, and whether or not participants had patients with CD, were 
significantly associated with some of the aspects of diagnosing CD investigated. The 
clinical import of these will be discussed in Chapter Seven. 
5.5.4 Part A: Managing CD 
In Part A of the survey, management questions related solely to the issue of annual 
reviews for patients with CD, and what these might comprise. Almost 70% of 
respondents thought that such a review was probably or definitely necessary, and 
78.2% thought that GPs should be the clinicians carrying them out. More than 40% 
indicated that they reviewed some or all of their coeliac patients already. There was 
a wide range of suggestions about what an annual review might include, but the 
majority suggested that it should include blood tests of some sort (e.g. full blood 
count, ferritin and/or iron studies, vitamin B12 and folate). There was also a range 
of suggestions about what symptoms it would be important to check for, and what 
should be included in a physical examination. 
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5.5.5 Part B: Newly diagnosed CD 
Among those participants with patients with CD who went on to answer the second 
part of the survey, there was a reasonably even split between those who referred 
their newly diagnosed patients to a dietitian themselves, and those whose 
experience was that gastroenterologists did this. They were also fairly evenly 
divided between those who almost never referred for DEXA scanning and those 
who did. The majority of those who almost never referred had indicated that they 
were not aware that this might be necessary. More than 50% mostly or almost 
always discussed with these patients the need for their first-degree relatives to be 
tested for CD, but much smaller numbers discussed joining CNZ as frequently. 
Almost 25% were not aware that involvement with CNZ might be necessary for 
these patients. 
5.5.6 Part B: Long-term management 
Issues canvassed in this final section of the survey related largely to the ongoing 
review and monitoring of patients with CD, and included questions on reinforcing 
the importance of the GFD, retesting serology, testing for associated conditions, and 
whether or not to give influenza and pneumococcal vaccinations.  
Just over 60% of respondents indicated that they reviewed patients specifically 
with respect to their CD either 6-monthly, annually, or opportunistically when they 
came for other things. More than 50% made a point of regularly reinforcing the 
importance of adhering to the GFD. 
There was a wide range of practices when it came to retesting coeliac serology, 
with no clearly favoured option among those given. There was somewhat more 
consistency with respect to testing for associated conditions, with more than 50% 
screening their patients from time to time or annually, and another 23% 
investigating them if they had suggestive symptoms. There was also a range of 
practices when it came to the frequency of recommending influenza vaccinations, 
but more than 60% of participants indicated they almost never recommended 








: Results from the Laboratory Data Study 
6.1 Introduction 
As outlined in Chapter Three, the third component of the research undertaken for 
this work comprised the investigation and evaluation of data relating to testing for 
CD gathered from SCL, a major laboratory services provider in New Zealand. 
Additional information about the ethnicities of people being tested for CD was 
obtained from the New Zealand MoH.  
This chapter begins by reporting inclusion and exclusion criteria for data used 
for analysis, and then presents results under the following headings: 
 Rates of testing. 
 Who was tested?  
 Who did the testing?  
 Which tests were done? 
 What was found? 
 What happened next? 
 CD incidence. 
Otago-Southland data, which constitute the biggest dataset, are presented first 
in each section, followed by the considerably smaller sets of more recent results 
from Nelson-Marlborough and South Canterbury. Trends apparent in results from 
Hawkes Bay and Taupo are also presented for comparison, but complete analysis of 
data from these regions has not been undertaken. The reasons for this are explained 
in the following section. The chapter concludes by summarising the key findings. 
6.1.1 Selection of data for analysis 
As outlined in Chapter Three, data were provided by SCL for the period from 1 
January 2003, through to 31 December 2015. They came from all centres served by 
SCL, with the exception of Wellington and Wairarapa, which only came into their  
stable of laboratories in late 2015. This amounted to 149,129 lines of data, each 
connected to a CD-related testing event carried out by SCL, but not all of which were 
appropriate to include in all aspects of analysis. (Table 6.1) 
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Table 6.1: Summary of SCL data included and excluded from analysis 
Data included in all 
aspects of analysis 
Data included in some 
aspects of analysis 
Data excluded 
Otago-Southland:       
2007 – 2015 
Otago-Southland:       
2006 
All regions: 2003 – 2005 
Nelson-Marlborough: 
2013 – 2015 
Hawkes Bay:               
2007 – 2015 
Nelson-Marlborough and 
South Canterbury: 2012 
South Canterbury:     
2013 – 2015 
Taupo:                          
2008 – 2015 
All data from Canterbury 
 
As discussed in Chapter Three, up until the middle of 2006, SCL was a co-
provider of services in all the regions in which it had laboratories, and for some of 
these (e.g. Canterbury) they were a minor player only, processing around 20% of 
tests originating from community providers such as GPs. Data from 2003 to 2005 
therefore incompletely represented what was happening with regards to testing for 
CD at the time in all regions, so they were excluded from analysis. 
The most comprehensive set of results was from Otago-Southland, where SCL 
has been the sole provider of laboratory services since July 2006. Because 2006 data 
were incomplete, this material was largely excluded from analysis although some 
aspects have been utilised. In particular, 2006 information was included when 
determining which patients tested each year had previously been tested. Otago-
Southland data from 2007 onwards have been extensively analysed and underpin 
the substantive part of the following sections.  
Nelson-Marlborough and South Canterbury data were available from mid-
2012, when both areas came under the SCL umbrella. Because the 2012 data from 
these regions were incomplete, only data pertaining to the three years from 1 
January 2013 were included in analysis. 
Both the Hawkes Bay and Canterbury regions have separate laboratories 
carrying out testing requested by community providers, and hospital-based 
practitioners. Data from the Hawkes Bay and Canterbury DHB laboratories (which 
includes biopsy data) were not available for this project, thus the datasets for these 
regions were incomplete. As the Canterbury data were also only available from mid-
2012, they were completely excluded from analysis. However, the Hawkes Bay data 
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covered an extensive period of time and gave an indication of trends in community-
provider practice in that region, so some analysis of this dataset was undertaken. 
Taupo is unique among the centres for which data were obtained in that it is a 
smaller centre within a larger DHB region. It does have a hospital for which SCL is 
the laboratory provider, but the hospital itself offers only limited services, with the 
majority of specialist procedures being performed at the DHB’s larger Rotorua 
Hospital. This includes endoscopy services for the investigation of patients with 
positive CD serology tests, and many outpatients’ clinics. Laboratory services for 
Rotorua hospital are not provided by SCL, therefore data relating to biopsies were 
not available for analysis. It is also likely that there would have been patients tested 
for CD at the request of specialists at Rotorua hospital, and these data too were 
unavailable. In addition to those seen in Rotorua, some patients from Taupo are also 
seen at Waikato Hospital (Hamilton), which is the tertiary provider for the region. 
It is difficult to predict how many people would have been seen in either Rotorua or 
Hamilton although it seems probable that the numbers would have been small. 
Because Taupo data are therefore also incomplete, they have not been included in 
all aspects of analysis. 
When these exclusion criteria were applied, 80,777 lines of data remained for 
inclusion in either complete or partial analysis. Of these, 65,263 were available for 
full analysis.  
6.2 Rates of testing 
Rates of testing were calculated by first determining how many tests had been 
requested in each region, and how many patients had had those tests. Where 
sufficient data were available, further calculations were then conducted to identify 
how many new patients had been tested each year. (Table 6.2) These data were then 
combined with New Zealand Census data. The information presented in Table 6.2 is 




Table 6.2: Summary data relating to “testing events” (TE), total patients tested (TPT), 
and new patients tested (NPT), in Otago-Southland (OS), Nelson-Marlborough (NM), 
and South Canterbury (SC), by year 
Year OS TE OS TPT OS NPT NM TE NM TPT SC TE SC TPT 
2007 4362 4157 3955     
2008 4985 4738 4284     
2009 4790 4580 3940     
2010 5572 5302 4445     
2011 5566 5282 4213     
2012 6242 5935 4614     
2013 6838 6517 5128 2325 2267 1325 1264 
2014 7309 6995 5299 2782 2692 1110 1066 
2015 8001 7669 5631 3010 2901 1046 1018 
Totals 53665 51175 41509 8117 7860 3481 3348 
6.2.1 Otago-Southland 
In the 10-year period from 1 January 2007 to 31 December 2015 there were 53,665 
occasions on which some form of serological or genetic testing relating to CD was 
requested from SCL in Otago-Southland. These “testing events” steadily increased 
in number from 4362 in 2007, to 8001 in 2015. In that period, tests were carried 
out on 51,175 patients, with the annual number of patients tested increasing from 
4157 to 7669. When year-to-year repeat testing was excluded, the total number of 
new patients tested by SCL in relation to CD from 2007 to 2015 was determined to 
be 41,509. Overall, in the 9-year period between 2007 and 2015, there was a 1.8-
fold increase in the number of CD tests being carried out per annum, and a 1.4-fold 





Figure 6-1: Testing events and numbers of patients tested for CD by SCL in Otago-
Southland, 2007 – 2015  
The incomplete data from SCL for 2006 included 3035 CD-related tests 
performed on 2914 patients. When these patients were included in calculations to 
determine how many new patients were tested each year, it became apparent that 
by 2015 just over 25% of the patients being tested had had a previous test (or tests) 
performed by SCL at some point in the preceding decade. Given that the 2006 
dataset is incomplete, this figure under-represents the true state of affairs, although 
this is likely to be by only a small margin.  
According to New Zealand Census data, the population of the Otago-Southland 
DHB region was 286,224 in 2006, and by 2013 had reached 297,423. Assuming that 
the rate of population increase remained relatively steady at 0.56%, the estimated  
population in 2015 was 300,623. This information was used to calculate annual 
rates of testing for CD at the beginning and end of the time period under 
consideration. (Table 6.3) 




Testing events   
(% population) 
Patients tested (% 
population) 
New patients 
tested (% popn) 
2007 287,824 4362 (1.5) 4157 (1.4) 3955 (1.4) 






















Testing events per year Patients tested per year New patients per year
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As is demonstrated in Table 6.3, population rates of testing for CD increased 
between 2007 and 2015 across all three parameters evaluated. Each of these 
increases was statistically significant on two-sample proportions testing, 
(p<0.0001). In addition to the figures shown, by the end of 2015, 13.8% (41,509 
individuals) of the Otago-Southland population had been tested for CD at least once 
since 2007. 
6.2.2 Nelson-Marlborough and South Canterbury 
The population for the Nelson-Marlborough DHB region was recorded as 136,995 
in the 2013 Census. This was an increase of 5.3% from the 2006 population, which 
gave an estimated annual increase of approximately 0.76%. Extrapolating from the 
2013 figure, and assuming a steady rate of population increase, the population of 
Nelson-Marlborough for 2015 was estimated to have been 138,975. In South 
Canterbury the 2013 census-derived DHB population was 55,626, an increase of 
3.2% on the 2006 population. Once again, assuming a steady rate of population 
increase annually, the 2015 population was estimated to have been 56,126.  
Because data available for the Nelson-Marlborough and South Canterbury 
regions pertained to only three years, it was not possible to form an accurate picture 
of long-term trends in CD testing with respect to time. This was particularly the case 
for determining numbers of first tests for CD carried out each year, because there 
was no information available about patients’ testing histories. However, it was 
possible to make snapshot comparisons with Otago-Southland with respect to the 
2015 rates of testing for CD. The data also showed that in the three years to 2015, 
testing rates increased in Nelson-Marlborough but fell in South Canterbury. (Table 
6.4) Within each region, these changes in population testing rates were statistically 
significant on two-sample proportions testing, (p<0.0001), however the differences 




Table 6.4: Nelson-Marlborough and South Canterbury population rates of testing for 




Testing events   
(% population) 




2013 136,995 2325 (1.7) 2267 (1.7) 
 2015 138,975 3010 (2.2) 2901 (2.1) 
South 
Canterbury 
2013 55,626 1325 (2.4) 1264 (2.3) 
 2015 56,126 1046 (1.9) 1018 (1.8) 
 
When patients tested in 2015 who had also been tested in either 2013 or 2014 
were removed from calculations, the Nelson-Marlborough population testing rate 
fell to 1.9% (2660/138,975). The testing rate in South Canterbury fell to 1.6% 
(893/56,126). These rates remained statistically significantly different from the 
2013 rates, p=0.0001 for Nelson-Marlborough, and p<0.0001 for South Canterbury. 
6.2.3 Hawkes Bay and Taupo 
As for Otago-Southland, the 2007 Hawkes Bay population was interpolated from 
2006 and 2013 DHB-region census data, which was also used to estimate the 2015 
population. Because there were no DHB specific census data for Taupo (being a 
small centre within a larger DHB), these figures were derived from New Zealand 
Census District data. (Table 6.5) 
Testing data (albeit incomplete) were available from Hawkes Bay and Taupo 
for a similar time period to that from Otago-Southland. As with Otago-Southland, 
rates of testing in Hawkes Bay increased, (p=0.014), although overall a smaller 
proportion of the population was tested each year. In contrast to this, rates of 
testing in Taupo fell, (p<0.0001), but testing rates in the mid-2000s were higher 
there than in either Otago-Southland or Hawkes Bay at the equivalent time. (Table 
6.5) Once again, analysis was by two-sample proportions testing. 
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Table 6.5: Hawkes Bay and Taupo population rates of testing for CD, first and last 




Testing events   
(% population) 
All patients tested 
(% population) 
Hawkes Bay 2007 148,740 892 (0.60) 858 (0.58) 
 2015 152,694 1258 (0.82) 992 (0.65) 
Taupo 2008 32,558 614 (1.9) 587 (1.8) 
 2015 33,049 436 (1.3) 353 (1.1) 
 
Over the 9-year period from 2007, 5.1% (7813 individuals) of the Hawkes Bay 
population were tested for CD at least once at an SCL laboratory. But, as previously 
noted, the population is also served by a DHB laboratory, so these figures 
underestimate the true figure of total CD testing in the region at the time. 
In Taupo the number of new patients tested fell steadily from 2008 until 2013, 
when 276 people were tested for the first time by SCL, a rate of 0.84% 
(276/32,907). By the end of 2015 this had climbed back to 353, a rate of 
approximately 1.1%. Overall, in the time period for which data are available, 2853 
people in Taupo had a first-test for CD performed at SCL, constituting approximately 
8.6% of the population. This figure also underestimates total CD testing, because 
additional tests would have been requested by Rotorua and Hamilton-based 
specialists, and performed at other laboratories. It is not possible to predict how 
many people this was likely to have involved, although it is probable that the 
number was not great. 
6.3 Who was tested? 
When analysing the demographic characteristics of those patients who had 
undergone testing for CD, it was clearly apparent that women were tested more 
frequently than men. This difference held across all the regions for which data were 
available, the number of testing events per year, the number of patients tested per 
year, the number of first-test patients per year, and for the entire period of time 
under consideration. Graphs in the following sections present these data. Age and 
ethnicity data for the populations tested are also presented, in subsequent sections. 
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6.3.1 Gender-specific data from Otago-Southland  
Otago-Southland data were analysed with respect to the gender of patients tested, 
as proportions of testing events, patients tested per year, and first-tests per year 
respectively. (Figures 6-2, 6-3 and 6-4) For the entire period for which data were 
available, only six patients were listed as “gender unknown” – one in each year from 
2010 to 2015. 
 
 
Figure 6-2: CD testing events for males and females in Otago-Southland, by year 
 
















































Figure 6-4: Numbers of males and females having first test for CD in Otago-Southland, 
by year 
From each of these figures it is apparent that consistently more women than men 
were being tested for CD, in each category assessed, (p<0.0001), and in every year, 
(p<0.0001).  
A direct comparison was made in the trends for new tests per year conducted 
on men and women. (Figure 6-5) 
 
 
Figure 6-5: Comparison of new male and female patients testing in Otago-Southland, 














































As illustrated in Figure 6-5, over this time period, the gap between the absolute 
numbers of men and women having a first test for CD widened. However, when 
these numbers were analysed with respect to the proportions of the total number 
of tests they represented, the gap in fact narrowed. Thus, in 2007, 33.4% 
(1324/3955) of new patients were men, rising to 35.5% (1882/5299) in 2014, 
although dropping back to 34.7% (1954/5631) in 2015. On two-sample 
proportions testing, the 2014 increase from 2007 was statistically significant, 
(p=0.045), but the 2015 increase was not, (p=0.223). 
Ratios of women to men tested across the categories analysed were calculated, 
and found to have fluctuated with time. Some showed an overall increase, and some 
showed a decrease. (Table 6.6)  
Table 6.6: Female:Male ratios for CD testing, Otago-Southland 2007 – 2015  





2007 1.99 1.98 1.99 
2008 1.99 2.00 1.99 
2009 2.02 2.02 2.03 
2010 2.11 2.09 2.04 
2011 2.10 2.08 2.01 
2012 2.13 2.12 2.02 
2013 2.07 2.06 1.97 
2014 2.00 1.99 1.81 
2015 2.07 2.07 1.88 
All years 2.05 2.05 1.96 
 
None of the differences between 2007 and 2015 reached statistical significance on 
two-sample proportions testing. 
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6.3.2 Gender-specific data from Nelson-Marlborough and South Canterbury 
Despite the fact that testing data for Nelson-Marlborough and South Canterbury 
were only available for the three years from 2013 until 2015, they nonetheless gave 
an indication of testing trends emerging in those regions. (Figures 6-6 and 6-7) 
Numbers of first tests were not calculated because the time period was too short to 
make this meaningful. 
 
Figure 6-6: CD testing events for males and females in Nelson-Marlborough and South 
Canterbury, by year 
 
Figure 6-7: Numbers of males and females tested for CD in Nelson-Marlborough and 
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These figures both illustrate that, as in Otago-Southland, women being tested for CD 
consistently outnumbered men being similarly tested, albeit in smaller proportions 
in South Canterbury. Female to male testing ratios were calculated for both regions, 
which clearly demonstrated this difference. (Table 6.8) 
Table 6.7: Female:Male ratios for CD testing, Nelson-Marlborough and South 
Canterbury 2013 – 2015  




2013 2.13 2.13 
2014 2.16 2.13 
2015 2.01 2.01 
South Canterbury 
2013 1.94 1.94 
2014 1.82 1.82 
2015 1.71 1.72 
 
None of the differences in testing ratios between 2013 and 2015 reached statistical 
significance in either region. 
6.3.3 Gender-specific data from Hawkes Bay and Taupo 
Although the datasets for both Hawkes Bay and Taupo were incomplete, from the 
data that were available it was apparent that the patient groups who had been 
tested for CD in SCL laboratories were similar, but not identical to those from the 
Otago-Southland region. As in the south, many more women than men were tested, 
although the ratios between the two groups varied a little more in the northern 
areas. (Figures 6-8, 6-9, 6-10, and 6-11) It is unclear how these figures would 
change with the addition of data from DHB and other laboratory service providers 




Figure 6-8: SCL CD testing events for males and females in Hawkes Bay, by year 
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6.3.4 Age-specific data from Otago-Southland 
The age of patients tested for CD in Otago Southland between 2007 and 2015 ranged 
from 9 days old, to 98 years old. The mean age for adults was relatively stable at 
around 42 years of age, while that for children (those up to and including 16 years 
of age) was just over 8 years old. This has steadily increased since 2010. (Table 6.8)  
Table 6.8: Age range, mean (standard deviation; s.d.) and median age of patients 
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* Mean and median calculations of age were performed using age in years at the time 
of testing, except for children up to the age of 2 years old. Calculations for children up 





As well as the 9-days old baby, ten other infants younger than four months of 
age were tested. At the other end of the spectrum, a number of the very elderly were 
also tested for CD. In every year for which data were available there were patients 
aged 90 years or older who were tested for CD for the first time, with numbers 
ranging from two to 13 per year.   
The number of testing events each year and the number of first CD tests 
performed per year were analysed by age-group. The cohorts were grouped into 
those under 17 years of age (the age at which young people come under the care of 
adult-focused health services), and then in ten year age-bands above this. (Figures 
6-12 and 6-13) 
 
 





















CD testing events by age-group and year
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Figure 6-13: Number of first CD tests in Otago-Southland grouped by age, per year 
As shown in these graphs, from 2010 onwards, the age-group having the 
greatest number of tests for CD were the 17- to 26-year olds. They were followed 
by the under-17-year olds (a group which, it should be noted, covered a wider age 
range), who prior to 2010 were the most tested group. The third largest group to be 
tested was the 37- to 46-year olds. These comparisons held true for both the 
number of testing events, and the number of first tests carried out each year.  
All age-groups had an increase in both the number of testing events carried out 
per year, and the number of first tests per year. This included the over-86-year olds, 
for whom testing events increased from 16 in 2007, to 33 in 2015, and first tests 
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Figure 6-14: Number of CD testing events in Otago-Southland per age-group, per year 
 
 
Figure 6-15: Number of first CD tests in Otago-Southland per age-group, per year 
Between 2007 and 2015, the greatest increases in numbers of testing events, 
and in patients being tested for the first time, occurred in the 17 to 26 years old age-
group. They were followed by the under-17-year olds, and then the 57- to 66-year 
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Figure 6-16: Increases in numbers of testing events and first tests in Otago-Southland 
in each age-group, between 2007 and 2015 
6.3.5 Age-specific data from other regions 
The age ranges of patients tested in each of the other regions were similar to those 
of Otago-Southland, although there were fewer very young babies tested elsewhere. 
All regions tested the very elderly, including two 97-year olds. (Table 6.9) 
Table 6.9: Cumulative age ranges of patients tested for CD in other regions 
Region Age Range Time span 
Nelson-Marlborough 4 months to 97 years 2013 to 2015 
South Canterbury 6 months to 97 years 2013 to 2015 
Hawkes Bay 6 months to 94 years 2007 to 2015 
Taupo 5 months to 90 years 2008 to 2015 
 
Excluded from this table is a serology test from one of the regions, which was 
requested to be carried out on an umbilical cord blood sample. The laboratory did 
not process the request and indicated to the requester the reasons why this would 
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Because data from Nelson-Marlborough and South Canterbury were complete, 
albeit for a shorter period of time, mean and median ages of patients tested for CD 
were also calculated for these regions. (Table 6.10) 
Table 6.10: Mean (standard deviation; s.d.) and median age of patients tested for CD 



































44 years 10.2 years (4.4) 11 years 
* See note for Table 6.8 (page 272) 
 
As with the Otago-Southland data, information from these two regions were further 




Figure 6-17: CD testing events per age-group in Nelson-Marlborough (NM) and South 
Canterbury (SC), 2013 – 2015  
As evident in this figure, children comprised the biggest group of those tested for 
CD in both regions in recent years. What is less apparent from the chart is that in 
Nelson-Marlborough the number of people over the age of 86 years being tested 
doubled from 13 in 2014 to 26 in 2015. 
As already noted, the data from Hawkes Bay and Taupo were incomplete, 
missing those patients tested at the Hawkes Bay DHB laboratory, and Rotorua 
Hospital (and occasionally Waikato Hospital) respectively. This will have influenced 
age-related calculations, particularly with regards to children in Hawkes Bay who 
may have been seen by a paediatrician. However, cumulative means and medians 
were calculated for both regions, to give an indication of the age-profiles of those 
being tested for CD through SCL.  
In the Hawkes Bay the mean age for adults being tested for CD by the SCL 
laboratory between 2007 and 2015 was 46.7 years (s.d. 17.4 years), and the median 
age was 47 years. For Taupo these figures were 45.6 years (s.d. 17.2 years) and 46 
years respectively, for the time period 2008 to 2015. These figures are all slightly 
higher than the Otago-Southland values given earlier. With regards to children, the 
mean age of those tested through SCL was 9.9 years (s.d. 4.6 years) in Hawkes Bay, 


















CD testing events by age-group and year, NM and SC
≤ 16 yrs 17 - 26 yrs 27 - 36 yrs 37 - 46 yrs 47 - 56 yrs
57 - 66 yrs 67 - 76 yrs 77 - 86 yrs >86 yrs
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were 10-years and 9-years. The Hawkes Bay values are higher than those from 
Otago-Southland, while the Taupo values are equivalent. 
On analysis of testing patterns across the age groups for these two regions, it 
was apparent that in Taupo the greatest number of tests carried out each year was 
consistently on children. Among adults being tested there was an even spread of 
testing across the ages from 17 years old through to 56 years old. Between them, 
these age-groups constituted on average 72% (range 70% to 76%) of adults tested 
every year between 2008 and 2015. In contrast to this, in Hawkes Bay the trend was 
that more tests were carried out on adults in the 37- to 56-years old age groups, 
although from 2012 more tests began to be conducted on children. In 2013 the 
children were the most tested, despite DHB data (which would include the bulk of 
paediatrician-derived test requests) not being included in this set. 
6.3.6 Ethnicity Data 
National Health Index number information was available for more than 99.5% of all 
patients tested for CD by SCL, in each of the regions being considered in this study. 
Using this information, ethnicity data were obtained from the New Zealand MoH. To 
be consistent with MoH and SNZ practice, discussed in Chapter Three, prioritised 
ethnicity was used for all analyses. 
In every region for which data were available, the vast majority of patients had 
a prioritised ethnicity of European – either “New Zealand European”, “Other 




Table 6.11: Percentages of those tested for CD with prioritised ethnicity European 
(New Zealand or other) in Otago-Southland (OS), Hawkes Bay (HB), Taupo, Nelson-
Marlborough (NM), and South Canterbury (SC) 
 2007 2008 2009 2010 2011 2012 2013 2014 2015 
OS 90.3 90.2 90.2 89.6 89.5 88.2 88.0 87.4 87.2 
HB 88.0 88.0 85.8 83.5 87.3 84.9 83.0 84.1 79.4 
Taupo  85.6 82.4 84.6 83.6 82.2 82.4 80.2 81.3 
NM       89.9 89.6 89.7 
SC       89.3 88.6 87.1 
 
New Zealand Māori were the next largest group identified in each region, 
except South Canterbury. In that region, the numbers of people with either an 
unidentifiable response, or who did not give any ethnicity, exceeded those with a 
prioritised ethnicity of Māori. (Table 6.12) 
Table 6.12: Percentages of those tested for CD in each region with prioritised ethnicity 
New Zealand Māori 
 2007 2008 2009 2010 2011 2012 2013 2014 2015 
OS 4.3 4.1 4.5 4.5 4.5 5.1 4.9 5.0 5.7 
HB 6.4 6.8 6.6 7.8 8.4 8.7 10.1 10.9 12.3 
Taupo  8.7 12.8 9.2 11.9 13.3 12.5 11.1 12.8 
NM       5.3 5.5 4.8 
SC       3.8 3.3 4.3 
 
The collated group of “Not stated”, “Refused to Answer”, “Response 
Unidentifiable”, and “Don’t know” was the third largest grouping in all regions apart 
from South Canterbury, constituting between 2% and 3% of patients tested per 
year.  
No other ethnic group in any region reached a level of 1% of the tested 
population in any year, apart from in Hawkes Bay in 2010 and 2015. In 2010 1.1% 
(9/796) of patients tested at SCL identified as Indian, while in 2015 this figure had 
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increased to 2.3% (23/992) of patients. These figures should be viewed with 
caution however, given that the dataset from this region does not include tests 
conducted at the DHB laboratory. It is not possible to predict the profiles of patients 
who were tested there, and how their inclusion would have impacted on the overall 
proportions of patient groups who were tested. People who identified as Indian, 
Chinese, or “other Asian” tended to be the next most tested groups, in the other 
regions albeit in small numbers. In no other region, did representation of any of 
these groups (or any other) among the tested populations exceed 1% in any year 
for which data were available. 
6.4 Who did the testing? 
Data relating to who requested blood tests for CD were available for all regions. 
However, for Hawkes Bay and Taupo, where additional laboratories provide some 
services in the region, this was incomplete. Because one of the variables of interest 
in this study was variation in practice between regions, which may be demonstrated 
in the origins of testing requests, analysis was limited to the regions from which 
data were complete. For both Taupo and Hawkes Bay, tests requested by 
practitioners other than GPs would be under-represented in the data available, 
rendering comparisons between groups within each region, and between each 
region, relatively meaningless.  
Data from Otago-Southland, Nelson-Marlborough and South Canterbury are 
presented with respect to total CD-related testing events each year. (Tables 6.13 
and 6.14) Those requesting the tests were categorised into the following groups: 
GP, Paediatrics, Gastroenterology, Other Specialty, Other Health Professional, and 
Unknown. Almost every other specialty discipline was represented in the “Other 
Specialty” group, with the biggest groups being Endocrinology and Rheumatology. 
“Other Health Professionals” included Nurses (both GP practice nurses and 







Table 6.13: Origins of CD testing event requests in Otago-Southland, 2007 – 2015  




doctor or clinic 
(% total requests) 
Gastroenterology; 
doctor or clinic 
(% total requests) 
Other Specialty; 
doctor or clinic 







2007 3344 (76.7%) 175 (4.0%) 243 (5.6%) 390 (8.9%) 16 194  4362 
2008 3700 (74.2%) 317 (6.4%) 371 (7.4%) 536 (10.8%) 16 45  4985 
2009 3579 (74.7%) 359 (7.5%) 356 (7.4%) 470 (9.8%) 16 10 4790 
2010 4214 (75.6%) 360 (6.5%) 348 (6.2%) 633 (11.4%) 14 3 5572 
2011 4149 (74.5%) 383(6.9%) 387 (7.0%) 627 (11.3%) 18 2 5566 
2012 4803 (76.9%) 408 (6.5%) 377 (6.0%) 625 (10.0%) 25 4 6242 
2013 5300 (77.5%) 479 (7.0%) 416 (6.1%) 609 (8.9%) 33 1 6838 
2014 5660 (77.4%) 498 (6.8%) 418 (5.7%) 632 (8.6%) 95  6 7309 








Table 6.14: Origins of CD testing event requests in Nelson-Marlborough and South Canterbury, 2013 – 2015  




doctor or clinic 
(% total requests) 
Gastroenterology; 
doctor or clinic 
(% total requests) 
Other Specialty; 
doctor or clinic 








2013 1900 (81.7%) 68 (2.9%) 199 (8.6%) 150 (6.5%) 4 4 2325 
2014 2266 (81.5%) 97 (3.5%) 235 (8.4%) 179 (6.4%) 5 0 2782 
2015 2498 (83.0%) 86 (2.9%) 221 (7.3%) 200 (6.6%) 4 1 3010 
South Canterbury 
2013 1052 (79.4%) 69 (5.2%) 24 (1.8%) 160 (12.1%) 20  0 1325 
2014 882 (79.5%) 59 (5.3%) 35 (3.2%) 109 (9.8%) 25  0 1110 




During the time period under consideration, more than 1000 individual 
practitioners in Otago-Southland were responsible for the testing event requests 
analysed. In Nelson-Marlborough there were over 320 practitioners who requested 
CD testing, while in South Canterbury the number was approximately 165. (As some 
tests over the years originated in Emergency Departments and Outpatients’ Clinics, 
it was not possible to determine whether the same individual, or a number of 
individuals, were responsible for these requests. For the purposes of this analysis, 
each of these entities was counted once.) 
In Otago-Southland the 2014 spike in the number of requests from “Other 
health professionals” (to 1.3% of total requests) was comprised almost entirely of 
requests from two Nurse Practitioners, both working in the primary care sector. 
The “Unknown” category in 2007 and 2008 (4.4% and 0.9% of requests 
respectively) was almost exclusively made-up of requests originating in Southland 
Hospital, but for which no further identifying details about the requesters were 
available. This issue had been resolved by 2008. Other “unknown” providers were 
people about whom it was not possible to find information, despite extensive 
searches of the New Zealand Medical Register, New Zealand Nursing Register, and 
the internet.  
The “Other health professional” requests in South Canterbury came almost 
exclusively from two Nurse Practitioners, both working in rural primary care. The 
“Other Specialty” group in this region was largely comprised of general surgeons, 
who were also endoscopists. 
6.5 Which tests were done? 
The tests carried out by SCL in the time period being investigated fell into two 
groups: CD antibody testing, and HLA testing for CD-associated markers. In the 
course of analysing the available data, it became apparent that the tests performed 
in the first of these two groups had been determined as much by laboratory 
protocol, as by those requesting the tests. These protocols have changed over time, 
and have variously included IgA and IgG-AGA, IgA-EMA, IgA-tTG antibodies and, 
since 2015, IgA and IgG-DGP antibodies.  
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6.5.1 Coeliac antibody testing 
 In 2006 when “coeliac antibodies” were requested, these initially consisted of IgA- 
and IgG-AGA and IgA-EMA tests. In the early part of the year, AGA and EMA results 
that were either inconclusive or suggestive of CD had an IgA-tTG test added by 
laboratory staff, to assist with their interpretation. From March 2006, IgA-tTG tests 
began to become a routine addition to the CD testing panel, although this was not 
always consistently applied.  
By 2007 SCL’s testing protocols had been consolidated, with the laboratory 
preferentially carrying out IgA-tTG tests for the investigation of CD, and actively 
discouraging the use of AGA tests. Results would often come with the message:  
When screening for coeliac disease, TTG testing is more sensitive and 
specific than the anti-gliadin antibody (AGA) assay. Therefore routine 
AGA testing has been discontinued. However since the gliadin test may 
have value in other settings, it will still be available if specifically 
requested. 
IgA-EMA tests were added to high-negative and most positive IgA-tTG results, and 
were sometimes also performed singly, if specifically requested.  
From late 2015, DGP tests became part of SCL’s routine CD testing for some 
patients: children up to and including 6-years of age; patients with a high-normal 
IgA-tTG; patients with IgA deficiency. In these cases DGP testing was added by the 
laboratory. However, at the time of completing this study this was not yet a funded 
test so healthcare providers could not routinely request it. Its use was at the 
discretion of the laboratory, on application to the DHB for funding. 
From 2007 total IgA levels were also measured alongside tTG levels, however 
from mid-2010 this changed. In that year SCL-Dunedin adopted a policy of only 
testing total IgA when the IgA-tTG level was not sufficiently high for the laboratory 
scientists to be confident that the patient had adequate IgA levels. 
The total number of CD antibody tests performed by SCL from 2007 to 2015 
were collated. (Table 6.15) Since all tests were processed in a single laboratory and 
according to the same protocols, data from all regions were combined for this table. 
Otago-Southland and Hawkes Bay contributed to all years, Taupo from 2008 




Table 6.15: Numbers of CD serology tests conducted by SCL per year, all regions 
Year Total IgA tTG tests EMA tests 
2007 5124 5155 438 
2008 6412 6442 418 
2009 6117 6141 357 
2010 5527 6797 397 
2011 2182 6774 359 
2012 1069 7318 247 
2013 1646 11687 432 
2014 2043 12535 410 
2015 1411 13526 467 
 
The dataset provided for this time period did not include any AGA tests, because by 
2007 the laboratory no longer regarded AGA as an appropriate test for CD. Results 
of DGP tests were also not included in the dataset provided.  
6.5.2 HLA testing 
The test that is performed only when requested (as opposed to in accordance with 
laboratory protocol) is that for HLA-DQ2/DQ8, often referred to as “the gene test”. 
Complete sets of data relating to requests for this test were available for Otago-
Southland, Nelson-Marlborough, and South Canterbury, and are considered here. 



























2007 104 2.4%     
2008 139 2.8%     
2009 140 2.9%     
2010 203 3.6%     
2011 214 3.8%     
2012 275 4.4%     
2013 312 4.6% 52 2.2% 20 1.5% 
2014 217 3.0% 52 1.9% 34 3.1% 
2015 311 3.9% 72 2.4% 22 2.1% 
Totals 1915  176  76  
 
As is apparent in this table, with the exception of 2014, in Otago-Southland requests 
for HLA testing steadily increased over the years encompassed in this study, as did 
the percentage of total tests that they comprised. The three year time period of data 
relating to the other two regions is too short to determine any patterns in practice, 
although it does appear that HLA tests are requested less frequently there. 
Included in the number of HLA tests requested in Otago-Southland were 41 
duplicate tests – that is, tests conducted on patients who had already had an HLA 
test performed at an earlier date. The timeframe between repeat tests ranged from 
five days to seven years, with 17 of the 41 repeat tests having been requested by the 
same practitioner who had requested the first test. In the shorter time-period 
analysed for the other two regions there were no duplicate tests requested in 
Nelson-Marlborough, and only one in South Canterbury. It is reassuring to note that 
all repeat tests returned the same results as the original tests. 
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As noted earlier in this chapter, over the nine year period from 2007 more than 
1000 individual practitioners requested CD testing of some sort in Otago-Southland. 
Over the same period, 287 of these practitioners requested HLA testing be carried 
out. In Nelson-Marlborough there were approximately 328 practitioners who 
requested CD testing from the beginning of 2013 until the end of 2015, while in 
South Canterbury the number was approximately 165 for the same period. HLA test 
requests were made by 62 practitioners in Nelson-Marlborough, and 31 
practitioners in South Canterbury. Thus over 25% of Otago-Southland practitioners, 
and around 18% of Nelson-Marlborough and South Canterbury practitioners made 
a request for HLA testing on at least one occasion. 
Analysis of who requested HLA tests, revealed that GPs were the major 
contributor of these requests. (Figures 6-18 and 6-19)  
 
 
Figure 6-18: HLA requests in Otago-Southland each year, by requester 
On further study of the data contributing to this graph, it became apparent that 
a relatively small number of practitioners were responsible for the majority of test 
requests. This was particularly the case for tests requested by practitioners in the 
“Other” category (specialists other than Paediatricians or Gastroenterologists), 
with marked increases from 2013 onwards. In 2013 a single practitioner accounted 
for 53.6% (15/28) of requests from this group. The same practitioner accounted for 
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Over the entire period under consideration, 1259 HLA requests originated 
from GPs. Of these, 384 (30.5%) were generated by just three practitioners, while 
the top 10 requesters between them accounted for almost half (49.7%, 626/1259) 
of all requests. 
 
 
Figure 6-19: HLA requests for Nelson-Marlborough and South Canterbury each year, 
by requester 
In Nelson-Marlborough, over the three years from 2013, a single GP was 
responsible for 45% (54/120) of requests originating in primary care, which 
amounted to 30.7% of requests overall. The next highest GP requester ordered 
9.2% (11/120) of tests, while the remaining 55 GP requests came from 38 
practitioners. Of the total group of HLA test requesters, Paediatricians were the next 
most represented group, accounting for 16.5% (29/176) of requests. These came 
from eight individual doctors as well as an outpatients’ clinic and a children’s ward. 
In South Canterbury, requests were more evenly distributed among practitioners. 
A Gastroenterologist made the highest number of requests (21.5%, 16/76), 
followed by one GP who ordered 11 tests (14.5% of the total number). 
Patients who underwent HLA testing could be grouped into one of three 
categories of investigation. The largest of these categories was testing in 
conjunction with serology tests, presumably as part of the investigation for possible 
CD. The second group were patients for whom HLA tests were requested following 
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serology results. There were two scenarios in which such a recommendation might 
have been made, to help the requester clarify a patient’s risk of CD: in the presence 
of ambiguous serology results (usually elevated tTG in conjunction with normal 
EMA); and when a patient had been found to be low or deficient in IgA. The third, 
and smallest, category was patients for whom HLA testing would seem, from the 
available data, to be the sole CD-related investigation that they had undergone. For 
these patients it is possible that additional CD testing may have occurred in another 
region (e.g. for patients recently moved into an area), or that their serology tests 
predated the time period of this study. This is particularly likely to have been the 
case for patients in the Nelson-Marlborough and South Canterbury regions, given 
that data for these areas were only available from the beginning of 2013. 
It is difficult to calculate a precise figure for the number of tests requested 
secondary to a laboratory recommendation, but it is possible to estimate this from 
the data available. In Otago-Southland, the proportion of HLA tests likely to have 
arisen following a laboratory recommendation ranged from approximately 50% (in 
2007) to 29% (in 2015). This would be consistent with there being particular 
practitioners who were routinely and frequently testing for HLA-DQ2/DQ8 in the 
later years of this study.  
6.6 What was found? 
Results of CD testing were grouped and analysed under the following headings: 
positive tTG results; correlations between tTG and EMA tests; results suggestive of 
IgA deficiency; and other findings.k Data from all regions for which they were 
available were included in this component of the analysis. 
 
                                                        
 
k Results for HLA testing were only available for Otago-Southland. This was because the tests 
themselves were not carried out by SCL, which instead acted as a clearing house for test samples 
that were forwarded to the Canterbury Health Laboratory. As all requests initially went through SCL, 
these were included in the study dataset. Results of tests from Otago-Southland patients were sent 
back to SCL for release to requesters, and thus were also included in that dataset. Results for patients 
from the other regions were sent directly to the relevant health practitioners, so did not form part 
of the information available for the project. 
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6.6.1 Positive IgA-tTG antibody results 
As discussed in Chapter Three, SCL used Quantalite tTG test kits throughout the 
period of this study. The ULN for these kits is 20 units, therefore any test above that 
level was regarded as positive. The numbers of positive tTG results returned in 
Otago-Southland, Nelson-Marlborough, and South Canterbury were tabulated, 
along with the percentages of all tTGs performed that these comprised. (Tables 6.17 
and 6.18) 
Table 6.17: Positive IgA-tTG results relative to all IgA-tTG tests performed in Otago-













% of new 
patient 
tTGs 
2007 4286 171 3.99 3954 137 3.46 
2008 4911 223 4.54 4312 173 4.01 
2009 4724 207 4.38 3974 155 3.90 
2010 5462 236 4.32 4494 166 3.69 
2011 5441 230 4.23 4273 154 3.60 
2012 6043 213 3.52 4651 142 3.05 
2013 6674 235 3.52 5182 157 3.03 
2014 7184 263 3.66 5370 164 3.05 
2015 7854 308 3.92 5706 171 3.00 
TOTAL 52,579 2086 3.97 41,916 1419 3.39 
 
It is apparent from this table that early in the study period there was an increase in 
the number of positive IgA-tTG tests as a proportion of total tests being performed. 
However since 2008 these proportions have steadily fallen among patients having 
a first test for CD. The differences in proportions were statistically significant on 
two-sample proportions testing between 2008 and 2015, (p=0.002), but not 
between 2007 and 2015, (p=0.166).  
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For Nelson-Marlborough and South Canterbury the figures given for new 
patient tests are less reliable, as the data available to determine these figures 
encompassed a much shorter period of time. Thus it is possible that some of the 
people newly appearing in the SCL data each year had had earlier tests performed 
by another provider. Nonetheless, the impression given by the data presented is 
that proportions of new-patient positive tests were relatively stable in both regions. 
(Table 6.18) 
Table 6.18: Positive IgA-tTG results relative to total IgA-tTG tests performed in Nelson-

















2013 2303 62 2.69 2261 54 2.39 
2014 2747 90 3.28 2565 73 2.85 
2015 2957 85 2.87 2643 64 2.42 
TOTAL 8007 237 2.96 7469 191 2.56 
South Canterbury 
2013 1308 45 3.44 1260 40 3.17 
2014 1087 45 4.14 988 31 3.14 
2015 1034 38 3.68 893 28 3.14 
TOTAL 3429 128 3.73 3141 99 3.15 
 
When the proportions of new-patient positive tests for all three regions were 
compared for the years 2013 through to 2015, there were no statistically significant 
differences detected between any two regions in any year. 
6.6.1.1 Gender-specific analyses of Otago-Southland positive IgA-tTG test data 





Table 6.19: Gender-specific analysis of new-patient tTG tests and positive new-patient 
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(32.1%) 






























































































As demonstrated in this table, and consistent with earlier gender-specific data, 
women and men had IgA-tTG testing done in ratios of approximately 2:1 throughout 
the time period studied. Ratios within the numbers of patients having positive tests 
showed a little more variability, particularly in 2012, 2014 and 2015, although none 
of these annual differences between the genders reached statistical significance on 
Pearson Chi-square testing. On two-sample tests of proportions, no significant 
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differences were detected in the rates of positive tests between men and women as 
proportions of total tests per gender-group in any year, or overall. 
6.6.1.2 Age-specific analyses of Otago-Southland positive IgA-tTG test data 
Similar analyses to those pertaining to gender were carried out with respect to age 
and positive IgA-tTG tests. (Table 6.20) Patients up to and including the age of 16-
years were counted as children. 
Table 6.20: Age-specific analysis of new-patient IgA-tTG tests and positive new-patient 
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The variables of primary interest in this table are the percentages of children and 
adults tested for IgA-tTG antibodies who returned positive results. With the 
exception of 2012, a greater proportion of children who were tested were found to 
have positive results, that is, an IgA-tTG level greater than 20 units. 
In 2009, 2011, and 2014 there were statistically significant differences 
between children and adults with respect to the likelihood of having a positive IgA-
tTG test, (p=0.042, p=0.034, and p=0.037 respectively, on Pearson Chi-square 
testing). When all years were combined this was highly significant, (p<0.0001). 
Two-sample tests of proportions comparing positive tests among children with 
those in adults also detected significant differences in 2009 and 2011, (p=0.042 and 
p=0.034). Once again, when all years were combined the difference was highly 
significant, (p<0.0001). 
The mean age of children returning positive IgA-tTG results ranged from a 
minimum of 7.6 years (in 2010) to a maximum of 10.7 years (in 2012). Among 
adults this range was 39.8 years (in 2012) and 43.3 years (in 2013). 
6.6.2 Correlations between IgA-tTG and EMA results 
In the early years encompassed in this project, EMA tests were routinely included 
in the CD testing panel. In later years they were only performed on patients 
returning a positive or high-normal tTG result, the rationale being that the two tests 
together are a more reliable indicator of the presence of CD, over either test alone.   
Analysis was undertaken to compare the results of the two tests, using 
combined data from the regions. Results of tTG tests were grouped according to 
whether they were very high (≥150 units), high (100 – 149 units), moderately high 
(60 – 99 units), or low-high (21 – 59 units). EMA results were reported as positive, 
weakly positive, negative, or indeterminate/equivocal. Positive EMA tests were 




Table 6.21: Correlation between EMA results and grouped positive IgA-tTG results 
tTG range EMA done EMA positive EMA percentage 
positivity 
≥150 647 646 99.9% 
100 - 149 251 244 97.2% 
60 - 99 304 245 80.6% 
21 - 59 1203 193 16.0% 
 
Because there was such a marked difference in positivity between the two 
lower groups, the low-high group was analysed further, to more accurately identify 
the IgA-tTG level at which EMA positivity dropped off. (Table 6.22) 
Table 6.22: EMA positivity relative to low-high IgA-tTG values 
tTG range EMA done EMA positive EMA percentage 
positivity 
50 – 59 118 53 44.9% 
40 – 49 238 58 24.4% 
30 – 39 317 58 18.3% 
21 – 29  530 24 4.5% 
 
The other reported EMA results (weak-positive, equivocal, and indeterminate) 
were more commonly associated with lower tTGs. There were 180 weak-positive 
EMA results in total, and these were much more prevalent in the low-high tTG 
group, increasing from 17 of the 304 (5.6%) moderately-high tTGs to 163 of the 
1203 (13.5%) low-high results. There were 13 equivocal results, and 32 
indeterminate results, one each associated with a high tTG, and the rest 
predominantly occurring with low-high tTGs. 
At the other end of the spectrum, there were nine positive and 19 weak-positive 
EMA tests in patients with normal IgA-tTG antibody levels. The overall number of 
normal IgA-tTG tests over the time period in which these results occurred was close 
to 74,000, rendering these extremely rare events. 
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6.6.3 Low and deficient IgA levels 
As discussed in Chapter Two, the primary tTG antibody and EMA tests for CD are 
both IgA-based, and therefore rely on the patient having enough IgA to produce 
antibodies in the presence of gluten, which the tests then measure.  
In SCL laboratories, when a patient’s IgA levels are found to be deficient, or 
lower than the accepted normal range for his or her age, a comment is generally 
included in the reporting of the result. In the dataset available for this study the 
information came in various guises. In some cases “*******” appeared in either the 
tTG result column, or the IgA column, or both. In other cases, the tTG and IgA results 
columns were empty, but in many cases the information was obtained only by 
searching individual patient laboratory records, on the basis that the reported IgA 
level was low.  
In Otago-Southland there were 348 tTG antibody tests done on 259 patients 
who were either IgA-deficient, or low in IgA. These results all came with a 
recommendation that the patients concerned should have an HLA test done to help 
exclude CD, or undergo duodenal biopsy to confirm the diagnosis. IgG-DGP testing 
was also offered on some occasions in the later years for which data were available. 
In the other regions, the numbers of patients similarly affected were: Nelson-
Marlborough 25; South Canterbury 14; Hawkes Bay 28; and Taupo 11. However, 
given the variability in how the laboratory reported results for these patients, these 
figures could well underestimate the true numbers. 
6.6.4 Other findings 
Across the regions there were 252 results reported as “*******”, which required a 
search on each patient’s laboratory records to clarify what was meant by this. There 
was a range of reasons for this type of report, but the majority were an indication 
that the blood sample taken from the patient had haemolysed, rendering it 





Table 6.23: Laboratory comments indicated by ******* 
Laboratory Comment Number affected Repeat tests 







Already tested/ result 
reported elsewhere 
14 N/A 
Testing panel related 
comment 
10 N/A 
IgA related 31 N/A 
 
In later years some of these samples were able to be tested for DGP, but many 
patients were re-bled so that the IgA-tTG could be repeated.  
6.7 What happened next? 
From the laboratory data available it was not possible to establish the management 
implemented (e.g. GFD started or not) for the patients who had been tested for CD. 
However, it could be determined that for substantial numbers of them, a first test of 
CD serology was not the last CD-related investigation they underwent. Many went 
on to have repeat serology testing, some had subsequent HLA testing, and some 
went on to have a duodenal biopsy. The following sections present material about 
these follow-up actions for patients from Otago-Southland, Nelson-Marlborough 
and South Canterbury. 
6.7.1 Repeat blood testing (serology and/or HLA testing) 
As indicated early in this chapter, in each year under consideration in this study 
many patients had more than one test for CD. In addition to this, several thousand 
patients were tested repeatedly over two or more years. Some of these were people 
with biopsy-proven CD, some were those with positive serology but for whom there 
was no evidence that they had ever undergone biopsy, some were those with 
ambiguous serology, and some were people with negative tests. Within these 
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groups were patients who also had multiple tests in one or more of the years in 
which they were tested. 
Analysis was undertaken to establish the numbers of Otago-Southland patients 
who had more than one CD-related test in any one year, from the beginning of 2007 
until the end of 2015. (Table 6.24) Year by year this amounted to 2304 patients, but 
when patients also having tests in more than one year were removed, the total was 
2202 (5.3% of the 41,509 individual patients tested over the time period).  
Table 6.24: Repeat CD testing figures for Otago-Southland patients, 2007 – 2017  
 Total patients Number of 
tests 
Patients having repeat tests within a year, 
year by year 
2304 4794 
Unique patients having repeat tests 
within a year 
2202 
Patients having repeat tests in more than 
one year 
95 433 
Patients tested in one year only, but on 
more than one occasion 
2107 4361 
 
Included in these figures are 714 patients who had an HLA test performed, either 
singly or with repeat serology. 
For both Nelson-Marlborough and South Canterbury, the time period for which 
data were available was too short to form an accurate picture of how many people 
were tested in multiple years. However, from the beginning of 2013 until the end of 
2015 3.9% of patients tested in Nelson-Marlborough, and 3.1% of those tested in 
South Canterbury had had more than one test in a year. 
In Otago-Southland the number of repeat tests per year being performed on 
patients ranged from two to seven. In Nelson-Marlborough this range was from two 
to four, while in South Canterbury the maximum number of times a single patient 
was tested in a year was three. (Table 6.25) 
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Table 6.25: Number of individual patients tested for CD more than once per year 




patients      
(2007 – 2015) 
Nelson-Marlborough 
patients                
(2013 – 2015) 
South Canterbury 
patients         
(2013 – 2015) 
2 2,044 236 129 
3 138 9 2 
4 13 1  
5 3   
6 2   
7 1   
 
Analysis of the numbers of patients in Otago-Southland who had year-to-year 
repeat tests was also performed. (Table 6.26) Available information from 2006 was 
included in this analysis because on examining the data from subsequent years, it 
was apparent that many patients had first been tested in 2006. However, the figures 
given for first tests in 2006 will be an underestimate of the true number, given that 
additional patients were tested by the region’s alternative laboratory provider still 
operating at the time.  
The total values given along the bottom of the table represent the number of 
patients tested each year. The diagonal totals (in bold) are the numbers of patients 
having their first test in each year. The smaller values in each column are the 
numbers of patients in each year who had already been tested for CD, and the year 
in which they had that first test. So, for example, in 2010 there were 5302 patients 
tested for CD, of whom 4445 were being tested for the first time, while 170 had first 
been tested in 2006, 214 in 2007, 242 in 2008, and 231 in 2009. (Note: patients 




Table 6.26: Year-to-year tests for CD in Otago-Southland with year of first test 
identified 
 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
2006 2914 202 193 166 170 162 188 151 143 154 
2007  3955 261 227 214 198 201 196 184 190 
2008   4284 247 242 232 187 197 209 194 
2009    3940 231 225 202 193 204 195 
2010     4445 252 274 207 242 248 
2011      4213 269 209 215 207 
2012       4614 236 236 247 
2013        5128 263 296 
2014         5299 307 
2015          5631 
Total 2914 4157 4738 4580 5302 5282 5935 6517 6995 7669 
 
For the time period 1 January 2006 to 31 December 2015, the “grand totals” for each 
of the groups identified were: 
 Overall patients tested: 54,089 
 New patients tested: 44,423 
 Patients tested in each year also tested in more than one year: 9666 
Among the 9666 patients tested in more than one year were people who were 
counted more than once, either because they had more than one test in one of the 
years they were tested, or because they had tests in multiple years. Further analysis 
revealed that the number of individuals who were tested in more than one year was 
7295 (13.5% of the overall patient group). The majority of these had been tested in 
two or three different years, but two patients had been tested every year between 
2006 and 2015.  Only a small proportion had a positive test when they were first 
tested. (Table 6.27)  
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Number of patients having a single test in more 
than one year 
6376 268 
Number of patients having more than one test 
in one or more years 
919 127 
Number of patients tested in more than one 
year following a positive first test 
395 
Number of patients tested in 5 or more years 176 34 
Number of patients tested annually for 4 or 
more consecutive years 
126 32 
 
Of the 126 patients who had annual testing for four or more years, 69 (54.8%) 
were children being tested by Paediatricians, with the majority of tests originating 
from the Paediatrics Diabetes Clinics. General practitioners were the next largest 
group to be regularly testing patients, being the principal annual test requesters for 
47 patients (37% of the sample).  
Among the 69 paediatric patients, nine had had positive serology when first 
tested, a further three developed positive serology during the period in which they 
were being monitored, and one who was IgA-deficient was found to be biopsy-
positive and was subsequently monitored with IgG-DGP testing. 
One adult patient had 17 tTG tests over a period of six years, following a first 
test that was positive. Serology in this patient was repeatedly positive, and the 
patient also underwent four duodenal biopsies. The first of these was normal, the 
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next two showed partial villous atrophy, and the fourth one was reported as normal. 
All but two of the serology tests requested for this patient were done so by GPs. 
Another patient had 13 tests in the space of 11 months (over two calendar 
years). The initial test was requested by a GP, the second by a secondary care 
provider, and all subsequent ones apparently by a GP. All tests were negative, and 
it seems likely that CD serology had inadvertently been included on a monthly 
request card as it was always done in conjunction with other tests. 
6.7.1.1 Repeat testing by gender 
As with numbers of testing events and numbers of patients being tested for CD, 
women outnumbered men when it came to having repeat tests within a year, and 
from year to year. 
On further scrutiny of figures pertaining to repeat testing within a year for 
Otago-Southland patients, it was apparent that this was a function of the overall 
numbers of male and female patients being tested per year, rather than women 
being more likely to have repeat tests. (Table 6.28)  
Table 6.28: Repeat tests per year as a proportion of patients tested per year by gender 












2007 1395 122 (9%) 2762 265 (10%) 
2008 1577 177 (11%) 3161 299 (9%) 
2009 1515 141 (9%) 3065 262 (9%) 
2010 1716 152 (9%) 3585 378 (11%) 
2011 1712 161 (9%) 3569 385 (11%) 
2012 1902 182 (10%) 4032 416 (10%) 
2013 2131 192 (9%) 4385 425 (10%) 
2014 2337 199 (9%) 4657 406 (9%) 




On Pearson Chi-square analysis comparing repeat testing with no repeat testing 
among men and women, there were no statistically significant differences detected. 
Differences between the groups approached significance in 2008, (p=0.057), and 
2010, (p=0.056). 
6.7.2 Duodenal biopsies 
As discussed in Chapter Two, histological examination of duodenal biopsy samples, 
obtained during endoscopy, remains the recommended “gold standard” for 
diagnosing CD. Unfortunately, details relating to biopsies undertaken in the 
population comprising this study were not included in the dataset provided by the 
laboratory, however it was possible to obtain these by searching the laboratory 
records of each person who had had positive serology tests. As SCL processes all 
histology samples obtained from patients in Otago-Southland, Nelson-Marlborough, 
and South Canterbury, the relevant patient records for these regions were readily 
accessible. However, in Taupo and Hawkes Bay the endoscopies at which samples 
are obtained are performed (and therefore processed) at centres that do not use 
SCL as their laboratory service provider. Access to laboratory providers other than 
SCL was outside the scope of this study, and for this reason these regions have been 
excluded from further analysis. 
Laboratory records were accessed for all patients with IgA-tTG levels higher 
than 20; for patients with any EMA result other than negative (thus including the 
few with normal IgA-tTG but positive or weakly positive EMA); and for patients with 
results suggestive of IgA deficiency. Any duodenal biopsy results were identified 
and retrieved for further analysis. While there may also have been a small number 
of patients with normal serology who underwent endoscopy, given the many 
thousands of normal results, it was not practical to search for these as well.  
In total, from the beginning of 2007 until mid-June 2016, there were 1063 CD-
related biopsy procedures performed on 979 Otago-Southland patients. This 
included 77 patients who had more than one endoscopy, two of whom who had 
three, one of whom who had four, and one of whom who had five procedures. It also 
included 11 patients who had had their serology test in 2006, and five patients who 
had their biopsies performed at another centre, four in Christchurch, and the other 
in South Canterbury.  
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Of the 979 patients biopsied, 685 were female and 294 were male. Children and 
young people under the age of 17-years underwent 269 biopsy procedures (25.4% 
of the total). The youngest child to have an endoscopy was 11-months old and the 
oldest adult was 85-years old. The numbers of endoscopies performed for duodenal 
biopsy decreased with increasing age. (Figure 6-20) 
 
 
Figure 6-20: Numbers of biopsy procedures performed per age-group in Otago-
Southland on people with positive CD serology (or IgA deficiency), January 2007 – June 
2016 
In Nelson-Marlborough there were 114 CD-related biopsy procedures 
performed on 109 patients, from the beginning of 2013 until mid-June 2016. Of 
these, 71 were female and 38 were male. The youngest child biopsied was 3-years 
old, and the oldest adult was 80-years old. Children and young people under the age 
of 17-years had 30 procedures, which constituted 26.5% of the total number.  
Over the same time period 49 biopsy procedures were performed on 43 
patients in South Canterbury. Males slightly outnumbered females in this group, 
with numbers of 23 and 20 respectively. The youngest child biopsied was 4-years 
old, and the oldest person was 68-years old. In this region 15 of the 49 procedures, 
or 30.6%, were carried out on children. (It is possible that some people in South 
























This is particularly likely to be the case for children, in whom there were only small 
numbers of biopsies performed, none of which were on the very young.) 
6.7.2.1 Time to duodenal biopsy 
In all three regions, the vast majority of biopsies were performed as a consequence 
of serology testing indicating that CD was possible, but 48 preceded that testing. In 
these cases, serology (which was found to be positive) had been performed 
following a biopsy that showed the hallmark histological features of CD. From 
laboratory data it was not possible to discern why these endoscopies had been 
undertaken. In Nelson-Marlborough and South Canterbury it is quite likely that 
earlier tests had been performed at the alternative laboratory provider before SCL 
took over services there, but in Otago-Southland it is more likely that they were 
performed for clinical reasons other than a suspicion of CD. It may also be that 
serology had been performed in another region, prior to the patient coming to 
Otago-Southland. For whatever reason, duodenal biopsies were taken at the time of 
endoscopy, suggesting the diagnosis of CD which was subsequently confirmed by 
serology. 
There were also a number of patients in Otago-Southland for whom there was 
an extremely long time lapse between a first positive serology test and a duodenal 
biopsy result being recorded. The longest period was 5.5 years, but between 2007 
and 2014 there were another 49 patients for whom this gap was more than a year. 
For several of these people the delay to biopsy was in excess of three years. From 
the data available, it is not possible to determine why this might have occurred, but 
it is highly likely that patient preference will have played a significant role in this. 
Many of these patients had multiple IgA-tTG tests in the intervening years. 
With these groups of patients excluded, the median time to biopsy in Otago-
Southland ranged from 10 weeks in 2007, to 14 weeks in 2012, and back to 12 
weeks in 2015. The mean time to biopsy ranged from 12 (± 8) weeks in 2007, to 17 
(±13) and (±12) weeks in 2010 and 2011 respectively, and back to 14 (± 9) weeks 
in 2015. In Nelson-Marlborough the median time to biopsy was approximately 10 
weeks each year from 2013 to 2015, while the mean time was between 12 (±9) and 
13 (±10) weeks. In South Canterbury the median time varied between 11 and 17 
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weeks, while the mean ranged between 16 (±10) and 19 (±13) weeks, with 2015 
seeing the longest periods for both. 
6.7.2.2 Duodenal biopsy rates 
The rates at which patients with positive CD serology results went forward for 
duodenal biopsy varied over time, and according to how high their IgA-tTG result 
was. (Table 6.29) These results were grouped as very high (≥150 units), high (100–
149 units), moderately high (60–99 units), and low-high (21–59 units).  
Rates were determined by comparing the numbers of biopsies performed each 
year with the number of biopsies that were indicated. All positive results for 
patients that had not yet been followed by a biopsy were included in this “biopsy 
indicated” figure, which meant that the results from patients who had positive tests 
over a number of years before having a biopsy were all counted. Results from 
patients implied in laboratory reports as having CD without evidence of them ever 
having had a biopsy were also included in this figure, as the data available could not 
provide any certainty that this was the clinical situation. Completed biopsies were 
counted with respect to the year in which the serology test had been requested, 
rather than the year in which the biopsies were performed.  
Repeat biopsies and positive results from tests performed after patients had 
had biopsies were also excluded from the calculation of these biopsy rates. Biopsies 
performed on IgA-deficient patients were considered separately, and the relevant 




Table 6.29: Rates of duodenal biopsy for patients with raised IgA-tTG antibodies in 
Otago-Southland, 2007 – 2015  




Biopsy Indicated Done Indicated Done Indicated Done Indicated Done 
2007 45 33 19 11 18 9 57 14 
Rate 73.3% 57.9% 50% 24.6% 
2008 61 42 21 19 18 14 84 36 
Rate 68.9% 90.5% 77.8% 42.9% 
2009 43 28 11 6 18 9 91 38 
Rate 65.1% 54.5% 50% 41.8% 
2010 53 44 20 16 17 9 97 42 
Rate 83% 80% 52.9% 43.3% 
2011 48 39 20 15 18 9 80 24 
Rate 81.3% 75% 50% 30% 
2012 47 38 14 12 27 18 73 26 
Rate 80.9% 85.7% 66.7% 35.6% 
2013 55 40 21 10 13 10 73 33 
Rate 72.7% 47.6% 76.9% 45.2% 
2014 56 41 17 9 27 19 70 36 
Rate 73.2% 52.9% 70.4% 51.4% 
2015 57 43 14 10 27 21 102 46 
Rate 75.4% 71.4% 77.8% 45.1% 
 
On closer inspection of the figures in Table 6.29, it is apparent that there was 






Figure 6-21: Changes over time of duodenal biopsy rates per IgA-tTG category, Otago-
Southland 2007 – 2015  
When biopsy rates for 2015 were compared with those of 2007, it was evident 
that these had increased for all IgA-tTG result categories. Pearson Chi-square tests 
comparing biopsy with no biopsy for each of these categories in 2007 and 2015 
showed that the differences were statistically significant for the low-high category, 
(p=0.01), and approached significance for the moderately high category, (p=0.053). 
Differences in the other two categories were not statistically significant. However, 
given the assumptions made about the data when calculating the biopsy rates, these 
values should be interpreted with caution. 
The overall annual biopsy rate was also determined and can be seen to have 

































Figure 6-22: Annual total duodenal biopsy rates for Otago-Southland, 2007 – 2015  
Biopsy rates were also calculated for Nelson-Marlborough and South 
Canterbury. (Tables 6.30 and 6.31)  
Table 6.30: Rates of duodenal biopsy for patients with raised IgA-tTG antibodies in 
Nelson-Marlborough, 2013 - 2015 
Year Very high tTG High tTG Moderately 
high tTG 
Low high tTG 
Biopsy Indicated Done Indicated Done Indicated Done Indicated Done 
2013 15 11 14 12 3 3 13 5 
Rate 73.3% 85.7% 100% 38.5% 
2014 22 15 10 3 7 6 28 14 
Rate 68.2% 30% 85.7% 50% 
2015 18 11 7 6 6 5 28 12 
Rate 61.1% 85.7% 83.3% 42.9% 
 
The overall biopsy rates for each year in Nelson-Marlborough were 68.9% (2013), 
56.7% (2014), and 57.6% (2015), however the three year time-period is too short 




























Table 6.31: Rates of duodenal biopsy for patients with raised igA-tTG antibodies in 
South Canterbury, 2013 – 2015  
Year Very high tTG High tTG Moderately 
high tTG 
Low high tTG 
Biopsy Indicated Done Indicated Done Indicated Done Indicated Done 
2013 7 5 6 2 7 3 21 5 
Rate 71.4% 33.3% 42.9% 23.8% 
2014 10 6 4 2 3 2 13 4 
Rate 60% 50% 66.7% 30.8% 
2015 7 3 1 1 5 2 13 4 
Rate 42.9% 100% 40% 30.8% 
 
Overall biopsy rates for South Canterbury were 36.6% (2013), 46.7% (2014), and 
38.5% (2015). Once again the short time-period limits the usefulness of this 
information, however it is apparent that fewer biopsies per positive antibody test 
were performed in this region. This may in part be accounted for by patients 
travelling outside the region for further assessment. 
6.7.2.3 Duodenal biopsy rates by gender and age 
When the profiles of the patients who did and did not have biopsies were studied 
further, the following details emerged with respect to gender. (Table 6.32) 








≥150 73.4% 75.5% 0.640 
100 – 149 78.0% 64.5% 0.089 
60 – 99 60.0% 66.4% 0.406 
21 – 59 30.6% 45.7% <0.001 




In contrast to these overall figures for Otago-Southland, in Nelson-Marlborough the 
overall biopsy rates were 61.7% for males and 59.5% for females, (p=0.778), and 
those in South Canterbury were 55.3% and 30.5% respectively, (p=0.015). The only 
statistically significant differences between the regions were between the biopsy 
rates for South Canterbury women and those of Otago-Southland women and 
Nelson-Marlborough women, (p<0.0001 for both comparisons). 
Biopsy rates per age-group were also calculated for each region, and can be 
seen to fluctuate between ages and also within ages between IgA-tTG levels. (Tables 
6.33 and 6.34) 




















≥150 77.6% 72.8% 69.0% 75.0% 72.7% 80.5% 57.1% 85.7% 
100 – 
149 
64.3% 65.2% 75.0% 62.5% 66.7% 91.7% 60.0% 50.0% 
60 – 99 68.8% 58.1% 75.9% 61.5% 58.3% 65.0% 85.7% 0.0% 
21 – 59 30.1% 45.9% 53.3% 49.0% 38.4% 37.9% 34.0% 23.3% 
Overall 57.2% 57.2% 63.5% 58.0% 53.5% 60.3% 46.2% 34.1% 
 





















69.0% 64.0% 60.9% 50.0% 51.9% 66.7% 80.0% 20.0% 
SC 
Overall 




6.7.2.4 Duodenal biopsy results  
The results of every duodenal biopsy performed for CD in the three regions for 
which data were available were scrutinised for evidence of the presence or absence 
of the disease. Information gathered from this process was collated and 
summarised. (Table 6.35) 
Table 6.35: Results for all CD-related duodenal biopsies, all regions combined 
Biopsy result Number of patients 






A small number of samples were inconclusive. For some of these the 
pathologist was explicit about this, writing that “CD cannot be excluded”, the 
findings “could be” CD, or that the findings were “inconclusive”. However, in some 
reports this interpretation was omitted and only minimal changes were cited. 
Samples that were reported as duodenitis, cases in which mild but insignificant 
lamina propria inflammation was observed, two cases for which the full report was 
not accessible, and one case of adenocarcinoma, were all included in this table 
under the heading “Other”.  
Biopsies were counted as positive if the pathologist indicated in his or her 
report that the result was consistent with CD (or other similar wording).  In general 
results were not reported with overt reference to any of the recognised 
classifications discussed in Chapter Two of this work. All reports had a comment 
about villous architecture, variously described as normal, or as showing evidence 
of severe, complete, variable, moderate, or mild villous atrophy. Almost invariably 
there was a comment about the presence or absence of increased IELs, and of a 
chronic inflammatory infiltrate or plasma cells in the lamina propria. Only 
sometimes was there comment about crypt hyperplasia, and only three reports 
included a comment on the quality of the biopsy samples.   
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At the mild end of the spectrum of changes there did seem to be some variation 
in interpretation between pathologists. Several biopsies were reported as showing 
normal villous architecture, and mild or focal intraepithelial lymphocytosis. On 
many occasions this was then reported as being “consistent with coeliac disease”. 
Sometimes this was qualified with a “mild” or “early”, but often it was not. On a few 
occasions it was classified as duodenitis rather than CD. On one occasion the report 
was reclassified at a later date from “compatible with coeliac disease”, to “focal 
increased intraepithelial lymphocytes, otherwise normal”. In two other cases the 
reverse situation occurred, with biopsies that were initially reported as normal 
being reviewed and subsequently reported as showing normal villous architecture 
with increased intraepithelial lymphocytes and inflammation in the lamina propria, 
consistent with CD.  
In Otago-Southland the youngest child to have a positive biopsy was 23-months 
old, and the oldest person was 85-years old. In Nelson-Marlborough these ages 
were 3-years and 74-years, and in South Canterbury 6-years and 64-years 
respectively. 
Biopsy results from the three regions were then tabulated according to IgA-tTG 
results. (Table 6.36) Repeat biopsies were not included unless they clearly followed 
a recent tTG test.  
Table 6.36: Biopsy outcomes with respect to IgA-tTG levels, Otago-Southland, Nelson-









≥150 411 400 97.8% 6/411 (1.5%) 
100 - 149 138 122 88.4% 15/138 (10.9%) 
60 - 99 143 119 83.2% 18/143 (12.6%) 
21 - 59 369 196 53.1% 152/369 (41.2%) 
 
The biopsy reports associated with very high tTG levels (≥150) that were not 
clearly positive for CD were examined individually. This revealed the following: 
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 Two results were equivocal, with one report saying that it “could be” 
CD, and the other saying that CD was “not excluded” and that results 
should be correlated with serology; 
 One result showed evidence of a mild increase in intraepithelial 
lymphocytes only, but this biopsy was on a patient with a previous 
clearly positive biopsy who may well have been on a GFD; 
 One result showed “blunted villi only” but this patient went on to have 
a further biopsy five months later that showed marked villous atrophy; 
 One sample was called “peptic duodenitis” with findings of “varying 
degrees of shortening and flattening of villi”, a mixed inflammatory 
infiltrate in the lamina propria, but no increase in intraepithelial 
lymphocytes. 
 Two normal biopsies were from young children aged 3- and 5-years 
old. The younger of these was biopsied five months after the high IgA-
tTG level had been identified (so may well have no longer been 
consuming gluten), while there was a gap of 10 weeks for the other 
child. 
 Three adolescents, aged 13, 16, and 19, also returned normal biopsies. 
One of these was performed six weeks after the IgA-tTG test result, 
another was almost four months later, and the third was eight months 
following the positive serology, with no further serology testing done 
in the interim. 
 The other normal biopsy was from a 40-year old and was carried out 
10 weeks after serology testing. 
The profiles of those with normal biopsies and high IgA-tTG levels (100 – 149) 
were also reviewed. The time between serology testing and biopsy ranged between 
four and 14 weeks for this group of patients. Of the group, six were children aged 
10-years or younger. One of these children had had a negative EMA test in 
association with the high IgA-tTG, and was later also found to be HLA negative. Two 
of the children went on to have clearly positive biopsies some years after the 
original, in the presence of persistently raised serology. One of the adults in the 
group had a number of biopsies over the years, some of which showed evidence of 
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CD, and others which were reported as normal. This patient had consistently 
abnormal serology.  
Further analysis of the low-high tTG group was carried out by separating the 
results into smaller bands. As the IgA-tTG level went down, the number of biopsies 
that were normal went up. Similarly, the number of normal biopsies accounted for 
by patients with lower tTG levels was also higher. (Figure 6-23) The blue line 
represents the percentage of biopsies that were carried out on patients at each tTG 
level that were found to be normal, while the orange line shows the percentage of 
the total number of normal biopsies accounted for by patients with these tTG levels.  
 
Figure 6-23: Percentage of normal biopsies relative to low-high IgA-tTG levels 
When considering biopsy positivity at these lower IgA-tTG levels the situation was 
not surprisingly reversed. Only 38.0% of patients with an IgA-tTG level between 21 
and 29 units had a positive biopsy. This increased to 53.7% for those with levels 
between 30 and 39 units, 65.1% for those between 40 and 49 units, and 66.7% once 
the level was between 50 and 59 units. 
In addition to the patients with raised IgA-tTG levels, there were also nine 
patients who underwent biopsy with levels within the normal range (i.e. less than 
21 units) but an EMA that was either positive, weak-positive, equivocal, or 
indeterminate. Of these nine patients, four had positive biopsies and the remaining 
five were normal. Two of the people with positive biopsies had positive EMAs, one 
had a weak-positive EMA, and one was indeterminate. 
All EMA results for patients who had undergone duodenal biopsy were 
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Positive EMA 695 48 2 745 
Weak positive EMA 51 12 1 64 
Equivocal/ 
Indeterminate EMA 
9 3 2 14 
Negative EMA 54 127 4 185 
Totals 809 190 9 1008 
 
Among the study population who had had an EMA test performed, this table 
demonstrates that 93.3% (695/745) of positive EMA tests were associated with a 
positive biopsy, and that 68.6% (127/185) of negative EMA tests were associated 
with a negative biopsy. Conversely, 29.2% (54/185) of patients with a negative EMA 
were found to have biopsy evidence of CD, constituting 6.7% (54/809) of those 
people with CD. And of those patients who had a positive EMA, 6.4% (48/745) had 
normal biopsies. These patients comprised 25.3% (48/190) of all those whose 
biopsies showed no evidence of disease. 
A third group on whom duodenal biopsies were performed were patients who 
had been identified as being low or deficient in IgA. Across the three regions for 
which biopsy data were available this amounted to approximately 300 people, of 
whom 90 had duodenal biopsies. Within this group, four patients had two biopsy 
procedures, and another person had five procedures. Among these IgA-deficient 
patients, 16 were found to have biopsy evidence of CD. One of these had a normal 
biopsy initially, and then a repeat biopsy two years later that was reported as being 
consistent with CD. This equated to a CD positivity rate of 17.8% in this group. 
The patient who had five endoscopies for biopsy was initially found to have 
villous atrophy and intraepithelial lymphocytosis attributed to CD. Subsequent 
biopsies were conducted with refractory CD being under consideration, 
presumably because the patient was not recovering as expected (this is inferred 
from the laboratory reports examined). This patient was, however, found to be HLA-
DQ2 and DQ8 negative, and was tested twice to confirm this. One of these tests was 
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undertaken at the National Tissue Typing Laboratory, regarded as the most reliable 
of HLA test providers in New Zealand. The patient’s most recent biopsy was 
reported as being consistent with autoimmune enteropathy, an alternative, but 
rare, differential diagnosis for CD. 
6.7.3 After positive biopsies 
Details about the management of the patients with biopsy-proven CD were not 
discernible from laboratory data, although it was possible to determine who among 
them had subsequent tTG testing. From the data available it was apparent that 438 
of the 897 patients (48.4%) with positive or inconclusive biopsies had had further 
tTG testing, and 411 (45.8%) had not. The remaining 48 patients included those 
whose biopsies were too recent for follow-up tests to be included in the dataset 
provided, and IgA-deficient patients for whom IgA-tTG testing is clearly not helpful. 
As already outlined earlier in this chapter, 87 patients (9.6%) also had repeat 
biopsies as part of their ongoing management, of which the majority showed an 
improvement from their initial investigation. 
6.8 Incidence of Coeliac Disease 
From the data available for Otago-Southland it was possible to calculate incidence 
rates for CD over the nine years between 2007 and 2015. This gives some indication 
of how readily the condition was being identified. Incidence rates were tabulated 
on the basis of positive biopsies alone, and in the year in which the biopsy was 
performed (as opposed to when serology was first positive). Total population, and 



















2007 45 287,824 15.6 8.5 22.5 
2008 70 289,424 24.2 14 34.0 
2009 76 291,024 26.1 16.8 35.1 
2010 75 292,624 25.8 13.2 37.6 
2011 90 294,224 30.6 23.6 37.4 
2012 96 295,824 32.5 18.6 45.8 
2013 72 297,423 24.2 14.4 33.6 
2014 98 299,023 32.8 17.1 47.8 
2015 93 300,623 30.9 15.0 46.3 
 
It is apparent from these data that the annual incidence of biopsy-proven CD in 
Otago-Southland almost doubled between 2007 and 2015, with a pronounced 
increase in diagnoses among women. 
Age-standardised incidence figures were also calculated. Census age-related 
data are presented in 5-year blocks, so these were combined into 15-year groupings 




Table 6.39: Incidence rates of biopsy-proven CD by age-band in Otago-Southland, 
2007 – 2015  
Year 













2007 14.9 22.6 16.9 13.7 14.1 0 
2008 35.2 22.6 22.2 27.2 19.0 5.2 
2009 33.3 25.8 29.3 27.0 21.0 5.1 
2010 35.1 27.4 34.9 18.4 15.2 10.1 
2011 35.1 46.7 38.8 18.2 19.7 5.0 
2012 27.6 54.7 39.2 27.9 16.7 4.9 
2013 36.8 25.7 16.2 21.2 30.1 4.8 
2014 31.2 43.3 31.0 35.5 24.7 9.6 
2015 36.6 56.1 27.7 22.4 17.5 4.7 
 
As displayed in this table, age-related diagnoses of CD have fluctuated over time, 
although the overall trend is that they have increased since 2007 across all ages (as 
grouped here). This is most noticeable in the 15- to 29-years old age-group. (The 
population has increased in each of these age-bands except for the 30- to 44-years 
old group, in which it fell by over 4000 between the 2006 and 2013 censuses.) 
The overall population incidence rates and gender-specific rates were 
calculated for Nelson-Marlborough and South Canterbury for the three years for 
which data were available. (Table 6.39) The 2013 rates may underestimate the true 
situation because there may have been biopsies conducted that year as a 
consequence of testing that had been done in 2012 at an alternative laboratory 
provider. These tests would not have appeared in the SCL data provided and 



















2013 24 136,995 17.5 15.0 19.9 
2014 21 137,985 15.2 17.9 12.7 
2015 32 138,975 23.0 11.8 33.6 
South Canterbury 
2013 7 55,626 12.6 3.7 21.2 
2014 8 55,876 14.3 21.9 7.0 
2015 6 56,126 10.7 18.2 3.5 
 
The three year period encompassed by these data is too short to determine any 
consistent trends in practice. It is evident that incidence rates have varied in both 
regions over that time, particularly with respect to gender. It is highly likely that the 
lower South Canterbury rates will also have been affected by that region’s lower 
biopsy rates of patients with positive IgA-tTG tests. 
6.9 Key findings of the study 
Enormous amounts of data were available for analysis for this component of the 
overall study. The important findings they revealed are summarised as follows. 
6.9.1 Rates of testing 
The numbers of tests performed and the number of people being tested for CD in 
Otago-Southland steadily increased over the period of time considered in this study: 
from 1.4% of the population in 2007 to 1.9% of the population in 2015, (p<0.0001). 
In Nelson-Marlborough rates also increased in the three years analysed, while they 
fell over that time-period in South Canterbury. By 2015, the proportions of the 
population tested in the year in all three regions were not significantly different. 
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6.9.2 Who was tested? 
Throughout the period analysed, in all regions from which data were available, 
women consistently outnumbered men with respect to testing for CD. Over time the 
differences in proportions of men and women having a first test for CD in Otago-
Southland narrowed slightly.  
Patients being tested were grouped as children or adults, with children being 
all those under the age of 17-years old. In Otago-Southland, the mean and median 
ages for children being tested were both between 8- and 9-years old, with both 
increasing slightly over time. The adult mean age ranged between 41 and 42 years, 
and the median between 40 and 42 years. When the populations being tested were 
grouped according to age, it was apparent the younger cohorts (up to 17-years, and 
17- to 26-years old) were tested more frequently. All cohorts showed an increase in 
testing over time. Mean and median ages for both children and adults were higher 
in Nelson-Marlborough and South Canterbury, and in Hawkes Bay and Taupo. 
In all regions by far and away the majority of people tested were of New 
Zealand European or Other European ethnicity. 
6.9.3 Who did the testing? 
Over the years analysed in Otago-Southland between 74.2% and 79.8% of test 
requests arose in general practice. In Nelson-Marlborough more than 80% of tests 
were GP-initiated, while in South Canterbury the figure was around 80%. 
Gastroenterologists and paediatricians were the two next most frequent test 
requesters. 
6.9.4 Which tests were done? 
The tests performed as part of coeliac antibody testing were largely determined by 
laboratory protocol. In the period under investigation this almost always included 
IgA-tTG antibody testing, and sometimes included testing for EMA. 
Testing for HLA-DQ2/DQ8 was done on the basis of practitioner requests. 
These showed a steady increase throughout the study period. In Otago-Southland 
and Nelson-Marlborough, a small number of practitioners accounted for the 
majority of test requests, while in South Canterbury they were more evenly spread 
across a number of providers. 
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6.9.5 What was found? 
The proportion of positive IgA-tTG antibody tests among patients being newly 
tested for CD in Otago-Southland peaked in 2008 at 4.01%, and fell steadily from 
then to 3.00% in 2015. Proportions of positive tests in Nelson-Marlborough and 
South Canterbury in 2015 were not significantly different from this. 
 Among men and women the rates of positive tests varied from year to year, but 
were not significantly different between the two groups in any year. With respect 
to age, children had higher rates of positive tests than adults, and this difference 
reached statistical significance in some years, and for the time-period overall. 
6.9.6 What happened next? 
In Otago-Southland between 2006 and 2015, more than 2000 people had more than 
one test for CD in any one year. This included several patients who had multiple 
tests. More than 7000 people had CD tests in more than one year, the vast majority 
of whom had negative tests. 
6.9.6.1 Duodenal biopsies 
Rates of patients going on from a positive IgA-tTG test to duodenal biopsy fluctuated 
from year to year, and depending on the IgA-tTG level. The lowest rates of biopsy 
were among those with test results in the low-high range (i.e. between 21 and 59 
units). Between 2007 and 2015 biopsy rates increased for all IgA-tTG result 
groupings. Biopsy rates in Nelson-Marlborough appeared to be comparable to those 
in Otago-Southland, but those in South Canterbury were lower than both the other 
regions. 
In Otago-Southland women had higher rates of biopsy overall, as opposed to 
the other two regions where men tended to have higher rates. The lower rates of 
biopsy among women in South Canterbury were statistically significantly different 
from rates in the other two regions. 
With respect to the outcomes of biopsies, 97.8% of patients who were biopsied 
with very high IgA-tTG antibody levels (i.e. ≥150 units) returned a positive result. 
This level of positivity among biopsies fell to 88.4% for IgA-tTGs in the 100 to 149 
unit range, 83.2% for those between 60 and 99 units, and 53.1% for results between 
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21 and 59 units. Among IgA-deficient patients who were biopsied, 17.8% were 
found to have biopsy evidence of CD. 
Following positive biopsies, 48.4% of patients had further IgA-tTG testing, and 
9.6% went on to have repeat biopsies. 
6.9.7 Incidence of CD  
The annual incidence of biopsy-proven CD in Otago-Southland increased from 15.9 
per 100,000 in 2007, to 30.9 per 100,000 in 2015. Among women the increase was 
from 22.5 to 46.3 per 100,000, while for men it was from 8.5 to 15.0 per 100,000. 
Incidence rates fluctuated within different age-groups, but over the same period of 
time all age-groups saw an overall increase in diagnoses. 
In Nelson-Marlborough the 2015 incidence was 23 per 100,000; 11.8 and 33.6 
per 100,000 for men and women respectively. In South Canterbury the 2015 picture 
was somewhat different, with an overall CD incidence of 10.7 per 100,000; 18.2 per 






As set out in Chapter One of this thesis, this project evolved out of a desire to 
determine what GPs in New Zealand know about CD. The central hypothesis was 
that GPs in this country have limited disease-specific knowledge about the 
condition, and that this might be apparent across the three domains of recognition, 
diagnosis, and management. The central investigation designed to test this 
hypothesis was the survey of GPs, the results of which were presented in Chapter 
Five. To offer some context in which to interpret the findings of the survey, New 
Zealand gastroenterologists were also surveyed, and an audit of laboratory data 
was conducted to provide some evidence with which GPs’ reported practices could 
be corroborated (or not).  
This chapter first considers the strengths and limitations of the project as a 
whole, and of its constituent studies, and then discusses the findings that emerged 
from each of them. It explores how these relate to the recent literature discussed in 
Chapter Two, and some of the implications that ensue with respect to each of the 
major facets of care relating to CD: recognition, diagnosis, and management.  
7.1.1 Overall strengths and limitations  
This is the first time that primary care practitioners anywhere have been 
investigated in this way with respect to CD. It is also the first time data from three 
separate sources such as those described have been brought together to enable 
such a thorough exploration of the topic. As such, this work has much to contribute 
to ongoing discussions about CD, and the overall project benefits from the fact that 
data were drawn from several sources, enabling the central questions to be 
examined from different perspectives. Evidence gathered from each investigation 
has been able to be used to inform the interpretation of data from the other 
investigations, permitting more robust conclusions to be drawn. The extensive 
literature relating to CD has also been thoroughly reviewed, providing a 
comprehensive context in which to situate this project.  
However, the scale of the work involved in managing three separate studies, 
and the vast body of background material, meant that the project as a whole has 
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been affected by the length of time it has taken to bring it to its conclusion. This is 
especially so with respect to the application of data gathered from the survey of 
gastroenterologists, which was conducted early on. It is reasonable to expect that 
some of the practices of gastroenterologists identified through this survey may have 
changed in the interim, particularly with the emergence of recent guidelines 
documents relating to CD. The breadth of territory covered in these studies has also 
meant that it has not been practical to thoroughly explore every interesting finding 
that emerged. That task will continue into the future. 
7.1.2 Strengths and limitations of the survey of gastroenterologists 
The strengths of the survey of gastroenterologists lie in the rigour of its 
development. Before implementation, the tool that was to be used was critically 
appraised and then reworked to address areas of ambiguity, and so that it more 
readily suited the New Zealand environment. It was pre-tested and pilot-tested, and 
amended following each of these events. In addition to this, exhaustive searches 
were undertaken to identify eligible participants, and multiple attempts were made 
to engage them, via a range of different approaches. These efforts generated a 
response rate of approximately 55%, which is a very reasonable representation of 
the New Zealand gastroenterologist population at the time.  
Beyond gender and region of work, it was not possible to determine how 
gastroenterologist non-respondents might have differed from those who 
participated, but it seems unlikely that they would have included many more people 
with a specific interest in CD, or who saw large numbers of patients with CD for 
long-term management. Respondents diverged in their views on a number of issues 
canvassed in the survey, and there is no reason to believe that non-respondents 
would have been any more or less likely to agree on these matters. Given that there 
were few response outcomes that differed significantly according to any of the 
demographic variables investigated, it seems unlikely that differences (or 
similarities) in demography would be a source of non-response bias. 
Surgeon endoscopists and gastroenterology trainees were also invited to take 
part in this survey, and their absence (in the case of the surgeons) or very low 
numbers (with respect to trainees, whose responses were subsequently excluded 
from analysis) means that results from this survey cannot be generalised to apply 
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to these groups, which is a limitation. While surgeons are unlikely to be involved in 
the management of CD, it is not inconceivable that they will occasionally make the 
diagnosis in patients referred to them for upper endoscopy. It is uncertain whether 
such patients would then be referred to a gastroenterologist or back to their GPs for 
follow-up. It is reasonable to conclude that, as with the gastroenterologists, there 
would be variations in practice within groups of surgeons and trainees. In all 
probability variations will also occur between the three groups of practitioners, 
adding to the mixed messages being communicated to patients and GPs, especially 
about how best to manage CD. 
A further strength of the survey was in the high levels of consistency in 
responses to questions that explored the same issue from slightly different 
perspectives (e.g. the place of rebiopsy in Lucy’s follow-up and in general, presented 
in Figure 4-5, Chapter Four). This suggests that the survey instrument was reliably 
measuring what it was intended to measure. 
Additional possible limitations of this study reside with the more general 
limitations of using surveys to measure practitioner behaviour. As has been pointed 
out in the literature,434,447,448 and discussed in Chapter Three, survey-based studies 
tend to lead to an over-estimation of participants’ practice. Every effort was made 
to mitigate this possibility by using vignettes to provide context,447 and by framing 
the closed-question scales in terms of how likely participants would be to undertake 
a particular action, rather than asking them to identify which actions they would 
take for any given scenario.  
7.1.3 Strengths and limitations of the survey of GPs 
As with the survey of gastroenterologists, the strengths of the survey of GPs also lie 
in the attention that was paid to its development, and to addressing each of the four 
potential sources of survey error identified by Dillman.435(p.17) This included using 
the most comprehensive database available from which to draw potential 
participants; adopting a stratified sampling technique to ensure equal 
representation across DHBs, rural and urban areas, and by gender; using an 
incentive and several other design techniques to encourage recipients of the survey 
to complete it; and pre-testing and pilot-testing both the content and format of the 
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hardcopy version to minimise the risk of participants misunderstanding questions 
and therefore giving inaccurate responses. 
Another strength was in the response options for the Likert-type scales for 
several questions that separated out the “almost never” option into three variants. 
This allowed for a more nuanced interpretation of these responses, particularly 
with respect to participant knowledge, the key area of interest for the survey. 
Utilising both online and hardcopy formats emerged as a strength, by providing 
different access points for participants. This enabled a broader range of people to 
be invited to participate and gave people the option of completing the survey in 
their preferred mode of response. The increasing appeal of completing surveys 
online was evidenced by early responses to the initial invitation to participate that 
also included a link to the survey itself, and by the fact that more than half of 
completed responses were online. Having an online option also reduced the costs 
of sending out hard copies, as people who had already responded online were able 
to be removed from the mailing list. It also meant that the timing of when the 
request to participate was received could be managed. Thus the online survey was 
sent at lunchtime on a Thursday: not on a Friday, when GPs are often busy in the 
lead-up to the weekend, but close enough to the weekend that potential participants 
might remember that it was awaiting their attention; and not at the end of the day 
when people are often trying to get their day’s work finished so that they can head 
home. 
The principal disadvantage of having two versions of the survey was that it led 
to differences in what participants were completing. While one of these differences 
(namely the inclusion of altered liver function tests as an indication for testing for 
CD in the paper-based version but not in the online format) arose due to human 
error, and therefore could have been prevented, others arose because of inherent 
limitations in how questions could be formatted online. This was particularly the 
case when the Likert-scale options invited comment within them. (See, for example, 
Appendix F, Part A, question 16.) This could easily be accommodated in the 
hardcopy version, but necessitated the use of separate questions online. When it 
came to merging survey responses from the two formats, special care had to be 
taken to ensure that this was done accurately for these questions. 
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There were advantages and disadvantages with both formats. Paper-based 
versions allowed participants to annotate their answers with comments, many of 
which gave additional insight into responses. However, it also enabled respondents 
to skip questions, and/or to select more than the requested number of responses to 
individual questions. This made coding completed surveys challenging, and 
necessitated making judgement calls about what could and could not be included. 
In one case several questions were not answered and it appeared that the 
explanation for this was that the respondent had inadvertently turned over two 
pages together, completely overlooking that part of the survey.  
On the other hand, the online version was configured such that respondents 
had to answer each question before moving to the next, and could only give one 
answer per question. This had both positive and negative consequences. It meant 
that those who completed the survey answered all questions, and that coding their 
responses was straightforward. But it also led to some people not finishing the 
survey – evidently giving up part way through. While it is not possible to know why 
those people did not finish, it is conceivable that this was in part due to not being 
able to leave out questions they did not feel able to answer, or where they would 
have liked to give a more nuanced response than was possible (e.g. by selecting two 
answers, and/or annotating their response). 
A problem specific to this survey that emerged as it was underway was the lack 
of a “don’t know” option for several of the questions. As noted in Chapter Five, at 
least one person indicated that he would not participate because of this, and he is 
unlikely to have been the only person who felt this way. This absence was not 
identified as an issue in pilot-testing of the survey. On reflection it seems likely that 
this was because the group of people who participated in the pilot had a greater 
than average knowledge about CD (having heard several presentations about it at a 
range of local continuing medical education events) and could therefore complete 
the survey without having to resort to a “don’t know” response. This was completely 
unforeseen at the time pilot-testing was being undertaken. 
7.1.3.1 Generalisability of results and non-response bias 
The interpretation of results from the survey of GPs is limited by the response rate 
of 35.5%. While this level of response is better than other recent surveys of 
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GPs,452,453 and the large study sample group means that a substantial number 
(n=692) of completed surveys were available for analysis, it nonetheless raises 
issues about the generalisability of results.  
There are multiple reasons why intended recipients in a study may not 
complete a survey, some of which may lead to bias, and some of which are less likely 
to do so. These include survey fatigue, being too busy, and not being interested in 
the topic.  
A variable that is unlikely to contribute to bias is having a blanket policy not to 
complete surveys. Such a position may be held by practices, such that staff opening 
mail for intended recipients do not pass on any surveys received, or by individual 
practitioners. The respondent who wrote about surveys being used to “pillory GPs” 
quoted in Chapter Five exemplifies this, although this view is perhaps somewhat 
more negative than others. A Canadian study published in 2012 found that more 
than a third of physicians to whom they sent a survey had an office policy not to 
participate.458 That figure is not known for New Zealand. 
More likely to lead to bias in survey results are those people who choose not to 
participate in surveys on a case-by-case basis. This decision may simply be a 
reflection of how busy the potential participant is at the time, but may also arise 
because he or she does not feel they have enough knowledge to take part. In a 
survey such as the present one, in which knowledge was being assessed, such 
decisions will have influenced the overall outcomes. Another reason for not 
participating may be perceived relevance of the study to the practitioner. The 
person who wrote saying that he had “not seen one patient with this condition” in 
50 years of practice perhaps falls into this category. This is a somewhat surprising 
assertion and could indicate a failure to recognise CD in his patients. It seems 
plausible to conclude that his knowledge about CD was limited (corroborated by his 
comment that his patients with DH all “had gluten allergy”) but, because he chose 
not to participate, this was not captured by the study. 
With respect to the generalisability of data gathered in the survey of GPs, one 
other fact warrants consideration. In this survey, women outnumbered men, both 
in terms of the overall proportion of participants (60.7% female and 38.9% male), 
and in terms of proportions of intended recipients who completed the survey 
(44.6% female and 26.9% male). On analysis of survey data it became apparent that 
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gender did have a statistically significant impact on several responses, which fact 
must be borne in mind when drawing conclusions about the outcomes that 
emerged. 
7.1.4 Strengths and limitations of the laboratory data study 
The great strength of the laboratory study was that an extensive set of “real world” 
data was available for investigation, as opposed to data that had been generated 
specifically for the purposes of research. For Otago-Southland, blood testing data 
were complete for a substantial period of time enabling an accurate picture to be 
drawn about the investigation of CD in that region. The availability of data from 
other regions, though limited, enabled cautious comparisons to be drawn. 
For the purposes of this study as it was initially conceived, it was a limitation 
that data on testing for CD are not collected and collated at a national level. However 
had such a dataset existed it may well have been unmanageable in size. And while 
perhaps not a limitation, it was certainly a challenge to have to individually search 
for duodenal biopsy results. In addition to this, the lack of a central repository of 
information about patients who had undergone duodenal biopsy did mean that 
those with normal blood tests but positive histology have not been identified. A 
further limitation was lack of access to information from the alternative laboratory 
providers in Hawkes Bay and Taupo, meaning that data from those regions were 
incomplete thus limiting the conclusions that can be drawn from them. 
7.2 Recognising Coeliac Disease in New Zealand 
The principal vehicle for investigating the recognition of CD in New Zealand in this 
study was the survey of GPs. Specifically, the first series of questions asked 
respondents to indicate how likely they would be to test for CD given certain clinical 
situations. Evidence of testing rates from 2007 to 2015 that emerged from the 
laboratory study are also of relevance when considering whether or not recognition 
may have improved over time. 
7.2.1 GP survey data 
Results from questions One and Two in the GP survey paint a mixed picture. It is 
clear from the data they generated that there are some presentations that are well 
recognised as being indicators of potential CD. These include patients presenting 
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with chronic diarrhoea, or iron deficiency anaemia, or having IBS or a first-degree 
relative with CD. In each of these circumstances, and in the situation of a patient 
presenting with two or more of the symptoms that were cited in the question, a very 
clear majority of respondents indicated they would be likely or highly likely to test 
for CD. A clear, but slightly smaller majority were also likely or highly likely to test 
patients with persistent fatigue or unexplained folate deficiency. 
Chronic diarrhoea has long been associated with CD and, as a signifier of 
malabsorption, comes within the Oslo definition of classical coeliac disease.22 It is 
not surprising therefore that it is a presentation that is highly likely to trigger GPs 
to test for CD. It is also not unreasonable to expect that non-respondents to the 
survey would be similarly likely to test affected patients.  
The other symptoms or conditions that were most likely to lead to testing could 
be regarded as representing a broader understanding of the manifestations of CD. 
It is therefore encouraging to see such high numbers of respondents indicating a 
high likelihood of testing under these circumstances. This might suggest that 
knowledge of CD has expanded to encompass non-classical and potentially 
asymptomatic variants of the condition. However, it cannot be expected that non-
responders to the survey would be as likely to test in these situations, if one of the 
principal reasons for non-participation could have been lack of knowledge about 
CD. 
It is less encouraging that far fewer respondents indicated they would be likely 
to test in the presence of other symptoms and conditions also known to be 
associated with CD, and that for some of these, the majority indicated they would 
be unlikely to do so. These include abnormal liver function tests, unexplained 
neurological symptoms, T1DM, autoimmune thyroid disease, Down Syndrome, and 
Turner Syndrome. Some of these conditions also drew higher numbers of neutral 
responses, one interpretation of which is that participants were unsure of their 
relevance to CD. Vavricka et al.279 found that the delay to diagnosis that many 
patients with CD experience is largely attributable to their doctors failing to 
consider it as a possibility. These findings suggest that for patients with less clear-
cut presentations this may well remain the case in New Zealand. 
As discussed in Chapter Two, the NICE Guidelines (and others) relating to 
testing for CD make clear recommendations that testing should either be offered, or 
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at least considered, in any of the situations cited in the preceding paragraph. At the 
time the survey was conducted the 2015 NICE guidelines had yet to be released. The 
questionnaire itself was based on the 2009 version.280 On comparing these directly 
with participant responses, it is reassuring to see that the majority of “should do 
testing” scenarios that had been included in the first two questions of the survey did 
in fact elicit high levels of likely or highly likely to test responses. This was especially 
the case for symptoms and signs (Question One), but much less so for associated 
conditions (Question Two). And although this study is not directly comparable with 
that of Spencer et al.43 referred to in Chapter One, these data suggest that New 
Zealand GPs are more likely to test for CD in patients with iron-deficiency anaemia 
than their North American counterparts. 
As discussed in Chapter Five, in an effort to gain a more global impression of 
likely testing patterns, participants’ responses for each row of the question matrices 
were collated, and their cumulative scores tabulated and grouped. (Figures 5-9 and 
5-10) Appropriate score ranges for both questions were defined, and participants’ 
cumulative scores analysed to determine whether they sat above, below or within 
these ranges. This process necessarily involved making somewhat arbitrary 
decisions about values to assign to each symptom, sign, or condition, thus results 
should be interpreted with caution. Nonetheless, the impression these scores give 
is that despite there being some presentations that are highly likely to trigger 
testing, in general respondents to the survey were likely to be under-testing for CD. 
As reported in Chapter Five, the mean cumulative scores for each question were 
both within the “possibly under-testing” range. With respect to presenting 
symptoms, just under 34% of participants were in the “likely to be appropriately 
testing” range, while only 26% scored similarly with respect to associated 
conditions.  
The gender of participants was significantly associated with overall testing 
patterns, but rurality, and whether or not they had patients with CD was not. On the 
whole, female participants were more likely to test for CD in a wider range of 
settings than their male counterparts, and their mean cumulative scores for both 
symptoms and conditions were significantly higher. Perhaps not surprisingly, 
already having patients with CD also appeared to influence likelihood of testing, 
although this was also found to be impacted upon by gender. Given that women 
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were over-represented in this survey, it is likely that the results may somewhat 
overstate the level of recognition of possible CD in the wider GP community. 
7.2.2 Laboratory data 
Data on rates of testing derived from the laboratory results reported in Chapter Six 
would tend to support the suggestion that the recognition of CD is indeed 
expanding, at least in some regions. Rates of new-patient testing for CD steadily 
(and significantly) increased in Otago-Southland between 2007 and 2015, and over 
the same period overall rates of testing at the SCL community laboratory also 
increased in the Hawkes Bay. Between 2013 and 2015 testing rates in Nelson-
Marlborough also increased, although this time period is too short to enable any 
firm conclusions to be drawn about trends. 
The Otago-Southland data are complete for the region for the period 2007 to 
2015. The majority of requests originated in general practice, and there was an 
overall increase in this proportion over time, suggesting an increased awareness of 
the condition among GPs. However, additional factors may also have contributed. 
Firstly, there may have been an increase in CD prevalence in the region, leading to 
more patients presenting with symptoms suggestive of the condition triggering a 
test request (although this too requires the person requesting the test to have 
recognised such symptoms). An increase in prevalence would be consistent with 
studies from elsewhere in the world that have identified this.210,211,213 It is also likely 
that some of the increase in testing will have arisen due to patient request, as CNZ 
have worked to raise the profile of CD in the general population. In the survey of 
GPs, 8.8% of respondents cited “patient request” as a reason for testing for CD. 
In contrast, rates of testing fell in Taupo between 2008 and 2015 (although 
these data were incomplete), and in South Canterbury between 2013 and 2015. It 
is not clear why this might be. In Taupo it is conceivable that a proportion of the fall 
is accounted for by increasing numbers of patients being tested in laboratories 
other than SCL, and it is not possible to know how many people this might have 
involved. In South Canterbury, as for Nelson-Marlborough, the time period under 
consideration was too short to draw any meaningful conclusions on this issue. One 
possible explanation is that more people had been tested in the period leading up 
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to 2013, meaning the pool of untested patients in the study period was smaller, and 
therefore fewer people required testing. 
Of note, the data from all the regions included in the dataset provided by SCL 
clearly show that practitioners in this country are almost exclusively testing New 
Zealand (and other) European people for CD. The survey of GPs did not explore this 
issue, but these data suggest that looking for CD in people from other ethnic 
groupings is not something that GPs do often. This is despite the fact that it is now 
well recognised that CD affects people from a range of countries beyond those in the 
UK, Europe and Scandinavia.  
Consistent with earlier research by Evans et al.,37 the laboratory data also show 
that women were tested at twice the rate of men across all but one of the regions 
investigated. (In South Canterbury the ratio of testing was somewhat lower, but 
women still clearly outnumbered men among those being tested.) Evans et al.37 
offered some thoughts about why this might be the case in their study, taking the 
position that CD “is equally prevalent in men and women” as their starting 
point.(p.1140) Their reasoning included that women are more likely than men to 
seek medical advice for gastrointestinal symptoms, and that pre-menopausal 
women have a higher incidence of iron deficiency and testing for CD may form part 
of the assessment of that. As discussed in Chapter Two, it is now more widely 
accepted that CD probably occurs more frequently in women, which, along with the 
reasons suggested by Evans et al., might explain their more frequent testing in this 
study. It may also be that GPs are less likely to associate CD with their male patients 
so are less likely to test them for it. However, if the testing of men is only done at a 
higher symptom threshold (that is, when CD is symptomatically more likely) than 
for women, one might have expected the proportion of positive tests for men to be 
higher than those for women. The data available in this study do not support that 
hypothesis. 
The Evans study also noted that over the decade of their investigation the 
proportion of positive coeliac serology tests fell from 5.7% to 2.6%.37 They 
postulated that, coupled with their finding of increased rates of testing, this was 
likely to be due to testing being requested “at a lower symptom threshold”.(p.1140) 
Similarly in their study in Wales, Hurley et al.45 noted a fall in the rate of positive 
tests from 5.8% in 1996 to 1.1% in 2005, again in the context of a substantial 
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increase in the overall numbers of tests being requested. In the present study the 
proportion of positive tests also fell, but not to a significant extent. In the later years 
for which data were available, the proportion of positive new tests in Otago-
Southland was stable at around 3.0%, while the number of tests requested in each 
year continued to increase. This might suggest that practitioners requesting tests in 
this region have a slightly higher symptom threshold for testing than their UK 
counterparts had, or perhaps that they are getting gradually more accurate in 
identifying possible CD. 
7.3 Diagnosing Coeliac Disease in New Zealand 
Having recognised that CD may be a possibility for a patient, the next step on the 
path to making the diagnosis is to appropriately test for it, and correctly interpret 
the results of tests undertaken. The survey of GPs explored both these issues, and 
the laboratory data provide some supporting evidence about the actual practice of 
clinicians in some regions in New Zealand. The survey of gastroenterologists also 
investigated the actions that practitioners would be likely to take, and the advice 
they would be likely to give to a GP when the diagnosis was uncertain. 
7.3.1 Testing for CD: Survey data 
As presented in Chapter Five, there is little uncertainty among GPs about how to 
test for CD, with the majority of respondents to the GP survey indicating they would 
request “coeliac antibodies” from their laboratory provider, or would specify that 
they wanted to test tTG and/or EMA antibodies. Few would request DGP antibodies, 
suggesting that this is a test that most are not yet familiar with, while reassuringly 
only three people indicated they would request the now obsolete gliadin antibodies. 
It is probable that non-respondents to the survey would be similarly familiar with 
the tests to request for CD, although the number who might still want to do gliadin 
antibody testing may be higher. Laboratory protocols are now such that this test is 
no longer available, and patients will generally be tested for CD with a pre-
determined panel of investigations. 
Participants’ understanding of the role of HLA-DQ2/DQ8 testing in the 
diagnostic process is perhaps less clear, with a small number of respondents 
indicating they would include this in their initial work-up. As discussed in Chapter 
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Two, this approach has been suggested by some,18 and can be useful in certain 
settings when excluding CD would be helpful, but is not recommended in any of the 
current guidelines pertaining to adults. A small number of participants commented 
that they would request an HLA test as a follow-up test for clarification, but from 
the data available it is not possible to determine why those who indicated they 
would request an HLA test as part of their initial testing would do so. 
Of more concern with respect to testing for CD was the finding that almost half 
of all respondents would test someone who was already on a GFD. The majority of 
these respondents indicated they would recommend that the person re-introduce 
gluten into their diet, but would test anyway even if the patient refused to do so. 
This implies a lack of clarity of thinking around the necessity of a person consuming 
an adequate amount of gluten for CD testing to be reliable. (Laboratory evidence 
that small numbers of children who would not yet be old enough to be consuming 
gluten had been tested for CD supports this suggestion). The survey did not explore 
the issue further by asking what value participants saw in testing patients who were 
not consuming gluten, and nor did it explore how participants would interpret test 
results in this setting. 
Perhaps not surprisingly, the small number of respondents who would simply 
test without making any recommendation about restarting gluten were statistically 
more likely to have no coeliac patients under their care. Whether or not this is 
clinically significant is arguable. It is reasonable to assume that doctors with 
patients with a particular condition are likely to have increased knowledge about 
that condition, but which is cause and which is consequence is difficult to determine. 
However, it is at least conceivable that it is lack of knowledge (as evidenced in this 
instance by apparently not being aware that a patient should be consuming gluten 
for CD testing to be reliable) that has led to some of these respondents not having 
any patients with diagnosed CD. Assuming that this survey somewhat overestimates 
practices with respect to CD (as discussed earlier), this would at least make this a 
potentially clinically significant finding. 
7.3.1.1 The gluten challenge 
An issue related to testing patients who have already excluded gluten from their 
diets is that of what constitutes an adequate gluten challenge. This was canvassed 
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in both the GP and gastroenterologist surveys and drew a range of responses from 
both groups. The majority of gastroenterologist respondents would recommend 
that adults consume somewhere between two and four slices of wheat-bread daily 
for at least four weeks, while GP respondents were divided between those who did 
not know, and those who thought similarly to the gastroenterologists.  
As discussed in Chapter Two, until relatively recently the suggested gluten 
challenge was four slices of bread daily for six weeks. In recent years this 
recommendation has been modified such that, with the exception of the 2015 NICE 
Guidelines,71 guidelines now advocate a less onerous regime of 1.5 slices of bread 
daily for at least two weeks, longer if the patient can tolerate it.69,70,72 Among the 
options suggested by the gastroenterologists and those GPs who were prepared to 
commit themselves to an answer on this, the vast majority fell within parameters 
that would be likely to enable CD to be detected (if the patient were able to complete 
the recommended challenge). The fact that there are variations in practice is 
therefore likely to be of little clinical significance. This is apart from the possibility 
that such apparent inconsistencies between practitioners may lead to patients’ loss 
of confidence in their doctors, when they talk among themselves and learn that their 
treatment was different from each other’s.   
For those GPs who indicated that they did not know what constituted an 
adequate gluten challenge there are a range of resources available for them to 
consult, although it may take some searching to find them. In New Zealand, DHBs 
are increasingly moving to utilising HealthPathways,l an online tool for guiding 
clinical practice and, in particular, referrals into the secondary care setting. Many 
now have a pathway for CD, and these include information about the gluten 
challenge, however these vary between regions. When accessed in late 2017, two 
DHBs advised two slices of bread daily, while the remainder advised four (either 
precisely or “about”), while the recommended duration ranged between four and 
six weeks.  
                                                        
 




7.3.2 Testing for CD: Laboratory data 
Given that laboratory protocols determine which of the coeliac antibody tests will 
be performed in the investigation of CD, the most interesting data with respect to 
testing to emerge from the laboratory study pertains to testing for HLA-DQ2/DQ8. 
This is a test that is conducted on request, thus giving potential insight into 
practitioner knowledge.  
From the Otago-Southland data it would seem that awareness about HLA 
testing is increasing. This is evidenced by the fact that early in the study period 
approximately half of all HLA tests were done following a laboratory 
recommendation to do so, but by the final year of the study this figure had fallen to 
less than one-third. But the data also show that throughout the study period only a 
relatively small proportion of the practitioners who tested for CD ever requested 
HLA testing, and that a very small number of individuals accounted for the majority 
of these test requests.  
Collectively these data, along with data from Nelson-Marlborough and South 
Canterbury, suggest that knowledge about the place of HLA-DQ2/DQ8 in the wider 
context of testing for CD remains patchy. It is apparent that there are a small 
number of practitioners in each region (of whom not all are GPs, and none are 
gastroenterologists) who are requesting it more frequently than the guidelines 
indicate is appropriate. But it is not unreasonable to assume that at least some 
practitioners now recognise that it does have its place, for example when being able 
to exclude CD is important. The fact that the majority of people who have tested for 
CD have never requested an HLA-DQ2/DQ8 test may well reflect the fact that they 
are aware that its role is limited, but it may also be that some of them do not know 
that the test exists, or that as GPs they are allowed to request it. 
One other finding of note that arose from these data is the thousands of people 
with negative IgA-tTG antibody tests who had multiple tests over the years. While 
HLA testing could have a role in limiting the number of patients having such repeat 
testing, these data suggest that there is a need for clearer recommendations to guide 
the practice of clinicians with patients experiencing persistent symptoms possibly 
attributable to CD, who repeatedly have negative serology tests. Given that the 
survey of GPs elicited that many respondents would test for CD in patients already 
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on a GFD, such recommendations should include a reminder that consuming 
adequate amounts of gluten is a pre-requisite for an accurate test. 
7.3.3 Diagnosing CD: Survey data 
Perhaps the most crucial step in correctly diagnosing CD lies in the interpretation 
of CD test results, and the actions that follow that. In the survey of GPs this was 
investigated from two angles: the frequency with which respondents referred 
people with positive serology for upper endoscopy, and the combinations of results 
they would be likely to accept as confirming that a patient does indeed have CD.  
In line with current and previous guidelines, a clear majority of respondents 
indicated that when a patient returned a positive serology test they referred for 
gastroscopy almost always or most of the time. A clear majority of respondents also 
indicated they advised patients to continue to eat gluten until after they had had 
their gastroscopy. This stands in contrast to the findings of Spencer et al.,43 who 
found that 80% of family medicine doctors in North America were likely to 
implement a GFD prior to patients with positive serology undergoing endoscopy. 
Given that these are longstanding expectations relating to the diagnosis of CD, it is 
to be hoped that in New Zealand people who did not participate in the survey 
behave similarly to those who did take part, although there is no certainty that this 
will be the case.  
These issues also drew a large number of comments, many of which made it 
clear that access to timely endoscopy is often problematic, and that this had an 
impact on participants’ advice about continuing to eat gluten. Patient reluctance to 
undergo endoscopy also influenced referral practices. There was clearly also a 
degree of misapprehension about the correlation between symptoms and 
pathology, with a small group of participants noting that whether or not they 
referred for endoscopy would depend on the presence and/or severity of 
symptoms. Comments also illustrated some confusion among respondents 
regarding the reason for arranging duodenal biopsy. Two people indicated that the 
reason for confirming the diagnosis with a biopsy was in order for patients to be 
able to access subsidised gluten-free foods, and that now that these were much 
more readily available in supermarkets, there was no longer any need to do so. 
Although these last two factors appeared to influence the referral decisions of 
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relatively small numbers of participants, it is very likely that there will be others 
among those who did not complete the survey who think similarly. 
In a related question, participants were asked to rate how likely they would be 
to accept a range of combinations of results as confirming the diagnosis of CD. This 
question is perhaps the best indicator of patchy knowledge about the condition. 
Thus, while almost all respondents would accept positive serology followed by 
positive duodenal biopsy as confirming the presence of CD (and those who did not 
had very likely reversed the polarity of question’s measurement scale), almost 
three-quarters would also be likely (or highly likely) to accept positive serology 
followed by an improvement in symptoms on a GFD as being sufficient to confirm 
the diagnosis. As presented in Table 5.11 and Figure 5-18 in Chapter Five, almost 
two-thirds were likely or highly likely to accept positive serology along with 
positive HLA-DQ2/DQ8, and a clear majority responded similarly with respect to 
positive serology that returned to normal on commencing a GFD. A majority 
indicated that they would be likely or highly likely to accept positive serology alone 
as confirmation that a patient had CD.  
The question did not tease out these issues more carefully by, for example, 
putting numerical values on the positive serology. To do so would have rendered it 
unwieldly. It is entirely possible that the degree of positivity of serology does 
influence participants’ behaviour such that they might be more likely to rely on 
serology alone if it were very high. The laboratory data, which will be discussed in 
the next section, suggests that this may be a reasonable approach to take, but it also 
indicates that this is not in fact how many GPs appear to behave. Nor did this 
particular question allow scope to include patient preference, so it is also 
reasonable to accept that actual practice is more nuanced than implied by these 
results, and would depend on variables other than the options given. Nonetheless it 
is also not unreasonable to conclude that many respondents were unclear about the 
reliability of serology, symptoms, and response to a GFD as being indicative of the 
presence of CD, and that this uncertainty is likely to be more prevalent among those 
who chose not to participate in the study. The risk is that, along with there being 
many people in whom the diagnosis of CD has been overlooked, there are also likely 
to be people in our communities who have been wrongly diagnosed with CD, based 
on incomplete information. 
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Of some concern with respect to overall knowledge about CD was the finding 
that just over 20% of respondents would accept positive HLA-DQ2/DQ8 alone in 
making the diagnosis of CD. Although four of these responses were probably due to 
participants reversing the polarity of the measurement scale, this still leaves 20% 
who apparently believe that this is reasonable. There were also high numbers of 
neutral responses to this option. Taken together these findings would tend to 
support the premise discussed earlier in this chapter that GPs are uncertain (and in 
some cases misinformed) about the role of HLA testing and CD. This adds weight to 
the need for caution if HLA testing were to be incorporated into testing guidelines, 
as suggested by Anderson et al.18 
As with the recognition of CD, gender and whether or not participants had 
patients with CD influenced some of their likely behaviours with respect to 
diagnosing the condition. Thus the women who took part were more likely to refer 
people with positive CD serology for endoscopy, while the men were more likely 
only to refer some of the time or almost never. Given that women are over-
represented in this study, it is reasonable to infer from these analyses that overall 
rates of referral for endoscopy are likely to be lower in the real world than among 
this study population. This would seem to have been borne out in the laboratory 
data, as will be discussed on the following page.  
There was no evidence that either rurality, or the predominant SES of practice 
populations, influenced responses relating to referrals for endoscopy, although 
more detailed analysis of the second may paint a more nuanced picture of this issue. 
 With respect to results that would lead to respondents confirming a patient 
had CD, it was curious to find that those participants who indicated that they did 
have patients with CD under their care were significantly more likely to accept 
positive serology alone as confirmation of the diagnosis. This begs the question 
about how their coeliac patients had been diagnosed, a factor that was not explored 
in this survey. This group of respondents were also more likely to almost always 
refer for endoscopy, which seems a contradiction. However, referring for 
endoscopy is not the same as patients actually undergoing the procedure. A range 
of variables may disrupt this process, and the apparent discrepancy between these 
two questions may simply be a reflection of this. 
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The survey of gastroenterologists also explored the issue of diagnosis, within 
the context of a GP seeking advice about a patient with moderately raised IgA-tTG 
antibodies refusing endoscopy. As presented in Chapter Four, participants varied in 
their responses to this question. A clear majority were likely or highly likely to 
advise that a diagnosis of CD was unreliable without a biopsy, and a similar majority 
were also likely or highly likely to recommend HLA testing. But there were also 
those who would advise that the diagnosis of CD could be assumed to be correct, 
either on the basis of the serology testing alone, or if antibodies fell on the GFD. With 
this range of views being expressed by gastroenterologists advising GPs, it is not 
surprising that GPs hold a range of positions on how to appropriately reach a 
diagnosis of CD. 
7.3.4 Diagnosing CD: Laboratory data 
The SCL data presented in Chapter Six provide an insight into aspects of real world 
diagnosis of CD, augmenting the data gathered in the survey of GPs. What they 
confirm is that not all patients who return a positive IgA-tTG test go on to have a 
duodenal biopsy. They also seem to support the concern expressed by many survey 
participants about the challenges in accessing timely endoscopy for their patients, 
with the mean time between first blood test and biopsy being as high as 17 (±13) 
weeks in Otago-Southland in 2010, and 19 (±13) weeks in South Canterbury in 
2015. But perhaps most importantly of all, these data have enabled correlations to 
be drawn between positive IgA-tTG antibody levels (tested with Quantalite kits) 
and biopsy results. In the current environment, in which the place of biopsy in 
confirming a CD diagnosis is hotly debated, these correlations may prove invaluable 
in formulating future recommendations to guide referral practices. 
7.3.4.1 Biopsy rates following positive serology 
In the regions for which data were available from SCL, overall rates of patients 
undergoing duodenal biopsy varied over time. In Otago-Southland rates in the early 
years of the study period were low (48.4% in 2007), especially when compared with 
similar studies from overseas.37,459 By 2015 Otago-Southland rates had increased to 
60%, but in contrast South Canterbury levels were low at 38.5%. 
Rates of biopsy fluctuated among patients with higher IgA-tTG levels, but were 
clearly lower among those with results in the low-high range. While proportions 
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were reasonably comparable in Otago-Southland and Nelson-Marlborough, they 
fluctuated more widely in South Canterbury. Notably, women in South Canterbury 
had significantly lower overall rates of biopsy than in the other two regions, as did 
people in the 17- to 36-years old age-groups. It is not possible to determine why 
this might be, although it is likely that there will have been a combination of factors 
at play. South Canterbury is a smaller and somewhat more rural region than the 
other two areas included in this part of the study, both of which are likely to 
influence health-related behaviours of patients. For example, it may be that people 
elected to go outside the region (to a larger centre such as Christchurch) to undergo 
endoscopy. 
There are of course many reasons why duodenal biopsy may not follow a 
positive blood test. Chief among these is patient choice. This in turn may be 
influenced by a range of variables, among them: time to biopsy and not wanting to 
continue eating gluten in the interim; ready availability of gluten-free food options 
(so not feeling the need to have biopsy confirmation to gain access to a Special 
Authority number for subsidised foods); an aversion to the procedure itself; or an 
assumption that the blood test result is enough evidence of the presence of CD to 
accept that as the explanation for symptoms. This last attitude is the one most likely 
to be influenced by patients’ doctors and, as already discussed, is a view that the 
data from the GP survey suggest is held by many GPs. 
The waters around the issue of the need for biopsy to confirm the diagnosis of 
CD have been somewhat muddied by the promulgation of the 2012 ESPGHAN 
Guidelines for diagnosis in children.12 As discussed extensively in Chapter Two, 
these recommendations continue to be debated, and their application to adults is 
contested. And though these debates have for the most part been conducted within 
the academic literature, and in particular in journals aimed at gastroenterologists, 
clearly the uncertainty about the need for histological confirmation of the diagnosis 
is influencing GP practice. 
7.3.4.2 Correlations between serology and histology 
One of the most important findings to emerge from the laboratory data presented 
in Chapter Six was the 97.8% correlation between very high (≥150 units) IgA-tTG 
antibody levels and positive histology. This is similar to the findings of Zanini et 
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al.,160 and Wakim-Fleming et al.,162 and would tend to contradict the view expressed 
by Kurien et al.153 that the PPV of serology testing in “unenriched” populations is 
not high enough to confidently diagnose CD. That the correlation was not closer to 
100% may be accounted for by the possibility that at least some among the 11 
patients with very high antibody results and apparently normal (or inconclusive) 
biopsies had already commenced a GFD prior to their endoscopy. For some of these 
people a biopsy was not performed until several months after the positive blood 
test making this a very likely scenario. Correlations reached almost 90% for 
antibody levels in the 100 to 149 range also.  
These correlations are encouraging to find in an era in which the need for 
biopsy confirmation of CD is being debated, although a caveat applies. These data 
relate only to Quantalite IgA-tTG kits, as used by SCL during the period under 
investigation. If other laboratories use the same kits then it is highly likely that a 
similar study would reveal similar results, but comparable performance from other 
kits used in New Zealand cannot be assumed. It should also be noted that, as 
presented in Chapter Six, almost none of the pathology reports examined for this 
study explicitly referred to the Modified Marsh criteria (or any other recognised 
classification) when reaching the diagnosis of CD. All reports did include a comment 
on villous architecture and IELs, but at the mild end of the spectrum of histological 
changes there was some evidence of variability between pathologists on whether 
or not they would conclude that the changes were consistent with CD. In the 
absence of comments about crypt hyperplasia, patients with reportedly normal 
villous architecture and increased IELs would seem to have Type 1 Marsh-
Oberhuber changes. Debate continues about whether this should be classified as 
CD.110 In the very high IgA-tTG group this amounted to 4.9% of positive biopsy 
results, although the presence of these very high antibody levels, particularly when 
they occurred in conjunction with a positive EMA, should be sufficient 
corroborating evidence to support the diagnosis.65 
The data that emerged with respect to the likelihood of having a positive biopsy 
in the presence of IgA-tTG levels in the low-high range are also important when 
considered alongside the rates of endoscopy among these patients. When compared 
with those who had higher antibody levels, their rates of endoscopy were 
considerably lower. From the data available it was not possible to determine what 
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happened to these people. Some may have been told they had CD and commenced 
on a GFD, while others may have been told the opposite. In either case there is a risk 
that that advice was incorrect with the associated negative impact on patient 
wellbeing. 
Because there were no data available in this study from patients with negative 
serology who underwent duodenal biopsy, it is not possible to formally calculate 
PPVs at the differing IgA-tTG levels. However, from the data that were available, for 
a patient with an IgA-tTG of 29 units (Quantalite kit) told to commence a GFD there 
was an approximately 60% chance that this was unnecessary, while there was also 
an almost-40% chance that telling such a patient that CD was unlikely would result 
in a missed diagnosis. For tTG levels between 30 and 39 units these chances were 
fairly evenly split. In the light of these findings, especially in the context of scarce 
endoscopy resources, it would seem reasonable to recommend that GPs focus their 
energies with regards to referring patients for endoscopy on those patients with 
lower levels of IgA-tTG antibodies, for whom the diagnosis of CD is less certain. 
7.3.5 The incidence of CD in three regions of New Zealand 
As discussed in the early parts of this thesis, one of the initial intentions of this 
project was to try to ascertain the prevalence of CD across New Zealand. For reasons 
already outlined, this proved not to be possible. What was possible was to 
determine the annual incidence of CD in some of the regions in which laboratory 
services are provided by SCL, as presented in Chapter Six.  
Between 2007 and 2015 the incidence of CD in Otago-Southland steadily 
increased. In fact, the incidence figures that emerged for this region are some of the 
highest in the world, at least among those that have been presented in the research 
literature.45,247-250,460 (Although the higher local figures will have been partly 
contributed to by the more liberal approach to diagnosis taken by pathologists 
discussed in the previous section.) 
The peak Otago-Southland incidence of 32.8 per 100,000 in 2014 is second only 
to the 33 per 100,000 recorded in Finland in 2005, a rate that had fallen to 29 per 
100,000 by 2013.251 Two things should be noted about this comparison however. 
Firstly, the Finns only diagnosed CD when there was villous atrophy and crypt 
hyperplasia present on duodenal biopsy, which would exclude several of the 
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patients diagnosed locally over the past decade. And secondly, the Finnish figures 
refer to the country as a whole, rather than a single region. It is apparent from the 
additional SCL data available from Nelson-Marlborough and South Canterbury, 
which both had lower incidence rates than Otago-Southland, that the picture is 
varied across this country. It is not clear why this might be.  
It is possible that Otago-Southland has a higher prevalence of CD than other 
regions in New Zealand, although why that would be so is also unclear. Were this to 
be the case, it would be consistent with research from elsewhere (discussed in 
Chapter Two), which has demonstrated variations in CD prevalence even in 
adjacent locations.4,180 The alternative explanation for the higher Otago-Southland 
prevalence is that clinicians in the region look for it more frequently (which is 
consistent with testing rates data), suggesting a greater awareness of the need to 
consider the diagnosis for their patients. Otago-Southland is my home territory, and 
CD is a topic on which I have given many presentations over the years. Given that 
CME was the leading source for updating information about CD cited by participants 
in the survey of GPs, these laboratory data may well be evidence of the impact such 
education meetings can have. This would be consistent with the experience in 
Finland, in which their high rates of diagnosis of CD have been attributed to targeted 
education.53 
Nelson-Marlborough and South Canterbury incidence rates are both more 
comparable to international figures, with Nelson-Marlborough at the upper end and 
South Canterbury at the lower. As already noted, testing rates in South Canterbury 
were lower than other regions in this study, and the numbers of people with 
positive serology progressing to biopsy in the region were also lower, both factors 
that will have contributed to the calculated incidence rates. But, just as it might be 
that CD is more prevalent in Otago-Southland, it is equally possible that CD is less 
prevalent in South Canterbury, which might also have contributed to these findings. 
As with the international studies, local incidence rates counted only those 
people with biopsy-proven disease. Given that every year many patients with 
positive serology did not undergo endoscopy, and that many of these had very high 
IgA-tTG antibody levels and positive EMA, the true incidence of CD will be higher 
than that stated. 
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There is much more that could be analysed and discussed with respect to the 
incidence data generated in this study but which is beyond the scope of the present 
work. This additional discussion will be undertaken in papers to be submitted 
subsequent to the completion of this thesis. 
7.3.6 When the diagnosis is uncertain: Gastroenterologist survey data 
The conundrum presented by a patient (Joshua) with elevated coeliac antibodies 
and normal histology was explored in the survey of gastroenterologists, and yielded 
a range of responses. Perhaps not surprisingly the presence or absence of 
symptoms significantly influenced likely behaviour. This is despite the fact that it is 
well documented that symptoms are not a reliable indicator of disease, and their 
absence does not necessarily mean the disease is also absent.22  
With respect to some aspects of Joshua’s management it seems hard to justify 
these differences in practice. For example, it is curious that respondents were 
divided on the place of testing for HLA-DQ2/DQ8, especially when he was 
asymptomatic, as a negative test in this situation would have been extremely 
helpful. Checking EMA also seems sensible, as a positive test might suggest that the 
IgA-tTG was a true positive, and that potential CD was therefore a likely 
diagnosis.461 This scenario was derived from the study by Parakkal et al.,56 who 
likewise found that their participants were divided on both these issues. This 
included their panel of experts, only a small majority of whom would have tested 
his HLA status or EMA in the absence of symptoms. 
The situation with regards to implementing a GFD in the presence or absence 
of symptoms is probably more clear cut, although the research to support this has 
only emerged since this survey was undertaken. When Joshua was reported as 
being asymptomatic, a clear majority of respondents indicated that a GFD was not 
required. When he was reported to be symptomatic, one third of participants would 
advise starting a GFD, while 40% maintained their position that a watch and wait 
approach would be reasonable. Recent studies endorse the view that in patients 
with normal histology it would be reasonable to adopt a watch and wait 
approach,462,463 at least for those who remain asymptomatic.  
As presented in Chapter Four, there were a number of participant demographic 
variables that significantly influenced their responses to aspects of this scenario, 
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particularly when Joshua was asymptomatic. However, given the small numbers of 
study participants overall, and the even smaller numbers in the various subgroups, 
it is not clear that this is important. Irrespective of the drivers of differences in 
practice, what has an impact on patients (and their GPs) is that those differences 
exist at all. While it may not matter a great deal if one “Joshua” has an EMA test and 
the next one does not, it will have a profound impact on one asymptomatic “Joshua” 
if he is commenced on a GFD when another is not. And it makes it challenging for 
GPs to make consistent management recommendations to their patients if they 
receive conflicting advice from the specialists they consult. 
7.4 Managing Coeliac Disease in New Zealand 
As set out in Chapter Two, the overarching aim of management for patients with CD 
is to improve their quality of life, ideally achieved through mucosal healing. In the 
majority of patients this should lead to symptom resolution, and a reduction in the 
incidence of long-term complications. It has become clear over time that, although 
the GFD remains central to effecting these outcomes, it is no longer sufficient to 
regard this as the sole focus of care. It is also clear that recommendations regarding 
the optimal management of CD have long been highly variable,28,29,307 and more 
recent guidelines do not yet agree on many aspects of care. It has been repeatedly 
pointed out in the literature that the management of CD is an area that needs further 
work to enable a consistent and evidence-based approach to be applied.e.g.28-30,307 It 
is in this context that the surveys of gastroenterologists and GPs explored likely 
practices relating to the management of CD in adult patients in New Zealand. And 
while there were aspects of management on which there were high levels of 
consensus, not surprisingly both surveys also found areas of considerable 
variability. 
Among participants in the survey of gastroenterologists there was widespread 
agreement that in the first year after diagnosis it was important to ensure a patient’s 
symptoms were improving and abnormal blood test results were resolving. They 
were also consistently of the view that over the long term the importance of 
adhering to a GFD was reinforced on a regular basis. However, beyond these aspects 
of care, levels of accord among respondents fell, which is consistent with the 2010 
findings of Silvester and Rashid.55 In practical terms what this means is that the way 
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in which a person with CD is managed in New Zealand is likely to vary according to 
whom they saw for the initial diagnosis, and the recommendations that that 
practitioner makes regarding their subsequent treatment. This will be heightened 
by the fact that among GPs who completed the GP survey, there was little 
consistency in likely practice across any of the management topics explored. 
7.4.1 Key variations in the management of CD 
A moderate majority of participants in the survey of gastroenterologists indicated 
that follow-up IgA-tTG testing within the first year following diagnosis was 
important or very important, but they varied on when this should take place. They 
were divided about whether this should take place routinely at six months or a year, 
or only if symptoms did not resolve. Almost 70% were likely to include a 
recommendation about this follow-up testing when discharging a patient back to 
his or her GP. They were somewhat more divided on the place of periodic IgA-tTG 
monitoring over the longer term, with almost 40% rating this as not important.  
Participants in the GP survey were uncertain about the importance of follow-
up serology testing, both in the short term and as part of longer term management. 
Over a quarter indicated that they were not aware that this might be necessary, and 
almost another fifth indicated that they did not think it was necessary. Only very 
small numbers would retest routinely, with testing most likely to be undertaken if 
a patient’s symptoms recurred or did not settle, or at a patient’s request. The 
laboratory data analysis demonstrated that just under half of patients with a 
positive (or inconclusive) biopsy had subsequent antibody testing. 
As discussed in Chapter Two, currently available guidelines all make 
recommendations to repeat serology testing in the year following 
diagnosis.69,70,72,132 While it is agreed that antibody levels do not necessarily 
indicate what is happening at the level of the intestinal mucosa with respect to 
healing, it is also generally accepted that strict adherence to the GFD should at least 
lead to a fall in titres. Antibody levels that are not falling should therefore prompt a 
review with the patient to determine whether he or she is continuing to ingest 
gluten, either deliberately or unintentionally. This opportunity is lost when patients 
are not retested.  
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Variations in practice among gastroenterologists were also evident relating to 
the importance of rebiopsy in the first 12 months after diagnosis. Just over half of 
participant gastroenterologists did not regard this as important, but just over a 
third of their colleagues took the opposite view. Perhaps not surprisingly this was 
to some degree influenced by the number of tenths worked in private practice. An 
additional few participants reported that they thought that rebiopsy was important, 
but not until more time had elapsed. Collectively these responses suggest that some 
patients in New Zealand will have a follow-up biopsy more-or-less routinely, while 
many will not. 
Participants who indicated that they were likely or highly likely to rebiopsy 
their patients routinely were significantly more likely to use guidelines as a source 
of information about CD. This is interesting given that, as identified by Silvester and 
Rashid,55 “practice guidelines do not offer any specific guidance regarding who 
should receive a repeat biopsy routinely”.(p.507) As discussed in Chapter Two, 
current guidelines do not explicitly recommend this approach, although they all 
endorse the practice in certain circumstances. Their collective reticence to make a 
strong recommendation on routine rebiopsy is in large part because the evidence 
that this intervention leads to an improvement in clinical outcomes for patients 
remains contested.  
Referral for DEXA scanning was another issue on which gastroenterologists 
were divided. This too is an issue that has not been clearly resolved between the 
guidelines groups. Just over half of respondents indicated they thought it was 
important for a referral to be made for DEXA scanning for newly diagnosed patients, 
while others indicated that the decision would depend on the presence of additional 
risk factors, and a few that DEXA scanning is not important at all. Their differences 
in approach were reflected in the responses of participants in the GP survey. Thus 
nearly half of GP respondents almost never referred patients for DEXA scanning, 
with the majority of these people indicating that they were not aware that this might 
be necessary.  
In addition to these aspects of follow-up care, participants in the GP survey also 
displayed mixed appreciation of the role of CNZ in supporting patients with CD. All 
the available guidelines direct that contact with a support group is an important 
component of coeliac management. Almost a quarter of GP respondents were not 
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aware that a recommendation to contact CNZ might be necessary, while close to 
40% almost never recommended this to their coeliac patients. However, a clear 
majority of respondents to the survey of gastroenterologists indicated that they 
discussed this issue with newly diagnosed patients almost all or most of the time, 
so it seems likely that a substantial proportion of patients will receive this advice. 
With respect to management over the longer term, issues such as the need for 
vaccination against influenza and pneumococcal infection drew high numbers of 
neutral responses from the gastroenterologists. Among GP respondents the 
majority indicated that they were not aware that pneumococcal vaccination might 
be necessary, but they would give the influenza vaccination at least some of the 
time. This may reflect a broader view of the importance of influenza prevention in 
general, rather than its specific relevance to CD. As discussed in Chapter Two, 
positions on these two aspects of long-term care are not yet consistent in the 
literature relating to CD, and that is clearly reflected in these findings. 
7.4.2 Annual reviews 
Guidelines documents pertaining to CD have long recommended that patients with 
the condition should be reviewed on an annual basis, specifically with respect to 
their CD.307 Despite this, research suggests that this is not the norm, at least as far 
as adults are concerned.29  
The surveys of gastroenterologists and GPs indicate that the experiences of 
patients in New Zealand are likely to be highly variable. A moderate majority of 
gastroenterologists regarded annual reviews as important or very important, and 
believed that GPs should be the practitioners to conduct them. However, fewer than 
two-thirds of those who thought this were likely to recommend the practice in their 
discharge letters. Almost 70% of GPs thought that such reviews were probably or 
definitely necessary, with a clear majority agreeing that GPs were the appropriate 
clinicians to perform them.  
Among those GP respondents with patients with CD in their practices, there 
was a range of practices with respect to reviewing their disease management, with 
the biggest single group being the 30% who did so opportunistically when their 
patients presented with something else. A smaller group indicated they did this 
routinely. It seems unlikely that non-responders to this survey would be any more 
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likely than survey participants to regularly review these patients, and it seems 
much more plausible to assume that they would be less likely to do so. 
The questions relating to annual reviews stirred many participants to 
comment, with some expressing concerns about the costs of implementing such a 
programme. The costs they foresaw were to their patients, who would have to pay 
for the consultation, and to themselves in terms of their time in an already stretched 
primary care sector. Many more also indicated that they would need additional 
information about what to include in such a review. Alongside this, there were many 
and varied ideas about what an annual review should encompass. It is clear that this 
is an area that would benefit from the dissemination of further information, 
although given the differences between guidelines documents, there is work still to 
be done on developing an agreed set of recommendations to suit the New Zealand 
environment. 
7.5 Why opinions and practices might differ 
Given the lack of consistency of recommendations across available CD guidelines, it 
is not surprising that for many aspects of care, opinions about their importance 
varied among gastroenterologists who participated in the survey, and likely 
practice differed widely among GPs. This is especially so for management and, as 
evidenced in research from elsewhere,29 this is not a problem that is unique to New 
Zealand.  
With respect to the findings of the present survey of gastroenterologists, these 
may have been influenced by the fact that at the time it was conducted in late 2013 
the WGO and ACG Guidelines were relatively new, and the BSG and NICE were yet 
to update their recommendations. Perhaps compounding this was the fact that just 
over a third of participants did not rate guidelines documents as one of their 
preferred sources of information about CD. 
When a similar question was asked of GPs about sources of information they 
utilised relating to CD, only very small numbers indicated that they would refer to 
practice guidelines. This is also not surprising given that, with the exception of a 
summary of the NICE Guidelines published in the BMJ,132 all other CD-related 
guidelines (relating to the care of adults) have been published in the specialist 
gastroenterology literature.68-70 Instead GPs are more likely to rely on CME 
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meetings, bpacnz, and their patients with CD for their information. Unfortunately 
much of the bpacnz information on CD has not been updated for some years, with 
the most recent material (relating to dietary advice and prescription foods) dating 
back to 2011,464 and their last comprehensive review of CD dating to 2007.465 More 
than half of GP respondents also indicated that letters from gastroenterologists 
were an important source of their information, highlighting the degree of 
gastroenterologist influence on practice. And while not an important source of 
information for participants in this survey, it is likely that over time 
HealthPathways will become so. As already mentioned earlier in this chapter, these 






It has to be concluded from the studies that comprise this project that GPs in New 
Zealand, as in other countries, do indeed have limited disease-specific knowledge 
with respect to CD in adults. And although the deficits in knowledge are patchy 
rather than universal, it is likely that CD remains under-recognised, 
underdiagnosed, and sub-optimally managed.  
The evidence gathered in these studies does suggest that, over time, knowledge 
about CD has improved. Rates of recognition (evidenced by testing) and diagnosis 
(evidenced by incidence) have clearly increased, at least in some of the regions from 
which laboratory data were available. In particular, Otago-Southland incidence 
rates compare very favourably with data from elsewhere in the world. The survey 
of GPs demonstrated that there are several clinical presentations that are highly 
likely to prompt testing for CD, but there are also situations in which it is probable 
that CD is still being missed. This may be because it is not tested for, or because 
positive IgA-tTG tests are not appropriately followed up. There are also likely to be 
people being wrongly diagnosed, as more weight than is warranted is given to 
results such as a positive HLA-DQ2/DQ8 test. But it is in the management of the 
condition that there is most room to improve. This is evidenced by the lack of 
consistency in the views of gastroenterologists about what follow-up care should 
include, which is reflected in the varied practices of GPs. Such differences in practice 
are entirely consistent with what is happening elsewhere, and with the fact that 
even the guidelines documents produced by experts diverge. 
Standing at the centre of a project such as this are patients, in this case those 
with CD, be they already diagnosed or awaiting recognition. From the work 
presented here it is clear that there is work still to be done to improve the health 
outcomes of both groups of people. The following recommendations seek to begin 
that process. 
8.1 Recommendations to the New Zealand Society of Gastroenterologists 
One of the most important findings to emerge from the survey of 
gastroenterologists was that respondents to the survey held differing views and/or 
had differing practices relating to patients with CD, or possible CD. What was most 
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surprising about these differences was that they occurred not just between DHB 
regions, but also within them, among practitioners who presumably worked 
alongside each other. And while the majority of differences in practice did not reach 
statistical significance, they do represent variations in patient care. The clinical 
import of these variations will differ according to the nature of the practice that is 
in question, but what they will do is send mixed messages to GPs, who carry out the 
bulk of long-term management, and to their patients who simply want to know that 
they are receiving appropriate treatment. It is unlikely that variations in practice 
will have substantially lessened in the years since the survey was conducted. 
 It would be of great value to patients and GPs alike if the NZSG sponsored an 
effort to develop an agreed set of CD practice guidelines appropriate for the 
New Zealand clinical environment. These should include policies relating to 
rebiopsy, DEXA scanning, and retesting serology, along with a template on 
which annual reviews of patients with CD could be based. Such guidelines 
could be promulgated among gastroenterologists, but also surgeon 
endoscopists, who were not represented in this survey, but who will on 
occasion diagnose patients with CD.  
 Such guidelines should be made available to those developing CD-related 
HealthPathways to ensure that consistent messages are given everywhere in 
New Zealand. 
8.2 Recommendations to Coeliac New Zealand 
Over the past decade CNZ has put a great deal of effort into educating GPs about CD, 
with some evidence of success. This needs to continue, but could become more 
focused.  
 From the survey of GPs it was apparent that they were much less likely to 
test for CD in the presence of some symptoms than others, and that testing 
in patients with conditions known to be associated with CD was less 
common than it could be. Targeting advice to address these evident gaps in 
knowledge may reap more benefits than a continued broad brush injunction 
to simply test more people. 
 Respondents to the GP survey indicated a clear preference for CME meetings 
as a source of information about CD. Coeliac New Zealand should continue to 
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have a presence at major GP CME events, and to sponsor expert 
presentations, to increase the organisation’s visibility and be a ready source 
of reliable resources about the condition. 
 GP survey respondents also indicated that their patients with CD are an 
important source of information about the condition, so perhaps this is a 
resource that CNZ could tap into more explicitly. For example, they could 
provide newly diagnosed people with guidelines about management to 
discuss with their GPs. Such a resource could also be made available to 
gastroenterologists to give to patients at the time of diagnosis. 
8.3 Recommendations for Future Research 
(A) One of the most important sets of findings to emerge from the laboratory study 
was the correlation data between IgA-tTG levels and biopsy results. If it were 
possible to safely exclude patients with very high IgA-tTG titres from the need for 
upper endoscopy, this would reduce demand for the service, and perhaps improve 
access for patients in whom the diagnosis is less clear cut. It would also mean that 
those patients for whom the diagnosis could be confirmed on the basis of serology 
alone would not be required to undergo an invasive procedure, and could begin 
treatment without delay. 
 In an environment in which access to endoscopy resources is often limited, 
and in the context of ongoing debate about the place of duodenal biopsy in 
diagnosing CD, there is an urgent need to repeat this part of the laboratory 
study in other laboratories, especially those that do not use the Quantalite 
kits used by SCL. This would inform future decision-making about the 
requirement for duodenal biopsy to confirm the diagnosis. It would also 
enable analysis of the comparability of test-kits used throughout New 
Zealand. 
 Repeating analyses of testing and biopsy data in regions other than Otago-
Southland would enable incidence rates to be calculated for other parts of 
New Zealand. This would permit comparisons to be made between regions, 
and could lead to further investigations of differences and similarities where 




(B) Guidelines documents have long recommended that patients with CD be 
reviewed annually, but it is clear from both the surveys in this project that there is 
some way to go before such reviews become routine in New Zealand. Among the 
obstacles to this happening are issues relating to cost, and a lack of clarity about 
what they should involve.  
 It would be of benefit to patients and GPs alike if a tool were to be developed 
that could enable GPs to triage their patients with CD so that those for whom 
the benefit might be greatest could be prioritised for regular review. Such a 
tool might take the form of an online questionnaire that patients completed 
(via patient portals such as ManageMyHealth), with questions about 
symptoms and dietary adherence, for example. It might also include a panel 
of blood tests. Any such instrument would need to be developed in 
accordance with evidence-based practice, and with the input of people with 
CD.  
 
(C) Several attempts have been made to find reliable ways of measuring CD-related 
QoL. To date none of these tools are particularly workable for use in the busy 
primary care setting. 
 It would be of benefit to patients, GPs, and researchers evaluating the impact 
of new treatments for CD (for example), if a less cumbersome instrument to 
measure QoL could be developed. This might take the form of a screening 
tool, responses to which would indicate whether a patient needed a more in-
depth exploration of how they were managing. 
 
(D) The study by Anderson et al.18 suggested that the addition of HLA-DQ2/DQ8 
testing for patients with positive coeliac serology could be used to more accurately 
ration scarce endoscopy resources by excluding those with false-positive antibody 
tests. 
 A cost-benefit study in the New Zealand context of adding HLA testing for 
patients with positive coeliac serology would enable a recommendation to 




8.4 Final comments 
No doctor ever sets out to treat his or her patients with anything less than the best 
possible care. Sometimes that care does not reach the standards that we might set 
for ourselves, and sometimes it does not meet the expectations of our patients and 
their supporters. Blind spots in knowledge about a condition will often be a 
contributing factor when these situations arise. 
As documented in Chapter One of this thesis, CNZ has long held concerns about 
care relating to CD in this country, particularly with respect to delays in diagnosis. 
The results contained in this project suggest that there remains some justification 
for their concern, but that over time the situation has improved. If the lessons 
learned in the course of this project can be applied, and the recommendations 
derived from these three studies implemented, there is every reason to believe that 
such improvements will continue, and that the care of patients with coeliac disease 
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“The Committee expressed concern with the assumed response rate of 30%, as noted 
in Section 2.1, and as to whether this is scientifically valid and asks for further 
comment on this.” 
Response: 
It is well recognised that General Practitioners are difficult to engage with survey-based 
research. A review on the issue conducted by Creavin et al.1 in 2011 found that response 
rates reported in the literature ranged between 31% and 71%, while a study in the 
Australian Family Physician2 also published in 2011 reported that “GP response rates to 
surveys are lower than those from the general population”.  
There are a number of resources available that outline evidence-based steps which 
researchers can take to enhance the likely response rate to mailed surveys.3,4 These 
include enclosing postage-paid return envelopes with the survey, having a prize draw 
associated with participation, and sending out reminders at regular intervals following 
the initial mail out. Dr Kenrick is aware of this literature and will be implementing many 
of these recommendations in an effort to maximise the response rate to the proposed 
survey. 
Section 2.1 of the protocol in fact said “assuming the response rate could be as low as 
30%”, in order to account for the high number of surveys we propose to send out. This 
is one of the steps Dr Kenrick will be taking to ensure that enough responses are 
gathered to be able to make meaningful internal comparisons between participants. 
We acknowledge that if the response rate is indeed as low as 30%, then the 
generalisability of the study’s findings to the wider General Practice community will be 
limited. Discussion of this issue and its possible implications would be included in any 
reporting of the study. 
References: 
(1) Creavin ST, Creavin AL, Mallen CD. Do GPs respond to postal questionnaire surveys? 
A comprehensive review of primary care literature. Fam Pract 2011; 28: 461-467 
(2) Bonevski B, Magin P, Horton G, Foster M, Girgis A. Response rates in GP surveys. 
Trialling two recruitment strategies. Aust Fam Phys 2011; 40: 427-30 
(3) Edwards PJ, Roberts I, Clarke MJ, DiGuiseppi C, Wentz R, Kwan I, Cooper R, Felix LM, 
Pratap S. Methods to increase response to postal and electronic questionnaires. 
Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: MR000008. DOI: 
10.1002/14651858.MR000008.pub4.  
(4) VanGeest JB, Johnson TP, Welch VL. Methodologies for improving response rates in 
















Appendix B: Survey from Parakkal et al.1 
Celiac Questionnaire for Gastroenterologists 
AGE ________ 
GENDER  ________ 
YEARS IN PRACTICE   ________ 
SPECIALITY   ___________________________________________ 
CLINICAL HOURS PER WEEK   ________ 
RESEARCH HOURS PER WEEK   ________ 
MEMBERSHIP IN CELIAC SOCIETIES? (if yes, indicate which one)  
___________________________________________ 
NUMBER OF CELIAC DISEASE PATIENTS SEEN PER MONTH  ________ 
PRACTICE SETTING (Please circle) 
PRIVATE 
SOLO  GI GROUP  MULTISPECIALTY GROUP 
HEALTH MAINTENANCE ORGANIZATION 
UNIVERSITY BASED 
VETERAN’S AFFAIRS HOSPITAL 
OTHERS 





INTERNATIONAL (PLEASE NAME COUNTRY OF PRACTICE)______________________  
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Please rate the appropriateness of the tests/ interventions on a RAND appropriateness 
scale of 1-9 in the following clinical vignettes. 
RAND    Appropriateness Scale (RAS) 
 
 1 2 3 4 5 6 7 8 9 
1 = extremely inappropriate 
5 = equivocal (neither clearly appropriate nor clearly inappropriate) 
9 = extremely appropriate 
Vignette #1 
Five years ago, a 25 yr old Caucasian male was diagnosed with probable celiac disease 
on the basis of positive IgG anti-Gliadin antibodies and started on a gluten free diet 
(GFD). He now wants to know if he really has celiac disease as the GFD is severely 
affecting his quality of life. 
1) Please rate the appropriateness of the following diagnostic tests as an initial 
step in the work up: 
Rating of Appropriateness 
(Circle One) 
a) Ig A anti-TTG antibodies 1    2    3    4    5    6    7    8    
9 
b) Ig A anti-Endomysial antibodies 1    2    3    4    5    6    7    8    
9 
c) Serum Ig A levels 1    2    3    4    5    6    7    8    
9 
d) IgA and IgG anti-Gliadin antibodies 1    2    3    4    5    6    7    8    
9 
e) EGD with Duodenal biopsy at presentation 1    2    3    4    5    6    7    8    
9 
f) None of the above 1    2    3    4    5    6    7    8    
9 
 
2) Please rate the appropriateness of testing for the absence of HLA DQ2/8 
heterodimer status to rule out celiac disease in this patient: 
 
Rating of appropriateness: (Circle One)                    1    2    3    4    5    6    7    8    9 
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3) Please rate the appropriateness of a gluten challenge to diagnose celiac disease in 
the above scenario: 
 
Rating of appropriateness: (Circle One)                    1    2    3    4    5    6    7    8    9 
 
4) If you were to proceed with a gluten challenge, what is the minimum quantity of 
gluten intake you would ask the patients to consume per day? (Circle One) 
a) 5 grams/day 
b) 10 grams/day 
c) 20 grams/day 
 
5) What is the duration of gluten intake you would allow before you would perform 
investigations to confirm celiac disease in the above scenario? (Circle One) 
a) 2 weeks 
b) 4 weeks 
c) 8 weeks 
d) 12 weeks 
e) As soon as symptoms develop 
 
6) What would be a safe amount of non cross-contaminated oats that can be 
consumed in a day by a patient with celiac disease while on a GFD? (Circle One) 
a) Avoid consuming any oats 
b) No more than 2 ounces per day 
c) No more than 5 ounces per day 
 
Vignette#2 
A 20 yr old went to his primary care physician because his paternal uncle was recently 
diagnosed with celiac disease. He has no gastrointestinal symptoms, but was tested 
and found to have elevated Ig A anti-TTG antibodies.  He was referred to your office 
for an EGD and duodenal biopsy to confirm celiac disease. 
RAND    Appropriateness Scale (RAS) 
 
 1 2 3 4 5 6 7 8 9 
1 = extremely inappropriate 
5 = equivocal (neither clearly appropriate nor clearly inappropriate) 




1) If, in the above scenario, the biopsy results were to be normal (Marsh type 0), 
indicate the appropriateness of the next set of investigations on a RAS scale of 1-9: 
Rating of appropriateness 
(Circle one) 
a) Review biopsy with an experienced pathologist      1    2    3    4    5    6    7    8    9 
b) Repeat biopsy                                                                 1    2    3    4    5    6    7    8    9 
c) Genetic testing for HLA DQ2/8 status                        1    2    3    4    5    6    7    8    9 
d) IgA anti-endomysial antibody                                     1    2    3    4    5    6    7    8    9 
e) M2A capsule study                                                        1    2    3    4    5    6    7    8    9 
f) Small bowel radiograph                                                1    2    3    4    5    6    7    8    9 
g) Start on GFD and repeat serology later to document  
fall in titer                                                                        1    2    3    4    5    6    7    8    9 
 
2) In the above vignette if the patient were to report significant gastrointestinal 
symptoms along with positive celiac serology but normal biopsy (Marsh type 0), 
indicate the appropriateness of the next set of investigations on a RAS scale of 1-9. 
Rating of appropriateness 
(Circle One) 
a) Review biopsy with an experienced pathologist      1    2    3    4    5    6    7    8    9 
b) Repeat Biopsy                                                                 1    2    3    4    5    6    7    8    9 
c) Genetic testing for HLA DQ2/8 status                        1    2    3    4    5    6    7    8    9 
d) IgA anti-endomysial antibody                                     1    2    3    4    5    6    7    8    9 
e) Start on GFD and repeat serology later to  
document fall in titer                                                    1    2    3    4    5    6    7    8    9 
 
3) Evaluate the role of gluten free diet in this scenario of positive serology and 
normal histology in a symptomatic patient on a RAS scale of 1-9: 
Rating of appropriateness 
(Circle One) 
a) GFD only if repeat biopsy is positive                          1    2    3    4    5    6    7    8    9 
b) GFD only if Positive for HLA DQ 2 OR 8                      1    2    3    4    5    6    7    8    9 
c) GFD if either repeat biopsy or HLA DQ2 OR  
8 is positive                                                                     1    2    3    4    5    6    7    8    9 
d) No role for GFD if biopsy and genetic testing  
is negative                                                                       1    2    3    4    5    6    7    8    9 
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e) Start on GFD and repeat serology later to document  
fall in titer                                                                        1    2    3    4    5    6    7    8    9 
4)   In the above scenario, is there a role for the development of non-invasive tests to     
      diagnose or rule out celiac disease before proceeding for small intestinal biopsy? 
Indicate by circling yes or no                                                       YES                NO 
Vignette#3 
A 28 yr old Caucasian female is referred to your office with a diagnosis of dermatitis 
herpetiformis (DH) for evaluation of coexistent celiac disease. She currently has no 
gastrointestinal symptoms but she has a family history of celiac disease. 
RAND    Appropriateness Scale (RAS) 
 
 1 2 3 4 5 6 7 8 9 
1 = extremely inappropriate 
5 = equivocal (neither clearly appropriate nor clearly inappropriate) 
9 = extremely appropriate 
 
1) Please rate the appropriateness of the following investigations on a RAS SCALE OF 
1-9: 
Rating of appropriateness  
(Circle One) 
a) Ig A anti-TTG antibodies                                               1    2    3    4    5    6    7    8    9 
b) Ig A anti-Endomysial antibodies                                  1    2    3    4    5    6    7    8    9 
c) Serum Ig A levels                                                            1    2    3    4    5    6    7    8    9 
d) IgA and IgG anti-Gliadin antibodies                            1    2    3    4    5    6    7    8    9 
 
2)   If, in the above scenario, she has antibodies that are diagnostic of celiac disease, 
rate the appropriateness of the possible next step in investigation on a RAS scale 
of 1-9: 
Rating of appropriateness 
(Circle One) 
a) Duodenal biopsy, which if positive will start GFD and 
if negative do nothing                                                   1    2    3    4    5    6    7    8    9 
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b) Start GFD and no role for duodenal biopsy              1    2    3    4    5    6    7    8    9 
c) Duodenal biopsy to confirm celiac disease but 
start GFD regardless of result                                      1    2    3    4    5    6    7    8    9 
3)   If you decide to start her on a GFD, rate the appropriateness of the reason on a 
RAS scale of 1-9: 
Rating of appropriateness 
(Circle One) 
a) It would improve the rash of DH                                1    2    3    4    5    6    7    8    9 
b) It would improve intestinal mucosal morphology   1    2    3    4    5    6    7    8    9 
c) It would improve both the rash and the mucosal  
morphology                                                                    1    2    3    4    5    6    7    8    9 
RAND    Appropriateness Scale (RAS) 
 
 1 2 3 4 5 6 7 8 9 
1 = extremely inappropriate 
5 = equivocal (neither clearly appropriate nor clearly inappropriate) 
9 = extremely appropriate 
 
Vignette#4 
The following are a series of mini vignettes on conditions or manifestations where one 
might consider testing for celiac disease. 
1) Please rate the appropriateness for screening for celiac disease in 
asymptomatic patients with the following conditions: 
Rating of appropriateness  
(Circle One) 
a) Type 1 Diabetes Mellitus                                         1    2    3    4    5    6    7    8    9 
b) Autoimmune thyroiditis                                          1    2    3    4    5    6    7    8    9 
c) Down syndrome                                                       1    2    3    4    5    6    7    8    9 
d) Turner syndrome                                                     1    2    3    4    5    6    7    8    9 
e) Selective Ig A deficiency                                         1    2    3    4    5    6    7    8    9 
f) First degree relative of celiac patient                  1    2    3    4    5    6    7    8    9 
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RAND    Appropriateness Scale (RAS) 
 
 1 2 3 4 5 6 7 8 9 
1 = extremely inappropriate 
5 = equivocal (neither clearly appropriate nor clearly inappropriate) 
9 = extremely appropriate 
 
2) In the following diseases rate the appropriateness of repeated serology testing 
if initial serology is negative for celiac disease: 
Rating of appropriateness  
(Circle One) 
a) Type 1 Diabetes Mellitus                                       1    2    3    4    5    6    7    8    9 
b) Down syndrome                                                      1    2    3    4    5    6    7    8    9 
c) First degree relatives of celiac patients              1    2    3    4    5    6    7    8    9 
d) Selective IgA deficiency                                          1    2    3   4    5    6    7    8    9 
3) Please rate the appropriateness for screening for celiac disease in 
asymptomatic patients with the following  manifestations: 
Rating of appropriateness  
(Circle One) 
a) Premature osteoporosis                                        1    2    3    4    5    6    7    8    9 
b) Delayed puberty                                                      1    2    3    4    5    6    7    8    9 
c) Iron deficiency anemia                                           1    2    3    4    5    6    7    8    9 
d) Unexplained elevation of liver transaminases   1    2    3    4    5    6    7    8    9 
e) Primary biliary cirrhosis                                         1    2    3    4    5    6    7    8    9 
f) Autoimmune hepatitis                                           1    2    3    4    5    6    7    8    9 
g) Unexplained infertility                                           1    2    3    4    5    6    7    8    9 
h) Recurrent migraine                                                 1    2    3    4    5    6    7    8    9 





Thank You for Participating In This Survey 
 
Please include your e mail ID in the space below if you wish to be informed of the 
results when the study is completed. This information will be kept confidential 
during the analysis, presentation and publication of these data. 
 




1. Parrakal D, Du H, Semer R, Ehrenpreis ED, Guandalini S. Do 
gastroenterologists adhere to diagnostic and treatment guidelines for celiac 







Appendix C: The RAND Appropriateness Method explained 
The RAND Appropriateness Method (RAM) was developed in the 1980s by a team 
at University of California, Los Angeles (UCLA) and the RAND Corporation, as a tool 
to assess health systems for the appropriateness of care being provided.1 The 
particular area of interest was that of the underuse and overuse of surgical 
procedures, and the consequent variability in health care being provided to 
different patients and populations. It has subsequently come to be used to develop 
guidance for appropriate treatment across a range of disciplines. An appropriate 
treatment is defined by RAND as being one for which “the expected health benefit 
… exceeds the expected negative consequences … by a sufficiently wide margin that 
the procedure is worth doing, exclusive of cost”.1 (p.1)  
The RAM is grounded in the belief that expert opinion must be considered 
alongside the best available evidence when making decisions about the 
appropriateness of a treatment because “(a)lthough robust scientific evidence 
about the benefits of many procedures is lacking, physicians must nonetheless 
make decisions every day about when to apply them”(p.1). Thus central to the RAM 
is the role of the expert panel which participates in a modified Delphi process, to 
evaluate a specific treatment option (or options) for appropriateness in a range of 
related clinical scenarios. But the authors of the RAM User’s Manual are careful to 
explain that while the process will identify when experts have a consensus view on 
the appropriateness or otherwise of an intervention, this is not a tool to forge that 
consensus.  
For the procedure in question, generally the process follows the following 
steps: 
 An extensive literature review is undertaken to gather and synthesise 
the available evidence relating to its use. 
 A list of indications for its possible use, often in the form of clinical 
scenarios, is developed. This may run to hundreds of individual items. 
 A list of definitions of potentially ambiguous terms is also developed, 
to try and minimise variation in how the scenarios may be interpreted 
by panel members. 
400 
 
 A panel of experts is selected. This may be by reviewing the literature 
for key researchers in the area, or consulting with relevant specialist 
societies. The panel may have up to 15 members although 9 is the 
number recommended by RAND. 
 The panel is asked to evaluate its appropriateness for use in each of the 
scenarios. They do this using a 9-point scale, where 1 means that 
expected harms greatly outweigh expected benefits, and 9 that 
expected benefits greatly outweigh expected harms. A score of 5 can 
either mean that the expected benefit/harm ratio is equal, or that the 
evaluator is unable to make that judgement. At this stage in the process 
each panellist conducts his or her evaluations individually, and 
independently of other participants. 
 Panellists’ responses are collated and the panel is then convened for a 
facilitated discussion. Each panellist is given a copy of the collated 
responses together with his or her own responses, and areas of 
disagreement are discussed. There is also an opportunity to modify the 
lists of indications and definitions. The discussion is designed to 
determine whether disagreement is due to true differences in opinion 
and clinical practice, or to misunderstanding and fatigue.  
 Following discussion each panellist is asked to re-rate the list of 
indications. This second round of ratings may be done within the 
context of the meeting, or in the few days immediately following. 
 Results are collated and then, according to the median scores of 
panellists and the level of disagreement among them, each indication is 
categorised as being appropriate (7-9), uncertain (4-6), or 
inappropriate (1-3). 
Following on from this process the results are then used to evaluate patient care 
retrospectively, or to guide future practice. 
The RAM is not without its critics, with concerns expressed by some about the 
potential for bias to occur at a number of points (e.g. in panel selection, in facilitator 
selection, in the literature review process); about the cost of the process; about 
potential ambiguity in the word “appropriateness”; and about the fact that there is 
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no room in the method for the patient’s perspective to be considered.2 Some of these 
concerns are addressed by more recent groups employing the method, and a 
systematic review published in 2012 found that the RAM does have acceptable 
reliability and validity for assessing overuse and underuse of surgical procedures.3  
The study by Parakkal et al., at least as it is reported in their published article,4 
bears little resemblance to the RAM as outlined above. While they did develop a set 
of scenarios and asked participants to evaluate the appropriateness of various 
interventions, their process seems otherwise unrelated to that developed by 
RAND/UCLA. They did not obviously provide their participants with the evidence 
to inform their decision making, and instead of an expert panel, they had two groups 
completing the task: one a group of 22 experts, the other a group of 169 conference-
goers. While this is a useful way to compare the practice of the two groups, it is not 
equivalent to the RAM. In addition to this, all participants only rated the scenarios 
once and there was no discussion or opportunity to identify areas of ambiguity or 
misunderstanding, which calls into question the validity of the RAND 
Appropriateness Scales (RAS) which they then developed.  
 
References 
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Method User’s Manual. Santa Monica: The RAND Corporation;2001. 
2. Hicks NR. Some observations on attempts to measure appropriateness 
of care. BMJ. 1994;309(6956):730-733. 
3.  Lawson EH, Gibbons MM, Ko CY, Shekelle PG. The appropriateness 
method has acceptable reliability and validity for assessing overuse and 
underuse of surgical procedures. J Clin Epidemiol. 2012;65(11):1133-
1143. 
4. Parakkal D, Du H, Semer R, Ehrenpreis ED, Guandalini S. Do 
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Appendix D: The Survey for Gastroenterologists 
Current Approaches to Adult Coeliac 
Disease 
If you are a gastroenterologist (consultant or registrar) or a surgeon endoscopist, I 
would be very grateful if you would complete the attached survey, which should take 
you no more than 20 minutes to do. 
This survey forms part of my PhD project in which I am investigating adult Coeliac 
Disease in New Zealand. I am working with gastroenterologists Michael Schultz and 
Andrew Day, and Dr Chrystal Jaye, from the Department of General Practice and Rural 
Health in the Dunedin School of Medicine. We are particularly interested in developing 
strategies to improve the care of patients with CD, by identifying gaps in current 
approaches to the diagnosis and management of the condition. This part of the project 
seeks to understand the role of specialists in the care of patients with CD, and their 
expectations of GPs who are also involved in this care.  
The survey presents three scenarios with questions which ask you to rate your likely 
responses. There is also scope for you to provide comments should you wish to do so. 
We are looking for information about your current practice, rather than the “right” 
answers.  
For this project to produce meaningful results we need as many people as possible to 
take part, so I would really appreciate your participation. Please note there are 
questions on both sides of each page. 




GP and PhD Candidate 
Dunedin School of Medicine  
 
This study has been approved by the University of Otago Human Ethics Committee (ref. H13/027). If you 
have any concerns about the ethical conduct of the research you may contact the Committee through the 
Human Ethics Committee Administrator (ph 03 479 8256). Any issues you raise will be treated in 
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Case Study A 
Lucy is a 35 year old woman who is referred to you for endoscopy. She has elevated IgA anti-TTG 
antibodies and has a long history of IBS-type symptoms. Her histology result is reported as showing Marsh 
3 changes, consistent with a diagnosis of coeliac disease. She should be referred to a dietician for advice 
on the gluten free diet. 
(1) In your experience, who would normally refer this patient to the dietician? (Please choose one) 
⃝ I would 
⃝ One of my team would 
⃝ Her GP would, on receipt of the histology report 
(2) Following her endoscopy, how important is it that she sees you (or a gastroenterologist colleague) to 
discuss the diagnosis? (Please choose one) 
⃝ Not important at all 
⃝ Not very important 
⃝ Neutral 
⃝ Important 
⃝ Very important 
(3) If you don’t think it is important for Lucy to come back to see you (or a gastroenterologist 
colleague), who should see her to discuss her diagnosis?  
____________________________________________________________________________________
_________________________________________________________________ 
(4) When considering Lucy’s management for the NEXT 12 MONTHS, how important are each of the 
following? Please rate each option on the 1 - 5 scale of importance, where: 
1 = not important at all  3 = neutral  5 = very important 
                     Rating of importance (circle one) 
An application is made for a Special Authority number for 
prescription gluten free foods 
1 2 3 4 5 
She is referred for a DEXA scan 1 2 3 4 5 
She has follow-up TTG testing 1 2 3 4 5 
She is reviewed to ensure any CD symptoms have resolved 1 2 3 4 5 
She is monitored to ensure abnormal blood tests (e.g. low 
iron) return to normal 
1 2 3 4 5 
She has a follow-up biopsy at around 12 months 1 2 3 4 5 
She is advised to join Coeliac NZ 1 2 3 4 5 
She is advised that her 1st degree relatives should be 
tested for CD 
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(5) Please comment on any of the above, or if there is anything else you consider would be an important 






(6) Who should be responsible for arranging the following aspects of her management, in the NEXT 12 
MONTHS? (Please tick one column for each aspect) 












Applying for a Special 
Authority number 
     
Referring her for a DEXA       
Advising her to join Coeliac NZ 
 
     
Advising her that her 1st 
degree relatives should be  
tested 
     
 






(8) When should follow-up TTG testing take place? (Choose as many options as you think appropriate) 
⃝ I don’t think this is necessary 
⃝ Routinely at 3 months 
⃝ Routinely at 6 months 
⃝ Routinely at 12 months 
⃝ Only if her symptoms don’t resolve 
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(9) When considering Lucy’s LONG TERM management, how important are each of the following?  
Please rate each option on the 1 - 5 scale of importance, where: 
1 = not important at all  3 = neutral  5 = very important 
Rating of importance (circle one) 
Regular reinforcement of the importance of the gluten free 
diet 
1 2 3 4 5 
Periodic TTG testing 1 2 3 4 5 
Periodic screening for associated conditions (e.g. thyroid 
disease) 
1 2 3 4 5 
Annual influenza vaccination 1 2 3 4 5 
5-yearly Pneumococcal vaccination 1 2 3 4 5 
 
(10) Please comment on any of the above, or if there is anything else you think it would be important to 






(11) How important is it that Lucy has an “Annual Review” of her coeliac management? (Please choose 
one) 
⃝ Not important at all 
⃝ Not very important 
⃝ Neutral 
⃝ Important 
⃝ Very important 
(12) Who should do this? (Please choose one) 
⃝ I don’t think this is necessary 
⃝ GP 
⃝ Practice Nurse 
⃝ Dietician 
⃝ Gastroenterologist 
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Following your confirmation that Lucy does have coeliac disease, you will at some stage send her back to 
the care of her GP. 
(13) In your letter to her GP, how likely are you to comment on each of the following issues which relate 
to Lucy’s management for the NEXT 12 MONTHS?  
Please rate each option on the 1 - 5 scale of likelihood, where: 
   1 = highly unlikely  3 = neutral  5 = highly likely 
                                           Rating of likelihood (circle one)  
She should see a dietician 1 2 3 4 5 
She is eligible for a Special Authority number 1 2 3 4 5 
She should have a DEXA scan 1 2 3 4 5 
She should have follow-up TTG testing 1 2 3 4 5 
She should be reviewed to ensure any CD symptoms have 
resolved 
1 2 3 4 5 
Her 1st degree relatives should be tested for CD 1 2 3 4 5 
She should be encouraged to join Coeliac NZ 1 2 3 4 5 
 
(14) How likely are you to comment on each of the following issues which relate to her LONG TERM 
management? 
Please rate each option on the 1 - 5 scale of likelihood, where: 
   1 = highly unlikely  3 = neutral  5 = highly likely 
                                          Rating of likelihood (circle one)  
The importance of the gluten free diet should be regularly 
reinforced 
1 2 3 4 5 
She should have periodic TTG testing  1 2 3 4 5 
She should have periodic screening for associated conditions  
(e.g. thyroid disease) 
1 2 3 4 5 
She should have an annual influenza vaccination 1 2 3 4 5 
She should have a 5-yearly Pneumococcal vaccination 1 2 3 4 5 
She should have an annual review of her coeliac disease 
management 
1 2 3 4 5 
 







Page 5 of 11 
Recently diagnosed coeliac disease 
Thinking more broadly than just Lucy in Case Study A, 
(16) In some countries it is recommended that all coeliac patients should be re-biopsied at approximately 
12 months following their diagnosis. How important do you think this is? 
⃝ Not important at all  
⃝ Not very important 
⃝ Neutral 
⃝ Important 
⃝ Very important 






(18) In general, when do you think adults with newly diagnosed coeliac disease should be referred for 
DEXA scanning? (Please choose one) 
 ⃝   Almost never       ⃝   Only in certain clinical situations       ⃝   Almost always 







(20) How often do you discuss joining Coeliac NZ with your newly diagnosed coeliac patients? (Please 
choose one) 
⃝   Almost never ⃝  Some of the time ⃝   About half the time ⃝   Most of the time 
⃝   Almost always 
(21) How often do you discuss the issue of testing first degree relatives with your newly diagnosed coeliac 
patients? (Please choose one) 
⃝   Almost never ⃝  Some of the time ⃝   About half the time ⃝   Most of the time 
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Case Study B 
Joshua is a 20 year old man referred to you with significantly elevated IgA anti-TTG antibodies. He was 
tested because his sister has recently been diagnosed with coeliac disease. When you question him about 
symptoms, he tells you he has never noticed any. 
(1) Which of the following would be your most likely course of action? (Please choose one) 
⃝ Proceed to biopsy 
⃝ Repeat his TTG, and biopsy if the level remains elevated 
⃝ Repeat his TTG, test endomysial antibodies and HLA DQ2/8 status, and biopsy if positive 
⃝ Repeat his TTG, test endomysial antibodies and HLA DQ2/8 status, and recommend a gluten 
free diet if positive  





(2) If you were to biopsy this patient and the results were reported as normal (Marsh 0), how likely would 
you be to do the following? 
Please rate each option on the 1 - 5 scale of likelihood, where: 
   1 = highly unlikely  3 = neutral  5 = highly likely 
                              Rating of likelihood (circle one)  
Review the biopsy result with a pathologist 1 2 3 4 5 
Repeat the biopsy in the near future 1 2 3 4 5 
Arrange for him to have a capsule endoscopy  1 2 3 4 5 
Check his HLA DQ2/8 status 1 2 3 4 5 
Check for endomysial antibodies 1 2 3 4 5 
Start him on a gluten free diet and repeat his serology 
tests at a later date, to document a fall in levels 
1 2 3 4 5 
Do nothing further, but advise repeat investigations at 
some future time, or if he becomes symptomatic 
1 2 3 4 5 
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(4) If Joshua’s biopsy result is confirmed to be Marsh 0, but he is HLA DQ2/8 positive and his TTG 
antibodies remain elevated, which of the following would you be most likely to advise him (and/or his 
GP)? (Please circle one) 
⃝ He has latent coeliac disease and should be treated with a gluten free diet 
⃝ He has latent coeliac disease so does not need treatment unless he becomes symptomatic 
⃝ He may or may not have coeliac disease. Take a watch and wait approach and reinvestigate in 
a year, or if he becomes symptomatic. 





(5) If Joshua were instead SYMPTOMATIC and had NORMAL histology, how likely would you be to do each 
of the following? 
Please rate each option on the 1 - 5 scale of likelihood, where: 
   1 = highly unlikely  3 = neutral  5 = highly likely 
                              Rating of likelihood (circle one)  
Review the biopsy result with a pathologist 1 2 3 4 5 
Repeat the biopsy in the near future 1 2 3 4 5 
Arrange for him to have a capsule endoscopy 1 2 3 4 5 
Check his HLA DQ2/8 status 1 2 3 4 5 
Check for endomysial antibodies 1 2 3 4 5 
Start him on a gluten free diet and repeat his serology 
tests at a later date, to document a fall in levels 
1 2 3 4 5 
Do nothing further, but advise repeat investigations at 
some future time 
1 2 3 4 5 
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(7) In this situation with a SYMPTOMATIC patient who has elevated TTG antibodies, is HLA DQ2/8 positive, 
and has a biopsy result confirmed as Marsh O, which of the following would you be most likely to advise 
the patient (and/or his GP)? (Please choose one) 
⃝ He has latent coeliac disease and should be treated with a gluten free diet 
⃝ He has latent coeliac disease so does not need treatment  
⃝ He may or may not have coeliac disease. Take a watch and wait approach and reinvestigate in 
a year 





Case Study C 
You are contacted by a local GP who has a patient whom she suspects has coeliac disease, based on 
symptoms and moderately positive IgA anti-TTG antibodies. The patient is unwilling to undergo endoscopy 
for biopsy, and has already commenced a gluten free diet. The GP asks you how you think she should 
proceed with this patient. 
(1) How likely would you be to suggest each of the following? 
Please rate each option on the 1 - 5 scale of likelihood, where: 
   1 = highly unlikely  3 = neutral  5 = highly likely 
                                         Rating of likelihood (circle one)  
Repeat the TTG to see if it has fallen on the gluten free 
diet. This supports the diagnosis of coeliac disease. 
1 2 3 4 5 
Test HLA DQ2/8 status to see whether coeliac disease is 
possible or not. 
1 2 3 4 5 
Inform the patient that diagnosing coeliac disease is 
unreliable without a biopsy; she should reconsider her 
decision. 
1 2 3 4 5 
Assume that the patient does have coeliac disease, and 
manage her accordingly. 
1 2 3 4 5 
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Several months later the patient is finding it a challenge to stick to the gluten free diet and would now like 
to have a biopsy to find out if she really does have coeliac disease. She realises she will have to re-introduce 
gluten into her diet. 
(3) How much gluten-containing food would you recommend that she needs to consume for an adequate 
gluten challenge? (e.g. slices of bread per day).  
____________________________________________________________________________________
____________________________________________________________________________________ 
(4) How long would you recommend she should continue eating gluten-containing food before she can 
be biopsied? (Please choose one) 
⃝ Until she is symptomatic 
⃝ For at least two weeks 
⃝ For at least four weeks 
⃝ For at least six weeks 
⃝ Other ; please specify: ___________________________________________________________ 
_________________________________________________________________________________ 
 
The patient does have coeliac disease, and wants to include oats in her diet. 
(5) What do you think about coeliac patients including non-cross-contaminated oats in their gluten free 
diet? (Please choose one) 
⃝ They should avoid consuming any oats 
⃝ Oats may be included in the GFD as soon as it is commenced 
⃝ Oats should only be included once the patient is asymptomatic 
⃝ Oats should only be included once the patient is asymptomatic and their serology has returned 
to normal 
⃝ Oats should only be included if the patient has biopsy-proven recovery of the gut 
⃝ Other;  please specify:  __________________________________________________________ 
_________________________________________________________________________________ 
(6) If patients choose to include oats in their gluten free diet, what is your practice with regards to re-
biopsy? (Please choose one) 
⃝ I don’t re-biopsy. If they become symptomatic I advise them to stop eating oats 
⃝ I routinely re-biopsy, irrespective of symptoms 
⃝ I re-biopsy if symptoms recur 
⃝ Other; please specify: ___________________________________________________________ 
_________________________________________________________________________________ 
 (7) Do you have any other comments you wish to make, with respect to the management (and/or 
diagnosis) of coeliac disease?  ____________________________________________________________ 
____________________________________________________________________________________ 




Thank you very much for completing this survey. In order to help us to interpret the information you have 
provided, we need some additional, descriptive information about you. Please could you also complete 
the following: 
(1) What is your current position? 
⃝   Consultant Gastroenterologist            ⃝   Consultant Surgeon            ⃝   Gastroenterology Registrar 
(2) How many years have you been practising in the area of gastroenterology? 
⃝   1 – 10         ⃝   11 – 20         ⃝   21 – 30         ⃝   >30         ⃝   I am a surgeon who does endoscopies 
(3) How many clinical tenths do you work in gastroenterology? 
⃝   < 3              ⃝   3 - 5               ⃝   6 - 8              ⃝   >8           ⃝   I am a surgeon who does endoscopies 
(4) Do you hold an academic post?  ⃝   Yes         ⃝   No 
(5) What is your gender?              ⃝   Male         ⃝   Female 
(6) In which country (or countries) did you undertake your UNDERGRADUATE training?  
____________________________________________________________________________________
____________________________________________________________________________________ 
(7) In which country (or countries) did you undertake your POSTGRADUATE training?  
____________________________________________________________________________________
____________________________________________________________________________________ 
(8) What are your areas of sub-speciality?  _________________________________________________ 
____________________________________________________________________________________ 
(9) In which DHB region (or regions) do you work?  __________________________________________ 
____________________________________________________________________________________ 
(10) In which practice setting (or settings) do you work?  
⃝   Public Hospital only                     ⃝   Private Practice only                    ⃝   Mix of Public and Private 
⃝ Other; please specify: _____________________________________________________________ 
 
(11) How many tenths do you work in private practice? 
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(12) Please comment on any factors about the setting (or settings) in which you work which may impact 
on your management of patients with possible coeliac disease. (E.g. patient expectations, resource 





(13) For each of the following clinical scenarios, how many ADULT Coeliac patients do you see? (Please 
tick the appropriate column for each scenario) 
 None < 10 per 
year 
1 – 10 
per 
month 
11 – 20 
per 
month 
> 20 per 
month 
New referral; diagnosis not previously 
considered 
     
For biopsy to confirm diagnosis      
For follow-up; recently diagnosed      
For follow-up; long-term diagnosed      
For review; concern about recovery or 
possible complications 
     
 
Other – please specify: ______________________________________________________________ 
(14) From which of the following sources are you most likely to get your information about Coeliac 
Disease? Please rate each option on the 1- 5 scale of likelihood, where: 
 
1 = highly unlikely, I never use this source             3 = neutral, I may or may not use this source  
  5 = highly likely, I often use this source 
                           Rating of likelihood (circle one)    
Gastroenterology Conferences 1 2 3 4 5 
Colleagues 1 2 3 4 5 
Practice Guidelines 1 2 3 4 5 
Medical Journals 1 2 3 4 5 
Coeliac NZ 1 2 3 4 5 
 
Other – please specify: ______________________________________________________________ 
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My name is Kristin Kenrick, and I am a GP and PhD candidate investigating adult 
Coeliac Disease in New Zealand. I am working with Michael Schultz and Andrew 
Day, whom you know through the Society, and Chrystal Jaye from the Department 
of General Practice and Rural Health in the Dunedin School of Medicine.  
My PhD research aims to develop strategies to improve the care of patients with CD, 
by identifying gaps in current approaches to the diagnosis and management of the 
condition. The first part of the project seeks to understand the role of specialists in 
the care of adults with coeliac disease, and their expectations of GPs who are also 
involved in this care. For this project to produce meaningful results we need as 
many people as possible to take part. 
If you are a gastroenterologist (consultant or registrar) or a surgeon 
endoscopist, we would be very grateful if you would follow this link Coeliac Disease 
Survey and complete an anonymous on-line survey. It presents three scenarios, 
with questions which ask you to rate your likely responses. We are looking for 
information about your current practice. We are not looking for “right” answers.  
This survey will take about 25 minutes to complete, but you can do this in more than 
one sitting if you choose, as you can save your answers and return to it later. 
The survey will be open for at least 4 weeks, and I will send a reminder email after 
2 weeks.  
If you would prefer to complete a paper-based version of the survey please email 
me (kristin.kenrick@otago.ac.nz) and I will send a form to you. 
This study has been approved by the University of Otago Human Ethics Committee 
(ref. H13/027). If you have any concerns about the ethical conduct of the research 
you may contact the Committee through the Human Ethics Committee 
Administrator (ph 03 479 8256). Any issues you raise will be treated in confidence 
and investigated and you will be informed of the outcome. 






First follow-up email 
Dear Colleagues, 
Thank you very much to those of you who have already completed the Coeliac 
Disease survey, which was sent out 2 weeks ago. 
If you are a gastroenterologist (consultant or registrar) or a surgeon endoscopist, 
and have not already done so, I would be very grateful if you would follow this link 
Coeliac Disease Survey and complete the anonymous on-line survey.  
This survey will take about 25 minutes to complete, but you can do this in more than 
one sitting if you choose, as you can save your answers and return to it later. 
If you would prefer to complete a paper-based version of the survey please email 
me (kristin.kenrick@otago.ac.nz) and I will send a form to you. 
With thanks again in anticipation of your support, 
 
Kristin Kenrick, 
GP and PhD Candidate. 
 
Second follow-up email 
Dear Gastroenterology Colleagues, 
Thank you very much to those of you who have completed the Coeliac Disease 
Survey, either on-line earlier in the year, or in hard-copy at the ASM last week. 
If you still have a hard-copy of the survey which you completed, but didn't get a 
chance to give back to me, I would be very grateful if you would please send it back 
to me. The address is:  
Dr K. Kenrick, Department of General Practice and Rural Health, University of Otago, 
P.O. Box 56, Dunedin 9054 
Alternatively if you have not yet done the survey and would like to do so on-line, 
please click on the following link: Coeliac Survey 







Letters to Auckland and female gastroenterologists 
Dear Doctor … 
Enclosed with this letter is a copy of the Coeliac Disease Survey which I first sent 
out in electronic form last year, and then gave out in hardcopy at the NZ 
Gastroenterology Society Annual Scientific Meeting in Wellington. You may have 
already seen it and, if you have already completed it, thank you for your help with 
this project, and please disregard this letter. 
If you have not completed this survey I would be very grateful if you would be able 
to do so now. At present gastroenterologists from the Auckland region are 
significantly under-represented in the responses I have received, which is why I am 
writing to you. Improving on this will add considerable weight to the findings of the 
project. 
This survey forms part of a PhD project in which I am investigating adult Coeliac 
Disease in New Zealand. I am working with gastroenterologists Associate Professor 
Michael Schultz and Professor Andrew Day, and Associate Professor Chrystal Jaye, 
from the Department of General Practice and Rural Health in the Dunedin School of 
Medicine. We are particularly interested in developing strategies to improve the 
care of patients with CD, by identifying gaps in current approaches to the diagnosis 
and management of the condition. This part of the project seeks to understand the 
role of specialists in the care of patients with CD, and their expectations of GPs who 
are also involved in this care. We are looking for information about your current 
practice, rather than the “right” answers. The survey should take you no more than 
20 minutes to complete. 
Please note there are questions on both sides of each page. 
I would really appreciate your help with this project. Please return your completed 
survey in the postage-paid envelope provided. 
Many thanks and best wishes, 
 
Kristin Kenrick 
GP and PhD Candidate 
Dunedin School of Medicine  
 
This study has been approved by the University of Otago Human Ethics Committee (ref. H13/027). If 
you have any concerns about the ethical conduct of the research you may contact the Committee 
through the Human Ethics Committee Administrator (ph 03 479 8256). Any issues you raise will be 





Dear Doctor … 
Enclosed with this letter is a copy of the Coeliac Disease Survey which I first sent 
out in electronic form last year, and then gave out in hardcopy at the NZ 
Gastroenterology Society Annual Scientific Meeting in Wellington. You may have 
already seen it and, if you have already completed it, thank you for your help with 
this project, and please disregard this letter. 
If you have not completed this survey I would be very grateful if you would be able 
to do so now. At present the response rate from women gastroenterologists is 
substantially lower than that from your male colleagues, which is why I am writing 
to you. Improving on this will add weight to the findings of the project. 
This survey forms part of a PhD project in which I am investigating adult Coeliac 
Disease in New Zealand. I am working with gastroenterologists Associate Professor 
Michael Schultz and Professor Andrew Day, and Associate Professor Chrystal Jaye, 
from the Department of General Practice and Rural Health in the Dunedin School of 
Medicine. We are particularly interested in developing strategies to improve the 
care of patients with CD, by identifying gaps in current approaches to the diagnosis 
and management of the condition. This part of the project seeks to understand the 
role of specialists in the care of patients with CD, and their expectations of GPs who 
are also involved in this care. We are looking for information about your current 
practice, rather than the “right” answers. The survey should take you no more than 
20 minutes to complete. 
Please note there are questions on both sides of each page. 
I would really appreciate your help with this project. Please return your completed 
survey in the postage-paid envelope provided. 
Many thanks and best wishes, 
 
Kristin Kenrick 
GP and PhD Candidate 
Dunedin School of Medicine  
 
This study has been approved by the University of Otago Human Ethics Committee (ref. H13/027). If 
you have any concerns about the ethical conduct of the research you may contact the Committee 
through the Human Ethics Committee Administrator (ph 03 479 8256). Any issues you raise will be 
treated in confidence and investigated, and you will be informed of the outcome. 
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Appendix G: Emails and reminder letters to GPs 
Initial email to GPs with both email and postal addresses available 
 
    
NZ GPs' Approach to Adult 
Coeliac Disease 




Dear Dr … 
 
I am a GP and am currently conducting some research on adult coeliac disease, a 
condition with increasing prevalence in our community. 
 
Next week I will be posting you a survey relating to this topic and I would be very 
grateful if you would take the time to complete it. If you complete the survey you will 
be eligible to enter a draw for a $750.00 travel voucher (to attend a conference or 
educational event of your choice) donated by BPAC NZ. 
 
If you would prefer to do the survey on-line you can do so by following the link at 
the end of this email. 
 
With thanks in anticipation of your participation, 
 
Kristin Kenrick, 
GP and PhD Candidate 
Dunedin School of Medicine. 
  
  







Initial email to GPs with email address only 
 
 
   
NZ GPs' Approach to Adult 
Coeliac Disease 




Dear Dr … 
 
I am a GP and am currently conducting some research on adult coeliac disease, a 
condition with increasing prevalence in our community. I want to be able to develop 
a set of New Zealand-specific guidelines which will enable us all to better deliver 
consistent and evidence-based care to our coeliac patients. 
 
To assist me with this project I really need information from GPs about their current 
practice relating to Coeliac Disease, so I would be very grateful if you would 
complete a survey by following the link at the end of this email. 
If you complete the survey you will be eligible to enter a draw for a $750.00 travel 
voucher (to attend a conference or educational event of your choice) donated by 
BPAC NZ. 
 
If you would prefer to do the survey in hardcopy format, please email me and I will 
send you a copy. 
With thanks in anticipation of your participation, 
 
Kristin Kenrick, 
GP and PhD Candidate 
Dunedin School of Medicine. 
  
  




  Please do not forward this email as its survey link is unique to you.  






Reminder email to GPs with both email and postal addresses 
 
  
   
NZ GPs' Approach to Adult 
Coeliac Disease 




Dear Dr … 
 
By now you should have received a hard copy of my Coeliac Disease survey. If you 
have not already done so, I would be very grateful if you would complete this and 
return it in the reply-paid envelope which was enclosed with it. The more responses 
I receive, the more reliable my findings will be. 
 
If you would prefer to do the survey online, please click on the link below, and put 
the hardcopy in your recycling bin. 
 
Participants who complete the survey are eligible to enter the draw to win a $750.00 
travel voucher donated by BPAC NZ. 
 
With thanks in anticipation of your participation, 
 
Kristin Kenrick, 
GP and PhD Candidate, 
Dunedin School of Medicine. 
  
  







Reminder email to GPs with email addresses only 
 
  
    
NZ GPs' Approach to Adult 
Coeliac Disease 




Dear Dr … 
 
Recently I emailed you about my Coeliac Disease survey. If you have not already 
done so, I would be very grateful if you would complete this by following the link 
below. The more responses I receive, the more reliable my findings will be. 
 
Participants who complete the survey are eligible to enter the draw to win a $750.00 
travel voucher donated by BPAC NZ. 
 
With thanks in anticipation of your participation, 
 
Kristin Kenrick, 
GP and PhD Candidate, 
Dunedin School of Medicine. 
  
  






Reminder letter to GPs who received hard copy only 
Dear Dr … 
Recently I sent you a survey entitled New Zealand General Practitioners’ 
Approach to Adult Coeliac Disease. 
As I write this I have not yet received a response from you, so I would be very 
grateful if you would be able to take some time to complete the enclosed copy. 
Alternatively, if you prefer to participate online, you can go to: 
www.surveymonkey.com/r/GP-Coeliac-Survey  
I would really appreciate your contribution to this research project because, to 
ensure that my results are meaningful, I need information from as many GPs as 
possible about their current practice relating to coeliac disease. If you have 
already completed the survey in the meantime, thank you very much. 
If you complete this survey you will be eligible to enter the draw for a 
$750.00 travel voucher to attend a conference or educational event of your 
choice, donated by bpacNZ. 
I have extended the timeframe to complete the survey until 5th June 2015. 
Many thanks and best wishes, 
 
Kristin Kenrick, 
GP and PhD Candidate 
Dunedin School of Medicine. 
 
 
 
 
 
 
 
 
 
 
 
